<SEC-DOCUMENT>0001571049-18-000206.txt : 20180330
<SEC-HEADER>0001571049-18-000206.hdr.sgml : 20180330
<ACCEPTANCE-DATETIME>20180330163151
ACCESSION NUMBER:		0001571049-18-000206
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		84
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180330
DATE AS OF CHANGE:		20180330

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Cyclacel Pharmaceuticals, Inc.
		CENTRAL INDEX KEY:			0001130166
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				911766850
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50626
		FILM NUMBER:		18726413

	BUSINESS ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922
		BUSINESS PHONE:		908-517-7330

	MAIL ADDRESS:	
		STREET 1:		200 CONNELL DRIVE
		STREET 2:		SUITE 1500
		CITY:			BERKELEY HEIGHTS
		STATE:			NJ
		ZIP:			07922

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	XCYTE THERAPIES INC
		DATE OF NAME CHANGE:	20001218
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>tv489461-10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k - none - 4.579785s</title>
  </head>
  <body style="width:595.31pt;">
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:19pt;margin-bottom:21.71pt;margin-left:27pt;width:541pt;">
        <div style="width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:8pt; text-align:center; width:541pt; line-height:15pt;font-weight:bold;font-size:14pt;">UNITED STATES <br >SECURITIES AND EXCHANGE COMMISSION </div>
        <div style="margin-top:1pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">Washington, D.C. 20549 </div>
        <div style="margin-top:12pt; text-align:center; width:541pt; line-height:17pt;font-weight:bold;font-size:16pt;">FORM 10-K </div>
        <div style="margin-top:2pt; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">(Mark One) </div>
        <div style=" float:left; line-height:11pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;font-size:10pt;">&#9746;<br ></div>
        <div style=" float:left; margin-top:2pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:520.5pt;font-weight:bold;font-size:10pt;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">For the fiscal year ended December&#160;31, 2017 <br >OR </div>
        <div style=" float:left; line-height:11pt; margin-top:2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;font-size:10pt;">&#9744;<br ></div>
        <div style=" float:left; margin-top:2pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:520.5pt;font-weight:bold;font-size:10pt;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:2pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">Commission file number 00-50626 </div>
        <div style="margin-top:12pt; text-align:center; width:541pt; line-height:17pt;font-weight:bold;font-size:16pt;">CYCLACEL PHARMACEUTICALS, INC. </div>
        <div style="margin-top:-2.4pt; text-align:center; width:541pt; line-height:10pt;font-size:8pt;">(Exact name of registrant as specified in its charter) </div>
        <table style="width:541pt;height:81pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Delaware </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">91-1707622 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 3.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(State or Other Jurisdiction <br >of Incorporation or Organization) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0.5pt 0pt 3.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(I.R.S. Employer <br >Identification No.) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">200 Connell Drive <br >Suite 1500 <br >Berkeley Heights, New Jersey </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:4.167pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">07922 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(Address of principal executive offices) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">(Zip Code)</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:10.59pt; text-align:center; width:541pt; line-height:12pt;font-size:10pt;">Registrant&#8217;s telephone number, including area code: <font style="font-weight:bold;">(908) 517-7330</font></div>
        <div style="margin-left:20pt; margin-top:2pt; width:521pt; line-height:12pt;font-size:10pt;">Securities registered under Section&#160;12(b) of the Exchange Act: </div>
        <table style="width:421pt;height:38.5pt;margin-left:60pt;margin-top:4pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204.5pt;">
              <div style="white-space:nowrap; text-align:center;">Title of each class </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:204.5pt;">
              <div style="white-space:nowrap; text-align:center;">Name of each exchange on which registered </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:204.5pt;">
              <div style="text-align:center;">Common Stock, $0.001 par value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:204.5pt;">
              <div style="text-align:center;">The NASDAQ Stock Market LLC </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.5pt;">
              <div style="text-align:center;">Preferred Stock, $0.001 par value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:204.5pt;">
              <div style="text-align:center;">The NASDAQ Stock Market LLC</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-left:20pt; margin-top:8.6pt; width:521pt; line-height:10pt;">Securities registered pursuant to Section&#160;12(g) of the Act: <font style="font-weight:bold;">None.</font></div>
        <div style="text-indent:20pt; margin-top:1.59pt; width:541pt; line-height:10pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act. &#8199;Yes&#8201;&#9744;&#8199;No&#8201;&#9746;</div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act. Yes&#8201;&#9744;&#8199;No&#8201;&#9746;</div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days. &#8199;Yes&#8201;&#9746;&#8199;No&#8201;&#9744;</div>
        <div style="text-indent:20pt; margin-top:1.59pt; width:541pt; line-height:10pt;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&#160;405 of Regulation&#160;S-T (&#167;232.405 of this chapter) during the preceding 12&#160;months (or for such shorter period that the registrant was required to submit and post such files). &#8199;Yes&#8201;&#9746;&#8199;No&#8201;&#9744;</div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (&#167;229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form 10-K or any amendments to this Form 10-K &#9744;. </div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of&#8201;&#8201; &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221; and &#8220;smaller reporting company&#8221; in Rule&#160;12b-2 of the Exchange Act: </div>
        <table style="width:541pt;height:33pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Large accelerated filer &#9744;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Accelerated filer &#9744;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Non-accelerated filer &#9744;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">Smaller reporting company &#9746;</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:264.5pt;">
              <div style="text-align:center;">[Do not check if a smaller reporting company]</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:264.5pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:8.59pt; width:541pt; line-height:10pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter): </div>
        <div style="margin-left:20pt; margin-top:1.6pt; width:521pt; line-height:10pt;">Emerging growth company &#9744;</div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act. &#9744;</div>
        <div style="text-indent:20pt; margin-top:1.59pt; width:541pt; line-height:10pt;">The aggregate market value of the registrant&#8217;s voting and non-voting common stock held by non-affiliates of the registrant (without admitting that any person whose shares are not included in such calculation is an affiliate), as of June&#160;30, 2017 (based upon the closing sale price of&#8201;&#8201; $3.77 of such shares on The NASDAQ Capital Market on June&#160;30, 2017) was $12,719,813. </div>
        <div style="margin-left:20pt; margin-top:1.6pt; width:521pt; line-height:10pt;">As of March 27, 2018, there were 11,997,447 shares of the registrant&#8217;s common stock outstanding.</div>
        <div style="margin-top:6pt; text-align:center; width:541pt; line-height:11pt;font-weight:bold;font-size:10pt;">DOCUMENTS INCORPORATED BY REFERENCE </div>
        <div style="text-indent:20pt; margin-top:1.6pt; width:541pt; line-height:10pt;">The following documents (or parts thereof) are incorporated by reference into the following parts of the Form 10-K: Certain information required in Part&#160;III of this Annual Report on Form 10-K is incorporated from the Registrant&#8217;s Proxy Statement for the Annual Meeting of Stockholders to be held on or about May&#160;31, 2018.</div>
        <div style="margin-top:2.29pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:3pt; width:541pt;">
          <div style="margin-left: 0pt; width: 541pt; margin-top: 0pt; font-size: 2pt; line-height: 0pt; border-bottom: 2pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:-10pt; width:541pt; line-height:12pt;font-size:10pt;"></div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">TABLE OF CONTENTS </div>
        <table style="width:456pt;height:458.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:48pt;">PART I</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT1">Item&#160;1.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT1">Business </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT1">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT1">1</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT1A">Item&#160;1A.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT1A">Risk Factors </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT1A">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT1A">18</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT1B">Item&#160;1B.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT1B">Unresolved Staff Comments </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT1B">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT1B">46</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT2">Item&#160;2.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT2">Properties </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT2">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT2">46</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT3">Item&#160;3.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT3">Legal Proceedings </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT3">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT3">47</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT4">Item&#160;4.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT4">Mine Safety Disclosures </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT4">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT4">47</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:48pt;">PART II</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT5">Item&#160;5.<br ></a></div>
              <div style=" float:left; line-height:12pt; text-align:left; width:378.83pt;"><a href="#tIT5">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT5">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:8.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT5">48</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT6">Item&#160;6.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT6">Selected Financial Data </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT6">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT6">48</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT7">Item&#160;7.<br ></a></div>
              <div style=" float:left; line-height:12pt; text-align:left; width:378.83pt;"><a href="#tIT7">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT7">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT7">48</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT7A">Item&#160;7A.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT7A">Quantitative and Qualitative Disclosures About Market Risk </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT7A">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT7A">58</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT8">Item&#160;8.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT8">Financial Statements and Supplementary Data </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT8">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT8">59</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT9">Item&#160;9.<br ></a></div>
              <div style=" float:left; line-height:12pt; text-align:left; width:378.83pt;"><a href="#tIT9">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT9">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT9">86</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT9A">Item&#160;9A.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT9A">Controls and Procedures </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT9A">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT9A">86</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT9B">Item&#160;9B.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT9B">Other Information </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT9B">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT9B">87</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:48pt;">PART III</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT10">Item&#160;10.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT10">Directors, Executive Officers and Corporate Governance </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT10">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT10">88</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT11">Item&#160;11.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT11">Executive Compensation </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT11">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT11">88</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:12pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT12">Item&#160;12.<br ></a></div>
              <div style=" float:left; line-height:12pt; text-align:left; width:378.83pt;"><a href="#tIT12">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT12">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT12">88</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT13">Item&#160;13.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT13">Certain Relationships and Related Transactions, and Director Independence </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT13">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT13">88</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT14">Item&#160;14.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT14">Principal Accountant Fees and Services </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT14">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT14">88</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="margin-left:48pt;">PART IV</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:427.33pt;white-space:normal;text-align:left;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:48pt;white-space:nowrap;"><a href="#tIT15">Item&#160;15.<br ></a></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:378.83pt;"><a href="#tIT15">Exhibits and Financial Statement Schedules </a></div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;"><a href="#tIT15">&#8203;</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:9.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tIT15">89</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">i</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT1">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART I </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;1.&nbsp;&nbsp;&nbsp;Business </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following Business Section contains forward-looking statements. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of certain risks, uncertainties and other factors including the risk factors set forth in Part&#160;I, Item&#160;1A of this Annual Report on Form 10-K. In this report, &#8220;Cyclacel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our&#8221; refer to Cyclacel Pharmaceuticals, Inc. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">General </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cyclacel is a clinical-stage biopharmaceutical company using cell cycle control, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel is a pioneer company in the field of cell cycle biology with a vision to improve patient healthcare by translating cancer biology into medicines. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a development pipeline of novel drug candidates. We have retained rights to commercialize our clinical development candidates and our business objective is to enter into selective partnership arrangements with these programs. Substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Cell Cycle Control Biology </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Loss of control of the cell cycle, the process by which cells grow and divide, lies at the heart of cancer. In normal cells, a complex set of interacting proteins tightly regulates progression through the phases of the cell cycle by which a cell grows, replicates its DNA and divides. This process also includes mechanisms known as cell cycle checkpoints, to ensure all necessary events of each cell cycle phase are completed before beginning the next phase. If the events are not completed correctly, the cells may commit suicide by a process of programmed cell death called apoptosis. Cyclin dependent kinases, or CDKs, are key regulators among the numerous proteins involved in cell cycle control processes. CDKs connect with proteins called cyclins to regulate cell cycle checkpoints and control transcription, DNA repair and metastatic spread. The discovery of CDKs and cyclins and their regulation of cell cycle checkpoint control were cited in the 2001 Nobel Prize in Physiology or Medicine. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have evaluated several families of anticancer drugs that impact the cell cycle, including, CYC065, sapacitabine and seliciclib. We believe that these drug candidates are differentiated from others in that they are orally-available and interact with unique target profiles and mechanisms and have the potential to treat multiple cancer indications. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Our development efforts focus on the following areas: </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Transcriptional Regulation: <br >Cyclin Dependent Kinase (CDK) Inhibitors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">CDKs are a family of enzymes first discovered as regulators of the cell cycle, but now understood to also provide pivotal functions in the regulation of transcription, DNA repair and metastatic spread. The precise selectivity of an individual CDK inhibitor molecule for certain specific CDKs is key to targeting particular tumor types and minimizing undesirable side effects through non-specific antiproliferative activity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In general, cell cycle regulation is less well controlled in cancer cells than in normal cells, which explains in part why cancer cells divide uncontrollably. Different CDKs are responsible for control of different aspects of proliferation, and when dysregulated, can be drivers of particular cancer sub-sets. Modulating CDK activity with targeted therapies is an attractive strategy to reinforce cell cycle control and decrease the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">1</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">rate of abnormal proliferation of cancer cells. The first Food and Drug Administration, or FDA, approval in March&#160;2015 of a CDK inhibitor for palbociclib, and more recently in 2017, ribociclib and abemaciclib, for a type of breast cancer, has led to great interest in the development of this class of drugs as oncology therapeutics. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cyclacel&#8217;s founding scientist, Professor Sir David Lane, is an internationally recognized authority in cell cycle biology, who discovered p53, a key tumor suppressor that malfunctions in about two-thirds of human cancers. Under his guidance, Cyclacel&#8217;s drug discovery and development programs concentrated on the CDK2/9 isoforms, which operate as key components of the p53 pathway. These efforts resulted in bringing two molecules into clinical trials: seliciclib, a first-generation CDK inhibitor, and CYC065, a second-generation CDK inhibitor, which has benefited from the Company&#8217;s clinical experience with seliciclib. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Seliciclib, our first-generation CDK inhibitor, is being evaluated in an all-oral Phase&#160;1/2 combination study with our sapacitabine in patients with BRCA mutations, and has been evaluated to date in approximately 450 patients. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">CYC065 is being evaluated in an ongoing, first-in-human, Phase&#160;1 trial in patients with advanced solid tumors. Similar to palbociclib, ribociclib and abemaciclib, CYC065 may be most useful as a therapy for patients with both liquid and solid tumors in combination with other anticancer agents, including Bcl-2 antagonists, such as venetoclax, or HER2 inhibitors, such as trastuzumab. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">DNA Damage Response, or DDR </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many cancers have defects in the way in which cells monitor and repair damaged DNA, collectively termed DNA damage response, or DDR. These deficiencies in DDR pathways render cells more susceptible to DNA damage. Many traditional cancer treatments, such as DNA-damaging chemotherapy and radiotherapy, are based on this finding. However, such treatments are often accompanied by significant and unwanted side effects. Developing treatments which target specific DDR deficiencies to preferentially kill cancer cells, while minimizing the impact on normal cells, has potential for more selective, better tolerated therapies to improve survival in multiple cancers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have focused on developing treatments targeting DNA damage pathways for several&#160;years. For example, drug candidate sapacitabine is an oral nucleoside analogue prodrug whose metabolite, CNDAC, generates single-strand DNA breaks, or SSB, either leading to arrest of the cell cycle at G2 phase or development of double-strand DNA breaks, or DSB. Repair of CNDAC-induced DSB is dependent on the homologous recombination, or HR repair pathway. BRCA mutations in cancer cells are a cause of HR deficiency, making such cancer cells more susceptible to cell death induced by sapacitabine. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are evaluating sapacitabine in a Phase&#160;1/2 combination study with seliciclib in patients with BRCA mutations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Sapacitabine in AML </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are also evaluating sapacitabine in SEAMLESS, a Phase&#160;3 study in acute myeloid leukemia, or AML, in the elderly, in an alternating schedule with decitabine. On February&#160;23, 2017 we announced that the trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control arm of decitabine alone. However an improvement in complete remission rate was observed. In the stratified subgroup of patients with low baseline peripheral white blood cell count, comprising approximately two-thirds of the study&#8217;s population, an improvement in overall survival was observed for the experimental arm. Data were reported at an oral presentation at the 59<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> American Society of Hematology Annual Meeting in December&#160;2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently retain virtually all marketing rights worldwide to the compounds associated with our drug programs. To optimize our commercial return, we intend to enter into selected partnering arrangements.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">2</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Oncology Development Programs </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have generated several families of anticancer drugs that act on the cell cycle, including nucleoside analogs, CDK inhibitors and PLK (polo-like kinase) inhibitors. In our development programs, we have intensively used biomarker analysis to help evaluate whether our drug candidates are having their intended effect through their assumed mechanisms at different doses and schedules. Biomarkers are proteins or other biological substances, or analytes, whose presence in patient samples can serve as an indicator or marker of diseases, or may highlight patients more likely to respond to a particular treatment. Biomarker data from early clinical trials may also enable us to design subsequent trials more efficiently and to monitor patient compliance with trial protocols. For example, we reported that sapacitabine efficacy is enhanced in tumor cells that are defective in homologous recombination DNA repair and that sapacitabine treatment increased a DNA damage marker in patient samples, and we have observed evidence of target engagement by CYC065 with prolonged suppression of an anti-apoptotic protein called Mcl-1 in peripheral blood cells in patient samples. We believe that, in the longer term, biomarkers may allow us to select patients who are more likely to respond to our drugs in clinical trials and to increase the benefit to such patients. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although a number of pharmaceutical and biotechnology companies are currently attempting to develop nucleoside analogs, CDK inhibitors and PLK inhibitors, we believe that our drug candidates are differentiated in that they are orally-available and demonstrate unique target profiles and mechanisms. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development Pipeline </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following table summarizes our development pipeline.</div>
        <table style="width:456pt;height:186pt;margin-top:2pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:114pt;text-align:left;">
              <div style="white-space:nowrap;">PROGRAM </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:132pt;">
              <div style="white-space:nowrap; text-align:center;">INDICATION </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:108pt;">
              <div style="white-space:nowrap; text-align:center;">DEVELOPMENT STATUS </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 1.667pt 0pt; width:66pt;">
              <div style="text-align:center;">COMMERCIAL <br >RIGHTS </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:114pt;text-align:left;">Transcriptional Regulation</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:132pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:114pt;text-align:left;">CYC065 CDK inhibitor </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div style="text-align:center;">Solid Tumors incl. Mcl-1, <font style="font-style:italic;">MYCN</font>, Cyclin E amplification </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:108pt;">
              <div style="text-align:center;">Phase&#160;1 part 2 (ongoing) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:66pt;">
              <div style="text-align:center;">Worldwide </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:114pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:132pt;white-space:normal;">
              <div style="text-align:center;">CLL combination with Bcl-2 inhibitor </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">CYC065 + venetoclax (preclinical) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:66pt;">
              <div style="text-align:center;">Worldwide </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 1pt 0pt; width:114pt;text-align:left;">DNA Damage Response</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:132pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:114pt;text-align:left;">Sapacitabine and seliciclib CDK inhibitor </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:132pt;">
              <div style="text-align:center;">BRCA mutation positive breast, ovarian, pancreatic cancer </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:108pt;white-space:nowrap;">
              <div style="text-align:center;">Phase&#160;1 part 3 (ongoing) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:66pt;">
              <div style="text-align:center;">Worldwide (except Japan) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:normal;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2pt 0pt 0.5pt 0pt; width:114pt;text-align:left;">Sapacitabine in AML Phase&#160;3 SEAMLESS study </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:132pt;">
              <div style="text-align:center;">AML &ge;70&#160;years unfit for or refused intensive chemotherapy </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:108pt;">
              <div style="text-align:center;">Phase&#160;3 completed (subgroup analysis) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 0.5pt 0pt; width:66pt;">
              <div style="text-align:center;">Worldwide (except Japan) </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:italic;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:9pt 0pt 1pt 0pt; width:114pt;text-align:left;">Mitosis Regulation</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:132pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:108pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:66pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2pt 0pt 1pt 0pt; width:114pt;text-align:left;">CYC140 PLK inhibitor </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt; width:132pt;">
              <div style="white-space:nowrap; text-align:center;">Solid Tumors and Blood Cancers </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt; width:108pt;white-space:normal;">
              <div style="text-align:center;">IND-directed development (completed) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2pt 0pt 1pt 0pt; width:66pt;">
              <div style="text-align:center;">Worldwide</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:20pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Transcriptional Regulation&#160;Program <br >Cyclin Dependent Kinase Inhibitors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cyclin Dependent Kinase Inhibitors, or CDKs, are enzymes that are central to the process of cell division and cell cycle control and play pivotal roles in cancer cell growth, survival and DNA damage repair. The best characterized CDK enzymes include CDK2, <font style="white-space:nowrap;">-4,</font><font xml:space="preserve"> </font><font style="white-space:nowrap;">-6</font> and <font style="white-space:nowrap;">-9.</font> Different CDK inhibitor drugs selectively target different sets of CDKs. This CDK inhibitory profile is key for treating particular tumor types and avoiding undesirable side effects through nonspecific or off-target activity. Cyclacel&#8217;s CDK inhibitors, CYC065 and seliciclib, target CDKs 2 and 9. CDK2/9 inhibition may also overcome aberrant cell cycle control in certain non-malignant diseases of proliferation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA approved CDK4/6 inhibitors, palbociclib, ribociclib and abemaciclib represent an important therapeutic advance and are associated with very promising progression-free survival advantages with good tolerability when combined with standard of care versus standard of care alone in patients with certain gynecological tumors, including forms of breast cancer. CDK4/6 inhibitors, such as palbociclib, induce senescence or dormancy of cancer cells, which may be associated with the emergence of resistance. If clinical manifestation of resistance becomes common, the therapeutic utility of CDK4/6 inhibitors could be hampered. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">3</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Pharmacological inhibition of the CDK2/9 isoforms has been shown to have potent anticancer effects in certain cancer types, including some that are resistant to approved treatments. CDK2/9 inhibitors have been shown to induce apoptosis of cancer cells. It is hoped that treatment with CDK2/9 inhibitors will result in clinically relevant, tumor cell death in patients with selected cancer types. Similar to the approved CDK 4/6 inhibitors, CDK2/9 inhibitors will likely be given in combination with other available anticancer agents. For example, a potential use of CDK2/9 inhibitors may be to overcome cyclin E dependent resistance to CDK4/6 inhibitors when given in combination with such CDK4/6 inhibitor. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Different CDKs are responsible for controlling different aspects of proliferation which, when dysregulated, can be drivers of particular cancer sub-sets. Our CDK clinical candidates target: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">CDK2, which drives cell cycle transition and activates major DNA double-strand break pathways; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">CDK9, which regulates transcription of certain genes, including cyclins, Mcl-1, MYC family and DNA double-strand break repair pathway components, through phosphorylation of RNA polymerase II. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">CYC065 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">CYC065 is a selective, second-generation inhibitor of CDK2/9 that causes apoptotic death of cancer cells at sub-micromolar concentrations and is bioavailable via oral and intravenous routes. Antitumor efficacy has been achieved <font style="font-style:italic;">in vivo</font> with once a day oral dosing at well tolerated doses. CYC065 is mechanistically similar but has much higher potency, <font style="font-style:italic;">in vitro</font> and <font style="font-style:italic;">in vivo,</font> improved metabolic stability and longer patent protection than seliciclib, Cyclacel&#8217;s first-generation CDK2/9 inhibitor. Translational biology data support development of CYC065 as a stratified medicine for solid and liquid tumors. CYC065 has been shown to inhibit CDK9-dependent oncogenic and leukemogenic pathways, including MYCN and mixed lineage leukemia rearrangements, or MLL-r. CYC065 and seliciclib both suppress the Mcl-1-mediated survival pathway in cancer cells, leading to rapid induction of apoptosis in Mcl-1 dependent cancer cells and reversal of drug resistance associated with the addiction of cancer cells to cyclin E, a partner protein of CDK2. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">CYC065 is in an ongoing, first-in-human, single agent, ascending dose, Phase&#160;1 trial to assess its safety, tolerability, pharmacokinetics and pharmacodynamics in patients with advanced solid tumors. In addition to determining safety and recommended dosing for Phase&#160;2, the study aims to investigate CYC065&#8217;s effects on the Mcl-1 biomarker, which is implicated in the evolution of resistance in cancer. In part 1 of the study, prolonged reduction of Mcl-1 was observed in 11 out of 13 patients treated at the recommended Phase&#160;2 dose, or RP2D following a single dose of CYC065, which was generally well tolerated. Preliminary anticancer activity was observed in 6 patients, of which 5 were treated at the RP2D and 3 of which were reported by investigators to have molecular features of their cancers associated with CYC065&#8217;s mechanism of action, including overexpression or amplification of Mcl-1, MYCN and/or cyclin E. The trial is being conducted at the Dana Farber Cancer Institute in Boston. Part&#160;2 of the Phase&#160;1 translational study will evaluate additional dosing schedules in patients with advanced solid tumors, in particular those tumors with amplification of Mcl-1, <font style="font-style:italic;">MYCN</font> and/or cyclin E, including subsets of high grade serous ovarian and uterine cancers. Biospecimens will be collected for assessment of biomarkers related to CYC065&#8217;s mechanism of action. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The molecular rationale and therapeutic potential of CYC065 in both hematologic and solid tumors is supported by published preclinical data as follows: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Induces cancer cell death and can combine beneficially with other anti-cancer drugs</font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:6pt; width:436pt; line-height:12pt;">CYC065 targets key CDK9-dependent oncogenic and leukemogenic survival pathways. Data presented at the 2016 Annual Meeting of the American Association of Cancer Research demonstrated that CYC065 can induce cell death and combined beneficially with anti-cancer drugs from the Bcl-2 and BET (Bromodomain and Extra-Terminal domain) inhibitor classes, in <font style="font-style:italic;">in vitro</font> models of B-cell lymphoma, including double-hit lymphomas. Combinations of CYC065 with the Bcl-2 inhibitor, venetoclax (ABT-199), or BET inhibitors were both synergistic. Short exposure to CYC065 was sufficient to downregulate MYCN, an oncogene product aberrantly expressed in many cancers, and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">4</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">Mcl-1, an anti-apoptotic member of the Bcl-2 family, and to induce cell death. CYC065 treatment had no impact on Bcl-2 levels. <font style="font-style:italic;">MYCN</font> overexpression and CDK inhibition have shown synthetic lethality. These data suggest there may be a therapeutic rationale to combine CYC065 and venetoclax for the treatment of genetically complex cancers, such as double-hit lymphomas. </div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Potent anticancer activity of CYC065 has been demonstrated <font style="font-style:italic;">in vivo</font> in AML xenograft models resulting in over 90% inhibition of tumor growth. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Prolonged survival and reduced tumor burden in MYCN-addicted neuroblastoma</font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The <font style="font-style:italic;">MYCN</font> oncogene is over-expressed in a number of different types of cancer, most notably neuroblastoma, but also rhabdomyosarcoma, medulloblastoma, astrocytoma, Wilms&#8217; tumor and small cell lung cancer. Amplification of the <font style="font-style:italic;">MYCN</font> oncogene is the most common genomic alteration in aggressive neuroblastomas, and is associated with poor clinical outcome. Preclinical data presented at the 2016 Childhood Cancer Meeting demonstrated that CYC065 prolonged survival in MYCN-addicted neuroblastoma models and neuroblastoma cells with <font style="font-style:italic;">MYCN</font> amplification and overexpression were found to be particularly sensitive. The mechanism of action of CYC065 included inhibition of <font style="font-style:italic;">MYCN</font> transcription, downregulation of N-MYC protein, blocking neuroblastoma cell proliferation and induction of apoptosis. There are no approved drugs that directly target MYCN, prompting the investigation of indirect approaches such as exploitation of a synthetic lethal relationship between MYCN amplification/overexpression and inhibition of CDK2. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-style:italic;"><font style="font-style:normal;">&#8226;</font><br >
        </div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;font-style:italic;">May reverse drug resistance associated with addiction of cancer cells to cyclin E, the partner protein of CDK2</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:6pt; width:436pt; line-height:12pt;">In 2011, independent investigators published preclinical evidence that CYC065 as a single-agent can induce tumor growth delay in HER2-positive breast cancer cells addicted to cyclin E and resistant to trastuzumab, while administration of CYC065 in combination with trastuzumab resulted in regression or sustained tumor growth inhibition. </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">May have activity in triple-negative breast cancer</font></div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; text-indent:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Data presented at the 2015 San Antonio Breast Cancer Symposium demonstrated in particular the mechanistic rationale for clinical development of CYC065 in basal-like triple negative breast cancer, or TNBC, a cancer with poor prognosis frequently associated with BRCA mutations. Molecular characteristics of TNBC include amplification or overexpression of Cyclin E, the partner protein of CDK2, and MYCN. CYC065 directs a pro-apoptotic mechanism in breast cancer cell lines, which includes transcriptional down regulation of key pro-survival and oncogenic regulators, including Mcl-1 and MYCN. CYC065&#8217;s potent anticancer activity has been confirmed in breast cancer xenograft animal models. Like seliciclib, CYC065 combined effectively with sapacitabine in breast cancer cell lines. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We anticipate that CYC065 will likely be best used in combination with available anti-cancer agents, similar to recently approved CDK4/6 inhibitors. Depending on the data from the ongoing Phase&#160;1 study, we are also interested in evaluating CYC065 in patients with hematological malignancies in light of profound signals of activity observed in preclinical studies. We have retained worldwide rights to commercialize CYC065. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Seliciclib </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Seliciclib, our first-generation CDK inhibitor, is a novel, orally-available, CDK2/9 inhibitor that has been evaluated in over 450 patients. As CYC065 has improved potency and pharmacological properties compared to seliciclib, we would expect to advance CYC065 ahead of seliciclib. However, as we have accrued significant clinical development experience with seliciclib, we are using it to evaluate CDK2/9 inhibitor activity in our DDR program. Once CYC065 has progressed sufficiently though clinical development, we would plan to substitute seliciclib with CYC065. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Seliciclib is also being evaluated in certain Investigator Sponsored Trials, or ISTs, to treat Cushing&#8217;s disease and rheumatoid arthritis, and in a license and supply agreement with ManRos Therapeutics SA for the treatment of cystic fibrosis. As with all ISTs and licensing agreements, we do not control the timing or </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">5</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">conduct of such studies and will report updates as the investigators and collaborators may notify us from time to time. We have retained worldwide rights to commercialize seliciclib, except as provided in the license agreement with ManRos Therapeutics for cystic fibrosis. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">DNA Damage Response program </div>
        <div style="margin-top:4pt; width:456pt; line-height:11pt;font-style:italic;">Sapacitabine and CDK inhibitor </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Both sapacitabine and CNDAC, its major metabolite, have demonstrated potent anti-tumor activity in preclinical studies. Sapacitabine is an orally-available prodrug of CNDAC, which is a novel nucleoside analog, or a compound with a structure similar to a nucleoside. A prodrug is a compound that has a therapeutic effect after it is metabolized within the body. CNDAC has a significantly longer residence time in the blood when it is produced in the body through metabolism of sapacitabine than when it is given directly. Sapacitabine acts through a novel mechanism whereby the compound interferes with DNA synthesis through the incorporation of CNDAC into DNA during replication or repair, triggering a beta-elimination reaction and leading to the formation of single-strand DNA breaks, or SSBs. During subsequent rounds of replication, SSBs are converted to double-strand breaks, or DSBs, which can be repaired by the homologous recombination, or HR repair pathway, or, if unrepaired, result in cell death. Both sapacitabine and its major metabolite, CNDAC, have demonstrated potent anti-tumor activity in preclinical studies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sapacitabine has been evaluated in both hematological cancers and solid tumors. Over 1,000 patients have received sapacitabine in Phase&#160;1, 2 and 3 studies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We hold the worldwide rights to commercialize sapacitabine, except for Japan, for which Daiichi Sankyo Co., Ltd., or Daiichi Sankyo, has a right of first negotiation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Phase&#160;1/2 clinical trial of sapacitabine and seliciclib in patients with advanced cancers </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In an ongoing Phase&#160;1, single-arm, dose escalation study, sapacitabine and seliciclib are orally-administered sequentially in patients with incurable advanced solid tumors unresponsive to conventional treatment or for which no effective therapy exists. In Part&#160;1 of the study 38 patients were treated with sapacitabine administered twice daily for 7&#160;days sequentially followed by seliciclib twice daily for 3&#160;days over a 21 day cycle, and in Part&#160;2, 29 patients were dosed with sapacitabine each morning followed by seliciclib each evening, each once daily for 5&#160;days per week for 2 weeks of a 28 day cycle. The primary objective of the trial is to determine the maximum tolerated dose with a secondary objective of antitumor activity of the combination. Sixty-seven patients have been treated in Parts 1 and 2 of the study, of which 44 were found to carry germline BRCA mutations and one a sporadic BRCA mutation. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The BRCA1 and BRCA2 gene mutations are the most common cause of homologous repair deficiency. In BRCA-mutated tumor cells, homologous recombination repair is defective and DNA double-strand break repair capacity is reduced and may via error-prone pathways, which can lead to genomic instability and cell death. Carriers of BRCA in their germline, have been reported to have a higher probability of developing breast, ovarian, prostate and pancreatic cancer than the general population. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">6</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Data from Part&#160;1 and 2 of the study were presented at the 2016 American Society of Clinical Oncology Annual Meeting. Antitumor activity was observed in the subgroup of 45 patients with breast, ovarian and pancreatic cancers who tested positive for BRCA mutations (44 germline and 1 sporadic) with an overall disease control rate of over 30%. Best responses were as follows: </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Best Responses </div>
        <table style="width:456pt;height:106.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PART 1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">PART 2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">BRCA carriers <br >(n=16) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Others <br >(n=22) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">BRCA carriers <br >(n=28) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Others <br >(n=1) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">CR </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">PR </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">SD </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">6</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1<font style="position:absolute;">*</font></td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">ORR (CR/PR) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">25<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">7<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">0<font style="position:absolute;">%</font></td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 0.5pt 0pt; width:186pt;text-align:left;">
              <div style="white-space:nowrap;">Disease Control (CR/PR/SD) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6&#8201;(37.5<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">6&#8201;(27.3<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">9&#8201;(32.1<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:12.63pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">1&#8201;(100.0<font style="position:absolute;">)%</font></td>
            <td style="padding:0pt;padding-left:13.13pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:3.5pt;line-height:3.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:5.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:11.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Patient with a sporadic BRCA mutation, i.e. not inherited. CR=complete response, PR=partial response, SD=stable disease, ORR=overall response rate.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">One CR and five PR were observed in BRCA mutation carriers with breast, ovarian and pancreatic cancers. No CR or PR was observed in BRCA negative patients. Treatment durations for three breast/&#8203;ovarian cancer responders in Part&#160;1 are 54, 93 and over 240 weeks and one breast cancer responder in Part&#160;2 over 76 weeks respectively. Treatment durations for the two pancreatic cancer responders, one each in Parts 1 and 2, are 21 and 16 weeks, respectively. Responders included patients who underwent prior treatment with PARP inhibitors and PARP na&#239;ve patients. Stable disease was observed in nine BRCA mutation carriers and one sporadic BRCA positive patient, with treatment durations ranging from 16 to 88 weeks. The overall response rate, or ORR, is 11% (Part&#160;1 ORR 25% and Part&#160;2 7%). The difference in Part&#160;1 and Part&#160;2 ORRs may suggest that the seliciclib dose in the Part&#160;2 schedule may be too low for enhancing the activity of sapacitabine. Dose limiting toxicities were reversible elevations in transaminase and bilirubin, neutropenia or febrile neutropenia and pneumonia. Adverse events were mild to moderate in intensity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pharmacodynamic effects of the seliciclib and sapacitabine combination were observed in skin biopsies. Part&#160;1 biopsies following treatment showed a 2.3-fold increase in DNA damage induced by sapacitabine, as measured by gamma-H2AX immunohistochemistry. Additional DNA damage occurred after treatment with seliciclib with a 0.58-fold further increase in gamma-H2AX staining. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There have been three recent approvals for the treatment of advanced ovarian cancer, including but not limited to BRCA-mutated (germline and/or somatic) associated advanced ovarian cancer, for the poly ADP-ribose polymerase, or PARP, inhibitors, olaparib, niraparib and rucaparib. We believe that sapacitabine, possibly administered alongside a CDK inhibitor, may offer an alternative or complementary approach to PARP inhibitors in this area of unmet medical need. Once mature data become available from a completed extension study of an additional 20 BRCA positive, patients with breast cancer and an ongoing Part&#160;3 evaluating alternative dosing schedules, we will consider further development plans. This will include making a decision to substitute seliciclib with CDK065 and/or evaluating combinations with a PARP inhibitor in patients with BRCA mutations or HR deficient cancers. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Sapacitabine in AML </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">SEAMLESS, randomized Phase&#160;3, pivotal trial of sapacitabine in elderly patients with AML </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On February&#160;23, 2017, we announced that the trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival, or OS, for the experimental arm versus an active control arm. An improved rate of complete remission, or CR, a secondary endpoint, was observed in patients who had discontinued therapy at the time of analysis. Other endpoints and safety were similar between the arms. In the stratified subgroup of patients with low baseline peripheral white blood cell count, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">7</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">comprising approximately two-thirds of the study&#8217;s population, an improvement in OS was observed for the experimental arm. The opposite was true for patients with high white blood cell count. Full results from the SEAMLESS study were presented at the 59<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> American Society of Hematology, or ASH Annual Meeting in December&#160;2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The study is chaired by Hagop M. Kantarjian, M.D., Chairman and Professor, Department of Leukemia, The University of Texas MD Anderson Cancer Center. SEAMLESS is a multicenter, randomized, Phase&#160;3 study of sapacitabine as a front-line treatment in approximately 485 elderly patients aged 70&#160;years or older with newly diagnosed AML who are not candidates for or have refused intensive induction chemotherapy. In SEAMLESS, an investigational arm of oral sapacitabine administered in alternating cycles with intravenous decitabine is compared with a control arm of intravenous decitabine administered alone. The primary efficacy endpoint is overall survival. Stratification factors at randomization were antecedent hematological disorders, baseline peripheral white blood cells and baseline bone marrow blasts. SEAMLESS completed enrollment in December&#160;2014 with approximately 110 centers participating in the United States and Europe. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2014, the study&#8217;s independent Data Safety Monitoring Board, or DSMB, conducted a planned interim analysis for futility after 247 events, or patient deaths, and the final safety review of 470 randomized patients. The DSMB found no safety concerns. However, the planned futility boundary had been crossed and the DSMB determined that, based on available interim data, it would be unlikely for the study to reach statistically significant improvement in survival. The DSMB saw no reasons why patients should discontinue treatment on their assigned arm and recommended that recruited patients stay on treatment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In accordance with the DSMB&#8217;s recommendations, we followed-up patients as per the study protocol until the prespecified 424 events had been observed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stratified and exploratory subgroup analyses have been completed and have defined a patient population who may benefit from treatment with the experimental arm. We plan to discuss the SEAMLESS data with European and US regulatory authorities. We previously submitted, and have received validation of, a Pediatric Investigation Plan, or PIP, to the EMA, or European Medicines Agency. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Randomized Phase&#160;2 clinical trial in older patients with MDS as a second-line treatment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have evaluated sapacitabine in an open-label, multi-center, randomized Phase&#160;2 trial as a second-line treatment in patients aged 60 or older with intermediate-2 or high-risk myelodysplastic syndromes, or MDS, after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine. The study randomized 63 patients with MDS of intermediate-2 (n=52) or high-risk (n=11) classification by the International Prognostic Scoring System, or IPSS, at study entry to receive sapacitabine every 4 weeks in 3 dosing schedules. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">At the 2013 ASH Meeting and Exposition, we announced one-year survival data, the study&#8217;s primary endpoint. The median overall survival for each arm was approximately 9.7&#160;months for Arm G, 9.7&#160;months for Arm H, and 7.6&#160;months for Arm I. The median overall survival for all three arms was approximately 8.6&#160;months. One-year survival was 38% for Arm G, 24% for Arm H, and 33% for Arm I. Nine patients had responded (2 CRs, 2 CRp, and 5 major HIs): 19% for Arm G, 10% for Arm H and 14% for Arm I and the time to response was one to four cycles. Median number of cycles was three with a range of one to over 23 and 30 patients received four or more cycles. Additionally, 23 patients achieved stable disease lasting longer than 16 weeks. The 30 day mortality from all causes was 5% in each of the three arms and ten patients, or approximately 16%, were still alive. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Median overall survival after treatment failure of front-line hypomethylating agents, such as azacitidine and/or decitabine, for patients with intermediate-2 or high-risk disease per IPSS, is reported in the literature to range between 5.9 and 4.3&#160;months. Patients with high-risk IPSS scores also have a high probability of experiencing transformation of their MDS into AML, an aggressive form of blood cancer with typically poor survival.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">8</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Orphan Designation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In 2008, sapacitabine received orphan drug designation for the treatment of both AML and MDS from the EMA, which confers a range of benefits to sponsor companies, including market exclusivity for a period of 10&#160;years following a product&#8217;s approval for either of these indications in Europe. In 2010, the FDA granted orphan drug designation to sapacitabine for the treatment of AML and MDS, which confers a range of benefits to sponsor companies, including market exclusivity for a period of seven&#160;years from the date of drug approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Programs </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Polo-Like-Kinase inhibitor: CYC140 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In our polo-like kinase, or PLK, inhibitor program, we have discovered potent and selective small molecule inhibitors of PLK1, a kinase active during cell division, which target the mitotic phase of the cell cycle. PLK was discovered by Professor David Glover, our Chief Scientist. We received a grant award of approximately $3.5&#160;million from the Biomedical Catalyst of the United Kingdom government to complete IND-directed preclinical development of CYC140, which was completed in November&#160;2016. Without additional funding, we will not be able to progress this program into clinical development. We have retained worldwide rights to commercialize CYC140. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Preclinical data presented at the 2016 28<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> EORTC-NCI-AACR Molecular Targets and Cancer Therapeutics Symposium demonstrated the therapeutic potential of CYC140 as a targeted anti-cancer agent. The data demonstrated that CYC140 is a selective PLK1 inhibitor which preferentially induces growth inhibition and cell death in malignant versus non-malignant cells. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Treatment of proliferating cells with CYC140 resulted in reduced phosphorylation of the PLK1 substrate phospho-nucleophosmin, accumulation of cells in mitosis and an increase in the proportion of mitotic cells with monopolar spindles, which are all features consistent with PLK1 inhibition. In a cell line panel derived from esophageal cancer and various non-malignant solid tissues, CYC140 was preferentially cytotoxic to malignant cells. Its differential cytotoxicity is further increased through pulse treatment. Malignant cells which are sensitive to CYC140 undergo complete growth inhibition and induction of cell death in response to treatment. In contrast, non-malignant cells are only temporarily arrested and normal cell cycle transit is restored. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Potent anti-tumor activity of CYC140 has been demonstrated in preclinical xenograft models of acute leukemia and solid tumors, including esophageal cancer, with tumor growth delay, tumor regression and cures being observed. Identification of several pharmacodynamic markers and demonstration of activity in a majority of malignant cell lines derived from acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and esophageal cancer support prospective clinical development of CYC140, alone and in several potential combinations with targeted agents. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Investigator-Sponsored Trials </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Preclinical results from several independent investigators suggest that cell cycle inhibitors, such as seliciclib and related molecules, arrest the progress of the cell cycle and may have therapeutic benefit in the treatment of patients with autoimmune and inflammatory diseases as well as in diseases characterized by uncontrolled cell proliferation. Published data indicate potential benefit in glomerulonephritis, graft-versus-host disease, idiopathic pulmonary fibrosis, lupus nephritis, polycystic kidney disease and rheumatoid arthritis. Based on these data investigators have approached us to be provided with seliciclib so that they can evaluate it in various indications in clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In this regard, there are ongoing investigator sponsored trials, or ISTs, evaluating oral seliciclib capsules in endocrinologic and inflammatory indications in patients who have failed prior treatments. In an IST at Cedars-Sinai, Los Angeles, supported in part by a grant from The National Institute of Diabetes and Digestive and Kidney Diseases, patients are being treated in an ongoing Phase&#160;2 trial to evaluate seliciclib as a potential therapy for Cushing&#8217;s disease. Cushing&#8217;s disease is characterized by abnormally high levels of cortisol, a stress hormone, associated with pituitary tumors, which are highly sensitive to cell cycle disruptions. In a European IST, oral seliciclib capsules are being evaluated as a potential treatment for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">9</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">rheumatoid arthritis, or RA. Investigators are evaluating whether seliciclib can benefit patients with RA by targeting proliferating fibroblasts. If confirmed, this would be a novel approach compared to approved RA therapies. This study is also being supported by an approximately $1.5&#160;million grant from the United Kingdom&#8217;s Medical Research Council. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration and Licensing Agreement </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On June&#160;29, 2015, Cyclacel entered into a collaboration, licensing and supply agreement with ManRos Therapeutics SA, or ManRos, for the exclusive development and commercialization by ManRos of our oral seliciclib capsules as a treatment for cystic fibrosis, or CF. Among other terms of the agreement, ManRos licensed rights to our proprietary clinical data to enable clinical development of seliciclib for CF indications. The agreement provides that we supply seliciclib investigational product for certain clinical trials in CF and technical assistance related to our know-how with CDK inhibitors to facilitate these trials. We have received upfront payments and may receive milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As with all ISTs and the collaboration and licensing agreement, we do not control the timing or conduct of such studies and will report updates as the investigators may notify us from time to time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Business Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to continue to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates and utilizing our area of historical expertise in cancer cell cycle and mitosis biological mechanisms. Our clinical development strategy is focused on two ongoing programs in transcriptional regulation and DNA damage response. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Focus on the cell cycle and cancer </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our core area of expertise is in cell cycle biology and our scientists include recognized leaders in this field. In addition, our senior management team has extensive experience in research, preclinical and clinical development and sales and marketing. The novel, mechanism-targeted cell cycle drugs we are developing are designed to be highly selective in comparison to conventional chemotherapies, potentially inducing death in cancer cells while sparing most normal cells which may give rise to fewer side-effects. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Thus, we believe that we are well placed to exploit the significant opportunities that this area offers for new drug discovery and development. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Develop anticancer drug candidates in all phases of the cell cycle and multiple compounds for particular cell cycle targets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Targeting a broad development program focused on multiple phases of the cell cycle allows us to minimize risk while maximizing the potential for success, and also to develop products that are complementary to one another. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Enter into partnering arrangements selectively, while developing our own sales and marketing capability </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently retain virtually all marketing rights to the compounds associated with our clinical-stage drug programs. To optimize our commercial return, we intend to enter into selected partnering arrangements and to retain co-promotion rights as appropriate. Historically, we have planned to develop compounds through the Phase&#160;2 proof-of-efficacy stage before seeking a partner. We may enter into partnering arrangements earlier than Phase&#160;2 proof-of-concept trials where appropriate, or in connection with drug programs outside our core competency in oncology. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Licenses </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Several of our programs are based on technology licensed from others. Our breach of an existing license or failure to obtain a license to technology required to develop, test and commercialize our products may seriously harm our business. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">10</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">In-license Agreement with Daiichi Sankyo </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On September&#160;10, 2003, we entered into a license agreement with Daiichi Sankyo Co., Ltd. of Japan or Daiichi Sankyo, with respect to patents and patent applications covering sapacitabine. Daiichi Sankyo filed patent applications claiming sapacitabine, certain crystalline forms and methods for its preparation and use which encompass our chosen commercial development form, as well as related know-how and materials. The license grants us the exclusive right to exploit and sublicense sapacitabine and any other products covered by the patents and patent applications owned by Daiichi Sankyo. The license was originally subject to certain third-party rights related to certain territories but the license has since been expanded to a worldwide territory. The license agreement also grants to us nonexclusive, sublicensed rights to CNDAC, which is both a precursor compound and initial metabolite of sapacitabine. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product. We agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. Under this agreement, $1.6&#160;million was paid in April&#160;2011, and further aggregate milestone payments totaling approximately $10.0&#160;million could be payable subject to achievement of specific contractual milestones and our decision to continue with these projects. The up-front fee and certain past reimbursements have been paid. Royalties are payable in each country for the term of patent protection in the country or for ten&#160;years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by us or our affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If we wish to appoint a third-party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal to develop and/or commercialize in Japan. Effective July&#160;11, 2011, the license was amended to irrevocably waive a termination right Daiichi Sankyo possessed under a provision of the agreement that required the Company to obtain regulatory approval to sell sapacitabine in at least one country by September&#160;2011, and releases the Company from all claims and liability of any kind arising under such provision. The amendment further provides that the royalty fee due from us to Daiichi Sankyo on future net sales of sapacitabine be increased by a&#160;percentage between 1.25% and 1.50%, depending on the level of net sales of sapacitabine realized. In general, however, the license may be terminated by us for technical, scientific, efficacy, safety, or commercial reasons on six&#160;months&#8217; notice, or twelve&#160;months if after a launch of a sapacitabine-based product, or by either party for material default. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Patents and Proprietary Technology </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Patents and Proprietary Rights </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We own 25 patents granted in the United States, 14 granted by the European Patent Office, or EPO, and 59 granted in other countries worldwide. In addition, we have a license to 48 patents granted in the US, by the EPO or worldwide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have 1 patent application pending in the United States, 6 before the EPO, 12 pending patent applications in other countries and one pending PCT application still in the international application phase. No assurances can be given that any patents will be issued with respect to the pending applications, nor that the claims will provide equivalent coverage in all jurisdictions. In addition to the pending patent applications referred to above that we own, there are 3 pending patent applications worldwide to which we have a license. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Intellectual Property Strategy </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We consider intellectual property rights to be vital and use a variety of methods to secure, protect and evaluate these rights. These methods include ownership and enforcement of patent rights, patent applications, license agreements with third parties, invention assignment, confidentiality and non-compete agreements with key employees and consultants, material transfer agreements, and trademark protection. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We give priority to obtaining substance of matter claims in the United States, the EPO, Japan and other important markets if such protection is available. We prefer substance of matter claims because they provide us with rights to the compounds themselves, and not merely a particular use. In addition to </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">11</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">substance of matter claims, we seek coverage for solid state forms, polymorphic and crystalline forms, medical uses, combination therapies, specific regimens, pharmaceutical forms of our compounds and synthetic routes where available and appropriate. Claims covering combination therapies, specific regimens and pharmaceutical forms can be valuable because the therapeutic effect of pharmaceuticals used in the anticancer field is often enhanced when individual therapeutics are used in particular combinations or dosed in a certain way. The availability of protection in these areas can, however, vary from jurisdiction to jurisdiction and combination claims are particularly difficult to obtain for many inventions. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">Since publications in the scientific or patent literature often lag behind actual discoveries, we are not certain of being first to make the inventions covered by each of our pending patent applications or the first to file those patent applications. Generally, patent applications in the United States are maintained in secrecy for a period of 18&#160;months or more, which increases the uncertainty we face. Moreover, the patent positions of biotechnology and pharmaceutical companies are highly uncertain and involve complex legal and factual questions. As a result, we cannot predict the breadth of claims allowed in biotechnology and pharmaceutical patents, or their enforceability. To date, there has been no consistent policy regarding the breadth of claims allowed in biotechnology patents. Third parties or competitors may challenge or circumvent our patents or patent applications, if issued. Because of the extensive time required for development, testing and regulatory review of a potential product, it is possible that before we commercialize any of our products, any related patent may expire, or remain in existence for only a short period following commercialization, thus reducing any advantage of the patent and the commercial opportunity of the product. </div>
        <div style="text-indent:20pt; margin-top:5.82pt; width:456pt; line-height:12pt;">If patents are issued to others containing valid claims that cover our compounds or their manufacture or use or screening assays related thereto, we may be required to obtain licenses to these patents or to develop or obtain alternative technology. We are aware of several published patent applications, and understand that others may exist, that could support claims that, if granted and held valid, would cover various aspects of our developmental programs, including in some cases particular uses of our drug candidates, sapacitabine, seliciclib, CYC065 or other therapeutic candidates, or substances, processes and techniques that we use in the course of our research and development and manufacturing operations. </div>
        <div style="text-indent:20pt; margin-top:5.81pt; width:456pt; line-height:12pt;">In addition, we understand that other applications and patents exist relating to potential uses of sapacitabine, seliciclib and CYC065 that are not part of our current clinical programs for those compounds. Although we intend to continue to monitor the pending applications, it is not possible to predict whether these claims will ultimately be allowed or if they were allowed what their breadth would be. In addition, we may need to commence litigation to enforce any patents issued to us or to determine the scope and validity of third-party proprietary rights. For example, in one case we opposed a European patent relating to human aurora kinase and the patent has been finally revoked (no appeal was filed). Litigation would create substantial costs. We are aware that other patents exist that claim substances, processes and techniques, which, if held valid, could potentially restrict the scope of our research, development or manufacturing operations. If competitors prepare and file patent applications in the United States that claim technology that we also claim, we may have to participate in interference proceedings in the United States Patent and Trademark Office to determine which invention has priority. These proceedings could result in substantial costs, even if the eventual outcome is favorable to us. An adverse outcome in litigation could subject us to significant liabilities to third parties and require us to seek licenses of the disputed rights from third parties or to cease using the technology, even a therapeutic product, if such licenses are unavailable or too expensive. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">CYC065 </div>
        <div style="margin-left:20pt; margin-top:4.81pt; width:436pt; line-height:12pt;">Issued patents for the CYC065 compound cover the United States, EPO and nine other countries. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Sapacitabine </div>
        <div style="text-indent:20pt; margin-top:4.81pt; width:456pt; line-height:12pt;">Issued patents for the sapacitabine compound expired in the United States in 2014 and elsewhere in 2012. Patents for the crystalline forms issued in the United States, EPO, Japan and thirteen other countries, and are pending in one further country. These patents expire in 2022. It may be possible to extend the term of a patent in the United States, Europe or Japan for up to five&#160;years to the extent it covers the sapacitabine compound or its crystalline form upon regulatory approval of that compound in the United States, Europe or Japan. There is no assurance that we will be able to obtain any such extension. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">12</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Separately, we own an issued United States patent with granted claims to a specified method of administration of sapacitabine, adding to the existing composition of matter patents and supporting market exclusivity out to 2030. We also own patents issued in the United States or in Europe which claim methods of use of sapacitabine with hypomethylating agents, including decitabine which has been tested in the SEAMLESS Phase&#160;3 trial, and with other anticancer drugs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Manufacturing </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have no in-house manufacturing capabilities and have no current plans to establish manufacturing facilities for significant clinical or commercial production. We have no direct experience in manufacturing commercial quantities of any of our products, and we currently lack the resources or capability to manufacture any of our products on a clinical or commercial scale. As a result, we are dependent on corporate partners, licensees or other third parties for the manufacturing of clinical and commercial scale quantities of all of our products. We believe that this strategy will enable us to direct operational and financial resources to the development of our product candidates rather than diverting resources to establishing a manufacturing infrastructure. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Government Regulation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA, EMA and comparable regulatory agencies in state and local jurisdictions impose substantial requirements upon the clinical development, manufacture, marketing and distribution of drugs. These agencies and other federal, state and local entities regulate research and development activities and the testing, manufacture, quality control, safety, effectiveness, labeling, storage, record keeping, approval, advertising and promotion of our drug candidates and commercialized drugs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For example, in the United States, the FDA regulates drugs under the Federal Food, Drug and Cosmetic Act and implementing regulations. The process required by the FDA before our drug candidates may be marketed in the United States generally involves the following: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">completion of extensive preclinical laboratory tests, preclinical animal studies and formulation studies, all performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">submission to the FDA of an Investigational New Drug Application, or IND, which must become effective before clinical trials may begin; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">performance of adequate and well-controlled clinical trials to establish the safety and efficacy of the drug candidate for each proposed indication; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">submission of a New Drug Application, or NDA, to the FDA; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">satisfactory completion of an FDA pre-approval inspection of the manufacturing facilities at which the product is produced to assess compliance with current good manufacturing practice requirements, or cGMPs, regulations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">FDA review and approval of the NDA prior to any commercial marketing, sale or shipment of the drug. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This testing and approval process requires substantial time, effort and financial resources, and we cannot be certain that any approvals for our drug candidates will be granted on a timely basis, if at all. Preclinical and other nonclinical tests include laboratory evaluation of product chemistry, formulation and stability, as well as studies to evaluate toxicity in animals. The results of preclinical tests, together with manufacturing information and analytical data, are submitted as part of an IND to the FDA. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA, within the 30-day time period, raises concerns or questions about the adequacy of the preclinical testing or the proposed conduct of the clinical trial, including concerns that human research subjects will be exposed to unreasonable health risks. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. Our submission of an IND, or those of our collaborators, may not result in FDA authorization to commence a clinical trial. A separate submission to an existing IND must also be made for each successive clinical trial conducted during product development. Further, an independent institutional review board, or IRB, for each medical center proposing to conduct the clinical trial must review and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">13</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">approve the plan for any clinical trial before it commences at that site and it must monitor the clinical trial until completed. The FDA or the clinical trial sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects or patients are being exposed to an unacceptable health risk. Clinical testing also must satisfy extensive Good Clinical Practice, or GCP, requirements, including those relating to informed consent. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Clinical Trials </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For purposes of an NDA submission, clinical trials are typically conducted in the following three sequential phases, which may overlap: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase&#160;1</font>:&nbsp;&nbsp;&nbsp;The clinical trials are initially conducted in a limited population to test the drug candidate for safety, dose tolerance, absorption, metabolism, distribution and excretion in healthy humans or, on occasion, in patients, such as cancer patients. Phase&#160;1 clinical trials can be designed to evaluate the impact of the drug candidate in combination with currently approved drugs. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase&#160;2:</font>&nbsp;&nbsp;&nbsp;These clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, to determine the efficacy of the drug candidate for specific targeted indications and to determine dose tolerance and optimal dosage. Multiple Phase&#160;2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trial. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Phase&#160;3:</font>&nbsp;&nbsp;&nbsp;These clinical trials are commonly referred to as pivotal clinical trials. If the Phase&#160;2 clinical trials demonstrate that a dose range of the drug candidate is effective and has an acceptable safety profile, Phase&#160;3 clinical trials are then undertaken in large patient populations to further evaluate dosage, to provide substantial evidence of clinical efficacy and to further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In some cases, the FDA may condition approval of an NDA for a drug candidate on the sponsor&#8217;s agreement to conduct a Phase&#160;4, which includes additional clinical trials to further assess the drug&#8217;s safety and effectiveness after NDA approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">New Drug Application </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The results of drug candidate development, nonclinical testing and clinical trials are submitted to the FDA as part of an NDA. The NDA also must contain extensive manufacturing information. Once the submission has been accepted for filing, by law the FDA has 180&#160;days to review the application and respond to the applicant. The review process is often significantly extended by FDA requests for additional information or clarification. The FDA may refer the NDA to an advisory committee for review, evaluation and recommendation as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations. The FDA may deny approval of an NDA if the applicable regulatory criteria are not satisfied, or it may require additional clinical data or an additional pivotal Phase&#160;3 clinical trial. Even if such data are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data from clinical trials are not always conclusive and the FDA may interpret data differently than we or our collaborators do. Once issued, the FDA may withdraw a drug approval if ongoing regulatory requirements are not met or if safety problems occur after the drug reaches the market. In addition, the FDA may require further testing, including Phase&#160;4 clinical trials, and surveillance programs to monitor the effect of approved drugs which have been commercialized. The FDA has the power to prevent or limit further marketing of a drug based on the results of these post-marketing programs. Drugs may be marketed only for the approved indications or indications and in accordance with the provisions of the approved label. Further, if there are any modifications to a drug, including changes in indications, labeling or manufacturing processes or facilities, we may be required to submit and obtain FDA approval of a new NDA or NDA supplement, which may require us to develop additional data or conduct additional nonclinical studies and clinical trials.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">14</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Fast Track Designation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA&#8217;s fast track program is intended to facilitate the development and to expedite the review of drugs that are intended for the treatment of a serious or life-threatening condition for which there is no effective treatment and which demonstrate the potential to address unmet medical needs for the condition. Under the fast track program, the sponsor of a new drug candidate may request the FDA to designate the drug candidate for a specific indication as a fast track drug concurrent with or after the submission of the IND for the drug candidate. The FDA must determine if the drug candidate qualifies for fast track designation within 60&#160;days of receipt of the sponsor&#8217;s request. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If fast track designation is obtained, the FDA may initiate review of sections of an NDA before the application is complete. This rolling review is available if the applicant provides and the FDA approves a schedule for the submission of the remaining information and the applicant pays applicable user fees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Additionally, the fast track designation may be withdrawn by the FDA if the FDA believes that the designation is no longer supported by data emerging in the clinical trial process. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">In some cases, a drug candidate may also qualify for one or more of the following programs: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Priority Review.</font>&nbsp;&nbsp;&nbsp;Under FDA policies, a drug candidate is eligible for priority review, or review within a six-month time frame from the time a complete NDA is accepted for filing, if the drug candidate provides a significant improvement compared to marketed drugs in the treatment, diagnosis or prevention of a disease. We cannot guarantee that any of our drug candidates will receive a priority review designation, or if a priority designation is received, that review or approval will be faster than conventional FDA procedures, or that the FDA will ultimately grant drug approval. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;"><font style="font-style:italic;">Accelerated Approval.</font>&nbsp;&nbsp;&nbsp;Under the FDA&#8217;s accelerated approval regulations, the FDA is authorized to approve drug candidates that have been studied for their safety and effectiveness in treating serious or life-threatening illnesses, and that provide meaningful therapeutic benefit to patients over existing treatments based upon either a surrogate endpoint that is expected to predict a clinical benefit or on the basis of an effect on a clinical endpoint other than patient survival. In clinical trials, surrogate endpoints are alternative measurements of the symptoms of a disease or condition that are substituted for measurements of observable clinical symptoms. A drug candidate approved on this basis is subject to rigorous post-marketing compliance requirements, including the completion of Phase&#160;4 or post-approval clinical trials to validate the surrogate endpoint or confirm the effect on the clinical endpoint. Failure to conduct required post-approval studies, or to validate a surrogate endpoint or confirm a clinical benefit during post-marketing studies, will allow the FDA to withdraw the drug from the market on an expedited basis. All promotional materials for drug candidates approved under accelerated regulations are subject to prior review by the FDA. In rare instances the FDA may grant accelerated approval of an NDA based on Phase&#160;2 data and require confirmatory Phase&#160;3 studies to be conducted after approval and/or as a condition of maintaining approval. We can give no assurance that any of our drugs will be reviewed under such procedures. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">When appropriate, we and our collaborators, as applicable, may seek fast track designation or accelerated approval for our drug candidates. We cannot predict whether any of our drug candidates will obtain a fast track or accelerated approval designation, or the ultimate impact, if any, of the fast track or the accelerated approval process on the timing or likelihood of FDA approval of any of our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Satisfaction of FDA regulations and requirements or similar requirements of state, local and the EMA typically takes several&#160;years and the actual time required may vary substantially based upon the type, complexity and novelty of the product or disease. Typically, if a drug candidate is intended to treat a chronic disease, as is the case with some of our drug candidates, safety and efficacy data must be gathered over an extended period of time. Government regulation may delay or prevent marketing of drug candidates for a considerable period of time and impose costly procedures upon our activities. The FDA or EMA may not grant approvals for new indications for our drug candidates on a timely basis, if at all. Even if a drug candidate receives regulatory approval, the approval may be significantly limited to specific disease </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">15</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">states, patient populations and dosages. Further, even after regulatory approval is obtained, later discovery of previously unknown problems with a drug may result in restrictions on the drug or even complete withdrawal of the drug from the market. Delays in obtaining, or failures to obtain, regulatory approvals for any of our drug candidates would harm our business. In addition, we cannot predict what adverse governmental regulations may arise from future United States or foreign governmental action. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Special Protocol Assessment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If a Phase&#160;2 clinical trial is the subject of discussion at an end-of-Phase&#160;2 meeting with the FDA, a sponsor may be able to request a Special Protocol Assessment, or SPA, the purpose of which is to reach agreement with the FDA on the design of the Phase&#160;3 clinical trial protocol design and analysis that will form the primary basis of an efficacy claim. If such an agreement is reached, it will be documented and made part of the administrative record, and it will be binding on the FDA and may not be changed unless the sponsor fails to follow the agreed-upon protocol, data supporting the request are found to be false or incomplete, or the FDA determines that a substantial scientific issue essential to determining the safety or effectiveness of the drug was identified after the testing began. Even if an SPA is agreed to, approval of the NDA is not guaranteed because a final determination that an agreed-upon protocol satisfies a specific objective, such as the demonstration of efficacy, or supports an approval decision, will be based on a complete review of all the data in the NDA. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Other regulatory requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any products manufactured or distributed by us or our collaborators pursuant to FDA or EMA approvals are subject to continuing regulation by the FDA or EMA, including record-keeping requirements and reporting of adverse experiences associated with the drug. Drug manufacturers and their subcontractors are required to register their establishments with the FDA or EMA and certain state agencies and are subject to periodic unannounced inspections by the FDA or EMA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP, which impose certain procedural and documentation requirements upon us and our third-party manufacturers. Failure to comply with the statutory and regulatory requirements can subject a manufacturer to possible legal or regulatory action, such as warning letters, suspension of manufacturing, seizure of product, injunctive action or possible civil penalties. We cannot be certain that we or our present or future third-party manufacturers or suppliers will be able to comply with the cGMP regulations and other ongoing FDA or EMA regulatory requirements. If our present or future third-party manufacturers or suppliers are not able to comply with these requirements, the FDA or EMA may halt our clinical trials, require us to recall a product from distribution, or withdraw approval of that product. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA or EMA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities and promotional activities involving the Internet. A company can make only those claims relating to safety and efficacy that are approved by the FDA or EMA. Failure to comply with these requirements can result in adverse publicity, warning letters, corrective advertising and potential civil and criminal penalties. Physicians may prescribe approved drugs for uses that are not described in the drug&#8217;s labeling and that differ from those tested by us and approved by the FDA or EMA. Such off-label uses are common across certain medical specialties. Physicians may believe that such off-label uses are the best treatment for many patients in varied circumstances. The FDA or EMA generally does not regulate the behavior of physicians in their choice of treatments. The FDA or EMA does, however, impose stringent restrictions on manufacturers&#8217; communications regarding off-label use. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Competition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The biotechnology and biopharmaceutical industries are rapidly changing and highly competitive. We are seeking to develop and market drug candidates that will compete with other products and therapies that currently exist or are being developed. Other companies are actively seeking to develop products that have disease targets similar to those we are pursuing. We face competition from many different sources, including commercial, pharmaceutical and biotechnology companies, academic institutions, government agencies and private and public research institutions. Many of our competitors have significantly greater financial, </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">16</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">manufacturing, marketing and drug development resources than we do. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Our commercial opportunity will be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer side effects or are less expensive than any products that we may develop. In addition, competitors compete in the areas of recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies and technology licenses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A large number of drug candidates are in development for the treatment of leukemia and lymphomas, MDS, breast, lung, and nasopharyngeal cancer. Several pharmaceutical and biotechnology companies have nucleoside analogs or other products on the market or in clinical trials which may be competitive to sapacitabine in both hematology and oncology indications. These include AbbVie, AstraZeneca, Onconova, Boehringer Ingelheim, BMS/Innate, Celgene, CTI Biopharma, Daiichi Sankyo, Eisai, Jazz, GlaxoSmithKline,Johnson &amp; Johnson, Lilly, MEI Pharma, Otsuka, Pfizer, Sanofi, Sunesis and Teva. Several pharmaceutical and biotechnology companies have CDK inhibitors in clinical trials including Bayer, Dainippon Sumitomo, G1 Therapeutics, Lilly, Merck, MetaMax, MEI Pharma, Nerviano Medical Sciences/Tiziana Life Sciences, Novartis, Otsuka/Astex, Pfizer, Piramal, and Tragara. Several companies are pursuing discovery and research activities in each of the other areas that are the subject of our research and drug development programs. We believe that Amgen, AstraZeneca, CASI Pharmaceuticals, Nerviano Medical Sciences, Nemucore, Otsuka/Taiho Oncology and Takeda are conducting clinical development of Aurora kinase inhibitors for hemato-oncology indications. We believe that Arbutus Biopharma, Boehringer Ingelheim, GlaxoSmithKline, Merck, Nerviano Medical Sciences/Trovagene and Takeda have commenced clinical trials with PLK1 inhibitor candidates for hemato-oncology indications. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Legal Proceedings </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">From time to time, we may be involved in routine litigation incidental to the conduct of our business. As of December&#160;31, 2017 we were not party to any material legal proceedings. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Employees </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of March 27, 2018, we had 12 full-time employees. Our employees are not represented by any collective bargaining agreements and management considers relations with our employees to be good. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Corporate information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We were incorporated in Delaware in August&#160;1997. Our corporate headquarters are located at 200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, and our telephone number is 908-517-7330. This is also where our medical and regulatory functions are located. Our research facility is located in Dundee, Scotland, which is also the center of our translational work and development programs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Available information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We file reports, proxy statements and other information with the Securities and Exchange Commission, or the SEC. Copies of our reports, proxy statements and other information may be inspected and copied at the public reference facilities maintained by the SEC at SEC Headquarters, Public Reference Room, 100 F Street, N.E., Washington D.C. 20549. The public may obtain information on the operation of the SEC&#8217;s Public Reference Room by calling the SEC at 1-800-SEC-0330. The SEC maintains a website that contains reports, proxy statements and other information regarding Cyclacel. The address of the SEC website is http://www.sec.gov. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We will also provide copies of our current reports on Form 8-K, annual reports on Form 10-K, quarterly reports on Form 10-Q and proxy statements, and all amendments to those reports at no charge through our website at www.cyclacel.com as soon as reasonably practicable after such material is electronically filed with, or furnished to, the SEC. We have not incorporated by reference in this Annual Report on Form 10-K the information on, or accessible through, our website. Copies are also available, without charge, from Cyclacel Pharmaceuticals, Inc., 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">17</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT1A">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;1A.&nbsp;&nbsp;&nbsp;Risk Factors </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">In analyzing our company, you should consider carefully the following risk factors. Factors that could cause or contribute to differences in our actual results include those discussed in the following subsection, as well as those discussed below in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and elsewhere throughout this Annual Report on Form 10-K. Each of the following risk factors, either alone or taken together, could adversely affect our business, operating results and financial condition, as well as adversely affect the value of an investment in our Company. The risks and uncertainties described below are not the only ones we face. Additional risks not currently known to us or other factors not perceived by us to present significant risks to our business at this time also may impair our business operations. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Risks Associated with Development and Commercialization of Our Drug Candidates </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our SEAMLESS Phase&#160;3 study failed to meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control. While we may discuss the data from the SEAMLESS Phase&#160;3 study with regulatory authorities once subgroup analyses are completed over the next few&#160;months, we may be unable to identify a viable path forward for continued development for, or be able to obtain regulatory approval for, or commercialize, this product indication.</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">To date, we have devoted significant research, development and clinical efforts and financial resources toward the development of sapacitabine. On February&#160;23, 2017, we announced top-line results from the pivotal Phase&#160;3 SEAMLESS study in elderly patients aged 70&#160;years or older with newly diagnosed AML, who are not candidates for or have refused intensive induction chemotherapy. The trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control. Our clinical development strategy in oncology will henceforth concentrate on our two ongoing, clinical programs in DNA damage response and transcriptional regulation, which include our area of historical expertise in CDK inhibitors. These programs target biomarker-selected patients, such as those with BRCA mutations or resistance to existing cancer therapies. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An improved rate of complete remission, a secondary endpoint, was observed in patients who had discontinued therapy at the time of analysis. While we plan to discuss the data from the SEAMLESS Phase&#160;3 study with European and U.S. regulatory authorities, we may be unable to salvage any value from the Phase&#160;3 trial and may be unable to identify a viable plan for continued clinical development of this product indication. Even if we are able to design further trials and identify a path forward toward potential regulatory approval, such development will likely require significant financial and personnel resources, and no assurance can be given that additional capital would be available or that such capital would be available at acceptable terms. Our continuing analyses of data from the topline Phase&#160;3 trial may also produce negative or inconclusive results. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical trial designs that were discussed with the FDA and the EMA and in some cases agreed to prior to their commencement may subsequently be considered insufficient for approval at the time of application for regulatory approval. Thus, our Special Protocol Assessment (&#8220;SPA&#8221;) regarding our SEAMLESS trial does not guarantee marketing approval of our sapacitabine oral capsules for the treatment of AML. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On February&#160;23, 2017, we announced top-line results from the pivotal Phase&#160;3 SEAMLESS study in elderly patients aged 70&#160;years or older with newly diagnosed AML, who are not candidates for or have refused intensive induction chemotherapy. The trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control. As the trial did not achieve the primary basis for an efficacy claim, the SPA agreement with the FDA is no longer binding on the FDA. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On September&#160;13, 2010, and as amended on October&#160;11, 2011, we reached agreement with the FDA regarding an SPA on the design of a pivotal Phase&#160;3 clinical trial for our sapacitabine oral capsules as a front-line treatment in elderly patients aged 70&#160;years or older with newly diagnosed AML, who are not candidates for intensive induction chemotherapy, or the SEAMLESS trial. An SPA is an agreement between a sponsor of an NDA and the FDA on the design of the Phase&#160;3 clinical trial protocol design and statistical analysis that will form the primary basis of an efficacy claim. If such an agreement is reached, it will be binding on the FDA unless the sponsor fails to follow the agreed upon protocol, data supporting the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">18</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">request are found to be false or incomplete, or the FDA determines that a substantial scientific issue essential to product efficacy or safety was identified. An SPA, however, neither guarantees approval nor provides any assurance that a marketing application will be approved by the FDA. There are companies that have been granted SPAs but that have ultimately failed to obtain final approval to market their drugs. In January&#160;2011, we opened enrollment in the lead-in portion of the SEAMLESS trial and in October&#160;2011, we opened enrollment in the randomized portion of the trial. We completed enrollment of the SEAMLESS trial in December&#160;2014. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, the FDA or EMA may revise previous guidance or decide to ignore previous guidance at any time during the course of clinical activities or after the completion of clinical trials. The FDA or EMA may raise issues relating to, among other things, safety, study conduct, bias, deviation from the protocol, statistical power, patient completion rates, changes in scientific or medical parameters or internal inconsistencies in the data prior to making its final decision. The FDA may also seek the guidance of an outside advisory committee prior to making its final decision. Even with successful clinical safety and efficacy data, including such data from a clinical trial conducted pursuant to an SPA, we may be required to conduct additional, expensive clinical trials to obtain regulatory approval. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical trials are expensive, time consuming, subject to delay and may be required to continue beyond our available funding and we cannot be certain that we will be able to raise sufficient funds to complete the development and commercialize any of our product candidates currently in clinical development, should they succeed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Clinical trials are expensive, complex, can take many&#160;years to conduct and may have uncertain outcomes. We estimate that clinical trials of our most advanced drug candidates may be required to continue beyond our available funding and may take several more&#160;years to complete. The designs used in some of our trials have not been used widely by other pharmaceutical companies. Failure can occur at any stage of the testing and we may experience numerous unforeseen events during, or as a result of, the clinical trial process that could delay or prevent commercialization of our current or future drug candidates, including, but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">delays in securing clinical investigators or trial sites for our clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">delays in obtaining Institutional Review Board, or IRB, and regulatory approvals to commence a clinical trial; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">slower than anticipated rates of patient recruitment and enrollment, or not reaching the targeted number of patients because of competition for patients from other trials, or if there is limited or no availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payors for the use of agents used in our clinical trials, such as decitabine in SEAMLESS, or other reasons; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">negative or inconclusive results from clinical trials, as demonstrated by our announcement on February&#160;24, 2017 that our SEAMLESS Phase&#160;3 study failed to reach its primary endpoint; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">unforeseen safety issues; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">uncertain dosing issues that may or may not be related to suboptimal pharmacokinetic and pharmacodynamics behaviors; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">approval and introduction of new therapies or changes in standards of practice or regulatory guidance that render our clinical trial endpoints or the targeting of our proposed indications obsolete; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">inability to monitor patients adequately during or after treatment or problems with investigator or patient compliance with the trial protocols; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">inability to replicate in large controlled studies safety and efficacy data obtained from a limited number of patients in uncontrolled trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">inability or unwillingness of medical investigators to follow our clinical protocols; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">unavailability of clinical trial supplies. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">19</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we suffer significant delays, setbacks or negative results in, or termination of, our clinical trials, we may be unable to continue development of our drug candidates or generate revenue and our development costs could increase significantly. Adverse events have been observed in our clinical trials and may force us to stop development of our product candidates or prevent regulatory approval of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Adverse or inconclusive results from our clinical trials may substantially delay, or halt entirely, any further development of our drug candidates. Many companies have failed to demonstrate the safety or effectiveness of drug candidates in later stage clinical trials notwithstanding favorable results in early stage clinical trials. Previously unforeseen and unacceptable side effects could interrupt, delay or halt clinical trials of our drug candidates and could result in the FDA or EMA denying approval of our drug candidates. We will need to demonstrate safety and efficacy for specific indications of use, and monitor safety and compliance with clinical trial protocols and other good clinical practice requirements throughout the development process. To date, long-term safety and efficacy has not been demonstrated in clinical trials for any of our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Toxicity and serious adverse events have been noted in preclinical and clinical trials involving certain of our drug candidates. For example, neutropenia and gastro-intestinal toxicity were observed in patients receiving sapacitabine and elevations of liver enzymes and a decrease in potassium levels has been observed in patients receiving seliciclib. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we have or may pursue clinical trials for CYC065, sapacitabine and seliciclib in more than one indication. There is a risk that unacceptable toxicity or adverse events observed in a trial for one indication could result in the delay or suspension of all trials involving the same drug candidate. Even if we believe that the data collected from clinical trials of our drug candidates are promising with respect to safety and efficacy, such data may not be deemed sufficient by regulatory authorities to warrant product approval. Clinical data can be interpreted in different ways. Regulatory officials could interpret such data in different ways than we do which could delay, limit or prevent regulatory approval. The FDA, EMA or we may suspend or terminate clinical trials at any time. Any failure or significant delay in completing clinical trials for our drug candidates, or in receiving regulatory approval for the commercialization of our drug candidates, may severely harm our business and reputation. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are making use of biomarkers, which are not scientifically validated, and our reliance on biomarker data may thus cause us to direct our resources inefficiently. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are making some use of biomarkers in an effort to facilitate our drug development and to optimize our clinical trials. Biomarkers are proteins or other substances whose presence in the blood can serve as an indicator of specific cell processes. We believe that these biological markers serve a useful purpose in helping us to evaluate whether our drug candidates are having their intended effects through their assumed mechanisms, and that they may thus enable us to identify more promising drug candidates at an early stage and to direct our resources efficiently. We also believe that biomarkers may eventually allow us to improve patient selection in connection with clinical trials and monitor patient compliance with trial protocols. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For most purposes, however, biomarkers have not been scientifically validated. If our understanding and use of biomarkers is inaccurate or flawed, or if our reliance on them is otherwise misplaced, then we will not only fail to realize any benefits from using biomarkers, but may also be led to invest time and financial resources inefficiently in attempting to develop inappropriate drug candidates. Moreover, although the FDA has issued for comment a draft guidance document on the potential use of biomarker data in clinical development, such data are not currently accepted by the FDA or other regulatory agencies in the United States, the European Union or elsewhere in applications for regulatory approval of drug candidates, and there is no guarantee that such data will ever be accepted by the relevant authorities in this connection. Our biomarker data should not be interpreted as evidence of efficacy. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Due to our reliance on contract research organizations and other third parties to conduct clinical trials, we may be unable to directly control the timing, conduct and expense of our clinical trials. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not have the ability to independently conduct clinical trials required to obtain regulatory approvals for our drug candidates. We must rely on third parties, such as contract research organizations, data management companies, contract clinical research associates, medical institutions, clinical investigators and contract laboratories to conduct our clinical trials. In addition, we rely on third parties to assist with </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">20</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">our preclinical development of drug candidates. If these third parties do not successfully carry out their contractual duties or regulatory obligations or meet expected deadlines, if the third parties need to be replaced or if the quality or accuracy of the data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our preclinical development activities or clinical trials may be extended, delayed, suspended or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize our drug candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to enter into and maintain successful strategic alliances for our drug candidates, we may have to reduce or delay our drug candidate development or increase our expenditures. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An important element of our strategy for developing, manufacturing and commercializing our drug candidates is entering into strategic alliances with pharmaceutical companies or other industry participants to advance our programs and enable us to maintain our financial and operational capacity. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We face significant competition in seeking appropriate alliances. We may not be able to negotiate alliances on acceptable terms, if at all. In addition, these alliances may be unsuccessful. If we fail to create and maintain suitable alliances, we may have to limit the size or scope of, or delay, one or more of our drug development or research programs. If we elect to fund drug development or research programs on our own, we will have to increase our expenditures and will need to obtain additional funding, which may be unavailable or available only on unfavorable terms. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">To the extent we are able to enter into collaborative arrangements or strategic alliances, we will be exposed to risks related to those collaborations and alliances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Although we are not currently party to any collaboration arrangement or strategic alliance that is material to our business, in the future, we expect to be dependent upon collaborative arrangements or strategic alliances to complete the development and commercialization of some of our drug candidates, particularly after the Phase&#160;2 stage of clinical testing. These arrangements may place the development of our drug candidates outside our control, may require us to relinquish important rights, or may otherwise be on terms unfavorable to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Dependence on collaborative arrangements or strategic alliances will subject us to a number of risks, including the risks that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may not be able to control the amount and timing of resources that our collaborators may devote to the drug candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our collaborators may experience financial difficulties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">we may be required to relinquish important rights such as marketing and distribution rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">business combinations or significant changes in a collaborator&#8217;s business strategy may also adversely affect a collaborator&#8217;s willingness or ability to complete its obligations under any arrangement; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">a collaborator could independently move forward with a competing drug candidate developed either independently or in collaboration with others, including our competitors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">collaborative arrangements are often terminated or allowed to expire, which would delay development and may increase the cost of developing our drug candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have no manufacturing capacity and will rely on third party manufacturers for the late stage development and commercialization of any drugs we may develop or sell. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not currently operate manufacturing facilities for clinical or commercial production of our drug candidates under development. We currently lack the resources or the capacity to manufacture any of our products on a clinical or commercial scale. We anticipate future reliance on a limited number of third party manufacturers until we are able, or decide to, expand our operations to include manufacturing capacities. If the FDA or EMA approve any of our drug candidates for commercial sale, or if we significantly expand our clinical trials, we will need to manufacture them in larger quantities and will be required to secure additional or alternative third-party suppliers to our current suppliers. To date, our drug candidates have </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">21</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">been manufactured in small quantities for preclinical testing and clinical trials and we may not be able to successfully increase the manufacturing capacity, whether in collaboration with our current or future third-party manufacturers or on our own, for any of our drug candidates in a timely or economic manner, or at all. Significant scale-up of manufacturing may require additional validation studies, which the FDA and EMA must review and approve. If we are unable to successfully increase the manufacturing capacity for a drug candidate, whether for late stage clinical trials or for commercial sale, or are unable to secure alternative third-party suppliers to our current suppliers, the drug development, regulatory approval or commercial launch of any related drugs may be delayed or blocked or there may be a shortage in supply. Even if any third-party manufacturer makes improvements in the manufacturing process for our drug candidates, we may not own, or may have to share, the intellectual property rights to such innovations. Any performance failure on the part of manufacturers could delay late stage clinical development or regulatory approval of our drugs, the commercialization of our drugs or our ability to sell our commercial products, producing additional losses and depriving us of potential product revenues. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">As we evolve from a company primarily involved in discovery and development to one also involved in the commercialization of drugs and devices, we may encounter difficulties in managing our growth and expanding our operations successfully. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In order to execute our business strategy, we will need to expand our development, control and regulatory capabilities and develop financial, manufacturing, marketing and sales capabilities or contract with third parties to provide these capabilities for us. If our operations expand, we expect that we will need to manage additional relationships with various collaborative partners, suppliers and other third parties. Our ability to manage our operations and any growth will require us to make appropriate changes and upgrades, as necessary, to our operational, financial and management controls, reporting systems and procedures wherever we may operate. Any inability to manage growth could delay the execution of our business plan or disrupt our operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our drug candidates are subject to extensive regulation, which can be costly and time-consuming, and we may not obtain approvals for the commercialization of any of our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The clinical development, manufacturing, selling and marketing of our drug candidates are subject to extensive regulation by the FDA and EMA in the United States, the European Union and elsewhere. These regulations also vary in important, meaningful ways from country to country. We are not permitted to market a potential drug in the United States until we receive approval of an NDA from the FDA or an MAA from the EMA. We have not received an NDA or MAA approval from the FDA or EMA for any of our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Obtaining an NDA or MAA approval is expensive and is a complex, lengthy and uncertain process. For example, the FDA approval process for a new drug involves submission of an IND, which must include information about preclinical studies, proposed clinical protocols and manufacturing information. Clinical development under an IND typically involves three phases of study: Phases 1, 2 and 3. The most significant costs associated with clinical development are typically the pivotal late Phase&#160;2 or Phase&#160;3 clinical trials, as they tend to be the longest and largest studies conducted during the drug development process. After completion of clinical trials, an NDA may be submitted to the FDA. In responding to an NDA, the FDA may refuse to file the application, or if accepted for filing, the FDA may request additional information or deny the application if it determines that the application does not provide an adequate basis for approval. If the NDA supports the safety and efficacy of the drug candidate and satisfies other requirements, the FDA may grant marketing approval. Failure to comply with the FDA and other applicable foreign and U.S. regulatory requirements may subject us to administrative or judicially imposed sanctions. These include warning letters, civil and criminal penalties, injunctions, product seizure or detention, product recalls, total or partial suspension of production and refusal to approve either pending NDAs, or supplements to approved NDAs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is substantial time and expense invested in the preparation and submission of an NDA or EMA, and regulatory approval is never guaranteed. Depending on the final data from our SEAMLESS study, we may meet with regulatory authorities in the United States and the European Union to discuss registration submissions for sapacitabine for the AML indication. As the trial did not meet its primary endpoint of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">22</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control, there can be no assurance that data from SEAMLESS will be sufficient to submit registration submissions or that regulatory authorities will accept or approve any such submissions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The FDA and other regulatory authorities in the United States and the EMA for the European Union and elsewhere exercise substantial discretion in the drug approval process. The number, size and design of preclinical studies and clinical trials that will be required for FDA or EMA approval will vary depending on the drug candidate, the disease or condition for which the drug candidate is intended to be used and the regulations and guidance documents applicable to any particular drug candidate. The FDA or EMA can delay, limit or deny approval of a drug candidate for many reasons, including, but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">those discussed in the risk factor which immediately follows; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the fact that FDA or EMA officials may find that our or our third party manufacturer&#8217;s processes or facilities are not in compliance with cGMP; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the fact that new regulations may be enacted by the FDA or EMA pursuant to which they may change their approval policies or adopt new regulations requiring new or different evidence of safety and efficacy for the intended use of a drug candidate. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our applications for regulatory approval could be delayed or denied due to problems with studies conducted before we in-licensed the rights to some of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We currently license some of the compounds and drug candidates used in our research programs from third parties. These include sapacitabine, which was licensed from Daiichi Sankyo. Our present research involving these compounds relies upon previous research conducted by third parties over whom we had no control and before we in-licensed the drug candidates. In order to receive regulatory approval of a drug candidate, we must present all relevant data and information obtained during our research and development, including research conducted prior to our licensure of the drug candidate. Although we are not currently aware of any such problems, any problems that emerge with preclinical research and testing conducted prior to our in-licensing may affect future results or our ability to document prior research and to conduct clinical trials, which could delay, limit or prevent regulatory approval for our drug candidates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if our product candidates receive regulatory approval, we may still face future development and regulatory difficulties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our product candidates, if approved, will also be subject to ongoing regulatory requirements for labeling, packaging, storage, advertising, promotion, record-keeping and submission of safety and other post-market information. In addition, approved products, manufacturers and manufacturers&#8217; facilities are required to comply with extensive FDA and EMA regulatory requirements and requirements of other similar agencies, including ensuring that quality control and manufacturing procedures conform to the FDA&#8217;s or EMA&#8217;s cGMP. As such, we and our contract manufacturers are subject to continual review and periodic inspections to assess compliance with cGMP. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. We will also be required to report certain adverse reactions and production problems, if any, to the FDA and EMA and to comply with certain requirements concerning advertising and promotion for our products. Promotional communications with respect to prescription drugs are subject to a variety of legal and regulatory restrictions and must be consistent with the information in the product&#8217;s approved label. Accordingly, we may not promote our approved products, if any, for indications or uses for which they are not approved. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we or a regulatory agency discovers previously unknown problems with a product, such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, or if a regulatory agency disagrees with the promotion, marketing or labeling of a product, it may impose restrictions on that product or us, including requiring withdrawal of the product from the market. If our product candidates fail to comply with applicable regulatory requirements, the FDA and EMA may: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">issue warning letters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">23</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">mandate modifications to promotional materials or require us to provide corrective information to healthcare practitioners; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">require us or our collaborators to enter into a consent decree or permanent injunction, which can include the imposition of various fines, reimbursements for inspection costs, required due dates for specific actions and penalties for noncompliance; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">impose other administrative or judicial civil or criminal penalties; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">withdraw regulatory approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">refuse to approve pending applications or supplements to approved applications filed by us or our potential future collaborators; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">impose restrictions on operations, including costly new manufacturing requirements; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">seize or detain products. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Even if we successfully complete the clinical trials for one or more of our product candidates, the product candidates may fail for other reasons. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even if we successfully complete the clinical trials for one or more of our product candidates, the product candidates may fail for other reasons, including, without limitation, the possibilities that the product candidates will: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fail to receive the regulatory approvals required to market them as drugs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be subject to proprietary rights held by others requiring the negotiation of a license agreement prior to marketing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be difficult or expensive to manufacture on a commercial scale; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">have adverse side effects that make their use less desirable; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fail to compete effectively with product candidates or other treatments commercialized by our competitors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are unable to receive the required regulatory approvals, secure our intellectual property rights, minimize the incidence of any adverse side effects or fail to compete with our competitors&#8217; products, our business, financial condition, and results of operations could be materially and adversely affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face intense competition and our competitors may develop drugs that are less expensive, safer, or more effective than our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A large number of drug candidates are in development for the treatment of leukemia, lung cancer, lymphomas and nasopharyngeal cancer. Several pharmaceutical and biotechnology companies have nucleoside analogs or other products on the market or in clinical trials which may be competitive to sapacitabine in both hematological and oncology indications. Our competitors, either alone or together with collaborators, may have substantially greater financial resources and research and development staff. Our competitors may also have more experience: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">developing drug candidates; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">conducting preclinical and clinical trials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">obtaining regulatory approvals; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">commercializing product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our competitors may succeed in obtaining patent protection and regulatory approval and may market drugs before we do. If our competitors market drugs that are less expensive, safer, more effective or more convenient to administer than our potential drugs, or that reach the market sooner than our potential drugs, we may not achieve commercial success. Scientific, clinical or technical developments by our </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">24</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">competitors may render our drug candidates obsolete or noncompetitive. We anticipate that we will face increased competition in the future as new companies enter the markets and as scientific developments progress. If our drug candidates obtain regulatory approvals, but do not compete effectively in the marketplace, our business will suffer. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The commercial success of our drug candidates depends upon their market acceptance among physicians, patients, healthcare providers and payors and the medical community. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our drug candidates are approved, or are approved by the FDA or EMA, together with another agent such as decitabine, the resulting drugs, if any, must still gain market acceptance among physicians, healthcare providers and payors, patients and the medical community. The degree of market acceptance of any of our approved drugs will depend on a variety of factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">timing of market introduction, number and clinical profile of competitive drugs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">our ability to provide acceptable evidence of safety and efficacy; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">relative convenience and ease of administration; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">pricing and cost-effectiveness, which may be subject to regulatory control; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">availability of coverage, reimbursement and adequate payment from health maintenance organizations and other third party payors; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">prevalence and severity of adverse side effects; and other potential advantages over alternative treatment methods. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any product candidate that we develop does not provide a treatment regimen that is at least as beneficial as the current standard of care or otherwise does not provide some additional patient benefit over the current standard of care, that product will not achieve market acceptance and we will not generate sufficient revenues to achieve profitability. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If our drug candidates or distribution partners&#8217; products fail to achieve market acceptance, we may not be able to generate significant revenue and our business would suffer. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Reimbursement decisions by third-party payors may have an adverse effect on pricing and market acceptance. If there is not sufficient reimbursement for our products, it is less likely that they will be widely used. Market acceptance and sales of our product candidates that we develop, if approved, will depend on reimbursement policies, and may be affected by future healthcare reform measures. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which drugs they will cover and establish payment levels. We cannot be certain that reimbursement will be available for our product candidates that we develop. Also, we cannot be certain that reimbursement policies will not reduce the demand for, or the price paid for, our products. If reimbursement is not available or is available on a limited basis, we may not be able to successfully commercialize any of our product candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our business may be affected by the efforts of government and third-party payors to contain or reduce the cost of healthcare through various means. For example, the Patient Protection and Affordable Care Act and the Health Care and Education Affordability Reconciliation Act of 2010, referred to jointly as ACA, enacted in March&#160;2010, substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the pharmaceutical industry. With regard to pharmaceutical products, the ACA may have the effect of expanding and increasing industry rebates for drugs covered under Medicaid programs and make changes to the coverage requirements under the Medicare Part&#160;D program. Additionally, since the 2016 federal elections, which resulted in the election of President Trump, the Republican presidential nominee, and Republican majorities in both houses of Congress, there have been judicial and Congressional challenges to certain aspects of the ACA. Both Congress and President Trump have expressed their intention to repeal or repeal and replace the ACA, and as a result, certain sections of the ACA have not been fully implemented or were effectively repealed. The uncertainty around the future of the ACA, and in particular the impact on reimbursement levels and the number of insured individuals, may lead to uncertainty or delay in the purchasing decisions of our customers, which may in </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">25</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">turn negatively impact our product sales. If there are not adequate reimbursement levels, our business and results of operations could be adversely affected. We cannot predict what further reform proposals, if any, will be adopted, when they may be adopted, or what impact they may have on our business, including whether it will impact the appetite of investors to make investments in companies like ours. Regardless of whether or not ACA is overturned or repealed, we expect both government and private health plans to continue to require healthcare providers, including healthcare providers that may one day purchase our products, to contain costs and demonstrate the value of the therapies they provide. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The United States and several other jurisdictions are considering, or have already enacted, a number of legislative and regulatory proposals to change the healthcare system in ways that could affect our ability to sell our products profitably. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access to healthcare. In the United States, the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. We expect to experience pricing pressures in connection with the sale of products that we develop, due to the trend toward cost containment and additional legislative proposals. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On December&#160;22, 2017, President Trump signed into law the &#8220;Tax Cuts and Jobs Act,&#8221; or TCJA, that significantly reforms the Internal Revenue Code of 1986, as amended, or the Code. The TCJA, among other things, includes changes to U.S. federal tax rates, imposes significant additional limitations on the deductibility of interest and net operating loss carryforwards, allows for the expensing of capital expenditures, and puts into effect the migration from a &#8220;worldwide&#8221; system of taxation to a territorial system. Our net deferred tax assets and liabilities have been revalued at December&#160;31, 2017 using the newly enacted U.S. corporate rate. This reduced our net deferred tax asset by $4.1&#160;million, which was offset by a corresponding decrease in the valuation allowance. We continue to examine the impact this tax reform legislation may have on our business. The impact of this tax reform is uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to such legislation and the potential tax consequences of investing in our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we are unable to compete successfully in our market place, it will harm our business. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There are existing products in the marketplace that compete with our products. Companies may develop new products that compete with our products. Certain of these competitors and potential competitors have longer operating histories, substantially greater product development capabilities and financial, scientific, marketing and sales resources. Competitors and potential competitors may also develop products that are safer, more effective or have other potential advantages compared to our products. In addition, research, development and commercialization efforts by others could render our products obsolete or non-competitive. Certain of our competitors and potential competitors have broader product offerings and extensive customer bases, allowing them to adopt aggressive pricing policies that would enable them to gain market share. Competitive pressures could result in price reductions, reduced margins and loss of market share. We could encounter potential customers that, due to existing relationships with our competitors, are committed to products offered by those competitors. As a result, those potential customers may not consider purchasing our products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The failure to attract and retain skilled personnel and key relationships could impair our drug development and commercialization efforts. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are highly dependent on our senior management and key clinical development, scientific and technical personnel. Competition for these types of personnel is intense. The loss of the services of any member of our senior management, clinical development, scientific or technical staff may significantly delay or prevent the achievement of drug development and other business objectives and could have a material adverse effect on our business, operating results and financial condition. We also rely on consultants and advisors to assist us in formulating our strategy. All of our consultants and advisors are either self-employed or employed by other organizations, and they may have conflicts of interest or other commitments, such as consulting or advisory contracts with other organizations, that may affect their </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">26</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">ability to contribute to us. We intend to expand and develop new drug candidates. We will need to hire additional employees in order to continue our clinical trials and market our drug candidates. This strategy will require us to recruit additional executive management and clinical development, scientific, technical and sales and marketing personnel. There is currently intense competition for skilled executives and employees with relevant clinical development, scientific, technical and sales and marketing expertise, and this competition is likely to continue. The inability to attract and retain sufficient clinical development, scientific, technical and managerial personnel could limit or delay our product development efforts, which would adversely affect the development of our drug candidates and commercialization of our potential drugs and growth of our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be exposed to product liability claims that may damage our reputation and we may not be able to obtain adequate insurance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because we conduct clinical trials in humans, we face the risk that the use of our drug candidates will result in adverse effects. We believe that we have obtained reasonably adequate product liability insurance coverage for our trials. We cannot predict, however, the possible harm or side effects that may result from our clinical trials. Such claims may damage our reputation and we may not have sufficient resources to pay for any liabilities resulting from a claim excluded from, or beyond the limit of, our insurance coverage or if the amount of the insurance coverage is insufficient to meet any liabilities resulting from any claims. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may also be exposed to additional risks of product liability claims. These risks exist even with respect to drugs that are approved for commercial sale by the FDA or other regulatory authorities in the United States, the European Union or elsewhere and manufactured in facilities licensed and regulated by the FDA, EMA or other such regulatory authorities. We have secured limited product liability insurance coverage, but may not be able to maintain such insurance on acceptable terms with adequate coverage, or at a reasonable cost. There is also a risk that third parties that we have agreed to indemnify could incur liability. Even if we were ultimately successful in product liability litigation, the litigation would consume substantial amounts of our financial and managerial resources and may exceed insurance coverage creating adverse publicity, all of which would impair our ability to generate sales of the litigated product as well as our other potential drugs. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be required to defend lawsuits or pay damages in connection with the alleged or actual violation of healthcare statutes such as fraud and abuse laws, and our corporate compliance programs can never guarantee that we are in compliance with all relevant laws and regulations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our commercialization efforts in the United States and elsewhere are subject to various federal and state laws pertaining to promotion and healthcare fraud and abuse, including federal and state anti-kickback, fraud and false claims laws. Anti-kickback laws make it illegal for a manufacturer to offer or pay any remuneration in exchange for, or to induce, the referral of business, including the purchase of a product. The federal government has published many regulations relating to the anti-kickback statutes, including numerous safe harbors or exemptions for certain arrangements. False claims laws prohibit anyone from knowingly and willingly presenting, or causing to be presented for payment to third-party payers including Medicare and Medicaid, claims for reimbursed products or services that are false or fraudulent, claims for items or services not provided as claimed, or claims for medically unnecessary items or services. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our activities relating to the sale and marketing of our products will be subject to scrutiny under these laws and regulations. It may be difficult to determine whether or not our activities comply with these complex legal requirements. Violations are punishable by significant criminal and/or civil fines and other penalties, as well as the possibility of exclusion of the product from coverage under governmental healthcare programs, including Medicare and Medicaid. If the government were to investigate or make allegations against us or any of our employees, or sanction or convict us or any of our employees, for violations of any of these legal requirements, this could have a material adverse effect on our business, including our stock price. Our activities could be subject to challenge for many reasons, including the broad scope and complexity of these laws and regulations, the difficulties in interpreting and applying these legal requirements, and the high degree of prosecutorial resources and attention being devoted to the biopharmaceutical industry and health care fraud by law enforcement authorities. During the last few&#160;years, numerous biopharmaceutical companies have paid multi-million dollar fines and entered into burdensome </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">27</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">settlement agreements for alleged violation of these requirements, and other companies are under active investigation. Although we have developed and implemented corporate and field compliance programs as part of our commercialization efforts, we cannot assure you that we or our employees, directors or agents were, are or will be in compliance with all laws and regulations or that we will not come under investigation, allegation or sanction. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, we may be required to prepare and report product pricing-related information to federal and state governmental authorities, such as the Department of Veterans Affairs and under the Medicaid program. The calculations used to generate the pricing-related information are complex and require the exercise of judgment. If we fail to accurately and timely report product pricing-related information or to comply with any of these or any other laws or regulations, various negative consequences could result, including criminal and/or civil prosecution, substantial criminal and/or civil penalties, exclusion of the approved product from coverage under governmental healthcare programs including Medicare and Medicaid, costly litigation and restatement of our financial statements. In addition, our efforts to comply with this wide range of laws and regulations are, and will continue to be, time-consuming and expensive. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If a supplier upon whom we rely fails to produce on a timely basis the finished goods in the volumes that we require or fails to meet quality standards and maintain necessary licensure from regulatory authorities, we may be unable to meet demand for our products, potentially resulting in lost revenues. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If any third-party manufacturer service providers do not meet our or our licensor&#8217;s requirements for quality, quantity or timeliness, or do not achieve and maintain compliance with all applicable regulations, demand for our products or our ability to continue supplying such products could substantially decline. As the third-party manufacturers are the sole supplier of the products, any delays may impact our sales. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In all the countries where we may sell our products, governmental regulations exist to define standards for manufacturing, packaging, labeling and storing. All of our suppliers of raw materials and contract manufacturers must comply with these regulations. Failure to do so could result in supply interruptions. In the United States, the FDA requires that all suppliers of pharmaceutical bulk material and all manufacturers of pharmaceuticals for sale in or from the United States achieve and maintain compliance with the FDA&#8217;s cGMPs. Similar requirements exist in the European Union through the EMA. Failure of our third-party manufacturers to comply with applicable regulations could result in sanctions being imposed on them or us, including fines, injunctions, civil penalties, disgorgement, suspension or withdrawal of approvals, license revocation, seizures or recalls of products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. In addition, before any product batch produced by our manufacturers can be shipped, it must conform to release specifications for the content of the pharmaceutical product. If the operations of one or more of our manufacturers were to become unavailable for any reason, any required FDA or EMA review and approval of the operations of an alternative supplier could cause a delay in the manufacture of our products. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The commercialization of our products will be substantially dependent on our ability to develop effective sales and marketing capabilities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">One of our primary strategies for product candidates under development is to develop compounds through the Phase&#160;2 stage of clinical testing and market or co-promote certain of our drugs. We currently have no sales, marketing or distribution capabilities. We will depend primarily on strategic alliances with third parties, which have established distribution systems and sales forces, to commercialize our drugs. To the extent that we are unsuccessful in commercializing any drugs ourselves or through a strategic alliance, product revenues may suffer, we may incur significant additional losses, and our share price would be negatively affected. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition to FDA restrictions on marketing of pharmaceutical products, several other types of state and federal healthcare laws, commonly referred to as &#8220;fraud and abuse&#8221; laws, have been applied in recent&#160;years to restrict certain marketing practices in the pharmaceutical industry. Other jurisdictions, such </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">28</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">as Europe, have similar laws. These laws include false claims and anti-kickback statutes. If we market our products and our products are paid for by governmental programs, it is possible that some of our business activities could be subject to challenge under one or more of these laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Federal false claims laws prohibit any person from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making, or causing to be made, a false statement to get a false claim paid. The federal healthcare program anti-kickback statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item or service covered by Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted to apply to arrangements between pharmaceutical manufacturers, on the one hand, and prescribers, purchasers or formulary managers, on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Most states also have statutes or regulations similar to the federal anti-kickback law and federal false claims laws, which apply to items and services covered by Medicaid and other state programs, or, in several states, apply regardless of the payor. Administrative, civil and criminal sanctions may be imposed under these federal and state laws. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Over the past few&#160;years, a number of pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of promotional and marketing activities, such as: providing free trips, free goods, sham consulting fees and grants and other monetary benefits to prescribers; reporting inflated average wholesale prices that were then used by federal programs to set reimbursement rates; engaging in off-label promotion; and submitting inflated best price information to the Medicaid Rebate Program to reduce liability for Medicaid rebates. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We face potential product liability exposure, and if successful claims are brought against us, we may incur substantial liability for a product candidate and may have to limit its commercialization. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The use of our product candidates in clinical trials and the sale of any products for which we may obtain marketing approval expose us to the risk of product liability claims. Product liability claims may be brought against us or our collaborators by participants enrolled in our clinical trials, patients, health care providers or others using, administering or selling our products. If we cannot successfully defend ourselves against any such claims, we would incur substantial liabilities. Regardless of merit or eventual outcome, product liability claims may result in: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">withdrawal of clinical trial participants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">termination of clinical trial sites or entire trial programs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">costs of related litigation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.79pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.79pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">substantial monetary awards to patients or other claimants; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.8pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.8pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">decreased demand for our product candidates and loss of revenues; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">impairment of our business reputation; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">diversion of management and scientific resources from our business operations; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the inability to commercialize our product candidates. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have obtained limited product liability insurance coverage for our clinical trials in the United States and in selected other jurisdictions where we are conducting clinical trials. Our primary product liability insurance coverage for clinical trials in the United States is currently limited to an aggregate of&#8201; $5.0&#160;million and outside of the United States, we have coverage for lesser amounts that vary by country. As such, our insurance coverage may not reimburse us or may not be sufficient to reimburse us for any expenses or losses we may suffer. Moreover, insurance coverage is becoming increasingly expensive, and, in the future, we may not be able to maintain insurance coverage at a reasonable cost or in sufficient amounts to protect us against losses due to product liability. We intend to expand our insurance coverage for products to include </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">29</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the sale of commercial products if we obtain marketing approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products approved for marketing. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash resources and adversely affect our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Defending against claims relating to improper handling, storage or disposal of hazardous chemical, radioactive or biological materials could be time consuming and expensive. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our research and development involves the controlled use of hazardous materials, including chemicals, radioactive and biological materials such as chemical solvents, phosphorus and bacteria. Our operations produce hazardous waste products. We cannot eliminate the risk of accidental contamination or discharge and any resultant injury from those materials. Various laws and regulations govern the use, manufacture, storage, handling and disposal of hazardous materials. We may be sued for any injury or contamination that results from our use or the use by third parties of these materials. Compliance with environmental laws and regulations may be expensive, and current or future environmental regulations may impair our research, development and production efforts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our business and operations would suffer in the event of system failures. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Despite the implementation of security measures, our internal computer systems, and those of our CROs and other third parties on which we rely, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our drug development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development of our product candidates could be delayed. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Our Business and Financial Condition </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our ability to raise additional capital in the future may not be available to us on reasonable terms, if at all, when or as we require additional funding. If we issue additional shares of our common stock or other securities that may be convertible into, or exercisable or exchangeable for, our common stock, our existing stockholders would experience further dilution. If we fail to obtain additional funding, we may be unable to complete the development and commercialization of our lead drug candidate, sapacitabine, or continue to fund our research and development programs. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have funded all of our operations and capital expenditures with proceeds from the issuance of public equity securities, private placements of our securities, interest on investments, licensing revenue, government grants, research and development tax credits and product revenue. In order to conduct the lengthy and expensive research, preclinical testing and clinical trials necessary to complete the development and marketing of our drug candidates, we will require substantial additional funds. We may have insufficient public equity available for issue to raise the required additional substantial funds to implement our operating plan and we may not be able to obtain the appropriate stockholder approvals necessary to increase our available public equity for issuance within a time that we may require additional funding. Based on our current operating plan, we expect our existing resources to be sufficient to fund our planned operations through at least the end of 2019, although our estimates may prove to be incorrect and we could spend our available financial resources faster than we currently expect. To meet our long-term financing requirements, we may raise funds through public or private equity offerings, debt financings or strategic alliances. Raising additional funds by issuing equity or convertible debt securities may cause our stockholders to experience substantial dilution in their ownership interests and new investors may have rights superior to the rights of our other stockholders. Raising additional funds through debt financing, if available, may involve covenants that restrict our business activities and options. To the extent that we raise </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">30</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">additional funds through collaborations and licensing arrangements, we may have to relinquish valuable rights to our drug discovery and other technologies, research programs or drug candidates, or grant licenses on terms that may not be favorable to us. Additional funding may not be available to us on favorable terms, or at all, particularly in light of the current economic conditions. If we are unable to obtain additional funds, we may be forced to delay or terminate our current clinical trials and the development and marketing of our drug candidates including sapacitabine. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As widely reported, global credit and financial markets have experienced extreme disruptions in the past several&#160;years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not continue to occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current financial markets deteriorate, or do not improve, it may make any necessary financing more difficult, more costly, and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development or other operating or strategic plans for our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">A recent vote by the United Kingdom electorate in favor of a referendum for its exit from the European Union could adversely impact our business, results of operations and financial condition. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The announcement in June&#160;2016 of the referendum of the United Kingdom&#8217;s Membership of the European Union, or Brexit, advising for the exit of the United Kingdom from the European Union, expected to occur by March&#160;2019, could cause disruptions to and create uncertainty surrounding our business, including affecting our relationships with our future customers, suppliers and employees, which could have an adverse effect on our business, financial results and operations. The referendum is non-binding; however, if passed into law, negotiations would commence to determine the future terms of the United Kingdom&#8217;s relationship with the European Union, including the terms of trade between the United Kingdom and the European Union. The effects of Brexit will depend on any agreements the United&#160;Kingdom makes to retain access to European Union markets either during a transitional period or more permanently. The measures could potentially disrupt the markets and tax jurisdictions in which we operate, including our wholly owned subsidiary Cyclacel Limited, which was organized under the laws of England and Wales, and our research facility in Dundee, Scotland, which is also the center of our translational work and development programs, and adversely change tax benefits or liabilities in these or other jurisdictions, and may cause us to lose potential customers, suppliers, and employees. In addition, Brexit could lead to legal uncertainty and potentially divergent national laws and regulations as the United Kingdom determines which European Union laws to replace or replicate. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The announcement of Brexit caused significant volatility in global stock markets and currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against foreign currencies in which we conduct business. The strengthening of the U.S. dollar relative to other currencies may adversely affect our results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The implementation of Brexit may also create global economic uncertainty, which may cause partners, suppliers and potential customers to closely monitor their costs and reduce their spending budget. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since Scottish voters were overwhelming in favor of the United Kingdom remaining in the European&#160;Union, Scotland may in the future seek independence from the United Kingdom, as it unsuccessfully sought to do by referendum in September&#160;2014. Any such efforts by Scotland to separate from the United Kingdom, even if unsuccessful, could lead to uncertainty and further disrupt the markets&#160;and tax jurisdictions in which we operate, and may cause us to lose potential customers, suppliers, and employees. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any of these effects of Brexit, among others, could materially adversely affect our business, business opportunities, results of operations, financial condition and cash flows. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">31</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are at an early stage of development as a company and we do not have, and may never have, any products that generate significant revenues. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are at an early stage of development as a company and have a limited operating history on which to evaluate our business and prospects. While we earned modest product revenues from the ALIGN business prior to terminating such operations effective September&#160;30, 2012, we have not generated any product revenues from our product candidates currently in development. We cannot guarantee that any of our product candidates currently in development will ever become marketable products. We must demonstrate that our drug candidates satisfy rigorous standards of safety and efficacy for their intended uses before the FDA, EMA and other regulatory authorities in the United States, the European Union and elsewhere. Significant additional research, preclinical testing and clinical testing is required before we can file applications with the FDA or EMA for approval of our drug candidates. In addition, to compete effectively, our drugs must be easy to administer, cost-effective and economical to manufacture on a commercial scale. We may not achieve any of these objectives. As our Phase&#160;3 study for AML did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control our clinical development programs are now all at an early stage of testing in Phase&#160;1/2. CYC065 is in a first-in-human Phase&#160;1 study and a combination of sapacitabine and seliciclib, is currently in a Phase&#160;1/2 clinical trial. We cannot be certain that the clinical development of these or any other drug candidates in preclinical testing or clinical development will be successful, that we will receive the regulatory approvals required to commercialize them or that any of our other research and drug discovery programs will yield a drug candidate suitable for investigation through clinical trials. Our commercial revenues from our product candidates currently in development, if any, will be derived from sales of drugs that will not become marketable for several&#160;years, if at all. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We have a history of operating losses and we may never become profitable. Our stock is a highly speculative investment. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have incurred operating losses in each year since beginning operations in 1996 due to costs incurred in connection with our research and development activities and selling, general and administrative costs associated with our operations, and we may never achieve profitability. As of December&#160;31, 2016 and December&#160;31, 2017, our accumulated deficit was $335.0&#160;million and $342.5&#160;million, respectively. Our net loss was $11.8&#160;million and $7.5&#160;million for the&#160;years ended December&#160;31, 2016 and 2017, respectively. In addition to the SEAMLESS study, which we announced on February&#160;23, 2017 announced failed to reach its primary endpoint, our drug candidates are in the early- to mid-stages of clinical testing and we must conduct significant additional clinical trials before we can seek the regulatory approvals necessary to begin commercial sales of our drugs. We expect to incur continued losses for several&#160;years as we continue our research and development of our drug candidates, seek regulatory approvals and commercialize any approved drugs. If our drug candidates are unsuccessful in clinical trials or we are unable to obtain regulatory approvals, or if our drugs are unsuccessful in the market, we will not be profitable. If we fail to become and remain profitable, or if we are unable to fund our continuing losses, particularly in light of the current economic conditions, you could lose all or part of your investment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to comply with the continued listing requirements of the NASDAQ Capital Market, our common stock may be delisted and the price of our common stock and our ability to access the capital markets could be negatively impacted. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is currently listed for trading on the NASDAQ Capital Market. We must satisfy NASDAQ&#8217;s continued listing requirements, including, among other things, a minimum stockholders&#8217; equity of&#8201;$2.5&#160;million and a minimum bid price for our common stock of&#8201;$1.00 per share, or risk delisting, which would have a material adverse effect on our business. A delisting of our common stock from the NASDAQ Capital Market could materially reduce the liquidity of our common stock and result in a corresponding material reduction in the price of our common stock. In addition, delisting could harm our ability to raise capital through alternative financing sources on terms acceptable to us, or at all, and may result in the potential loss of confidence by investors, suppliers, customers and employees and fewer business development opportunities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On February&#160;2, 2016, the Company received a letter from the Listing Qualifications Staff&#8201;(the &#8220;Staff&#8221;) of The NASDAQ Stock Market LLC indicating that the Company had not regained compliance with the </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">32</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">$1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market, as set forth in NASDAQ Listing Rule&#160;5450(a)(1), by the end of the previously granted compliance period that expired on February&#160;2, 2016. As a result, the Staff indicated that the Company would be subject to delisting unless it timely requested a hearing before a NASDAQ Listing Qualifications Panel (the &#8220;Panel&#8221;). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company had a hearing before the Panel on March&#160;31, 2016, at which it presented its plan to regain compliance with the minimum bid price requirement, and requested a further extension of time to do so. On April&#160;4, 2016, the Company received a written ruling from the Panel stating that the Panel had granted the Company&#8217;s request to remain listed on The NASDAQ Capital Market. At the 2016 Annual Meeting of Stockholders, which was held on May&#160;26, 2016, holders of the Company&#8217;s common stock approved a proposed amendment to the Company&#8217;s amended and restated certificate of incorporation, by way of a certificate of amendment, to effectuate a reverse stock split at a ratio of up to and including one-for-twenty. Pursuant thereto, the Board determined to use a ratio of one-for-twelve, and the reverse stock split became effective at 5:00&#160;p.m., Eastern Time, on May&#160;27, 2016, with the Company&#8217;s common stock trading on the NASDAQ Capital Market on a post-split basis at the open of business on May&#160;31, 2016. On June&#160;15, 2016, we received notification from the Staff that we have regained compliance with the minimum bid price rule for continued listing on The NASDAQ Capital Market. The notification stated that as of June&#160;14, 2016, we have evidenced a closing per share bid price of our common stock in excess of the $1.00 minimum closing bid price requirement for at least ten consecutive trading days. Accordingly, we have regained compliance with NASDAQ Listing Rule&#160;5550(a)(2) and will continue to trade on The NASDAQ Capital Market. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Notwithstanding the reverse stock split and our compliance with The NASDAQ Capital market requirements, we cannot be sure that our share price will comply with the requirements for continued listing of our common stock on The NASDAQ Capital Market in the future, or that we will comply with the other continued listing requirements. If our shares of Common Stock lose their status on the NASDAQ Capital Market, we believe that our shares of Common Stock would likely be eligible to be quoted on the inter-dealer electronic quotation and trading system operated by Pink OTC Markets Inc., commonly referred to as the Pink Sheets and now known as the OTCQB market. Our shares of Common Stock may also be quoted on the Over-the-Counter Bulletin Board, an electronic quotation service maintained by the Financial Industry Regulatory Authority. These markets are generally not considered to be as efficient as, and not as broad as, the NASDAQ Capital Market. Selling our shares of Common Stock on these markets could be more difficult because smaller quantities of shares would likely be bought and sold, and transactions could be delayed. In addition, in the event our shares of Common Stock are delisted, broker-dealers have certain regulatory burdens imposed upon them, which may discourage broker-dealers from effecting transactions in our Common Stock, further limiting the liquidity of our Common Stock. These factors could result in lower prices and larger spreads in the bid and ask prices for our Common Stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">To the extent we elect to fund the development of a drug candidate or the commercialization of a drug at our expense, we will need substantial additional funding. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We plan to market drugs on our own, with or without a partner, that can be effectively commercialized and sold in concentrated markets that do not require a large sales force to be competitive. To achieve this goal, we will need to establish our own specialized sales force, marketing organization and supporting distribution capabilities. The development and commercialization of our drug candidates is very expensive. To the extent we elect to fund the full development of a drug candidate or the commercialization of a drug at our expense, we will need to raise substantial additional funding to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fund research and development and clinical trials connected with our research; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">fund clinical trials and seek regulatory approvals; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">build or access manufacturing and commercialization capabilities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">implement additional internal control systems and infrastructure; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">commercialize and secure coverage, payment and reimbursement of our drug candidates, if any such candidates receive regulatory approval; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">33</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">maintain, defend and expand the scope of our intellectual property; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">hire additional management, sales and scientific personnel. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Our future funding requirements will depend on many factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the scope, rate of progress and cost of our clinical trials and other research and development activities, including our discussions with European and United States regulatory authorities concerning the top-line data from our pivotal Phase&#160;3 SEAMLESS study; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs and timing of seeking and obtaining regulatory approvals; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs associated with establishing sales and marketing capabilities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs of acquiring or investing in businesses, products and technologies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the effect of competing technological and market developments; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the payment, other terms and timing of any strategic alliance, licensing or other arrangements that we may establish. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we are not able to secure additional funding when needed, especially in light of the current economic conditions and financial market turmoil, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or future commercialization efforts. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include property, general liability, employment benefits liability, workers&#8217; compensation, products liability and clinical trials (U.S and foreign), and directors&#8217; and officers&#8217;, employment practices and fiduciary liability insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Any future workforce and expense reductions may have an adverse impact on our internal programs, strategic plans, and our ability to hire and retain key personnel, and may also be distracting to our management. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Any workforce and expense reductions similar to those carried out in September&#160;2008 and June&#160;2009 could result in significant delays in implementing our strategic plans. In addition, employees, whether or not directly affected by such reduction, may seek future employment with our business partners or competitors. Although our employees are required to sign a confidentiality agreement at the time of hire, the confidential nature of certain proprietary information may not be maintained in the course of any such future employment. In addition, any workforce reductions or restructurings would be expected to involve significant expense as a result of contractual terms in certain of our existing agreements, including potential severance obligations. Further, we believe that our future success will depend in large part upon our ability to attract and retain highly skilled personnel. We may have difficulty retaining and attracting such personnel as a result of a perceived risk of future workforce and expense reductions. Finally, the implementation of expense reduction programs may result in the diversion of the time and attention of our executive management team and other key employees, which could adversely affect our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Funding constraints may negatively impact our research and development, forcing us to delay our efforts to develop certain product candidates in favor of developing others, which may prevent us from commercializing our product candidates as quickly as possible. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development is an expensive process. As part of our operating plan, since announcing that our SEAMLESS trial failed to meet its primary endpoint, we have decided to focus our clinical development strategy in oncology on our two ongoing, clinical programs in transcriptional regulation and </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">34</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">DNA damage response, which include our area of historical expertise in CDK inhibitors, or additional programs. Because we have to prioritize our development candidates as a result of budget constraints, we may not be able to fully realize the value of our product candidates in a timely manner, if at all. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are exposed to risks related to foreign currency exchange rates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Some of our costs and expenses are denominated in foreign currencies. Most of our foreign expenses are associated with our research and development expenditures, including the operating costs of our United&#160;Kingdom-based wholly-owned subsidiary. When the United States dollar weakens against the British pound or the Euro, the United States dollar value of the foreign currency denominated expense increases, and when the United States dollar strengthens against the British pound or the Euro, the United States dollar value of the foreign currency denominated expense decreases. Consequently, changes in exchange rates, and in particular a weakening of the United States dollar, may adversely affect our results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Security breaches, loss of data and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business and our reputation. Our business and operations would suffer in the event of system failures. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the ordinary course of our business, we collect and store sensitive data, intellectual property and proprietary business information owned or controlled by ourselves or our customers. This data encompasses a wide variety of business-critical information including research and development information, commercial information, and business and financial information. We face four primary risks relative to protecting this critical information: loss of access; inappropriate disclosure; inappropriate modification; and inadequate monitoring of our controls over the first three risks. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We utilize information technology, or IT, systems and networks to process, transmit and store electronic information in connection with our business activities. The secure processing, storage, maintenance, and transmission of this critical information is vital to our operations and business strategy, and we devote significant resources to protecting such information. As use of digital technologies has increased, cyber incidents, including deliberate attacks and attempts to gain unauthorized access to computer systems and networks, have increased in frequency and sophistication. These threats pose a risk to the security of our systems and networks and the confidentiality, availability and integrity of our data. There can be no assurance that we will be successful in preventing cyber-attacks or successfully mitigating their effects. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Despite the implementation of security measures, our internal computer systems and those of our contractors and consultants are vulnerable to damage from such cyber-attacks, including computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such an event could cause interruption of our operations. For example, the loss of data from ongoing or completed clinical trials for our product candidates could result in delays in our regulatory approval efforts and significantly increase our costs. In addition, there can be no assurance that we will promptly detect any such disruption or security breach, if at all. To the extent that any disruption or security breach were to result in a loss of or damage to our data, or inappropriate disclosure of confidential or proprietary information, we could suffer reputational harm or face litigation or adverse regulatory action and the development of our product candidates could be delayed. </div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to our Intellectual Property </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we fail to enforce adequately or defend our intellectual property rights, our business may be harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our commercial success depends in large part on obtaining and maintaining patent and trade secret protection for our drug candidates, the methods used to manufacture those drug candidates and the methods for treating patients using those drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Sapacitabine is protected by granted, composition of matter patents claiming certain, stable crystalline forms of sapacitabine and their pharmaceutical compositions and therapeutic uses that expire in 2022 (and may be eligible for a Hatch-Waxman term restoration of up to five&#160;years, which could extend the expiration </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">35</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">date to 2027); United States and European granted patents that expire in 2029, claiming the combination of sapacitabine with hypomethylating agents, including decitabine, which is being tested as the active arm in the SEAMLESS Phase&#160;3 trial, and a United States granted patent claiming a specified method of administration of sapacitabine with patent exclusivity until July&#160;2030. We have used a stable, crystalline form of sapacitabine in nearly all our Phase&#160;1 and in all our Phase&#160;2 and Phase&#160;3 clinical studies. We have also chosen this crystalline form for commercialization. Additional patents and applications claim certain medical uses, combinations, formulations and dosing regimens of sapacitabine which have emerged in our clinical trials, as well as a process for the preparation of sapacitabine. Seliciclib is protected by granted patents and applications claiming certain medical uses of seliciclib, including combination use with sapacitabine, which have emerged in our preclinical research and clinical trials. The latest to expire of the granted patents expires in 2033. Failure to obtain, maintain or extend the patents could adversely affect our business. We will only be able to protect our drug candidates and our technologies from unauthorized use by third parties to the extent that valid and enforceable patents or trade secrets cover them. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our ability to obtain patents is uncertain because legal means afford only limited protections and may not adequately protect our rights or permit us to gain or keep any competitive advantage. Some legal principles remain unresolved and the breadth or interpretation of claims allowed in patents in the United&#160;States, the European Union or elsewhere can still be difficult to ascertain or predict. In addition, the specific content of patents and patent applications that are necessary to support and interpret patent claims is highly uncertain due to the complex nature of the relevant legal, scientific and factual issues. Changes in either patent laws or in interpretations of patent laws in the United States, the European Union or elsewhere may diminish the value of our intellectual property or narrow the scope of our patent protection. Our existing patents and any future patents we obtain may not be sufficiently broad to prevent others from practicing our technologies or from developing competing products and technologies. In addition, we generally do not control the patent prosecution of subject matter that we license from others and have not controlled the earlier stages of the patent prosecution. Accordingly, we are unable to exercise the same degree of control over this intellectual property as we would over our own. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Even if patents are issued regarding our drug candidates or methods of using them, those patents can be challenged by our competitors who may argue such patents are invalid and/or unenforceable. Patents also will not protect our drug candidates if competitors devise ways of making or using these product candidates without legally infringing our patents. The FDA and FDA regulations and policies and equivalents in other jurisdictions provide incentives to manufacturers to challenge patent validity or create modified, non-infringing versions of a drug in order to facilitate the approval of abbreviated new drug applications for generic substitutes. These same types of incentives encourage manufacturers to submit NDAs that rely on literature and clinical data not prepared for or by the drug sponsor. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Proprietary trade secrets and unpatented know-how are also very important to our business. We rely on trade secrets to protect our technology, especially where we do not believe that patent protection is appropriate or obtainable. However, trade secrets are difficult to protect. Our employees, consultants, contractors, outside scientific collaborators and other advisors may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Enforcing a claim that a third-party obtained illegally and is using trade secrets is expensive and time consuming, and the outcome is unpredictable. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Failure to obtain or maintain trade secret protection could adversely affect our competitive business position. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we do not obtain protection under the Hatch-Waxman Act and similar legislation outside of the United States by extending the patent terms and obtaining data exclusivity for our product candidates, our business may be materially harmed. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Depending upon the timing, duration and specifics of FDA marketing approval of sapacitabine and our other product candidates, if any, one or more of our United States patents may be eligible for limited patent term restoration under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five&#160;years as compensation for patent term lost during product development and the FDA regulatory review </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">36</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">process. However, we may not be granted an extension because, for example, of failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the applicable time period or the scope of patent protection afforded could be less than we request. If we are unable to obtain patent term extension or restoration or the term of any such extension is less than what we request, the period during which we will have the right to exclusively market our product will be shortened and our competitors may obtain approval of competing products following our patent expiration, and our revenue could be reduced, possibly materially. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may be subject to damages resulting from claims that our employees or we have wrongfully used or disclosed alleged trade secrets of their former employers. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Many of our employees were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although no claims against us are currently pending, we may be subject to claims that these employees or we have inadvertently or otherwise used or disclosed trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these claims. If we fail in defending such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. A loss of key research personnel or their work product could hamper or prevent our ability to commercialize certain potential drugs, which could severely harm our business. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction to management. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Confidentiality agreements with employees and others may not adequately prevent disclosure of our trade secrets and other proprietary information and may not adequately protect our intellectual property, which could limit our ability to compete. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Because we operate in the highly technical field of drug discovery and development of small molecule drugs, we rely in part on trade secret protection in order to protect our proprietary technology and processes. However, trade secrets are difficult to protect. We enter into confidentiality and intellectual property assignment agreements with our corporate partners, employees, consultants, outside scientific collaborators, sponsored researchers, and other advisors. These agreements generally require that the other party keep confidential and not disclose to third parties all confidential information developed by the party or made known to the party by us during the course of the party&#8217;s relationship with us. These agreements also generally provide that inventions conceived by the party in the course of rendering services to us will be our exclusive property. However, these agreements may not be honored and may not effectively assign intellectual property rights to us. Enforcing a claim that a party illegally obtained and is using our trade secrets is difficult, expensive and time consuming, and the outcome is unpredictable. In addition, courts outside the United States may be less willing to protect trade secrets. The failure to obtain or maintain trade secret protection could adversely affect our competitive position. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Intellectual property rights of third parties may increase our costs or delay or prevent us from being able to commercialize our drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is a risk that we are infringing or will infringe on the proprietary rights of third parties because patents and pending applications belonging to third parties exist in the United States, the European Union and elsewhere in the world in the areas of our research. Others might have been the first to make the inventions covered by each of our or our licensors&#8217; pending patent applications and issued patents and might have been the first to file patent applications for these inventions. We are aware of several published patent applications, and understand that others may exist, that could support claims that, if granted and held valid, could cover various aspects of our developmental programs, including in some cases particular uses of our drug candidates sapacitabine, seliciclib, CYC065 or other therapeutic candidates, or substances, processes and techniques that we use in the course of our research and development and manufacturing processes. We are aware that other patents exist that claim substances, processes and techniques, which, if held valid, could potentially restrict the scope of our research, development or manufacturing operations. In addition, we understand that other applications and patents exist relating to potential uses of sapacitabine, seliciclib and CYC065 that are not part of our current clinical programs for these compounds. Numerous third-party United States and foreign issued patents and pending applications exist in the area of kinases, including CDK and PLK for which we have research programs. For example, some pending patent </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">37</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">applications contain broad claims that could represent freedom to operate limitations for some of our kinase programs should they be issued unchanged. Although we intend to continue to monitor these applications, we cannot predict what claims will ultimately be allowed and if allowed what their scope would be. In addition, because the patent application process can take several&#160;years to complete, there may be currently pending applications, unknown to us, which may later result in issued patents that cover the production, manufacture, commercialization or use of our drug candidates. If we wish to use the technology or compound claimed in issued and unexpired patents owned by others, we will need to obtain a license from the owner, enter into litigation to challenge the validity of the patents or incur the risk of litigation in the event that the owner asserts that we infringe its patents. In one case we have opposed a European patent relating to human aurora kinase and the patent has been finally revoked (no appeal was filed). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There has been substantial litigation and other proceedings regarding patent and other intellectual property rights in the pharmaceutical and biotechnology industries. Defending against third party claims, including litigation in particular, would be costly and time consuming and would divert management&#8217;s attention from our business, which could lead to delays in our development or commercialization efforts. If third parties are successful in their claims, we might have to pay substantial damages or take other actions that are adverse to our business. As a result of intellectual property infringement claims, or to avoid potential claims, we might: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be prohibited from selling or licensing any product that we may develop unless the patent holder licenses the patent to us, which it is not required to do; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be required to pay substantial royalties or grant a cross license to our patents to another patent holder; decide to locate some of our research, development or manufacturing operations outside of Europe or the United States; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be required to pay substantial damages for past infringement, which we may have to pay if a court determines that our product candidates or technologies infringe a competitor&#8217;s patent or other proprietary rights; or </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.58pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.58pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">be required to redesign the manufacturing process or formulation of a drug candidate so it does not infringe which may not be possible or could require substantial funds and time. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may incur substantial costs as a result of litigation or other proceedings relating to patent and other intellectual property rights. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we choose to go to court to stop another party from using the inventions claimed in any patents we obtain, that individual or company has the right to ask the court to rule that such patents are invalid or should not be enforced against that third party. These lawsuits are expensive and would consume time and resources and divert the attention of managerial and scientific personnel even if we were successful in stopping the infringement of such patents. In addition, there is a risk that the court will decide that such patents are not valid and that we do not have the right to stop the other party from using the inventions. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There is also a risk that, even if the validity of such patents is upheld, the court will refuse to stop the other party on the ground that such other party&#8217;s activities do not infringe our rights to such patents. In addition, the United States Supreme Court has recently modified some tests used by the United States Patent and Trademark Office, or USPTO, in granting patents over the past 20&#160;years, which may decrease the likelihood that we will be able to obtain patents and increase the likelihood of challenge of any patents we obtain or license. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">38</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">pay these fees. The USPTO and various non-United States governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The patent applications of pharmaceutical and biotechnology companies involve highly complex legal and factual questions, which, if determined adversely to us, could negatively impact our patent position. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and involve complex legal and factual questions. The U.S. Patent and Trademark Office&#8217;s, or USPTO&#8217;s, standards are uncertain and could change in the future. Consequently, the issuance and scope of patents cannot be predicted with certainty. Patents, if issued, may be challenged, invalidated or circumvented. U.S.&#160;patents and patent applications may also be subject to interference proceedings, and U.S. patents may be subject to <font style="font-style:italic;">Inter Partes</font> Review (IPR) or reexamination proceedings in the USPTO (and foreign patents may be subject to opposition or comparable proceedings in the corresponding foreign patent office), which proceedings could result in either loss of the patent or denial of the patent application or loss or reduction in the scope of one or more of the claims of the patent or patent application. Similarly, opposition or invalidity proceedings could result in loss of rights or reduction in the scope of one or more claims of a patent in foreign jurisdictions. In addition, such interference, reexamination and opposition proceedings may be costly. Accordingly, rights under any issued patents may not provide us with sufficient protection against competitive products or processes. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, changes in or different interpretations of patent laws in the United States and foreign countries may permit others to use our discoveries or to develop and commercialize our technology and products without providing any compensation to us or may limit the number of patents or claims we can obtain. In particular, there have been proposals to shorten the exclusivity periods available under U.S.&#160;patent law that, if adopted, could substantially harm our business. The product candidates that we are developing are protected by intellectual property rights, including patents and patent applications. If any of our product candidates becomes a marketable product, we will rely on our exclusivity under patents to sell the compound and recoup our investments in the research and development of the compound. If the exclusivity period for patents is shortened, then our ability to generate revenues without competition will be reduced and our business could be materially adversely impacted. The laws of some countries do not protect intellectual property rights to the same extent as U.S. laws, and those countries may lack adequate rules and procedures for defending our intellectual property rights. For example, some countries do not grant patent claims directed to methods of treating humans and, in these countries, patent protection may take the form of alternative claim constructions or may not be available at all to protect our product candidates. In addition, U.S. patent laws may change, which could prevent or limit us from filing patent applications or patent claims to protect our products and/or technologies or limit the exclusivity periods that are available to patent holders. For example, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was recently signed into law and includes a number of significant changes to U.S. patent law. These include changes to transition from a &#8220;first-to-invent&#8221; system to a &#8220;first-to-file&#8221; system and to the way issued patents are challenged. These changes may favor larger and more established companies that have more resources to devote to patent application filing and prosecution. The USPTO has been in the process of implementing regulations and procedures to administer the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act may affect our ability to obtain, enforce or defend our patents. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will ultimately have on the cost of prosecuting our patent applications, our ability to obtain patents based on our discoveries and our ability to enforce or defend our issued patents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we fail to obtain and maintain patent protection and trade secret protection of our product candidates, proprietary technologies and their uses, we could lose our competitive advantage and competition we face would increase, reducing our potential revenues and adversely affecting our ability to attain or maintain profitability.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">39</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">Risks Related to Securities Regulations and Investment in Our Securities </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Failure to achieve and maintain internal controls in accordance with Sections&#160;302 and 404 of the Sarbanes-Oxley Act of 2002 could have a material adverse effect on our business and stock price. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;404 of the Sarbanes-Oxley Act of 2002 requires that we maintain internal control over financial reporting that meets applicable standards. As with many smaller companies with small staff, material weaknesses in our financial controls and procedures may be discovered. If we fail to maintain our internal controls or fail to implement required new or improved controls, as such control standards are modified, supplemented or amended from time to time, we may not be able to conclude on an ongoing basis that we have effective internal controls over financial reporting. Effective internal controls are necessary for us to produce reliable financial reports and are important in the prevention of financial fraud. If we cannot produce reliable financial reports or prevent fraud, our business and operating results could be harmed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We incur increased costs and management resources as a result of being a public company, and we may fail to comply with public company obligations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a public company, we face and will continue to face increased legal, accounting, administrative and other costs and expenses as a public company that we would not incur as a private company. Compliance with the Sarbanes Oxley Act of 2002, as well as other rules of the SEC, the Public Company Accounting Oversight Board and NASDAQ resulted in a significant initial cost to us as well as an ongoing compliance cost. As a public company, we are subject to Section&#160;404 of the Sarbanes Oxley Act relating to internal control over financial reporting. We have completed a formal process to evaluate our internal controls for purposes of Section&#160;404, and we concluded that as of December&#160;31, 2017, our internal control over financial reporting was effective. As our business grows and changes, there can be no assurances that we can maintain the effectiveness of our internal controls over financial reporting. In addition, our independent certified public accounting firm has not provided an opinion on the effectiveness of our internal controls over financial reporting for the year ended December&#160;31, 2017 because we are a smaller reporting company. In the event our independent auditor is required to provide an opinion on such controls in the future, there is a risk that the auditor would conclude that such controls are ineffective. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our operating results could be harmed. We have completed a formal process to evaluate our internal control over financial reporting. However, guidance from regulatory authorities in the area of internal controls continues to evolve and substantial uncertainty exists regarding our on-going ability to comply by applicable deadlines. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. Ineffective internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common stock may have a volatile public trading price. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An active public market for our common stock has not developed. Our stock can trade in small volumes which may make the price of our stock highly volatile. The last reported price of our stock may not represent the price at which you would be able to buy or sell the stock. The market prices for securities of companies comparable to us have been highly volatile. Often, these stocks have experienced significant price and volume fluctuations for reasons that are both related and unrelated to the operating performance of the individual companies. In addition, the stock market as a whole and biotechnology and other life science stocks in particular have experienced significant recent volatility. Like our common stock, these stocks have experienced significant price and volume fluctuations for reasons unrelated to the operating performance of the individual companies. Factors giving rise to this volatility may include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">disclosure of actual or potential clinical results with respect to product candidates we are developing; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">40</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">regulatory developments in both the United States and abroad; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">developments concerning proprietary rights, including patents and litigation matters; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">public concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">concern about the safety or efficacy of our product candidates or technology, or related technology, or new technologies generally; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">public announcements by our competitors or others; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">general market conditions and comments by securities analysts and investors. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For example, on February&#160;23, 2017, we announced top-line results from the pivotal Phase&#160;3 SEAMLESS study in elderly patients aged 70&#160;years or older with newly diagnosed AML, who are not candidates for or have refused intensive induction chemotherapy. The trial did not meet its primary endpoint of demonstrating statistically significant improvement in overall survival for the experimental arm versus an active control. As a result of this announcement, the last reported sale price of our common stock on The NASDAQ Capital Market on February&#160;23, 2017 dropped to $4.05 from a last reported sale price of our common stock on February&#160;22, 2017 of&#8201; $5.41. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We executed a reverse stock split in order to help maintain our continued listing on The NASDAQ Capital Market. The reduction in our outstanding shares may result in reduced liquidity for all stockholders and in increased volatility in our stock price over time. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The reduced trading volume which results from the decreased number of shares that are publically held may make it more difficult to buy or sell our stock, even though we may maintain our listing on The NASDAQ Capital Market. The reduced volume of stock trades that may result as a consequence of the reverse stock split may also increase the volatility of our stock price over time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fluctuations in our operating losses could adversely affect the price of our common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our operating losses may fluctuate significantly on a quarterly basis. Some of the factors that may cause our operating losses to fluctuate on a period-to-period basis include the status of our preclinical and clinical development programs, level of expenses incurred in connection with our preclinical and clinical development programs, implementation or termination of collaboration, licensing, manufacturing or other material agreements with third parties, non-recurring revenue or expenses under any such agreement, and compliance with regulatory requirements. Period-to-period comparisons of our historical and future financial results may not be meaningful, and investors should not rely on them as an indication of future performance. Our fluctuating losses may fail to meet the expectations of securities analysts or investors. Our failure to meet these expectations may cause the price of our common stock to decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If securities or industry analysts do not publish research or reports about us, if they change their recommendations regarding our stock adversely or if our operating results do not meet their expectations, our stock price and trading volume could decline. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us. If analysts do not publish research reports or one or more of these analysts who were publishing research cease coverage of us or fail to regularly publish reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline. Moreover, if one or more of the analysts who cover us downgrade our stock or if our operating results do not meet their expectations, our stock price could decline. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Anti-takeover provisions in our charter documents and provisions of Delaware law may make an acquisition more difficult and could result in the entrenchment of management. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We are incorporated in Delaware. Anti-takeover provisions of Delaware law and our amended and restated certificate of incorporation and amended and restated bylaws may make a change in control or efforts to remove management more difficult. Also, under Delaware law, our Board of Directors may adopt additional anti-takeover measures. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">41</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">We have the authority to issue up to 5&#160;million shares of preferred stock and to determine the terms of those shares of stock without any further action by our stockholders. If the Board of Directors exercises this power to issue preferred stock, it could be more difficult for a third party to acquire a majority of our outstanding voting stock and vote the stock they acquire to remove management or directors. Our amended and restated certificate of incorporation and amended and restated bylaws also provides staggered terms for the members of our Board of Directors. Under Section&#160;141 of the Delaware General Corporation Law, our directors may be removed by stockholders only for cause and only by vote of the holders of a majority of voting shares then outstanding. These provisions may prevent stockholders from replacing the entire board in a single proxy contest, making it more difficult for a third-party to acquire control of us without the consent of our Board of Directors. These provisions could also delay the removal of management by the Board of Directors with or without cause. In addition, our directors may only be removed for cause and amended and restated bylaws limit the ability our stockholders to call special meetings of stockholders. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">Under Section&#160;203 of the Delaware General Corporation Law, a corporation may not engage in a business combination with any holder of 15% or more of its capital stock until the holder has held the stock for three&#160;years unless, among other possibilities, the Board of Directors approves the transaction. Our Board of Directors could use this provision to prevent changes in management. The existence of the foregoing provisions could limit the price that investors might be willing to pay in the future for shares of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Certain severance-related agreements in our executive employment agreements may make an acquisition more difficult and could result in the entrenchment of management. </div>
        <div style="text-indent:20pt; margin-top:4.02pt; width:456pt; line-height:12pt;">In March&#160;2008 (as subsequently amended, most recently as of January&#160;1, 2017), we entered into employment agreements with our President and Chief Executive Officer and our Executive Vice President, Finance, Chief Financial Officer and Chief Operating Officer, which contain severance arrangements in the event that such executive&#8217;s employment is terminated without &#8220;cause&#8221; or as a result of a &#8220;change of control&#8221; (as each such term is defined in each agreement). The financial obligations triggered by these provisions may prevent a business combination or acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">In the event of an acquisition of our common stock, we cannot assure our common stockholders that we will be able to negotiate terms that would provide for a price equivalent to, or more favorable than, the price at which our shares of common stock may be trading at such time. </div>
        <div style="text-indent:20pt; margin-top:4.01pt; width:456pt; line-height:12pt;">We may not effect a consolidation or merger with another entity without the vote or consent of the holders of at least a majority of the shares of our preferred stock (in addition to the approval of our common stockholders), unless the preferred stock that remains outstanding and its rights, privileges and preferences are unaffected or are converted into or exchanged for preferred stock of the surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to our convertible preferred stock. </div>
        <div style="text-indent:20pt; margin-top:5.02pt; width:456pt; line-height:12pt;">In addition, in the event a third party seeks to acquire our company or acquire control of our company by way of a merger, but the terms of such offer do not provide for our preferred stock to remain outstanding or be converted into or exchanged for preferred stock of the surviving entity having rights, preferences and limitations substantially similar, but no less favorable, to our preferred stock, the terms of the Certificate of Designations of our preferred stock provide for an adjustment to the conversion ratio of our preferred stock such that, depending on the terms of any such transaction, preferred stockholders may be entitled, by their terms, to receive up to $10.00 per share in common stock, causing our common stockholders not to receive as favorable a price as the price at which such shares may be trading at the time of any such transaction. As of December&#160;31, 2017, there were 335,273 shares of our preferred stock issued and outstanding. If the transaction were one in which proceeds were received by the Company for distribution to stockholders, and the terms of the Certificate of Designations governing the preferred stock were strictly complied with, approximately $4.0&#160;million would be paid to the preferred holders before any distribution to the common stockholders, although the form of transaction could affect how the holders of preferred stock are treated. In such an event, although such a transaction would be subject to the approval of our holders of common stock, we cannot assure our common stockholders that we will be able to negotiate terms that would provide for a price equivalent to, or more favorable than, the price at which our shares of common stock may be trading at such time. Thus, the terms of our preferred stock might hamper a third party&#8217;s acquisition of our company. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">42</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our certificate of incorporation and bylaws and certain provisions of Delaware law may delay or prevent a change in our management and make it more difficult for a third-party to acquire us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our amended and restated certificate of incorporation and bylaws contain provisions that could delay or prevent a change in our Board of Directors and management teams. Some of these provisions: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">authorize the issuance of preferred stock that can be created and issued by the Board of Directors without prior stockholder approval, commonly referred to as &#8220;blank check&#8221; preferred stock, with rights senior to those of our common stock; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">provide for the Board of Directors to be divided into three classes; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit stockholder action by written consent. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of large stockholders to complete a business combination with, or acquisition of, us. These provisions may prevent a business combination or acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These provisions also make it more difficult for our stockholders to replace members of our Board of Directors. Because our Board of Directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt to replace our current management team. Additionally, these provisions may prevent an acquisition that would be attractive to stockholders and could limit the price that investors would be willing to pay in the future for our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We may have limited ability to pay cash dividends on our preferred stock, and there is no assurance that future quarterly dividends will be declared. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Delaware law may limit our ability to pay cash dividends on our preferred stock. Under Delaware law, cash dividends on our preferred stock may only be paid from surplus or, if there is no surplus, from the corporation&#8217;s net profits for the current or preceding fiscal year. Delaware law defines &#8220;surplus&#8221; as the amount by which the total assets of a corporation, after subtracting its total liabilities, exceed the corporation&#8217;s capital, as determined by its board of directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since we are not profitable, our ability to pay cash dividends will require the availability of adequate surplus. Even if adequate surplus is available to pay cash dividends on our preferred stock, we may not have sufficient cash to pay dividends on the preferred stock or we may choose not to declare the dividends. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our common and preferred stock may experience extreme price and volume fluctuations, which could lead to costly securities-related litigation, including securities class action litigation or securities-related investigations, which could make an investment in us less appealing. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The market price of our common and preferred stock may fluctuate substantially due to a variety of factors, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">announcements of technological innovations or new products or services by us or our competitors; announcements concerning our competitors or the biotechnology industry in general; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">new regulatory pronouncements and changes in regulatory guidelines; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">general and industry-specific economic conditions; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">additions to or departures of our key personnel; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">changes in financial estimates or recommendations by securities analysts; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">variations in our quarterly results; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">announcements about our collaborators or licensors; and changes in accounting principles </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">43</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The stock markets have from time to time experienced significant price and volume fluctuations that have affected the market prices for publicly traded securities. The market prices of the securities of biotechnology companies, particularly companies like us without product revenues and earnings, have been highly volatile and are likely to remain highly volatile in the future. This volatility has often been unrelated to the performance of particular companies. In the past, companies that experience volatility in the market price of their securities have often faced securities class action and derivative litigation, and as a public company, we could be subject to sanctions or investigations by NASDAQ, the SEC or other regulatory authorities. Moreover, market prices for stocks of biotechnology-related and technology companies frequently reach levels that bear no relationship to the performance of these companies. These market prices generally are not sustainable and are highly volatile. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a result of our recent announcement of top-line results from the pivotal Phase&#160;3 SEAMLESS study, our stock price declined substantially. In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Whether or not meritorious, litigation brought against us could result in substantial costs, divert our management&#8217;s attention and resources and harm our financial condition and results of operations. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The future sale of our common and convertible preferred stock and future issuances of our common stock upon conversion of our preferred stock could negatively affect our stock price and cause dilution to existing holders of our common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If our common or preferred stockholders sell substantial amounts of our stock in the public market, or the market perceives that such sales may occur, the market price of our common and preferred stock could fall. If additional holders of convertible preferred stock elect to convert their shares to shares of common stock at renegotiated prices, such conversion as well as the sale of substantial amounts of our common stock, could cause dilution to existing holders of our common stock, thereby also negatively affecting the price of our common stock. For example, in 2013, we issued an aggregate of 140,373 shares of our common stock in exchange for an aggregate of 877,869 shares of our preferred stock in arms-length negotiations between us and the other parties who had approached us to propose the exchanges. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we exchange the convertible preferred stock for debentures, the exchange will be taxable, but we will not provide any cash to pay any tax liability that any convertible preferred stockholder may incur. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">An exchange of convertible preferred stock for debentures, as well as any dividend make-whole or interest make-whole payments paid in our common stock, will be taxable events for United States federal income tax purposes, which may result in tax liability for the holder of convertible preferred stock without any corresponding receipt of cash by the holder. In addition, the debentures may be treated as having original issue discount, a portion of which would generally be required to be included in the holder&#8217;s gross income even though the cash to which such income is attributable would not be received until maturity or redemption of the debenture. We will not distribute any cash to the holders of the securities to pay these potential tax liabilities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If we automatically convert the preferred stock, there is a substantial risk of fluctuation in the price of our common stock from the date we elect to automatically convert to the conversion date. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may automatically convert the preferred stock into common stock if the closing price of our common stock exceeds $2,961 per share. There is a risk of fluctuation in the price of our common stock between the time when we may first elect to automatically convert the preferred and the automatic conversion date. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We do not intend to pay cash dividends on our common stock in the foreseeable future. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We do not anticipate paying cash dividends on our common stock in the foreseeable future. Any payment of cash dividends will depend on our financial condition, results of operations, capital requirements, the outcome of the review of our strategic alternatives and other factors and will be at the discretion of our Board of Directors. Accordingly, investors will have to rely on capital appreciation, if any, to earn a return on their investment in our common stock. Furthermore, we may in the future become subject to contractual restrictions on, or prohibitions against, the payment of dividends. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">44</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">The number of shares of common stock which are registered, including the shares to be issued upon exercise of our outstanding warrants, is significant in relation to our currently outstanding common stock and could cause downward pressure on the market price for our common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The number of shares of common stock registered for resale, including those shares which are to be issued upon exercise of our outstanding warrants, is significant in relation to the number of shares of common stock currently outstanding. If the security holder determines to sell a substantial number of shares into the market at any given time, there may not be sufficient demand in the market to purchase the shares without a decline in the market price for our common stock. Moreover, continuous sales into the market of a number of shares in excess of the typical trading volume for our common stock, or even the availability of such a large number of shares, could depress the trading market for our common stock over an extended period of time. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">If persons engage in short sales of our common stock, including sales of shares to be issued upon exercise of our outstanding warrants, the price of our common stock may decline. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Selling short is a technique used by a stockholder to take advantage of an anticipated decline in the price of a security. In addition, holders of options and warrants will sometimes sell short knowing they can, in effect, cover through the exercise of an option or warrant, thus locking in a profit. A significant number of short sales or a large volume of other sales within a relatively short period of time can create downward pressure on the market price of a security. Further sales of common stock issued upon exercise of our outstanding warrants could cause even greater declines in the price of our common stock due to the number of additional shares available in the market upon such exercise, which could encourage short sales that could further undermine the value of our common stock. You could, therefore, experience a decline in the value of your investment as a result of short sales of our common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">We are exposed to risk related to the marketable securities we may purchase. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We may invest cash not required to meet short term obligations in short term marketable securities. We may purchase securities in United States government, government-sponsored agencies and highly rated corporate and asset-backed securities subject to an approved investment policy. Historically, investment in these securities has been highly liquid and has experienced only very limited defaults. However, recent volatility in the financial markets has created additional uncertainty regarding the liquidity and safety of these investments. Although we believe our marketable securities investments are safe and highly liquid, we cannot guarantee that our investment portfolio will not be negatively impacted by recent or future market volatility or credit restrictions. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Our management team will have broad discretion over the use of the net proceeds from the recent sale of our securities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On July&#160;19, 2017, we entered into an underwriting agreement with Ladenburg Thalmann &amp; Co. Inc., acting as the representative of the several underwriters named therein relating to the issuance and sale of (i)&#160;3,154,000 Class&#160;A Units, each consisting of one share of the Company&#8217;s common stock and a warrant to purchase one share of common stock, and (ii) 8,872 Class&#160;B Units, each consisting of one share the Company&#8217;s Series&#160;A Convertible Preferred Stock, par value $0.001 per share, convertible into 500 shares of common stock at the initial conversion price and a warrant to purchase a number of shares of common stock equal to $1,000.00 divided by the conversion price. The net proceeds to the Company from the offering were approximately $13,700,000 after deducting underwriting discounts and commissions and other estimated Offering expenses. During the year ended December&#160;31, 2017, 8,608 shares of the Series&#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&#160;31, 2017, 264 shares of the Series&#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&#160;A Preferred Stock issued and outstanding at December&#160;31, 2017, are convertible into 132,000 shares of common stock. Our management team has discretion to direct the net proceeds from this offering. We intend to use all of the net proceeds, together with cash on hand, for general corporate purposes. General corporate purposes may include working capital, capital expenditures, development costs, strategic investments or possible acquisitions. Our management&#8217;s judgments may not result in positive returns on your investment and you will not have an opportunity to evaluate the economic, financial or other information upon which our management bases its decisions. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">45</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT1B">&#8203;</a><a name="tIT2">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful stockholder claims against us and may reduce the amount of money available to us. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As permitted by Section&#160;102(b)(7) of the Delaware General Corporation Law, our restated certificate of incorporation limits the liability of our directors to the fullest extent permitted by law. In addition, as permitted by Section&#160;145 of the Delaware General Corporation Law, our restated certificate of incorporation and restated bylaws provide that we shall indemnify, to the fullest extent authorized by the Delaware General Corporation Law, each person who is involved in any litigation or other proceeding because such person is or was a director or officer of our company or is or was serving as an officer or director of another entity at our request, against all expense, loss or liability reasonably incurred or suffered in connection therewith. Our restated certificate of incorporation provides that the right to indemnification includes the right to be paid expenses incurred in defending any proceeding in advance of its final disposition, provided, however, that such advance payment will only be made upon delivery to us of an undertaking, by or on behalf of the director or officer, to repay all amounts so advanced if it is ultimately determined that such director is not entitled to indemnification. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">If we do not pay a proper claim for indemnification in full within 60&#160;days after we receive a written claim for such indemnification, except in the case of a claim for an advancement of expenses, in which case such period is 20&#160;days, our restated certificate of incorporation and our restated bylaws authorize the claimant to bring an action against us and prescribe what constitutes a defense to such action. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Section&#160;145 of the Delaware General Corporation Law permits a corporation to indemnify any director or officer of the corporation against expenses (including attorney&#8217;s fees), judgments, fines and amounts paid in settlement actually and reasonably incurred in connection with any action, suit or proceeding brought by reason of the fact that such person is or was a director or officer of the corporation, if such person acted in good faith and in a manner that he reasonably believed to be in, or not opposed to, the best interests of the corporation, and, with respect to any criminal action or proceeding, if he or she had no reason to believe his or her conduct was unlawful. In a derivative action, (i.e., one brought by or on behalf of the corporation), indemnification may be provided only for expenses actually and reasonably incurred by any director or officer in connection with the defense or settlement of such an action or suit if such person acted in good faith and in a manner that he or she reasonably believed to be in, or not opposed to, the best interests of the corporation, except that no indemnification shall be provided if such person shall have been adjudged to be liable to the corporation, unless and only to the extent that the court in which the action or suit was brought shall determine that the defendant is fairly and reasonably entitled to indemnity for such expenses despite such adjudication of liability. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The rights conferred in the restated certificate of incorporation and the restated bylaws are not exclusive, and we are authorized to enter into indemnification agreements with our directors, officers, employees and agents and to obtain insurance to indemnify such persons. We have entered into indemnification agreements with each of our officers and directors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The above limitations on liability and our indemnification obligations limit the personal liability of our directors and officers for monetary damages for breach of their fiduciary duty as directors by shifting the burden of such losses and expenses to us. Although we obtained coverage under our directors&#8217; and officers&#8217; liability insurance, certain liabilities or expenses covered by our indemnification obligations may not be covered by such insurance or the coverage limitation amounts may be exceeded. As a result, we may need to use a significant amount of our funds to satisfy our indemnification obligations, which could severely harm our business and financial condition and limit the funds available to stockholders who may choose to bring a claim against our company. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;1B.&nbsp;&nbsp;&nbsp;Unresolved Staff Comments </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">None. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;2.&nbsp;&nbsp;&nbsp;Properties </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We lease our corporate headquarters in Berkeley Heights, New Jersey and a research and development facility in Dundee, Scotland. We believe that our existing facilities are adequate to accommodate our business needs. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">46</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT3">&#8203;</a><a name="tIT4">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;3.&nbsp;&nbsp;&nbsp;Legal Proceedings </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">From time to time, we may be involved in routine litigation incidental to the conduct of our business. As of December&#160;31, 2017, we were not a party to any material legal proceedings. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;4.&nbsp;&nbsp;&nbsp;Mine Safety Disclosures </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Not applicable.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">47</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT5">&#8203;</a><a name="tIT6">&#8203;</a><a name="tIT7">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART II </div>
        <div style=" float:left; line-height:11pt; margin-top:13.19pt; margin-bottom:0pt; text-align:left; width:36pt;white-space:nowrap;font-weight:bold;">Item&#160;5.<br ></div>
        <div style=" float:left; margin-top:13.19pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:419.5pt;font-weight:bold;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Market Information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our common stock is traded on The NASDAQ Capital Market, or NASDAQ, under the symbol &#8220;CYCC&#8221;. Our preferred stock currently trades on NASDAQ under the symbol &#8220;CYCCP&#8221;. The following table summarizes, for the periods indicated, the high and low sales prices for the common stock as reported by NASDAQ: </div>
        <table style="width:416pt;height:164.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:341.59pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">High </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Low </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">2017</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended March&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.14</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.13</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended June&#160;30, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">10.90</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.77</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended September&#160;30, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">3.87</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.56</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2.25</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">1.50</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">2016</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended March&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.45</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.60</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended June&#160;30, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">8.27</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.84</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended September&#160;30, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">9.72</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">4.21</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:341.59pt;text-align:left;">
              <div style="margin-left:10pt;">Quarter ended December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6.18</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">3.05</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:21.39pt; width:456pt; line-height:11pt;font-weight:bold;">Holders of Common Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On March 27, 2018, we had approximately 27 registered holders of record of our 11,997,447 shares of common stock outstanding. On March 27, 2018, the closing sale price of our common stock as reported by NASDAQ was $1.34 per share. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Dividends </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have never declared nor paid any cash dividends on our common stock and do not currently anticipate declaring or paying any cash dividends on our outstanding shares of common stock in the foreseeable future. We are, however, required to make or accrue quarterly dividend payments on our Preferred Stock. Except for dividends that may be paid on the Preferred Stock, we currently intend to retain all of our future earnings, if any, to finance operations. Any future determination relating to our dividend policy will be made at the discretion of our Board of Directors and will depend on a number of factors, including future earnings, capital requirements, financial conditions, future prospects, contractual restrictions and other factors that our Board of Directors may deem relevant. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;6.&nbsp;&nbsp;&nbsp;Selected Financial Data </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Smaller reporting companies are not required to provide information in response to this item. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;7.&nbsp;&nbsp;&nbsp;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cautionary Statement Regarding Forward-Looking Statements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">This report contains certain statements that may be deemed &#8216;forward-looking statements&#8217; within the meaning of United States securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of historical trends, current </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">48</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;font-style:italic;">conditions, expected future developments and other factors they believe to be appropriate. Certain factors that&#160;could cause results to differ materially from those projected or implied in the forward looking statements are set forth in this Annual Report on Form 10-K for the year ended December&#160;31, 2017 under the caption &#8220;Item&#160;1A&#8201;&#8212;&#8201;Risk factors&#8221;. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;font-style:italic;">We encourage you to read those descriptions carefully. We caution you not to place undue reliance on the forward-looking statements contained in this report. These statements, like all statements in this report, speak only as of the date of this report (unless an earlier date is indicated) and we undertake no obligation to update or revise the statements except as required by law. Such forward-looking statements are not guarantees of future performance and actual results will likely differ, perhaps materially, from those suggested by such forward-looking statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Overview </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2017, our focus has been on our transcriptional regulation program, pursuant to which we are evaluating our CYC065, cyclin dependent kinase, or CDK, inhibitor and our DNA damage response, or DDR, program, in which we are evaluating sapacitabine in combination with our CDK inhibitor seliciclib in solid tumors in a Phase&#160;1 study. Additionally, we have completed the analysis of data from SEAMLESS, the Phase&#160;3 study in acute myeloid leukemia, or AML. Data from the SEAMLESS study was presented at the 59<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">th</font> American Society of Hematology Annual Meeting. Based on the outcome of prespecified and exploratory subgroup analyses, we plan to discuss the data with European and US regulatory authorities. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">CYC065 is being evaluated in an on-going, first-in-human, Phase&#160;1 clinical trial being conducted at the Dana Farber Cancer Institute in Boston. The objective of part 1 of the clinical trial is to assess safety and recommended dosing for Phase&#160;2 (RP2D) in advanced cancer patients, based on determination of the biologically effective dose through measurement of CYC065&#8217;s effects on the Mcl-1 biomarker. Part&#160;1 is now complete and the RP2D has been selected, Part&#160;2 of the study will focus on patients with advanced solid tumors with amplification of cyclin E, Mcl-1 and/or <font style="font-style:italic;">MYCN</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In our DNA damage response program we are evaluating an all-oral Phase&#160;1 combination study with our sapacitabine and seliciclib, a first-generation CDK inhibitor, in patients with BRCA mutations. We are currently enrolling part 3 of this study. Additionally, we advanced our polo-like-kinase, or PLK inhibitor, CYC140, to IND-ready. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Corporate Developments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On July&#160;21, 2017, the Company announced the closing of an underwritten offering, with net proceeds of approximately $13.7&#160;million after deducting underwriting discounts and commissions and other estimated offering expenses, including full exercise of the underwriters&#8217; overallotment option. The Company issued and sold in the offering (i)&#160;3,154,000 Class&#160;A Units, each consisting of one share of the Company&#8217;s common stock, and a warrant to purchase one share of common stock, and (ii) 8,872 Class&#160;B Units, each consisting of one share of the Company&#8217;s Series&#160;A Convertible Preferred Stock convertible into 500 shares of common stock at the initial conversion price, and a warrant to purchase a number of shares of common stock equal to $1,000 divided by the conversion price. The price to the public in the offering was $2.00 per Class&#160;A Unit and $1,000 per Class&#160;B Unit. During the year ended December&#160;31, 2017, 8,608 shares of the Series&#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&#160;31, 2017, 264 shares of the Series&#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&#160;A Preferred Stock issued and outstanding at December&#160;31, 2017, are convertible into 132,000 shares of common stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Events </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Adoption of ASC Topic 606, <font style="font-style:italic;">Revenue from Contracts with Customers</font>. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Under this new guidance, the company must recognize revenue when it transfers promised goods or services to customers with an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The company has elected to adopt the guidance on a </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">49</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">modified retrospective basis and does not anticipate recording a material adjustment to opening accumulated deficit as of January&#160;1, 2018, the adoption date. The Company anticipates this standard will not have a material impact on its consolidated financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Dividend on Preferred Stock </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On December&#160;6, 2017, the Board of Directors declared a quarterly cash dividend in the amount of $0.15 per share on the Company&#8217;s Preferred Stock. The cash dividend was paid on February&#160;1, 2018 to the holders of record of the Preferred Stock as of the close of business on January&#160;12, 2018. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Results of Operations </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Years Ended December&#160;31, 2016 and 2017 </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;"><font style=" text-decoration:underline;">Results of Continuing Operations</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;"><font style=" text-decoration:underline;">Revenues</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes the components of our revenues for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands except&#160;percentages): </div>
        <table style="width:456pt;height:67.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Difference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">$ </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Grant revenue </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">843</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(843<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Collaboration and research and development revenue </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Total Revenue </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">843</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(843<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(100<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10pt; width:456pt; line-height:12pt;">Grant revenue is recognized as we incur and pay for qualifying costs and services under the applicable grant. Grant revenue is derived from various United Kingdom government and European Union grant awards. For the&#160;years ended December&#160;31, 2016 and 2017, we had grant revenue of approximately $0.8&#160;million and $0.0&#160;million, respectively. The decrease was the result of grant funding for the CYC140 program ending in 2016. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">The future </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We will not recognize further grant revenue for the CYC140 program, as the grant from the Biomedical Catalyst of the United Kingdom government ended in November&#160;2016. Although we may apply for additional grants in 2018, we are not certain of our ability to obtain such grants in 2018. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have entered into a collaboration, licensing and supply agreement with ManRos Therapeutics SA or ManRos. Receipt of further revenue under is dependent on the clinical progress of the program, which we do not control. We have received a $150,000 payment from ManRos as of December&#160;31, 2017 in anticipation of ManRos achieving a clinical milestone in 2018. This payment has been recorded as deferred revenues on the balance sheet (part of other current liabilities). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;"><font style=" text-decoration:underline;">Research and development</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expense all research and development costs as they are incurred. Research and development expenses primarily include: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Clinical trial and regulatory-related costs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Payroll and personnel-related expenses, including consultants and contract research organizations; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Preclinical studies and laboratory supplies and materials; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Technology license costs; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Stock-based compensation; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.6pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:6.6pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Rent and facility expenses for our office and laboratories. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">50</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following table provides information with respect to our research and development expenditures for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands except&#160;percentages): </div>
        <table style="width:456pt;height:79.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Difference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">$ </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Sapacitabine </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">6,239</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,661</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(3,578<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:9.75pt; text-align:right; white-space:nowrap;">(57<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:263.8pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Other costs related to research and development programs and management </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,238</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,576</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,662<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(51<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Total research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">9,477</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">4,237</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(5,240<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:5.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(55<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">Research and development expenses represented 63% and 45% of our operating expenses for the&#160;years ended December&#160;31, 2016 and 2017, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenditures decreased by approximately $5.2&#160;million to $4.2&#160;million for the year ended December&#160;31, 2017 from $9.5&#160;million for the year ended December&#160;31, 2016. Research and development expenditures relating to sapacitabine decreased by approximately $3.5&#160;million to $2.7&#160;million for the year ended December&#160;31, 2017 from $6.2&#160;million for the year ended December&#160;31, 2016. With the completion of enrolment of the study in December&#160;2014, the number of patients on the study has reduced in 2017 compared to 2016, and more trial sites have closed resulting in decreased expenditures. Other costs related to research and development programs, management and exploratory research decreased by $1.6&#160;million for the year ended December&#160;31, 2017 from $3.2&#160;million for the year ended December&#160;31, 2016, primarily as a result of decreased expenditures on the Biomedical Catalyst grant-funded CYC0140 program as the grant ended in 2016. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">The future </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We anticipate that overall research and development expenditures for the year ended December&#160;31, 2018 will increase compared to the year ended December&#160;31, 2017 due to the expansion of the CYC065 program. Costs related to the SEAMLESS clinical study sites will reduce and end in 2018, as these sites are closed. The timing and extent of SEAMLESS expenditure, related to possible registration submissions to regulatory authorities in Europe and the U.S., are dependent upon the final analysis of data. Additionally, expenditure on grant-funded programs will decrease because the CYC140 grant ended in November&#160;2016 and we currently have no new grant-funded programs.</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;"><font style=" text-decoration:underline;">General and administrative</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">General and administrative expenses include costs for administrative personnel, legal and other professional expenses and general corporate expenses. The following table summarizes the total general and administrative expenses for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands except&#160;percentages): </div>
        <table style="width:456pt;height:52.4999999999999pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Difference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">$ </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,516</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.335pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Total General and administrative </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,516</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">5,254</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6pt; text-align:right; white-space:nowrap;">(5<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:10.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">Total general and administrative expenses represented 37% and 55% of our operating expenses for the&#160;years ended December&#160;31, 2016 and 2017, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our general and administrative expenditures remained relatively flat with a modest decrease of 5% from $5.5&#160;million for the year ended December&#160;31, 2016 compared to $5.3&#160;million for the year ended December&#160;31, 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">The future </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect general and administrative expenditures for the year ended December&#160;31, 2018 to remain relatively flat as compared to our expenditures for the year ended December&#160;31, 2017. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">51</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;"><font style=" text-decoration:underline;">Other income (expense), net</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following table summarizes the other income (expense) for&#160;years ended December&#160;31, 2016 and 2017 (in thousands except&#160;percentages): </div>
        <table style="width:456pt;height:82.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Difference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">$ </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Foreign exchange gains (losses) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(39<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(312<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">(114<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Interest income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">219</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Other income, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">949</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">883</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,338</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Total other income, net </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">376</td>
            <td style="padding:0pt;padding-left:11.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,028</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">652</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">173</td>
            <td style="padding:0pt;padding-left:3.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.99pt; width:456pt; line-height:12pt;">Total other income, net, increased by approximately $0.7&#160;million, from approximately $0.4&#160;million for the year ended December&#160;31, 2016 to $1.0&#160;million for the year ended December&#160;31, 2017. The increase in other income is primarily related to income received under an Asset Purchase Agreement, or APA, with Life Technologies Corporation, or LTC, (formerly Invitrogen Corporation and currently a subsidiary of Thermo Fisher Scientific Inc.), in respect of certain assets and intellectual property owned by Xcyte Therapies, Inc., or Xcyte, and sold to LTC in December&#160;2005, prior to our reverse merger into Xcyte in March&#160;2006. The assets and technology were not part of our product development plan following the transaction between Xcyte and Cyclacel in March&#160;2006. We have no knowledge of LTC&#8217;s activities and cannot predict when we may receive income under the APA, if any. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">Foreign exchange gains (losses) </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Foreign exchange gains (losses) decreased by $0.3&#160;million to a loss of&#8201;approximately $39,000 for the year ended December&#160;31, 2017 compared to a gain of approximately $0.3&#160;million for the year ended December&#160;31, 2016. The announcement in June&#160;2016 of the referendum of the United Kingdom&#8217;s Membership of the European Union, or Brexit, advising for the exit of the United Kingdom from the European Union caused significant volatility in currency exchange rate fluctuations that resulted in the strengthening of the U.S. dollar against foreign currencies in which we conduct business, primarily the Euro and British Pound. The significant currency exchange rate fluctuations of the U.S. dollar relative to other currencies may adversely affect our results of operations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have a number of intercompany loans in place between our parent company based in New Jersey and our subsidiary based in Scotland. The intercompany loans outstanding are not expected to be repaid in the foreseeable future and the nature of the funding advanced is of a long-term investment nature. Therefore, all unrealized foreign exchange gains or losses arising on the intercompany loans are recognized in other comprehensive income until repayment of the intercompany loan becomes foreseeable. Favorable unrealized foreign exchange movements related to intercompany loans resulted in a gain of&#8201;$14.6&#160;million for the year ended December&#160;31, 2017 and an unfavorable unrealized foreign exchange movement resulted in a loss of&#8201;$27.4&#160;million for the year ended December&#160;31, 2016. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;">The future </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other income (expense), net will continue to be impacted by changes in foreign exchange rates and the receipt of income under the APA. As we are not in control of sales made by LTC, we are unable to estimate the level and timing of income under the APA, if any. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As the funding advanced through intercompany loans is that of a long-term investment in nature, unrealized foreign exchange gains and losses on such funding will be recognized in other comprehensive income (loss) until repayment of the intercompany loan becomes foreseeable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;"><font style=" text-decoration:underline;">Income tax benefit</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Credit is taken for research and development tax credits, which are claimed from the United Kingdom&#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">52</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The following table summarizes total income tax benefit for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands except&#160;percentages): </div>
        <table style="width:456pt;height:49.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Difference </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:263.8pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">$ </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">% </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:2.75pt 0pt 2pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax benefit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:4.6pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(990<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:263.8pt;text-align:left;">
              <div style="white-space:nowrap;">Total Income tax benefit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.6pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:4.6pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(990<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:9.75pt; text-align:right; white-space:nowrap;">(50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.835pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.48pt; width:456pt; line-height:12pt;">The income tax benefit decreased by approximately $.9&#160;million to $.9&#160;million for the year ended December&#160;31, 2017 from $2.0&#160;million for the year ended December&#160;31, 2016. The level of tax credits recoverable is linked directly to qualifying research and development expenditure incurred in any one year. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">The future </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect to continue to be eligible to receive United Kingdom research and development tax credits for the foreseeable future and will continue to elect to receive payment of the tax credit. The amount of tax credits we will receive is entirely dependent on the amount of eligible expenses we incur. As we expect our eligible expenses to be higher in the fiscal year ended December&#160;31, 2018, the level of tax credits recoverable is anticipated to be higher in 2018 compared to the fiscal year ended December&#160;31, 2017. The new US tax reform Bill enacted in December&#160;2017 is not expected to have a material effect on the company&#8217;s results of operations or financial position. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Liquidity and Capital Resources </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a summary of our key liquidity measures as of December&#160;31, 2016 and 2017 (in&#160;thousands): </div>
        <table style="width:416pt;height:97.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">16,520</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,910</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9pt 0pt 1pt 0pt; width:302pt;text-align:left;">Working capital:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:302pt;text-align:left;">
              <div style="margin-left:10pt;">Current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">19,617</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25,974</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:302pt;text-align:left;">
              <div style="margin-left:10pt;">Current liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(5,259<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(4,113<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Total working capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,358</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">21,861</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.49pt; width:456pt; line-height:12pt;">Since our inception, we have relied primarily on the proceeds from sales of common and preferred equity securities to finance our operations and internal growth. Additional funding has come through research and development tax credits, government grants, the sale of product rights, interest on investments, licensing revenue, and a limited amount of product revenue from operations discontinued in September&#160;2012. We have incurred significant losses since our inception. As of December&#160;31, 2017, we had an accumulated deficit of&#8201;$342.5&#160;million. </div>
        <div style="margin-left:20pt; margin-top:12pt; width:436pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash Flows </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cash provided by (used in operating, investing and financing activities for the&#160;years ended December&#160;31,2016 and 2017 is summarized as follows (in thousands): </div>
        <table style="width:416pt;height:67pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,079<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,480<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash provided by (used in) investing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,594</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">14,748</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">53</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-style:italic;">Operating activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash used in operating activities decreased by $2.6&#160;million, from $10.1&#160;million for the year ended December&#160;31, 2016 to $7.5&#160;million for the year ended December&#160;31, 2017. The decrease in cash used by operating activities was primarily the result of a decrease in research and development costs, largely related to the ongoing SEAMLESS trial. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Investing activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash provided by (used in) investing activities decreased by approximately $22,000 for the year ended December&#160;31, 2017 due to capital expenditure on IT equipment. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Financing activities </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash provided by financing activities was $14.8&#160;million for the year ended December&#160;31, 2017, primarily as a result of the approximately $13.7&#160;million in net proceeds from the July&#160;2017 underwritten public offering and approximately $1.1&#160;million in net proceeds from the issuance of common stock under the FBR Sales Agreement entered into in June&#160;2016 offset by dividend payments of approximately $0.2&#160;million to the holders of our 6% Preferred Stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Net cash provided by financing activities was $6.6&#160;million for the year ended December&#160;31, 2016, primarily as a result of approximately $5.1&#160;million in net proceeds from the issuance of common stock under the FBR Sales Agreement and approximately $0.2&#160;million in net proceeds from a Controlled Equity Offering Sales Agreement<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">SM</font> with Cantor Fitzgerald &amp; Co entered into in July&#160;2015 offset by dividend payments of approximately $0.2&#160;million to the holders of our 6% Preferred Stock. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Operating Capital and Capital Expenditure Requirements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We expect to continue to incur substantial operating losses in the future and cannot guarantee that we will generate any significant product revenues until a product candidate has been approved by the FDA or EMA in other countries and successfully commercialized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We believe that existing funds together with cash generated from operations, such as the R&amp;D tax credit, and recent financing activities, are sufficient to satisfy our planned working capital, capital expenditures and other financial commitments through 2019. However, we do not currently have sufficient funds to complete development and commercialization of any of our drug candidates. Current business and capital market risks could have a detrimental effect on the availability of sources of funding and our ability to access them in the future, which may delay or impede our progress of advancing our drugs currently in the clinical pipeline to approval by the FDA or EMA for commercialization. Additionally, we plan to continue to evaluate in-licensing and acquisition opportunities to gain access to new drugs or drug targets that would fit with our strategy. Any such transaction would likely increase our funding needs in the future. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Our future funding requirements will depend on many factors, including but not limited to: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the rate of progress and cost of our clinical trials, preclinical studies and other discovery and research and development activities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs associated with establishing manufacturing and commercialization capabilities; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs of acquiring or investing in businesses, product candidates and technologies; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the costs and timing of seeking and obtaining FDA and EMA approvals; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the effect of competing technological and market developments; and</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">54</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the economic and other terms and timing of any collaboration, licensing or other arrangements into which we may enter. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Until we can generate a sufficient amount of product revenue to finance our cash requirements, which we may never do, we expect to finance future cash needs primarily through public or private equity offerings, debt financings or strategic collaborations. Although we are not reliant on institutional credit finance and therefore not subject to debt covenant compliance requirements or potential withdrawal of credit by banks, we are reliant on the availability of funds and activity in equity markets. We do not know whether additional funding will be available on acceptable terms, or at all. If we are not able to secure additional funding when needed, we may have to delay, reduce the scope of or eliminate one or more of our clinical trials or research and development programs or make changes to our operating plan. In addition, we may have to partner one or more of our product candidate programs at an earlier stage of development, which would lower the economic value of those programs to us. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Contractual Obligations </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following table summarizes our long-term contractual obligations as of December&#160;31, 2017 (in&#160;thousands): </div>
        <table style="width:456pt;height:46pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:153pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="28">
              <div style="white-space:nowrap; text-align:center;">Payments Due by Period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:153pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Less than <br >1 year </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">1&#8201;&#8211;&#8201;3&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">3&#8201;&#8211;&#8201;5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.583pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">More than <br >5&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:153pt;text-align:left;">
              <div style="white-space:nowrap;">Operating Lease Obligation<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">(1)</font></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,679</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">688</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">687</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">956</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="32">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:12.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Operating lease obligations relate primarily to leasing of office and laboratory space at 1 James Lindsay Place, Dundee, UK. The lease, which was entered into in October&#160;2000, expires in October&#160;2025. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Off-Balance Sheet Arrangements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Since our inception, we have not had any off-balance sheet arrangements or relationships with unconsolidated entities or financial partnerships, such as entities often referred to as structured finance or variable interest entities, which are typically established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Critical Accounting Policies </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our discussion and analysis of our financial condition and results of operations is based on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities and expenses and related disclosure of contingent assets and liabilities. We review our estimates on an ongoing basis. We base our estimates on historical experience and on various other factors that we believe to be reasonable under the circumstances. Actual results may differ from these estimates. We believe the judgments and estimates required by the following accounting policies to be critical in the preparation of our consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our significant accounting policies are more fully described in Note 2 to our consolidated financial statements included elsewhere in this report. We believe the following critical accounting policies reflect our more significant estimates and assumptions used in the preparation of our consolidated financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Data management and monitoring of our clinical trials are performed with the assistance of contract research organizations, or CROs, or clinical research associates, or CRAs, in accordance with our standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, we accrue unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">55</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">participation in the trials are expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial. Any initial payment made to the clinical trial site is recognized upon execution of the clinical trial agreements and expensed as research and development expenses. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We grant stock options, restricted stock&#160;units and restricted stock to officers, employees, directors and consultants under the Company&#8217;s 2015 Equity Incentive Plan, or the 2015 Plan. The 2015 Plan replaced the Company&#8217;s Amended and Restated Equity Incentive Plan which expired in 2015. We measure compensation cost for all stock-based awards at fair value on date of grant and recognize compensation over the requisite service period. The fair value of restricted stock and restricted stock&#160;units is determined based on the number of shares granted and the quoted price of our common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using an option-pricing model, which includes variables such as the expected volatility of our share price, the anticipated exercise behavior of our employees, interest rates, and dividend yields. These variables are projected based on our historical data, experience, and other factors. Changes in any of these variables could result in material adjustments to the expense recognized for share-based payments. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We grant certain stock compensation awards that vest only upon achievement of certain performance conditions. If, in our judgment, achievement of those performance conditions is not probable, we do not recognize any compensation cost for those awards. As of December&#160;31, 2017, we have outstanding approximately 344,000 stock option awards that contain one or more performance conditions. We have estimated that approximately 40,000 of these awards are likely to vest, and have recognized less than $1,000 of compensation cost related to these specific awards during the year ended December&#160;31, 2017. Had we determined that the performance conditions for all of the stock compensation awards were probable of being met, we would have recognized significantly more compensation cost in our December&#160;31, 2017 consolidated statement of operations (loss). </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Revenue Recognition </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Revenue arrangements with multiple deliverables are accounted for in accordance with Financial Accounting Standards Board Accounting Standards Codification Subtopic 605-25, <font style="font-style:italic;">Multiple-Element Arrangements</font> (&#8220;ASC 605-25&#8221;). Under ASC 605-25, revenue arrangements with multiple deliverables are divided into separate&#160;units of accounting based on whether certain criteria are met, including whether the delivered item has stand-alone value to the customer. Consideration is allocated among the separate&#160;units of accounting based on their respective standalone selling prices, and the applicable revenue recognition guidance is applied to each of the separate&#160;units. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Non-refundable fees where we have no continuing performance obligations are recognized as revenues when collection is reasonably assured. In situations where continuing performance obligations exist, non-refundable fees are deferred and recognized ratably over the projected performance period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Milestone payments from license or collaboration agreements which are substantive and at risk at the time the agreement is executed are recognized upon completion of the applicable milestone event. Royalty revenues, if any, will be recognized based on reported product sales by third-party licensees. Research funding from any future agreement will be recognized as the related research services are performed. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Recent Accounting Pronouncements Not Yet Effective </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In July&#160;2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&#8220;ASU 2017-11), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2018. Early adoption is permitted, including </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">56</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February&#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&#160;identify the contract with a customer; (2)&#160;identify the performance obligations in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations in the contract; and (5)&#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal&#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company currently intends to use the modified retrospective method when it adopts the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">57</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT7A">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;7A.&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures About Market Risk </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As a smaller reporting company, we are not required to provide information response to this item. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">58</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="TOC2">&#8203;</a><a name="tIT8">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;8.&nbsp;&nbsp;&nbsp;Financial Statements and Supplementary Data </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">INDEX TO CYCLACEL PHARMACEUTICALS, INC. FINANCIAL STATEMENTS </div>
        <table style="width:456pt;height:113.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:427.33pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;text-align:center;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Page </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9.99999999999999pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tREP">Report of Independent Registered Public Accounting Firm </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tREP">60</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCBS">Consolidated Balance Sheets as of December&#160;31, 2016 and 2017 </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tCBS">61</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCSO">Consolidated Statements of Operations (Loss) for the&#160;years ended December&#160;31, 2016 and 2017 </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tCSO">62</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCSC">Consolidated Statements of Comprehensive Loss for the&#160;years ended December&#160;31, 2016 and 2017 </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tCSC">63</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tCSS">Consolidated Statements of Stockholders&#8217; Equity for the&#160;years ended December&#160;31, 2016 and 2017</a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tCSS">64</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tSCF">Consolidated Statements of Cash Flows for the&#160;years ended December&#160;31, 2016 and 2017 </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tSCF">65</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:427.33pt;text-align:left;">
              <div style="white-space:nowrap;"><a href="#tNOT">Notes to Consolidated Financial Statements </a></div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;"><a href="#tNOT">66</a></td>
            <td style="padding:0pt;padding-left:3.335pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">59</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tREP">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">To the Stockholders and the Board of Directors of Cyclacel Pharmaceuticals, Inc. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Opinion on the Financial Statements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have audited the accompanying consolidated balance sheets of Cyclacel Pharmaceuticals, Inc. and its subsidiaries (the Company) as of December&#160;31, 2016 and 2017, the related consolidated statements of operations (loss), comprehensive loss, changes in stockholders&#8217; equity and cash flows for the&#160;years then ended, and the related notes to the consolidated financial statements (collectively, the financial statements). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2016 and 2017, and the results of its operations and its cash flows for the&#160;years then ended, in conformity with accounting principles generally accepted in the United States of America. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Basis for Opinion </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is&#160;to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S.&#160;federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ RSM US LLP </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">We have served as the Company&#8217;s auditor since 2013. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">New York, New York <br >March 30, 2018</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">60</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCBS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:66pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS, INC. <br >CONSOLIDATED BALANCE SHEETS</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">(In thousands, except share and per share amounts) </div>
        <table style="width:456pt;height:498pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">ASSETS</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Current assets:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">16,520</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">23,910</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">3,097</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,064</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">19,617</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">25,974</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Property and equipment, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">19,662</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">26,003</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Current liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">2,497</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">1,558</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Accrued and other current liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,762</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">2,555</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total current liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,259</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,113</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Other liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">130</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">124</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total liabilities </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">5,389</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4,237</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Commitments and contingencies (Note 9)</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Stockholders&#8217; equity:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:336pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December&#160;31, 2016 and December&#160;31, 2017;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:336pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">6% Convertible Exchangeable preferred stock; 335,273 shares issued and outstanding at December&#160;31, 2016 and December&#160;31, 2017. Aggregate preference in liquidation of&#8201; $4,006,512 at December&#160;31, 2016 and December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:336pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Series&#160;A convertible preferred stock; 0 shares and 264 shares issued and outstanding at December&#160;31, 2016 and December&#160;31, 2017, respectively </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:336pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Common stock, $0.001 par value; 100,000,000 shares authorized at December&#160;31, 2016 and December&#160;31, 2017; 4,256,829 and 11,997,447 shares issued and outstanding at December&#160;31, 2016 and December&#160;31, 2017, respectively. </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Additional paid-in capital </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">350,051</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">365,057</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Accumulated other comprehensive loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(743<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:27pt; text-align:right; white-space:nowrap;">(794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Accumulated deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(335,039<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">(342,509<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total stockholders&#8217; equity </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">14,273</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:27pt; text-align:right; white-space:nowrap;">21,766</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total liabilities and stockholders&#8217; equity </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">19,662</td>
            <td style="padding:0pt;padding-left:1.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:27pt; text-align:right; white-space:nowrap;">26,003</td>
            <td style="padding:0pt;padding-left:4.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">61</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSO">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:205pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS, INC. <br >CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">(In thousands, except share and per share amounts) </div>
        <table style="width:456pt;height:359pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Revenues:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Grant revenue </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">843</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Operating expenses:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">9,477</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">4,237</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,516</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">5,254</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Total operating expenses</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">14,993</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">9,491</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Operating loss</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(14,150<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(9,491<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Other income (expense):</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Foreign exchange gains (losses) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">273</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(39<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Interest income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">37</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:10pt;">Other income, net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">66</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">949</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="margin-left:20pt;">Total other income (expense), net </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">376</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,028</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Loss from continuing operations before taxes</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(13,774<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(8,463<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax benefit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Net loss</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend on convertible exchangeable preferred shares </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Beneficial conversion feature of Series&#160;A convertible stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(3,638<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Conversion of Series&#160;A convertible preferred stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(3,537<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Net loss applicable to common shareholders</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(11,991<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(14,846<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">Basic and diluted earnings per common share:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 3.25pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss per share&#8201;&#8211;&#8201;basic and diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(3.50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.95<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Weighted average common shares outstanding </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,424,976</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">7,631,152</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">62</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSC">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:481.5pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS, INC. <br >CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">(In thousands) </div>
        <table style="width:456pt;height:82.5pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:336pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Translation adjustment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">27,204</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(14,687<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;">Unrealized foreign exchange gain (loss) on intercompany loans </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(27,351<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">14,636</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:336pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Comprehensive loss</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,938<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(7,521<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">63</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tCSS">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:18pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">CYCLACEL PHARMACEUTICALS, INC. <br >CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;font-size:10pt;">(In thousands, except share amounts) </div>
      </div>
      <div style="margin-top:18pt;margin-bottom:172.5pt;margin-left:46pt;width:504pt;">
        <table style="width:504pt;height:400.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;height:22.75pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Preferred Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Common Stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Additional <br >Paid-in <br >Capital </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Accumulated <br >Other <br >Comprehensive <br >Loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Accumulated <br >Deficit </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt;" colspan="4" rowspan="2">
              <div style="text-align:center; line-height:9pt; padding-bottom:0pt;">Total <br >Stockholders&#8217; <br >Equity </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;" rowspan="2">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:0pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Shares </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Amount </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:3pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Balances at December&#160;31, 2015</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">335,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">2,965,208</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">342,587</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(596<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(323,159<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">18,835</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Cumulative effect of change in Accounting </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:20pt;">Principle for ASU 2016-09 </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">89</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(89<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Issue of common stock on At Market <br >Issuance sales agreement </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">1,291,621</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">6,793</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">6,794</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Stock-based compensation </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">782</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">782</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Preferred stock dividends </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Unrealized foreign exchange on intercompany loans </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(27,351<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(27,351<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Translation adjustment </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">27,204</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">27,204</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Balances at December&#160;31, 2016</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">335,273</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,256,829</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">350,051</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(743<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">(335,039<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">14,273</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">8,872</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">3,154,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">13,681</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">13,684</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Series&#160;A Preferred stock conversions </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(8,608<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">4,304,000</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">4</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(4<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Warrant exercise </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">99,500</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">199</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Issue of common stock on At Market <br >Issuance sales agreement </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">183,118</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">1</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">1,065</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">1,066</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Stock-based compensation </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">266</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">266</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Preferred stock dividends </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10.5pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:2.5pt 0pt 0.5pt 0pt; width:159.2pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Unrealized foreign exchange on intercompany loans </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">14,636</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">14,636</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Translation adjustment </div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(14,687<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:26.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:22.5pt; text-align:right; white-space:nowrap;">(14,687<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:159.2pt;text-align:left;">
              <div style="margin-left:10pt;">Loss for the period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:33pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:9pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:9pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:159.2pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Balances at December&#160;31, 2017</div>
            </td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">335,537</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:6.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:33pt; text-align:right; white-space:nowrap;">11,997,447</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:7.5pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:6.54pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:0.969999999999999pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24pt; text-align:right; white-space:nowrap;">365,057</td>
            <td style="padding:0pt;padding-left:0pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">(794<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.66pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:26.25pt; text-align:right; white-space:nowrap;">(342,509<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.165pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt; width:3pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:22.5pt; text-align:right; white-space:nowrap;">21,766</td>
            <td style="padding:0pt;padding-left:6.49pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="50">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:201.5pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;font-size:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;font-size:10pt;">64</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tSCF">&#8203;</a></div>
      <div style="margin-top:46pt;margin-bottom:91pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS, INC. <br >CONSOLIDATED STATEMENTS OF CASH FLOWS</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">(In thousands) </div>
        <table style="width:456pt;height:475pt;margin-top:7pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:344pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Cash flows from operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Adjustments to reconcile net loss to net cash used in operating activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Depreciation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">133</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">32</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Gain on disposal of property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(12<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation expense </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">782</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">266</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Changes in operating assets and liabilities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Prepaid expenses and other assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">439</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,232</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Accounts payable and other current liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">370</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(1,540<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Net cash used in operating activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(10,079<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(7,480<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Cash flows from investing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Purchases of property and equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds from sale of property and equipment </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash provided by (used in) investing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">9</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(13<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:9.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Cash flows from financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds from issuance of equity securities, net of issuance costs </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">6,794</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">14,749</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Proceeds from the exercise of stock options and warrants, net of issuance costs</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">200</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Payment of preferred stock dividend </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Net cash provided by financing activities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">6,594</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">14,748</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Effect of exchange rate changes on cash and cash equivalents</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(444<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">135</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Net decrease in cash and cash equivalents</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(3,920<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">7,390</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents at beginning of period </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">20,440</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,520</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:344pt;text-align:left;">
              <div style="white-space:nowrap;">Cash and cash equivalents at end of period </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">16,520</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">23,910</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Supplemental cash flow information:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Cash received during the period for:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Interest </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">118</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,965</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,815</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">Non cash financing activities:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:344pt;text-align:left;">
              <div style="margin-left:10pt;">Accrual of preferred stock dividends </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:2.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">50</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:2pt;height:12pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:10pt;">The accompanying notes are an integral part of these consolidated financial statements.</div>
      </div>
      <div style="margin-top:2pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">65</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a><a name="tNOT">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CYCLACEL PHARMACEUTICALS, INC.</div>
        <div style="margin-top:6pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">NOTES TO CONSOLIDATED FINANCIAL STATEMENTS </div>
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">1.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Organization of the Company and Basis of Presentation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Cyclacel Pharmaceuticals Inc., (&#8220;Cyclacel&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel&#8217;s transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and exploratory subgroups from a Phase&#160;3 study of sapacitabine in elderly patients with AML. Cyclacel&#8217;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, drug candidates developed by the Company typically will require approvals or clearances from the FDA, EMA or other similar regulatory agencies in other countries prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was denied approval or clearance or such approval was delayed, or is unable to obtain the necessary financing to complete development and approval, there will be a material adverse impact on the Company&#8217;s financial condition and results of operations. The Company has relied upon government grants to fund its earlier stage programs and does not expect to be able to continue to be successful in obtaining government grants to fund the Company&#8217;s research and development expenditure. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Through December&#160;31, 2017, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity securities, private placements of securities, government grants, research and development tax credits, interest on investments, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of&#8201;$11.8&#160;million and $7.5&#160;million for the&#160;years ended December&#160;31, 2016 and 2017, respectively. As of December&#160;31, 2017, the Company had an accumulated deficit of&#8201;$342.5&#160;million. The Company expects to continue to generate operating losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidates, its preclinical programs and its administrative organization. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Going Concern </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern for a period of at least one year from the date the financial statements are issued. The Company expects that its cash of&#8201;&#8201;$23.9&#160;million as of December&#160;31, 2017 will be sufficient to fund its operating expenses and capital expenditure requirements through to the end of 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued, including: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a.<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company&#8217;s current financial condition, including its liquidity sources </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b.<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company&#8217;s conditional and unconditional obligations due or anticipated within one year </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">c.<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The funds necessary to maintain the Company&#8217;s operations considering its current financial condition, obligations, and other expected cash flows, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">d.<br ></div>
        <div style=" float:left; margin-top:7.59pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Other conditions and events, when considered in conjunction with the above that may adversely affect the Company&#8217;s ability to meet its obligations. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">66</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The future viability of the Company beyond 2019 is dependent on its ability to raise additional capital to finance its operations. The Company will need to raise substantial additional capital to pursue the transcriptional regulation program, evaluating CYC065, a CDK inhibitor, in patients with advanced cancers or the DNA damage response program, evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers Additional funding may not be available to the Company on favorable terms, or at all. If the Company is unable to obtain additional funds, it will need to reduce operating expenses, enter into a collaboration or other similar arrangement with respect to development and/or commercialization rights to sapacitabine or its CDK inhibitors, if available, or be forced to delay or reduce the scope of its CDK inhibitors and sapacitabine development programs, including any potential regulatory filings related to the SEAMLESS study, and/or limit or cease its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Reverse Stock Split </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;27, 2016, the Company completed a one-for-twelve reverse stock split (the &#8220;Reverse Stock Split&#8221;), which reduced the number of shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the par value of Cyclacel&#8217;s common stock remained unchanged at $0.001 per share. The Reverse Stock Split reduced the number of shares of the Company&#8217;s common stock that were outstanding at May&#160;27, 2016 from 36,075,730 to 3,006,311 after the cancellation of fractional shares. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise held fractional shares of the Company&#8217;s common stock as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. All amounts related to number of shares and per share amounts have been retroactively restated in these consolidated financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Basis of Presentation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Certain amounts in the prior year&#8217;s financial statements have been reclassified to conform to the current year&#8217;s presentation. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">2.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Summary of Significant Accounting Policies </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Use of Estimates </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals, stock-based compensation expense and the recognition of revenue. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&#8217;s consolidated financial statements. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Foreign Currency and Currency Translation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">67</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive loss. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s cash and cash equivalents balance at December&#160;31, 2017 was $23.9&#160;million and it maintains its cash accounts in several entities both within the United States and the United Kingdom. The total cash balances for amounts held in the United States are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per account. The Company has cash balances exceeding the balance insured by the FDIC that totaled approximately $23.0&#160;million at December&#160;31, 2017. The total cash balances for amounts held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme (&#8220;FSCS&#8221;) up to &#163;75,000 per account. The Company has cash balances exceeding the balance insured by the FSCS that totaled approximately $0.5&#160;million at December&#160;31, 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Property and Equipment </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five&#160;years. Amortization of leasehold improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, currently between five and fifteen&#160;years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss. Expenditures for maintenance and repairs are charged to operating expenses as incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Impairment of Long-lived Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Fair Value of Financial Instruments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Level&#160;1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">68</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:4pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:4pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Level&#160;2&#8201;&#8212;&#8201;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Segments </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company is managed and operated as one business which is focused on using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information with respect to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment with development operations in two geographic areas, namely the United States and the United Kingdom. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Revenue Recognition </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;"><font style=" text-decoration:underline;">Collaboration, supply and licensing agreements</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Consideration received is allocated to each of the separable elements in an arrangement using the relative selling price method. An element is separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor-specific objective evidence (&#8220;VSOE&#8221;) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. Revenue is recognized for each separate element when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Milestone payments which are non-refundable, non-creditable and contingent on achieving clinical milestones are recognized as revenues either on achievement of such milestones if the milestones are considered substantive or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. When determining if a milestone is substantive, the Company considers the following factors: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The degree of certainty in achieving the milestone </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The frequency of milestone payments </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The Company&#8217;s efforts, which result in achievement of the milestone </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">The amount of the milestone payment relative to the other deliverables and payment terms, and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8226;<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Whether the milestone payment is related to future performance or deliverables </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company records as deferred revenue any amounts received prior to satisfying the revenue recognition criteria. Deferred revenue not expected to be recognized within the next twelve&#160;months is reported as non-current deferred revenue. The Company recognized $0 and $0.2&#160;million deferred revenue as of December&#160;31, 2016 and 2017 respectively. The deferred revenue reported as of December&#160;31, 2017 relates to a prepayment received from ManRos Therapeutics SA for a development milestone that is not expected to be achieved until mid-2018 (see Note 3 for additional details). </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">69</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;">Royalty income is recognized when the licensee sells the underlying product. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;"><font style=" text-decoration:underline;">Grant revenue</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Other Income </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Other income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part of the Company&#8217;s ongoing operations and activities. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Research and Development Expenditures </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Research and development expenses consist primarily of costs associated with the Company&#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Clinical Trial Accounting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Data management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations (&#8220;CROs&#8221;) or clinical research associates (&#8220;CRAs&#8221;) in accordance with the Company&#8217;s standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are recognized upon execution of the clinical trial agreement and expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Patent Costs </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Patent prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Leased Assets </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The costs of operating leases are charged to operations on a straight-line basis over the lease term. Operating leases relate primarily to the Company&#8217;s research and development facilities and corporate headquarters. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Stock-based Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over three or four&#160;years. However, certain awards granted to members of the Company&#8217;s Board of Directors vest in their entirety on the one-year anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain&#160;years, the Company granted restricted stock&#160;units to employees that were dependent upon the fulfillment of certain clinical and financial conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes expense in the period that the award becomes probable of vesting (See Note 11&#8201;&#8212;&#8201;Stock-Based Compensation). </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified. The Company accounts for forfeitures as they occur. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">70</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The fair value of restricted stock and restricted stock&#160;units is determined based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected term of the award, interest rates, and dividend yields. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company relies exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Income Taxes </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue &amp; Customs (&#8220;HMRC&#8221;), the United Kingdom&#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Net Loss Per Common Share </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2016 and 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Comprehensive Income (Loss) </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">71</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the&#160;years ended December&#160;31, 2016 and 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Recently Issued Accounting Pronouncements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In July&#160;2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&#8220;ASU 2017-11&#8221;), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2018. Early adoption is permitted, including adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In August&#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In February&#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In May&#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&#160;identify the contract with a customer; (2)&#160;identify the performance obligations in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations in the contract; and (5)&#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal&#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">72</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company intends to use the modified retrospective method upon adoption of the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.59pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">3.<br ></div>
        <div style=" float:left; margin-top:15.59pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Significant Contracts </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Distribution, Licensing and Research Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of products employing the technology or falling under claims of patent applications. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The most significant licensing agreement is with Daiichi Sankyo. Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee, Phase&#160;3 entry milestone, and certain past reimbursements have been paid. A further $10.0&#160;million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones which are primarily related to regulatory approval in various territories, and the Company&#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten&#160;years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal, with the right of first refusal ending sixty days after notification, to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six&#160;months&#8217; notice, or twelve&#160;months&#8217; notice, if after a launch of a sapacitabine-based product, or by either party for material default. There were no milestones earned in 2016 or 2017. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Collaboration, Supply and Licensing Agreements </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In June&#160;2015, the Company entered into a collaboration, licensing and supply agreement with ManRos Therapeutics SA (&#8220;ManRos&#8221;), for the exclusive development and commercialization of the Company&#8217;s oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (&#8220;CF&#8221;). Among other terms of the agreement, ManRos licensed rights to the Company&#8217;s proprietary clinical data to enable clinical development of seliciclib for CF indications. The agreement provides for supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to the Company&#8217;s know-how to facilitate these trials. The Company received an up-front payment in July&#160;2015 and reached a development milestone in September&#160;2015. The Company will receive further milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">73</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The upfront and milestone payments have been allocated to the separate deliverables within the arrangement and recognized over the period in which the deliverables are met. The consideration allocated to the main deliverable&#8201;&#8212;&#8201;the transfer of the Company&#8217;s know-how&#8201;&#8212;&#8201;was determined based on its estimated standalone selling price, using a market approach that identified similar license deals for a Phase&#160;1/2 asset. The Company reviewed various licensing transactions in the public domain in the CF area and similar stage of asset development. In the year ended December&#160;31, 2016 and 2017, the Company recognized revenue of&#8201;&#8201;$0 and $0, respectively. In the fourth quarter of 2017, the Company received a $150,000 payment from ManRos in anticipation of ManRos achieving a clinical milestone in 2018. This payment has been recorded as deferred revenues on the balance sheet (part of other current liabilities) as the milestone was not achieved as of December&#160;31, 2017. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">4.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Cash and Cash Equivalents </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a summary of cash and cash equivalents at December&#160;31, 2016 and 2017 (in&#160;thousands): </div>
        <table style="width:416pt;height:79.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Cash </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">5,332</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1,103</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:2.167pt 0pt 1.833pt 0pt; width:302pt;white-space:normal;text-align:left;">
              <div style="margin-left:10pt; text-indent:-10pt;">Investments with original maturity of less than three&#160;months at the time of purchase </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,188</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.167pt 0pt 1.833pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">22,807</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:302pt;text-align:left;">
              <div style="margin-left:10pt;">Total cash and cash equivalents </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">16,520</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">23,910</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">Investments with original maturity of less than three&#160;months at time of purchase are made up of money market funds and commercial paper. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">5.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Fair Value of Financial Assets and Liabilities </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands): </div>
        <table style="width:416pt;height:76.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:194pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="text-align:center;">Fair Value Measurements <br >as of December&#160;31, 2016 Using: </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:194pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:194pt;text-align:left;">Assets:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:194pt;text-align:left;">
              <div style="margin-left:10pt;">Cash equivalents </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,188</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,188</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:194pt;text-align:left;">
              <div style="margin-left:20pt;">Total Assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,188</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">11,188</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:76.4999999999999pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:194pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:0pt;text-align:center;" colspan="22">
              <div style="text-align:center;">Fair Value Measurements <br >as of December&#160;31, 2017 Using: </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:194pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;1 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;2 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Level&#160;3 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">Total </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:194pt;text-align:left;">Assets:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:15pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:194pt;text-align:left;">
              <div style="margin-left:10pt;">Cash equivalents </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">22,807</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:15pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">22,807</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:194pt;text-align:left;">
              <div style="margin-left:20pt;">Total Assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">22,807</td>
            <td style="padding:0pt;padding-left:4.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:15pt; text-align:right; white-space:nowrap;">&nbsp;&nbsp;&nbsp;&#8212;</td>
            <td style="padding:0pt;padding-left:8.5pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">22,807</td>
            <td style="padding:0pt;padding-left:7.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">74</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">6.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Prepaid Expenses and Other Current Assets </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">The following is a summary of prepaid expenses and other current assets at December&#160;31, 2016 and 2017 (in thousands): </div>
        <table style="width:416pt;height:127.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development tax credit receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,730</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,054</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Prepayments </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">867</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">363</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Delaware tax receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">25</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">VAT receivable </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">327</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">409</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Deposits </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">132</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Other current assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">41</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">81</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Prepaid expenses and other current assets </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">3,097</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,064</td>
            <td style="padding:0pt;padding-left:10.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:18.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">7.<br ></div>
        <div style=" float:left; margin-top:18.99pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Property and Equipment </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Property and equipment consisted of the following at December&#160;31, 2016 and 2017 (in thousands): </div>
        <table style="width:416pt;height:113pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;height:9.25pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:44.85pt;" rowspan="2">
              <div style="white-space:nowrap; text-align:center; line-height:9pt; padding-bottom:0pt;">Lives in&#160;years </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;" rowspan="2">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;height:0pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:251.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:251.15pt;text-align:left;">
              <div style="white-space:nowrap;">Leasehold improvements </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0.5pt 1.5pt 0pt; width:44.85pt;">
              <div style="text-align:right;">5 to 15&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">792</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">835</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:251.15pt;text-align:left;">
              <div style="white-space:nowrap;">Research and laboratory equipment </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0.5pt 1.5pt 0pt; width:44.85pt;">
              <div style="text-align:right;">3 to 5&#8203;</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,438</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,854</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.15pt;text-align:left;">
              <div style="white-space:nowrap;">Office equipment and furniture </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0.5pt 2.5pt 0pt; width:44.85pt;">
              <div style="text-align:right;">3 to 5&#8203;</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,157</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">1,236</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:251.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.5pt 0pt; width:44.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,387</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">6,925</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:251.15pt;text-align:left;">
              <div style="white-space:nowrap;">Less: accumulated depreciation and amortization </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #CCEEFF;padding:0pt 0.5pt 0.5pt 0pt; width:44.85pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,342<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(6,896<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:251.15pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0.5pt 0.75pt 0pt; width:44.85pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:3.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:6.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="17">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">Depreciation and amortization expense for property and equipment was $0.1&#160;million and $32,000 for the&#160;years ended December&#160;31, 2016 and 2017, respectively. During the year ended December&#160;31, 2016, the Company sold fully depreciated assets for proceeds of approximately $12,000. The Company did not sell any property or equipment during the year ended December&#160;31, 2017. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">8.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Accrued and Other Current Liabilities </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Accrued and other current liabilities consisted of the following at December&#160;31, 2016 and 2017 (in&#160;thousands): </div>
        <table style="width:416pt;height:82.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:308pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:308pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:308pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">2,138</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,645</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:308pt;text-align:left;">
              <div style="white-space:nowrap;">Accrued legal and professional fees </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">194</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">248</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:308pt;text-align:left;">
              <div style="white-space:nowrap;">Other current liabilities </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">430</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">662</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:308pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,762</td>
            <td style="padding:0pt;padding-left:5.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,555</td>
            <td style="padding:0pt;padding-left:8.645pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">Other current liabilities in 2017 include $150,000 deferred income in respect of payment received in advance of achieving a milestone under the ManRos agreement (see Note 3&#8201;&#8212;&#8201;Significant Contracts).</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">75</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style=" float:left; line-height:11pt; margin-top:12pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">9.<br ></div>
        <div style=" float:left; margin-top:12pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Commitments and Contingencies </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">General </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Please refer to <font style="font-style:italic;">Note 3&#8201;&#8212;&#8201;Significant Contracts</font> for further discussion of certain of the Company&#8217;s commitments and contingencies. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Leases </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In October&#160;2000, the Company entered into a twenty-five year lease for its research and development facility in Dundee, Scotland. Rent expense, which includes lease payments related to the Company&#8217;s research and development facilities and corporate headquarters and other rent related expenses was $0.5 and $0.5&#160;million for each of the&#160;years ended December&#160;31, 2016 and 2017, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities leases as at December&#160;31, 2017 (in thousands): </div>
        <table style="width:416pt;height:123pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:348.75pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;text-align:center;" colspan="4">
              <div style="text-align:center;">Operating Lease <br >Obligation </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">2018 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">348</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">2019 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">344</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">2020 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">344</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">2021 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">344</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">2022 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">343</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">thereafter </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">956</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:348.75pt;text-align:left;">
              <div style="white-space:nowrap;">Total future minimum lease obligations </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">2,679</td>
            <td style="padding:0pt;padding-left:13.77pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="8">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:16pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">10.<br ></div>
        <div style=" float:left; margin-top:16pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Stockholders&#8217; Equity </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;"><font style=" text-decoration:underline;">The Company has completed the following equity issuances during the periods presented in the consolidated financial statements.</font></div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">July&#160;2017 Underwritten Public Offering </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On July&#160;21, 2017, the Company issued (i)&#160;3,154,000 Class&#160;A Units for $2 per unit, each consisting of one share of the Company&#8217;s common stock, and a warrant to purchase one share of common stock (the &#8220;Class&#160;A Warrants&#8221;), and (ii) 8,872 Class&#160;B Units, each consisting of one share of the Company&#8217;s Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;A Preferred Stock&#8221;), convertible into 500 shares of Common Stock at the initial conversion price, and a warrant to purchase a number of shares of common stock equal to $1,000.00 divided by the conversion price (the &#8220;Class&#160;B Warrants&#8221;) for $1,000 per unit. The net proceeds to the Company after the underwriters&#8217; exercise in full of the over-allotment option were approximately $13,700,000, after deducting underwriting discounts, commissions and other estimated offering expenses. The Class&#160;A Units and Class&#160;B Units have no stand-alone rights and the shares of common stock, Series&#160;A Preferred Stock and the Class&#160;A and Class&#160;B Warrants comprising those&#160;units were immediately separable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The common stock, Class&#160;A Warrants and Class&#160;B Warrants (together the &#8220;Warrants&#8221;) and Series&#160;A Preferred Stock are freestanding financial instruments. The Warrants are classified within equity (as a component of additional paid-in capital) in the consolidated balance sheet and are not remeasured on a recurring basis. The Series&#160;A Preferred Stock is classified within permanent equity in the consolidated balance sheet. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The proceeds from the Class&#160;A Units were allocated to common stock and Class&#160;A Warrants on a relative fair value basis. Similarly, the proceeds from the Class&#160;B Units were allocated to the Series&#160;A Preferred Stock and the Class&#160;B Warrants based on their relative fair values. Following the allocation of the offering proceeds associated with the Class&#160;B units, the Company determined that the Series&#160;A Preferred Stock had a beneficial conversion feature with an aggregate intrinsic value of approximately $3,638,000. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">76</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">As&#160;the Series&#160;A Preferred Stock contained no stated redemption date, and the conversion feature could be exercised at any time, the discount associated with the beneficial conversion feature was immediately charged against additional paid-in capital and treated as a deemed dividend for both financial reporting and earnings per share purposes. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">June&#160;2016 At Market Issuance </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On June&#160;23, 2016, the Company entered into an At Market Issuance Sales Agreement (the &#8220;FBR Sales Agreement&#8221;) with FBR Capital Markets &amp; Co. (&#8220;FBR&#8221;), under which the Company was authorized to issue and sell shares of its common stock, from time to time, through FBR, acting as its sales agent. Under the FBR Sales Agreement, FBR was authorized to sell such shares of common stock by any method that is deemed to be an &#8220;at the market offering&#8221;. The Company was not obligated to make any sales of common stock under the FBR Sales Agreement, and the Company was required to pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares of common stock sold through FBR. During the year ended December&#160;31, 2017, the Company sold 183,118 shares of common stock under the FBR Sales agreement for net proceeds of approximately $1.1&#160;million, and the FBR Sales Agreement terminated automatically by its terms. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">July&#160;2015 Controlled Equity Offering SM </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On July&#160;10, 2015, the Company entered into a Controlled Equity Offering<font style=" position:relative; bottom:4.25pt;font-size:7.5pt;">SM</font> Sales Agreement with Cantor Fitzgerald (the &#8220;Cantor Sales Agreement&#8221;) under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $8.35&#160;million through Cantor Fitzgerald. Under the Cantor Sales Agreement, Cantor Fitzgerald may sell shares of Cyclacel common stock by methods deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will pay Cantor Fitzgerald a commission of up to 3.0% of the gross sales price per share sold. Cyclacel is not obligated to make any sales under the Cantor Sales Agreement. Effective as of June&#160;17, 2016, and prior to entering into the FBR Sales Agreement, the Company and Cantor agreed to terminate the Cantor Sales Agreement. The Company had issued an aggregate of 114,078 shares pursuant to the Cantor Sales Agreement of which 41,996 were issued during the year ended December&#160;31, 2016 for net proceeds of approximately $0.2&#160;million. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">The following is a description of the Company&#8217;s outstanding equity instruments. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;"><font style=" text-decoration:underline;">Warrants</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, there were 7,490,500 warrants outstanding, each with an exercise price of $2.00. All such warrants were issued in connection with the July&#160;2017 Underwritten Public Offering and are immediately exercisable. The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing the cashless exercise provision of the warrants. On the expiration date, unexercised warrants will automatically be exercised via the &#8220;cashless&#8221; exercise provision. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Warrants exercised during the year ended December&#160;31, 2016 and 2017 were 0 and 99,500 respectively. Gross proceeds during the year for such exercises amounted to $199,000 with a weighted average exercise price of&#8201; $2.00 per share.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">77</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="margin-left:20pt; width:436pt; line-height:12pt;"><font style=" text-decoration:underline;">Series&#160;A Preferred Stock</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">8,872 shares of the Company&#8217;s Series&#160;A Preferred Stock were issued in the July&#160;2017 Underwritten Public Offering. Each share of Series&#160;A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing $1,000 by the initial conversion price of&#8201; $2.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series&#160;A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the year ended December&#160;31, 2017, 8,608 shares of the Series&#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&#160;31, 2017, 264 shares of the Series&#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&#160;A Preferred Stock issued and outstanding at December&#160;31, 2017, are convertible into 132,000 shares of common stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In the event of a liquidation, the holders of shares of the Series&#160;A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series&#160;A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series&#160;A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to the Series&#160;A Preferred Stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Subject to certain conditions, at any time following the issuance of the Series&#160;A Preferred Stock, the Company has the right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock in the event that (i)&#160;the volume weighted average price of our common stock for 30 consecutive trading days (the &#8220;Measurement Period&#8221;) exceeds 300% of the initial conversion price of the Series&#160;A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Series&#160;A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series&#160;A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;"><font style=" text-decoration:underline;">6% Convertible Exchangeable Preferred Stock</font></div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, there were 335,273 shares of the Company&#8217;s 6% Convertible Exchangeable (&#8220;Preferred Stock&#8221;) issued and outstanding at an issue price of&#8201;$10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February&#160;1, 2005. Any dividends must be declared by the Company&#8217;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of&#8201;$10.00 per share, plus accrued and unpaid dividends. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company&#8217;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the Certificate of Designations governing the terms of the Company&#8217;s Preferred Stock, including the requisite financial analysis and determination of a surplus. Accrued and unpaid dividends in arrears on preferred stock were $0.7&#160;million, or $1.95 per share, of preferred stock, as of December&#160;31, 2016 and 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s shares of common stock at a conversion rate of approximately 0.00507 shares of common stock for each share of Preferred Stock based on a price of&#8201;&#8201;$1,974. The Company has reserved 1,698 shares of common stock for </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">78</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">issuance upon conversion of the remaining shares of Preferred Stock outstanding at December&#160;31, 2016. The shares of previously-converted Preferred Stock have been retired, cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#8217;s common stock has exceeded $2,961, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&#160;24, 2011. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of&#8201;$10.00 per share. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s 6% Convertible Subordinated Debentures (&#8220;Debentures&#8221;) at the rate of&#8201;&#8201;&#8201;&#8201; $10.00 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&#160;years after the Exchange Date and have terms substantially similar to those of the Preferred Stock. No such exchanges have taken place as of December&#160;31, 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">For the year ended December&#160;31, 2017, the company declared dividends of&#8201;$0.15 per share quarterly on its Preferred Stock. These dividends were paid on May&#160;1, August&#160;1 and November&#160;1, 2017, and February&#160;1, 2018, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Common Stock </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Exercise of Stock Options </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">No stock options were exercised during the&#160;years ended December&#160;31, 2016 and 2017. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.78pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">11.<br ></div>
        <div style=" float:left; margin-top:15.78pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Stock-Based Compensation </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Stock based compensation has been reported within the following expense line items on the consolidated statement of operations for the&#160;years ended 2016 and 2017, as shown in the following table (in&#160;thousands): </div>
        <table style="width:416pt;height:72pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:290pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Year Ended <br >December&#160;31, <br >2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Year Ended <br >December&#160;31, <br >2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">305</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">72</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">General and administrative </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">477</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">194</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:290pt;text-align:left;">
              <div style="white-space:nowrap;">Stock-based compensation costs before income taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">782</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">266</td>
            <td style="padding:0pt;padding-left:17pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:18.78pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">2015 Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On May&#160;22, 2015, the Company&#8217;s stockholders approved the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The company has reserved 458,753 shares of the Company&#8217;s common stock under the 2015 </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">79</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">Plan. The 2015 Plan replaces the 2006 Equity Incentive Plan (the &#8220;2006 Plan&#8221;), under which there were no remaining reserved shares to be granted. Stock option awards granted under the Company&#8217;s equity incentive plans have a maximum life of 10&#160;years and generally vest over a one to four-year period from the date of grant. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During 2016, the Company granted 197,841 options to employees and directors with a grant date fair value of approximately $0.7&#160;million. Of these options, 189,091 are performance based, which will vest upon the fulfilment of certain clinical conditions and will terminate if they have not vested by December&#160;31, 2020. The Company determined that the satisfaction of the vesting criteria was not probable throughout 2016 and 2017 and, as a result, did not record any expense related to these awards for the&#160;years ended December&#160;31, 2016 and 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There were 170,853 options granted during the year ended December&#160;31, 2017. Of these options, 158,853 are performance based, which will vest upon the fulfillment of certain clinical conditions. The Company determined that the satisfaction of one of the conditions was probable as of December&#160;31, 2017, but that the other vesting criteria related to these awards were not probable as of December&#160;31, 2017. As such, the Company recognized compensation cost for these grants under the expectation that 25% of these awards will vest. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The weighted average grant-date fair values of options granted during the&#160;years ended December&#160;31, 2016 and 2017 were $3.66 and $1.59, respectively. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">As of December&#160;31, 2017, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions amounted to approximately $0.2&#160;million, which will be amortized over the weighted-average remaining requisite service period of 0.9&#160;years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">During the&#160;years ended December&#160;31, 2016 and 2017, the Company did not settle any equity instruments with cash. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There were no stock option exercises during the&#160;years ended 2016 and 2017. No income tax benefits were recorded for the&#160;years ended December&#160;31, 2016 and 2017 because the Company has accumulated net operating losses for tax purposes and is not likely to benefit from any deductions associated with exercises of granted option awards. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">Outstanding Options </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">A summary of the share option activity and related information is as follows: </div>
        <table style="width:456pt;height:211.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Number of <br >Options <br >Outstanding </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Exercise Price <br >Per Share </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Weighted <br >Average <br >Remaining <br >Contractual <br >Term (Years) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt;" colspan="4">
              <div style="text-align:center;">Aggregate <br >Intrinsic <br >Value ($000s) </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Options outstanding at December&#160;31, 2015 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">206,298</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">72.60</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">8.09</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Granted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">197,841</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">4.68</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Exercised </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Cancelled/forfeited </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(14,760<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">396.83</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Options outstanding at December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">389,379</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">25.80</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">5.83</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">121</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Granted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">170,853</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">1.93</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 0.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Exercised </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 0.5pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Cancelled/forfeited </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">(24,615<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">179.92</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.25pt 0pt 2.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Options outstanding at December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">535,617</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:21pt; text-align:right; white-space:nowrap;">11.10</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.23</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #CCEEFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.25pt 0pt 2.5pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Unvested at December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">386,682</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:21pt; text-align:right; white-space:nowrap;">3.64</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:13.5pt; text-align:right; white-space:nowrap;">8.84</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:1px solid #FFFFFF; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:230.37pt;text-align:left;">
              <div style="white-space:nowrap;">Vested and exercisable at December&#160;31, 2017</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">148,755</td>
            <td style="padding:0pt;padding-left:4.22pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:21pt; text-align:right; white-space:nowrap;">30.49</td>
            <td style="padding:0pt;padding-left:7.505pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:13.5pt; text-align:right; white-space:nowrap;">6.65</td>
            <td style="padding:0pt;padding-left:12.955pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;padding-bottom:1.75pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:12.57pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="26">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">80</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model using the following assumptions: </div>
        <table style="width:456pt;height:92.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:276pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:75pt;">
              <div style="text-align:center;">Year ended <br >December&#160;31, 2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:81pt;">
              <div style="text-align:center;">Year ended <br >December&#160;31, 2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:276pt;text-align:left;">
              <div style="white-space:nowrap;">Expected term (years) </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:75pt;">
              <div style="text-align:center;">5&#8201;&#8211;&#8201;6 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:81pt;">
              <div style="text-align:center;">6 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276pt;text-align:left;">
              <div style="white-space:nowrap;">Risk free interest rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:75pt;">
              <div style="text-align:center;">1.370%&#8201;&#8211;&#8201;1.500% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81pt;">
              <div style="text-align:center;">1.890%&#8201;&#8211;&#8201;2.265% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276pt;text-align:left;">
              <div style="white-space:nowrap;">Volatility </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:75pt;">
              <div style="text-align:center;">98%&#8201;&#8211;&#8201;104% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81pt;">
              <div style="text-align:center;">108% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276pt;text-align:left;">
              <div style="white-space:nowrap;">Expected dividend yield over expected term </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:75pt;">
              <div style="text-align:center;">0.00% </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81pt;">
              <div style="text-align:center;">0.00% </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:276pt;text-align:left;">
              <div style="white-space:nowrap;">Resulting weighted average grant date fair value </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:75pt;">
              <div style="text-align:center;">$3.66 </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:81pt;">
              <div style="text-align:center;">$1.59</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:22.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">12.<br ></div>
        <div style=" float:left; margin-top:22.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Employee Benefit Plans </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">Pension Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan totaled approximately $57,000 and $54,000 for the&#160;years ended December&#160;31, 2016 and 2017, respectively. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;font-weight:bold;">401(k) Plan </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The 401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of 100% of the employee&#8217;s deferral or 6% of the U.S. employee&#8217;s qualifying compensation. The 401(k) Plan is intended to qualify under Section&#160;401(k) of the Internal Revenue Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to the employees until withdrawn. Company matching contributions are tax deductible by the Company when made. Company employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit of&#8201;&#8201;$18,000 if under 50&#160;years old and $24,000 if over 50&#160;years old and to have those funds contributed to the 401(k) Plan. The Company made contributions of approximately $32,000 and $28,000 to the 401(k) Plan for the&#160;years ended December&#160;31, 2016 and 2017, respectively. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">13.<br ></div>
        <div style=" float:left; margin-top:15.99pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Taxes </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">(Loss) income from continuing operations before taxes is comprised of the following components for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands): </div>
        <table style="width:416pt;height:67.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Domestic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,011<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:13.5pt; text-align:right; white-space:nowrap;">(127<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Foreign </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,763<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(8,336<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations before taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,774<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:13.5pt; text-align:right; white-space:nowrap;">(8,463<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:12.98pt; width:456pt; line-height:12pt;">The benefit (provision) for income taxes from continuing operations consists of the following (in&#160;thousands): </div>
        <table style="width:416pt;height:98pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Current&#8201;&#8211;&#8201;domestic </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Current&#8201;&#8211;&#8201;foreign </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Current&#8201;&#8211;&#8201;total </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 0.5pt 0pt; min-width:11.25pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3.5pt 0pt 2.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Deferred&#8201;&#8211;&#8201;domestic </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax benefit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:17.25pt; text-align:right; white-space:nowrap;">1,983</td>
            <td style="padding:0pt;padding-left:7.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:11.25pt; text-align:right; white-space:nowrap;">993</td>
            <td style="padding:0pt;padding-left:14pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">81</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">The Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of&#8201;$2.0&#160;million and $1.0&#160;million for the&#160;years ended December&#160;31, 2016 and 2017, respectively, represent UK research and development (&#8220;R&amp;D&#8221;) tax credits for expenditures in the United Kingdom that are refundable. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss from continuing operations before income taxes is as follows (in thousands): </div>
        <table style="width:416pt;height:174.5pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 3.25pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Loss from continuing operations before taxes </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(13,774<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2.5pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(8,463<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Income tax expense computed at statutory federal tax rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(4,683<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(2,877<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Disallowed expenses and non-taxable income </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">12</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">3</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Loss surrendered to generate R&amp;D credit </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,945</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">856</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Additional research and development tax relief </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,827<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(1,262<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Change in valuation allowance </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,029</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(4,487<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Foreign items, including change in tax rates, and other </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,238</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">1,901</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Change in US Tax Rate </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">4,112</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:302pt;text-align:left;">
              <div style="white-space:nowrap;">Other foreign items </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">303</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">761</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.75pt 0pt; width:302pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(1,983<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(993<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:8.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.59pt; width:456pt; line-height:12pt;">On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;), which made significant changes to U.S. federal income tax law. The Company expects that certain aspects of the Tax Act will positively impact the Company&#8217;s future after-tax earnings in the U.S., primarily due to the lower federal statutory tax rate. Set forth below is a discussion of certain provisions of the Tax Act and our preliminary assessment of the effect of such provisions on the Company&#8217;s results of operations, cash flows and consolidated financial statements. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Tax Act will affect 2018 and forward, including but not limited to a reduction in the federal corporate rate from 35.0% to 21.0%, elimination of the corporate alternative minimum tax, a new limitation on the deductibility of certain executive compensation, limitations on net operating losses generated after December&#160;31, 2017 and various other items. We do not expect these changes to have a material impact on our financial statements due to the accumulated net operating losses in the U.S. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Tax Act provides for a one-time &#8220;deemed repatriation&#8221; of accumulated unrepatriated foreign earnings determined as of November&#160;2, 2017, or December&#160;31, 2017, whichever is greater. We do not expect to be subject to this provision due to the accumulated deficit in our foreign earnings for tax purposes. The Tax Act also created a new requirement that certain income earned by controlled foreign corporations must be included currently in the gross income of the U.S. shareholder under the Global Intangible Low-Taxed Income (GILTI) provision. We do not expect that any future foreign earnings will be subject to GILTI due to our US net operating losses. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In December&#160;2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Act. SAB 118 provides for a measurement period that should not extend beyond one year from the Act enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&#8220;ASC 740&#8221;). In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. Based on our initial analysis of </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">82</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the Tax Act, the Company has made reasonable estimates of its 2017 impact. As a result of the federal corporate tax rate reduction from 35% to 21%, we re-measured certain deferred tax assets and liabilities, which resulted in a reduction in our DTA of approximately $4.1&#160;million, that was offset by a decrease in our valuation allowance. As guidance and technical corrections, if any, are provided in the upcoming quarters, the Company will adjust its provisional estimates as required. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The primary difference between the income tax benefit at the statutory rate and the Company&#8217;s effective income tax expense for the year ended December&#160;31, 2017 was primarily attributable to the change in our valuation allowance and foreign operations. </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">Significant components of the Company&#8217;s deferred tax assets are shown below (in thousands): </div>
        <table style="width:416pt;height:143pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:317.5pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:2.5pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:3.25pt 0pt 2.5pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Net operating loss and tax credit carryforwards </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">42,851</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">38,948</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Depreciation, amortization and impairment of property and equipment </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">137</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">111</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Stock options </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">2,365</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">1,807</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Research and development credits </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,021</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">4,021</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Other </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 1.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Deferred tax assets </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">49,374</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.25pt 0pt 1.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">44,887</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3.5pt 0pt 2.5pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Valuation allowance for deferred tax assets </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(49,374<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3.5pt 0pt 2.5pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(44,887<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.25pt 0pt 2.75pt 0pt; width:317.5pt;text-align:left;">
              <div style="white-space:nowrap;">Net deferred tax assets </div>
            </td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:3.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt; width:2.5pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3.25pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:4.73pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4pt;line-height:4pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:10.8pt; width:456pt; line-height:12pt;">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. The Company adopted a 17% tax rate as of December&#160;31, 2017 in respect of the measurement of deferred taxes arising in the United Kingdom, which reflects the currently enacted tax rate and the anticipated timing of the unwinding of the deferred tax balances. In respect of the measurement of deferred taxes arising in the U.S, the Company has adopted a 21% tax rate as of December&#160;31, 2017. This has reduced from 34% as of December&#160;31, 2016 due to changes in U.S. tax laws enacted in December&#160;2017. The effect of the change in tax rates on the consolidated statement of operations is $nil, after consideration of the change in valuation allowance. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">A valuation allowance has been established, as realization of such assets is uncertain. The Company&#8217;s management evaluated the positive and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance of approximately $44.9&#160;million has been established at December&#160;31, 2017. The valuation allowance has decreased by approximately $4.5&#160;million in 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">In certain circumstances, as specified in the Tax Reform Act of 1986, due to ownership changes, the Company&#8217;s ability to utilize its net operating loss (&#8220;NOL&#8221;) carryforwards may be limited. The benefit of deductions from the exercise of stock options is included in the NOL carryforwards. As of December&#160;31, 2016 and 2017, the Company had federal NOLs of&#8201;$28.4&#160;million and $28.4&#160;million and foreign NOLs of&#8201;$178.2&#160;million and $186.2&#160;million, respectively. The Company&#8217;s federal NOLs will start to expire in 2026, and the state NOLs totaling $18.7&#160;million will start expiring in 2023. The Company&#8217;s foreign NOL&#8217;s do not expire under UK tax law. However, for losses created after April&#160;1, 2017 the use of these NOLs is restricted to an annual &#163;5&#160;million allowance in each standalone company or group and above this allowance, there will be a 50% restriction in the profits that can be covered by losses brought forward. The amount of profits restricted for the year ended December&#160;31, 2017 is $0. As of December&#160;31, 2017, the Company had a US&#160;R&amp;D credit carryforward of&#8201;$4.0&#160;million which will start expiring in 2019. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Utilization of the NOLs may be subject to a substantial annual limitation under Section&#160;382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section&#160;382 study as of June&#160;30, 2014 noting there was no ownership change from </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">83</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:12pt;">the Company&#8217;s formation through that date. No update to this study has been performed through December&#160;31, 2017. Management has evaluated all significant tax positions at December&#160;31, 2016 and 2017 and concluded that there are no material uncertain tax positions. The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Tax year 2016 remains open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the United Kingdom and the United States, as carryforward attributes generated in&#160;years past may still be adjusted upon examination by the United Kingdom&#8217;s H.M. Revenue &amp; Customs, the Internal Revenue Service (&#8220;IRS&#8221;) or state tax authorities. The Company is currently not under examination by the IRS or any other jurisdictions for any tax&#160;years. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because it is our intent to permanently reinvest such earnings outside of the United States. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that intention. As a result of the repeal of the Section&#160;902 foreign tax credit under the Tax Act, future distributions would not be offset by a foreign tax credit. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">14.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Net Loss Per Share </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows: </div>
        <table style="width:416pt;height:162pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Years ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:296pt;text-align:left;">Numerator:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="margin-left:10pt;">Net loss </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Dividend on convertible exchangeable preferred shares </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(200<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(201<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Beneficial conversion feature of Series&#160;A convertible stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">(3,638<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Conversion of Series&#160;A convertible preferred stock </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(3,537<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Net loss attributable to common shareholders </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(11,991<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(14,846<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.25pt 0pt 1pt 0pt; width:296pt;text-align:left;">Denominator:</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:1.667pt 0pt 1.333pt 0pt; width:296pt;white-space:normal;text-align:left;">
              <div style="margin-left:20pt; text-indent:-10pt;">Weighted-average number of common shares used in loss per share&#160;&#8211; basic and diluted </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">3,424,976</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:1.667pt 0pt 1.333pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">7,631,152</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Loss per share&#8201;&#8211;&#8201;basic and diluted </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(3.50<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:-0.204999999999998pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">(1.95<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:2.795pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:13.49pt; width:456pt; line-height:12pt;">Potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">84</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC2">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:416pt;height:91.5pt;margin-left:20pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Stock options </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">389,378</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">535,616</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Convertible preferred stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">1,698</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">1,698</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Series&#160;A preferred stock </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:30.75pt; text-align:right; white-space:nowrap;">132,000</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Common stock warrants </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">7,490,500</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">Total shares excluded from calculation </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:24.75pt; text-align:right; white-space:nowrap;">391,076</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:0pt; text-align:right; ">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:30.75pt; text-align:right; white-space:nowrap;">8,159,814</td>
            <td style="padding:0pt;padding-left:5.295pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:19.48pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">15.<br ></div>
        <div style=" float:left; margin-top:19.48pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Geographic Information </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Geographic information for the&#160;years ended December&#160;31, 2016 and 2017 is as follows (in thousands): </div>
        <table style="width:416pt;height:128pt;margin-left:20pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">Year Ended December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:296pt;text-align:left;">Revenue</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United Kingdom </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">843</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Total Revenue</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">843</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8212;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 1pt 0pt; width:296pt;text-align:left;">Net loss</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United States </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:23.25pt; text-align:right; white-space:nowrap;">(2,211<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:19.5pt; text-align:right; white-space:nowrap;">(127<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United Kingdom </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(9,580<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,343<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;border-bottom:1px solid #FFFFFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Total Net Loss</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:23.25pt; text-align:right; white-space:nowrap;">(11,791<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:4.48pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:19.5pt; text-align:right; white-space:nowrap;">(7,470<font style="position:absolute;">)</font></td>
            <td style="padding:0pt;padding-left:9.98pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <table style="width:416pt;height:142pt;margin-left:20pt;margin-top:13pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2pt 0pt; width:0pt;text-align:center;" colspan="10">
              <div style="white-space:nowrap; text-align:center;">December&#160;31, </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #FFFFFF;padding:0pt 0pt 0.5pt 0pt; width:296pt;text-align:left;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2016 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:2.75pt 0pt 2pt 0pt;" colspan="4">
              <div style="white-space:nowrap; text-align:center;">2017 </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 1pt 0pt; width:296pt;text-align:left;">Total Assets</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United States </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">15,197</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">23,522</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United Kingdom </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">4,465</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">2,481</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Total Assets</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">19,662</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">26,003</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:8.25pt 0pt 1pt 0pt; width:296pt;text-align:left;">Long Lived Assets, net</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3pt 0pt 1pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United States </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">2</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:3pt 0pt 1pt 0pt; min-width:21pt; text-align:right; white-space:nowrap;">0</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;background-color:#CCEEFF;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="border-bottom:1px solid #CCEEFF;padding:3pt 0pt 2pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;">United Kingdom </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">43</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:3.75pt; text-align:right; ">&#8203;</td>
            <td style="padding:3pt 0pt 2pt 0pt;border-bottom:1px solid #000000; min-width:21pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;border-bottom:1px solid #CCEEFF;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #CCEEFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:right;vertical-align:bottom;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.75pt 0pt 2.75pt 0pt; width:296pt;text-align:left;">
              <div style="white-space:nowrap;font-weight:bold;">Total Long Lived Assets, net</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">45</td>
            <td style="padding:0pt;padding-left:6.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:3.75pt; text-align:right; ">$</td>
            <td style="padding:2.75pt 0pt 2pt 0pt;border-bottom:3px double #000000; min-width:21pt; text-align:right; white-space:nowrap;">29</td>
            <td style="padding:0pt;padding-left:9.145pt;width:0pt;">&#8203;</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="height:4.5pt;line-height:4.5pt;">
            <td style="padding:0pt;font-size:0pt;line-height:0pt;" colspan="14">&#8203;</td>
          </tr>
        </table>
        <div style=" float:left; line-height:11pt; margin-top:19.48pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;font-weight:bold;">16.<br ></div>
        <div style=" float:left; margin-top:19.48pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:435.5pt;font-weight:bold;">Subsequent Events </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">On March&#160;7, 2018, the Board of Directors declared a quarterly cash dividend in the amount of&#8201;&#8201;$0.15 per share on the Company&#8217;s Preferred Stock. The cash dividend is due to be paid on May&#160;1, 2018 to the holders of record of the Preferred Stock as of the close of business on April&#160;11, 2018. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">85</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT9">&#8203;</a><a name="tIT9A">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="width:456pt; line-height:11pt;font-weight:bold;">Item&#160;9.&nbsp;&nbsp;&nbsp;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">None. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;9A.&nbsp;&nbsp;&nbsp;Controls and Procedures </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">(a) Disclosure Controls: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. An evaluation was performed under the supervision and with the participation of the Company&#8217;s management, including the Chief Executive Officer and Chief Financial Officer, on the effectiveness of the Company&#8217;s disclosure controls and procedures as of December&#160;31, 2017. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of December&#160;31, 2017, the end of the period covered by this report, our disclosure controls and procedures were effective. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We have concluded that the consolidated financial statements in this Annual Report on Form 10-K fairly present, in all material respects, our financial position, results of operations and cash flows as of the dates, and for the periods, presented, in conformity with U.S. GAAP. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">(b) Management&#8217;s Annual Report on Internal Control Over Financial Reporting: </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Internal control over financial reporting refers to the process designed by, or under the supervision of, our Chief Executive Officer and Chief Financial Officer, and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, and includes those policies and procedures that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:7pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:6.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Internal control over financial reporting cannot provide absolute assurance of achieving financial reporting objectives because of its inherent limitations. Internal control over financial reporting is a process that involves human diligence and compliance and is subject to lapses in judgment and breakdowns resulting from human failures. Internal control over financial reporting also can be circumvented by collusion or improper override. Because of such limitations, there is a risk that material misstatements may not be prevented or detected on a timely basis by internal control over financial reporting. However, these inherent limitations are known features of the financial reporting process, and it is possible to design into the process safeguards to reduce, though not eliminate, this risk. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in Internal Control&#8201;&#8212;&#8201;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in 2013. </div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">86</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT9B">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-indent:20pt; width:456pt; line-height:12pt;">Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December&#160;31, 2017. Management based this assessment on criteria for effective internal control over financial reporting described in &#8220;Internal Control-Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission. Management&#8217;s assessment included an evaluation of the design of the Company&#8217;s internal control over financial reporting and testing of the operational effectiveness of its internal control over financial reporting. Management reviewed the results of its assessment with the Audit Committee. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Based on this assessment, management determined that, as of December&#160;31, 2017, the Company&#8217;s internal control over financial reporting was effective to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with accounting principles generally accepted in the United States of America. </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">This annual report does not include an attestation report of the Company&#8217;s registered independent public accounting firm regarding internal control over financial reporting. Management&#8217;s report was not subject to attestation by the Company&#8217;s registered public accounting firm pursuant to rules of the Securities and Exchange Commission that permit the Company to provide only management&#8217;s report in this annual report. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-style:italic;">(c) Changes in Internal Control Over Financial Reporting </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">There have not been any changes in the Company&#8217;s internal control over financial reporting (as defined in Rule&#160;13a-15(f)) during the fiscal year ended December&#160;31, 2017 that have materially affected, or are reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;9B.&nbsp;&nbsp;&nbsp;Other information </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Not applicable.<br ></div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">87</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT10">&#8203;</a><a name="tIT11">&#8203;</a><a name="tIT12">&#8203;</a><a name="tIT13">&#8203;</a><a name="tIT14">&#8203;</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART III </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;10.&nbsp;&nbsp;&nbsp;Directors, Executive Officers and Corporate Governance </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information required by item 10 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2017 fiscal year pursuant to Regulation&#160;14A for its 2018 Annual Meeting of Stockholders. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;11.&nbsp;&nbsp;&nbsp;Executive Compensation </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information required by item 11 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2017 fiscal year pursuant to Regulation&#160;14A for its 2018 Annual Meeting of Stockholders. </div>
        <div style=" float:left; line-height:11pt; margin-top:15.98pt; margin-bottom:0pt; text-align:left; width:44pt;white-space:nowrap;font-weight:bold;">Item&#160;12.<br ></div>
        <div style=" float:left; margin-top:15.98pt; margin-bottom:0pt; line-height:11pt; text-align:left; width:411.5pt;font-weight:bold;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information required by item 12 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2017 fiscal year pursuant to Regulation&#160;14A for its 2018 Annual Meeting of Stockholders. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;13.&nbsp;&nbsp;&nbsp;Certain Relationships and Related Transactions, and Director Independence </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information required by item 13 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2017 fiscal year pursuant to Regulation&#160;14A for its 2017 Annual Meeting of Stockholders. </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;14.&nbsp;&nbsp;&nbsp;Principal Accountant Fees and Services </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">The information required by item 14 is incorporated herein by reference from the Company&#8217;s Proxy Statement, which will be filed with the SEC within 120&#160;days after the end of the Company&#8217;s 2017 fiscal year pursuant to Regulation&#160;14A for its 2018 Annual Meeting of Stockholders.</div>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">88</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a><a name="tIT15">&#8203;</a></div>
      <div style="margin-top:46pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">PART IV </div>
        <div style="margin-top:12pt; width:456pt; line-height:11pt;font-weight:bold;">Item&#160;15.&nbsp;&nbsp;&nbsp;Exhibits and Financial Statement Schedules </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:6.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(a)<br ></div>
        <div style=" float:left; margin-top:6.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Documents filed as part of this report are as follows: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.2pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(1)<br ></div>
        <div style=" float:left; margin-top:7.2pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">See &#8220;Index to Consolidated Financial Statements and Financial Statement Schedules&#8221; at Item&#160;8 of this Annual Report on Form 10-K. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(2)<br ></div>
        <div style=" float:left; margin-top:7.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">Other financial statement schedules have not been included because they are not applicable or the information is included in the financial statements or notes thereto. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:40pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(3)<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:395.5pt;">The following is a list of exhibits filed as part of this Annual Report on Form 10-K. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:7.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(b)<br ></div>
        <div style=" float:left; margin-top:7.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">Exhibits: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;height:494.5pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:42pt;">Exhibit&#160;<br >Number </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex1-1.htm">1.1</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex1-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex1-1.htm">&#8203;</a></td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex1-1.htm">Engagement Letter, dated March&#160;&#160;3, 2015, by and between Cyclacel Pharmaceuticals, Inc. and H.C.&#160;Wainwright &amp; Co., LLC (previously filed Exhibit&#160;1.1 to the Registrant&#8217;s Current Report on Form&#160;8-K, originally filed with the SEC on March&#160;&#160;4, 2015, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex1-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915005578/t1501582_ex10-1.htm">1.2</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915005578/t1501582_ex10-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915005578/t1501582_ex10-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915005578/t1501582_ex10-1.htm">Controlled Equity Offering Sales Agreement, dated July&#160;10, 2015, by and among the Company and Cantor Fitzgerald &amp; Co. (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally field with the SEC on July&#160;10, 2015, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915005578/t1501582_ex10-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916016223/t1601627_ex1-1.htm">1.3</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916016223/t1601627_ex1-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916016223/t1601627_ex1-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916016223/t1601627_ex1-1.htm">At Market Issuance Sales Agreement, dated as of June&#160;23, 2016, between the Company and FBR Capital Markets &amp; Co. (previously filed as Exhibit 1.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed wih the SEC on June&#160;23, 2016, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916016223/t1601627_ex1-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">3.1</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 3.1 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on April 1, 2013, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913026207/a13-1449_1ex3d1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">3.2</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">Certificate of Amendment to the Amended and Restated Certificate of Incorporation of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May 27, 2016, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104916015620/t1601433_ex3-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">3.3</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">Amended and Restated Bylaws of Cyclacel Pharmaceuticals, Inc. (Previously filed as Exhibit 3.2 to the Registrant&#8217;s Annual Report on Form 10-K, File No. 000-50626, originally filed with the SEC on March&#160;31, 2011 and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311031629/c14674exv3w2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">3.4</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">Certificate of Designation of 6% Convertible Exchangeable Preferred Stock (previously filed as Exhibit 3.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on November 5, 2004, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504186583/dex32.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">3.5</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">Certificate of Designation of Series A Preferred Stock (previously filed as Exhibit 3.5 to the Registrant&#8217;s Registration Statement on Form S-1 (No. 333-218305), originally filed with the SEC on July&#160;17, 2017, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex3-5.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">4.1</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">Specimen of Common Stock Certificate (previously filed as Exhibit 4.1 to Registrant&#8217;s Registration Statement on Form S-1, File No. 333-109653, originally filed with the SEC on February 17, 2004, as subsequently amended, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504023989/dex41.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">4.2</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">Specimen of Preferred Stock Certificate of Designation (previously filed as Exhibit 3.2 to Registrant&#8217;s Registration Statement on Form S-1, File No. 333-119585, originally filed with the SEC on October 21, 2004, as subsequently amended, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312504174775/dex32.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">4.3</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc. Common Stock (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on July&#160;1, 2011, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311063684/c19538exv4w1.htm">&#8203;</a></td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">89</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;height:593.5pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:42pt;">Exhibit&#160;<br >Number </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">4.4</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">Registration Rights Agreement, dated as of December&#160;14, 2012, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit 4.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;17, 2012, and incorporated herein by reference). </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912084453/a12-29566_1ex4d1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">4.5</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">Registration Rights Agreement, dated November 14, 2013, by and between the Company and Aspire Capital Fund, LLC (previously filed as Exhibit 4.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, originally filed with the SEC on November 14, 2013, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex4d1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">4.6</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">Form of Warrant to purchase shares of Cyclacel Pharmaceuticals, Inc.&#8217;s Common Stock (previously filed as Exhibit 4.3 to the Registrant&#8217;s Registration Statement on Form S-1 (No.&#160;333-218305), originally filed with the SEC on July&#160;17, 2017, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917006728/t1702095_ex4-3.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312505245710/dex21.htm">10.1</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312505245710/dex21.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312505245710/dex21.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312505245710/dex21.htm">Stock Purchase Agreement, dated December&#160;15, 2005, between Xcyte Therapies, Inc., and Cyclacel Group plc (previously filed as Exhibit 2.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;20, 2005, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312505245710/dex21.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312506008742/dex21.htm">10.2</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312506008742/dex21.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312506008742/dex21.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312506008742/dex21.htm">Amendment No. 1 to the Stock Purchase Agreement, dated January 13, 2006, between Xcyte Therapies Inc., and Cyclacel Group plc (previously filed as exhibit 2.1 to the Registrant&#8217;s current report on Form 8-K filed with the Commission on January 19, 2006, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000119312506008742/dex21.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">10.3&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">Amended and Restated Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May 24, 2012, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465912039873/a12-13056_1ex10d1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">10.4&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">Equity Incentive Plan (previously filed as Exhibit 10.1 to Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on May 22, 2015, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915004588/t1501247_ex10-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">10.5&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of January 1, 2014 (previously filed as Exhibit 10.4 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;24, 2014, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-4.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">10.6&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">Employment Agreement by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of January 1, 2014 (previously filed as Exhibit 10.5 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;24, 2014, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex10-5.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">10.7&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">Form of Change in Control Agreement by and between Cyclacel Pharmaceuticals, Inc. and Dr.&#160;Judy Chiao, dated as of December&#160;10, 2010 (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;14, 2010, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012310113504/c09737exv10w1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w2.htm">10.8</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w2.htm">Agreement between the Company and Scottish Enterprise dated March&#160;27, 2006 (previously filed as Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2009, originally filed with the SEC on August 13, 2009, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w3.htm">10.9</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w3.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w3.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w3.htm">Addendum to Agreement between the Company and Scottish Enterprise dated June&#160;22, 2009 (previously filed as Exhibit 10.3 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2009, originally filed with the SEC on August 13, 2009, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012309034517/c89287exv10w3.htm">&#8203;</a></td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">90</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:42pt;">Exhibit&#160;<br >Number </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">10.10#</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">License Agreement by and between Sankyo Co., Ltd. and Cyclacel Limited, dated September 10, 2003, and letter amendments dated April 1, 2004 and April 28, 2004 (previously filed as Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2011, originally filed with the SEC on August 12, 2011, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">10.11#</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">Amendment No. 4 to License Agreement between Daiichi Sankyo Company, Limited and Cyclacel Limited, dated July&#160;11, 2011 (previously filed as Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q, for the quarterly period ended June&#160;30, 2011, originally filed with the SEC on August 12, 2011, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000095012311076776/c17919exv10w2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex10d1.htm">10.12</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex10d1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex10d1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex10d1.htm">Common Stock Purchase Agreement, dated November 14, 2013, by and between Cyclacel Pharmaceuticals, Inc. and Aspire Capital Fund, LLC (previously filed as Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q, originally filed with the SEC on November 14, 2013, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000110465913084900/a13-19747_1ex10d1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex10-1.htm">10.13</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex10-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex10-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex10-1.htm">Form of Securities Purchase Agreement, by and between Cyclacel Pharmaceuticals, Inc. and certain investors (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on March&#160;4, 2015, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104915001620/t1500497_ex10-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">10.14&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of December&#160;22, 2016 (previously filed as Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;1, 2017, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-14.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">10.15&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of December&#160;22, 2016 (previously filed as Exhibit 10.15 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;1, 2017, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104917003095/t1700098_ex10-15.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">10.16&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of June&#160;27, 2017 (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on June&#160;27, 2017, and incorporated by reference).. </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">10.17&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">Employment Extension Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of June&#160;27, 2017 (previously filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on June&#160;27, 2017, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417034440/v469810_ex10-2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">10.18&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Spiro Rombotis, dated as of December&#160;6, 2017 (previously filed as Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;12, 2017, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">10.19&#8224;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">Employment Agreement, by and between Cyclacel Pharmaceuticals, Inc. and Paul McBarron, dated as of December&#160;6, 2017 (previously filed as Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K, originally filed with the SEC on December&#160;12, 2017, and incorporated by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000114420417063359/tv481140_ex10-2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">21</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">Subsidiaries of Cyclacel Pharmaceuticals, Inc. (previously filed as Exhibit 21 to the Registrant&#8217;s Annual Report on Form 10-K, originally filed with the SEC on March&#160;26, 2014, and incorporated herein by reference).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="http://www.sec.gov/Archives/edgar/data/1130166/000157104914000943/t1400075_ex21.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="tv489461_ex23-1.htm">23.1*</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex23-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex23-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:402pt;"><a style="-sec-extract:exhibit" href="tv489461_ex23-1.htm">Consent of Independent Registered Public Accounting Firm.</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv489461_ex23-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-1.htm">31.1*</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-1.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:402pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-1.htm">Certification of Spiro Rombotis, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-1.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:10pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-2.htm">31.2*</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-2.htm">&#8203;</a></td>
            <td style="padding:3.5pt 0pt 1.5pt 0pt; width:402pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-2.htm">Certification of Paul McBarron, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv489461_ex31-2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-1.htm">32.1**</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-1.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-1.htm">&#8203;</a></td>
            <td style="padding:2.167pt 0pt 1.5pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="tv489461_ex32-1.htm">Certification of Spiro Rombotis, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code).</a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-1.htm">&#8203;</a></td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">91</div>
      </div>
      <hr >
    </div>
    <div style="page-break-after:always; width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <table style="width:456pt;margin-top:0pt;border-collapse: collapse;">
          <tr style="line-height:9pt;white-space:nowrap;text-align:left;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:42pt;">Exhibit&#160;<br >Number </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.167pt 0pt; width:402pt;text-align:center;">
              <div style="white-space:nowrap; text-align:center;">Description</div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:42pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-2.htm">32.2**</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-2.htm">&#8203;</a></td>
            <td style="padding:0pt; width:6pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-2.htm">&#8203;</a></td>
            <td style="padding:1.917pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;"><a style="-sec-extract:exhibit" href="tv489461_ex32-2.htm">Certification of Paul McBarron, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (Subsections (a) and (b) of Section 1350, Chapter 63 of Title 18, United States Code). </a></td>
            <td style="padding:0pt; width:0pt;"><a style="-sec-extract:exhibit" href="tv489461_ex32-2.htm">&#8203;</a></td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:42pt;">101</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:2.167pt 0pt 0.833pt 0pt; width:402pt;white-space:normal;">The following materials from Cyclacel Pharmaceuticals, Inc.&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017, formatted in XBRL (Extensible Business Reporting Language): (i) the Condensed Consolidated Statements of Income, (ii) the Condensed Consolidated Balance Sheets, (iii) the Condensed Consolidated Statements of Cash Flows, and (iv)&#160;Notes to Condensed Consolidated Financial Statements.</td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
        <div style="margin-top:14.49pt; width:456pt;">
          <div style="margin-left: 0pt; width: 108pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">&#8224;<br ></div>
        <div style=" float:left; margin-top:11.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Indicates management compensatory plan, contract or arrangement.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.97pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">#<br ></div>
        <div style=" float:left; margin-top:9.97pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Confidential treatment has been granted with respect to certain portions of this exhibit, which portions have been omitted and filed separately with the Securities and Exchange Commission as part of an application for confidential treatment pursuant to the Securities and Exchange Act of 1934, as amended.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">*<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Filed herewith.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:9.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">**<br ></div>
        <div style=" float:left; margin-top:9.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Furnished herewith.</div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
      </div>
      <div style="clear:both;font-size:0pt;">&#8203;</div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">92</div>
      </div>
      <hr >
    </div>
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;"><a style="text-decoration:none;color:#003366;" href="#TOC">TABLE OF CONTENTS</a></div>
      <div style="margin-top:46pt;height:660pt;margin-left:70pt;width:456pt;">
        <div style="text-align:center; width:456pt; line-height:11pt;font-weight:bold;">SIGNATURES </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:11.5pt;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned. </div>
        <table style="width:462pt;margin-top:14pt;border-collapse: collapse;">
          <tr style="line-height:9.99999999999999pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 0.5pt 0pt; width:198pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1.833pt 0pt; width:0pt;" colspan="4">CYCLACEL PHARMACEUTICALS, INC. </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 1pt 0pt; width:198pt;">Date: March 30, 2018 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:9.167pt 0pt 1pt 0pt; min-width:246pt;white-space:normal;">
              <div style=" float:left; line-height:10pt; margin-top:0pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">By:<br ></div>
              <div style=" float:left; line-height:10pt; text-align:left; width:225.5pt;">/s/ Paul McBarron</div>
              <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
              <div style="margin-left:20.03pt; margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 225.97pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-left:20.03pt; margin-top:2pt;">Paul McBarron <br >Chief Operating Officer, Chief Financial Officer &amp; <br >Executive Vice President, Finance <br >(Principal Financial and Accounting Officer)</div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td colspan="3">&#8203;</td>
          </tr>
        </table>
        <div style="text-indent:20pt; margin-top:16.99pt; width:456pt; line-height:12pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated. </div>
        <table style="width:456pt;height:341.5pt;margin-top:14pt;border-collapse: collapse;">
          <tr style="line-height:8pt;white-space:nowrap;text-align:center;vertical-align:bottom;font-style:normal;font-weight:bold;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:8pt;">
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:120pt;">
              <div style="white-space:nowrap; text-align:center;">Signature </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:192pt;">
              <div style="white-space:nowrap; text-align:center;">Title </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:6pt;">&#8203;</td>
            <td style="border-bottom:1px solid #000000;padding:0pt 0pt 2.5pt 0pt; width:120pt;">
              <div style="white-space:nowrap; text-align:center;">Date </div>
            </td>
            <td style="padding:0pt;border-bottom:1px solid #FFFFFF; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.583pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Spiro Rombotis</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Spiro Rombotis </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.583pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">President &amp; Chief Executive Officer <br >(Principal Executive Officer) and Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.583pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 1.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Paul McBarron</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Paul McBarron </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 1.167pt 0pt; width:192pt;white-space:normal;">
              <div style="text-align:center;">Chief Operating Officer, Chief Financial Officer &amp; Executive Vice President, Finance (Principal Financial and Accounting Officer) and Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 1.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Dr.&#160;David U&#8217;Prichard</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Dr.&#160;David U&#8217;Prichard </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Chairman </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Dr.&#160;Christopher Henney</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Dr.&#160;Christopher Henney </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Vice Chairman </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Sir John Banham</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Sir John Banham </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Samuel L. Barker</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Samuel L. Barker </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Gregory Hradsky</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Gregory Hradsky </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018 </div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
          <tr style="line-height:11pt;white-space:nowrap;text-align:center;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">/s/ Lloyd Sems</div>
              <div style="margin-top:1.5pt;">
                <div style="margin-left: 0pt; width: 120pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:1pt; text-align:center;">Lloyd Sems </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:192pt;">
              <div style="text-align:center;">Director </div>
            </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:14.833pt 0pt 2.167pt 0pt; width:120pt;">
              <div style="text-align:center;">March 30, 2018</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <div style="margin-top:16pt;margin-bottom:21.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:5pt; text-align:center; width:456pt; line-height:11pt;">93</div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>2
<FILENAME>tv489461_ex23-1.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k_DIV_09_ex23-1 - none - 1.0770795s</title>
  </head>
  <body style="width:595.31pt;">
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:6pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">Exhibit&#160;23.1&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">We consent to the incorporation by reference in the Registration Statements (Nos. 333-219055, 333-205153, 333-183483, and 333-143786) on Form S-8 and (Nos. 333-211046 and 333-187801) on Form&#160;S-3 of Cyclacel Pharmaceuticals, Inc. of our report dated March&#160;30, 2018, relating to the consolidated financial statements of Cyclacel Pharmaceuticals, Inc. and subsidiaries, appearing in this Annual Report on Form 10-K of Cyclacel Pharmaceuticals, Inc. for the year ended December&#160;31, 2017. </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ RSM US LLP </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">New York, New York<br >March 30, 2018</div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>3
<FILENAME>tv489461_ex31-1.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k_DIV_10_ex31-1 - none - 0.705033s</title>
  </head>
  <body style="width:595.31pt;">
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:6pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">Exhibit&#160;31.1&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">I, Spiro Rombotis, certify that: </div>
        <div style=" float:left; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">I have reviewed this report on Form 10-K for the year ended December&#160;31, 2017 of Cyclacel Pharmaceuticals, Inc.; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2.<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">3.<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">4.<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15(d)-15(f)) for the registrant and have: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">c)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">d)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting: and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">5.<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions): </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.99pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a)<br ></div>
        <div style=" float:left; margin-top:8.99pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Date: March 30, 2018 </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ Spiro Rombotis</div>
        <div style="margin-top:0.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 180pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;">Spiro Rombotis </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">President &amp; Chief Executive Officer<br >(Principal Executive Officer) </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>4
<FILENAME>tv489461_ex31-2.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k_DIV_11_ex31-2 - none - 0.7001505s</title>
  </head>
  <body style="width:595.31pt;">
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:6pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">Exhibit&#160;31.2&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTIFICATIONS PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002 </div>
        <div style="margin-left:20pt; margin-top:6pt; width:436pt; line-height:12pt;">I, Paul McBarron, certify that: </div>
        <div style=" float:left; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">1.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">I have reviewed this report on Form 10-K for the year ended December&#160;31, 2017 of Cyclacel Pharmaceuticals, Inc.; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">2.<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">3.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">4.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e) and internal control over financial reporting (as defined in Exchange Act rules 13a-15(f) and 15(d)-15(f)) for the registrant and have: </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a)<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.18pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b)<br ></div>
        <div style=" float:left; margin-top:8.18pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of the financial statements for external purposes in accordance with generally accepted accounting principles; </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">c)<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report on such evaluation; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">d)<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; line-height:12pt; margin-top:8.19pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">5.<br ></div>
        <div style=" float:left; margin-top:8.19pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:435.5pt;">The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the Registrant&#8217;s board of directors (or persons performing the equivalent functions): </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.38pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">a)<br ></div>
        <div style=" float:left; margin-top:8.38pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.39pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">b)<br ></div>
        <div style=" float:left; margin-top:8.39pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Date: March 30, 2018 </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">/s/ Paul McBarron</div>
        <div style="margin-top:0.5pt; width:456pt;">
          <div style="margin-left: 0pt; width: 180pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
        </div>
        <div style="margin-top:4pt; width:456pt; line-height:12pt;">Paul McBarron </div>
        <div style="margin-top:6pt; width:456pt; line-height:12pt;">Chief Operating Officer, Chief Financial Officer<br >and Executive Vice President, Finance<br >(Principal Financial Officer) </div>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>5
<FILENAME>tv489461_ex32-1.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k_DIV_12_ex32-1 - none - 0.80073s</title>
  </head>
  <body style="width:595.31pt;">
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:6pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">Exhibit&#160;32.1&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (of subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Cyclacel Pharmaceuticals, Inc. (the&#160;&#8220;Company&#8221;) hereby certifies, to such officer&#8217;s knowledge, that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2017 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">Date: March 30, 2018 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div>/s/ Spiro Rombotis</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 222pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Spiro Rombotis<br >President &amp; Chief Executive Officer</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>6
<FILENAME>tv489461_ex32-2.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
  <head>
    <title>tv489461-10k_DIV_13_ex32-2 - none - 0.8388135s</title>
  </head>
  <body style="width:595.31pt;">
    <div style=" width:595.3pt;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
      <div style="padding:0pt;margin:0pt;font-family:calibri, arial, sans-serif;font-weight:normal;font-style:normal;font-size:8pt;line-height:8pt;">&#8203;</div>
      <div style="margin-top:46pt;margin-bottom:49.71pt;margin-left:70pt;width:456pt;">
        <div style="margin-top:6pt; text-align:right; width:456pt; line-height:12pt;font-weight:bold;">Exhibit&#160;32.2&#8203;</div>
        <div style="margin-top:12pt; text-align:center; width:456pt; line-height:11pt;font-weight:bold;">CERTIFICATION UNDER SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </div>
        <div style="text-indent:20pt; margin-top:6pt; width:456pt; line-height:12pt;">Pursuant to Section&#160;906 of the Sarbanes-Oxley Act of 2002 (of subsections (a)&#160;and (b)&#160;of section 1350, chapter 63 of title 18, United States Code), the undersigned officer of Cyclacel Pharmaceuticals, Inc. (the&#160;&#8220;Company&#8221;) hereby certifies, to such officer&#8217;s knowledge, that: </div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(i)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the Annual Report on Form 10-K of the Company for the year ended December&#160;31, 2017 (the &#8220;Report&#8221;) fully complies with the requirements of Section&#160;13(a) or Section&#160;15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <div style=" float:left; margin-left:20pt; line-height:12pt; margin-top:8.98pt; margin-bottom:0pt; text-align:left; width:20pt;white-space:nowrap;">(ii)<br ></div>
        <div style=" float:left; margin-top:8.98pt; margin-bottom:0pt; line-height:12pt; text-align:left; width:415.5pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </div>
        <div style="clear:both; padding:0pt; margin:0pt;font-size:0pt;line-height:0pt;">&#8203;</div>
        <table style="width:456pt;margin-top:8pt;border-collapse: collapse;">
          <tr style="line-height:12pt;white-space:nowrap;text-align:left;vertical-align:top;font-style:normal;font-weight:normal;font-variant:normal;text-transform:none;color:#000000;font-family:Times New Roman, Times, serif;font-size:10pt;">
            <td style="padding:0pt; width:0pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">Date: March 30, 2018 </td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt; width:6pt;">&#8203;</td>
            <td style="padding:0pt 0pt 1pt 0pt; width:222pt;">
              <div>/s/ Paul McBarron</div>
              <div style="margin-top:2.5pt;">
                <div style="margin-left: 0pt; width: 222pt; margin-top: 0pt; font-size: 1pt; line-height: 0pt; border-bottom: 1pt solid #000000; ">&#8203;</div>
              </div>
              <div style="margin-top:2pt;">Paul McBarron<br >Chief Operating Officer, Chief Financial Officer<br >and Executive Vice President, Finance</div>
            </td>
            <td style="padding:0pt; width:0pt;">&#8203;</td>
          </tr>
        </table>
      </div>
      <hr >
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>7
<FILENAME>cycc-20171231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated using Ez-XBRL version 8.0.1.0 [03/28/2018 12:18:54 AM] -->
<!-- Based on XBRL 2.1 -->
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<xbrli:xbrl xmlns:cycc="http://www.cyclacel.com/20171231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:utr="http://www.xbrl.org/2009/utr">
<link:schemaRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:type="simple" xlink:href="cycc-20171231.xsd"/>
<!-- Context Section  -->
<xbrli:context id="Context_Custom_01_Oct_2000T00_00_00_TO_31_Oct_2000T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2000-10-01
</xbrli:startDate>
<xbrli:endDate>
2000-10-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_22_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-05-22
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-05-01
</xbrli:startDate>
<xbrli:endDate>
2015-05-22
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2015T00_00_00_TO_10_Jul_2015T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:SalesAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-07-01
</xbrli:startDate>
<xbrli:endDate>
2015-07-10
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2015-01-01
</xbrli:startDate>
<xbrli:endDate>
2015-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jun_2016T00_00_00_TO_23_Jun_2016T00_00_00_EquitySaleAgreementAxis_FbrSalesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquitySaleAgreementAxis">cycc:FbrSalesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-06-01
</xbrli:startDate>
<xbrli:endDate>
2016-06-23
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:AgreementAxis">cycc:ControlledEquityOfferingSalesAgreementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:SalesAgentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RetirementPlanTypeAxis_PensionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">cycc:PensionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_US">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:EmployeesAndDirectorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cycc:CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedOptionsMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cycc:PerformanceBasedOptionsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:EmployeesAndDirectorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RetirementPlanTypeAxis_Plan401KMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">cycc:Plan401KMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2016-01-01
</xbrli:startDate>
<xbrli:endDate>
2016-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_US">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TaxCreditCarryforwardAxis_ResearchMember_IncomeTaxAuthorityAxis_ForeignCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cycc:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_As_Of_27_May_2017T00_00_00_TO_27_May_2017T00_00_00_StatementScenarioAxis_BeforeReverseStockSplitMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">cycc:BeforeReverseStockSplitMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_May_2017T00_00_00_TO_27_May_2017T00_00_00_StatementScenarioAxis_AfterReverseStockSplitMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">cycc:AfterReverseStockSplitMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-05-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-May-2016T00_00_00_TO_27-May-2016T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>2016-05-01</xbrli:startDate>
<xbrli:endDate>2016-05-27</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-06-30
</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_As_Of_21_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_21_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-21
</xbrli:instant>
</xbrli:period>
</xbrli:context>

<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-21
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>



<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>2017-07-21</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-07-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_Custom_01_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-07-01
</xbrli:startDate>
<xbrli:endDate>
2017-07-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_PensionPlanMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">cycc:PensionPlanMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_US">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:EmployeesAndDirectorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CommonStockWarrantsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">cycc:CommonStockWarrantsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:DaiichiSankyoCompanyLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:PropertyPlantAndEquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MinimumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cycc:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cycc:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_EquitySaleAgreementAxis_FbrSalesAgreementMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="cycc:EquitySaleAgreementAxis">cycc:FbrSalesAgreementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RangeAxis_MaximumMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_ManrosTherapeuticsSaManrosMember_TypeOfArrangementAxis_CollaborationSupplyAndLicensingAgreementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:ManrosTherapeuticsSaManrosMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">cycc:CollaborationSupplyAndLicensingAgreementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">cycc:Plan401KMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_PerformanceBasedOptionsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">cycc:PerformanceBasedOptionsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2017-01-01
</xbrli:startDate>
<xbrli:endDate>
2017-12-31
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:ConvertiblePreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_US">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">cycc:EmployeesAndDirectorsMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">cycc:Plan2015Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_TaxCreditCarryforwardAxis_ResearchMember_IncomeTaxAuthorityAxis_ForeignCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">cycc:OfficeEquipmentAndFurnitureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>


<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:DaiichiSankyoCompanyLimitedMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>


<xbrli:context id="Context_Custom_01_Mar_2018T00_00_00_TO_07_Mar_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:TitleOfIndividualAxis">us-gaap:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:startDate>
2018-03-01
</xbrli:startDate>
<xbrli:endDate>
2018-03-07
</xbrli:endDate>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_27_Mar_2018T00_00_00_TO_27_Mar_2018T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2018-03-27
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2015-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2016-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<xbrli:context id="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember">
<xbrli:entity>
<xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>
<xbrli:segment>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity>
<xbrli:period>
<xbrli:instant>
2017-12-31
</xbrli:instant>
</xbrli:period>
</xbrli:context>
<!-- Unit Section  -->
<!--
I~1\FVPHexeD5678YReqi>MrlsywiI~\FVP645<c444c555cT{h>H8F9:F<F188<;18<6G1E6651;H9GGFFE7;97 -->
<xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:unit id="USD_per_Share"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:unit id="Segment"><xbrli:measure>cycc:Segment</xbrli:measure></xbrli:unit>
<xbrli:unit id="EUR"><xbrli:measure>iso4217:EUR</xbrli:measure></xbrli:unit>
<xbrli:unit id="pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<!-- Element Section  --><dei:EntityRegistrantName contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">Cyclacel Pharmaceuticals, Inc.</dei:EntityRegistrantName>
<dei:EntityCentralIndexKey contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">0001130166</dei:EntityCentralIndexKey>
<dei:TradingSymbol contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">cycc</dei:TradingSymbol>
<dei:EntityCurrentReportingStatus contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">Yes</dei:EntityCurrentReportingStatus>
<dei:EntityVoluntaryFilers contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">No</dei:EntityVoluntaryFilers>
<dei:CurrentFiscalYearEndDate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">--12-31</dei:CurrentFiscalYearEndDate>
<dei:EntityFilerCategory contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">Smaller Reporting Company</dei:EntityFilerCategory>
<dei:EntityWellKnownSeasonedIssuer contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">No</dei:EntityWellKnownSeasonedIssuer>
<dei:EntityCommonStockSharesOutstanding contextRef="Context_As_Of_27_Mar_2018T00_00_00_TO_27_Mar_2018T00_00_00" unitRef="shares" decimals="INF">11997447</dei:EntityCommonStockSharesOutstanding>
<dei:EntityPublicFloat contextRef="Context_As_Of_30_Jun_2017T00_00_00_TO_30_Jun_2017T00_00_00" unitRef="USD" decimals="-3">12719813000</dei:EntityPublicFloat>
<dei:DocumentType contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">10-K</dei:DocumentType>
<dei:DocumentPeriodEndDate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">2017-12-31</dei:DocumentPeriodEndDate>
<dei:AmendmentFlag contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">false</dei:AmendmentFlag>
<dei:DocumentFiscalYearFocus contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">2017</dei:DocumentFiscalYearFocus>
<dei:DocumentFiscalPeriodFocus contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">FY</dei:DocumentFiscalPeriodFocus>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">16520000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">23910000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="-3">20440000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">3097000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">2064000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">19617000</us-gaap:AssetsCurrent>
<us-gaap:AssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">25974000</us-gaap:AssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">45000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">43000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">2000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">29000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">29000</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:PropertyPlantAndEquipmentNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">0</us-gaap:PropertyPlantAndEquipmentNet>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">19662000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">4465000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">15197000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">26003000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">2481000</us-gaap:Assets>
<us-gaap:Assets contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">23522000</us-gaap:Assets>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">2497000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccountsPayableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1558000</us-gaap:AccountsPayableCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">2762000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:AccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">2555000</us-gaap:AccruedLiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">5259000</us-gaap:LiabilitiesCurrent>
<us-gaap:LiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">4113000</us-gaap:LiabilitiesCurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">130000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:OtherLiabilitiesNoncurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">124000</us-gaap:OtherLiabilitiesNoncurrent>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">5389000</us-gaap:Liabilities>
<us-gaap:Liabilities contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">4237000</us-gaap:Liabilities>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:CommitmentsAndContingencies contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" xsi:nil="true"/>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:PreferredStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="-3">0</us-gaap:PreferredStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">4000</us-gaap:CommonStockValue>
<us-gaap:CommonStockValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">12000</us-gaap:CommonStockValue>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">350051000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AdditionalPaidInCapital contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">365057000</us-gaap:AdditionalPaidInCapital>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-743000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-794000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-335039000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:RetainedEarningsAccumulatedDeficit contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-342509000</us-gaap:RetainedEarningsAccumulatedDeficit>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">14273000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">21766000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00" unitRef="USD" decimals="-3">18835000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-323159000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-335039000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-596000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-743000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">342587000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">350051000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">3000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">4000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-342509000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-794000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">365057000</us-gaap:StockholdersEquity>
<us-gaap:StockholdersEquity contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">12000</us-gaap:StockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">19662000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:LiabilitiesAndStockholdersEquity contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">26003000</us-gaap:LiabilitiesAndStockholdersEquity>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>


<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_21-Jul-2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
<us-gaap:PreferredStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>


<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>


<us-gaap:PreferredStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">5000000</us-gaap:PreferredStockSharesAuthorized>





<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">8872</us-gaap:PreferredStockSharesIssued>

<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">264</us-gaap:PreferredStockSharesIssued>






<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesOutstanding>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">264</us-gaap:PreferredStockSharesOutstanding>




<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockParOrStatedValuePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="3">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesAuthorized contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">100000000</us-gaap:CommonStockSharesAuthorized>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">4256829</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesIssued contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">11997447</us-gaap:CommonStockSharesIssued>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">4256829</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_27_May_2017T00_00_00_TO_27_May_2017T00_00_00_StatementScenarioAxis_BeforeReverseStockSplitMember" unitRef="shares" decimals="INF">36075730</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_27_May_2017T00_00_00_TO_27_May_2017T00_00_00_StatementScenarioAxis_AfterReverseStockSplitMember" unitRef="shares" decimals="INF">3006311</us-gaap:CommonStockSharesOutstanding>
<us-gaap:CommonStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">11997447</us-gaap:CommonStockSharesOutstanding>
<us-gaap:RevenueFromGrants contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">843000</us-gaap:RevenueFromGrants>
<cycc:CollaborationAndResearchAndDevelopmentRevenue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</cycc:CollaborationAndResearchAndDevelopmentRevenue>
<cycc:CollaborationAndResearchAndDevelopmentRevenue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</cycc:CollaborationAndResearchAndDevelopmentRevenue>
<us-gaap:SalesRevenueNet contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">843000</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">843000</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueNet>
<us-gaap:SalesRevenueNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">0</us-gaap:SalesRevenueNet>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">9477000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:ResearchAndDevelopmentExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">4237000</us-gaap:ResearchAndDevelopmentExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">5516000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:SellingGeneralAndAdministrativeExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">5254000</us-gaap:SellingGeneralAndAdministrativeExpense>
<us-gaap:CostsAndExpenses contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">14993000</us-gaap:CostsAndExpenses>
<us-gaap:CostsAndExpenses contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">9491000</us-gaap:CostsAndExpenses>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-14150000</us-gaap:OperatingIncomeLoss>
<us-gaap:OperatingIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-9491000</us-gaap:OperatingIncomeLoss>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">273000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-39000</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">37000</us-gaap:InvestmentIncomeInterest>
<us-gaap:InvestmentIncomeInterest contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">118000</us-gaap:InvestmentIncomeInterest>
<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">66000</us-gaap:OtherNonoperatingIncome>
<us-gaap:OtherNonoperatingIncome contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">949000</us-gaap:OtherNonoperatingIncome>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">376000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:NonoperatingIncomeExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1028000</us-gaap:NonoperatingIncomeExpense>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-13774000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-8463000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-1983000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-993000</us-gaap:IncomeTaxExpenseBenefit>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-11791000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-11791000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">-9580000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">-2211000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-7470000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-7470000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_GB" unitRef="USD" decimals="-3">-7343000</us-gaap:NetIncomeLoss>
<us-gaap:NetIncomeLoss contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementGeographicalAxis_US" unitRef="USD" decimals="-3">-127000</us-gaap:NetIncomeLoss>
<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">200000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
<us-gaap:PreferredStockDividendsAndOtherAdjustments contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">201000</us-gaap:PreferredStockDividendsAndOtherAdjustments>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-11991000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-14846000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD_per_Share" decimals="2">-3.50</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:EarningsPerShareBasicAndDiluted contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">-1.95</us-gaap:EarningsPerShareBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="0">3424976</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="0">7631152</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">27204000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">27204000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-14687000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-14687000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-27351000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">-27351000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">14636000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
<cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AccumulatedOtherComprehensiveIncomeMember" unitRef="USD" decimals="-3">14636000</cycc:OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-11938000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:ComprehensiveIncomeNetOfTax contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-7521000</us-gaap:ComprehensiveIncomeNetOfTax>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">2965208</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4256829</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">11997447</us-gaap:SharesIssued>
<us-gaap:SharesIssued contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">335537</us-gaap:SharesIssued>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">6794000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">6793000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1066000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">1065000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">1000</cycc:StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1291621</cycc:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement>
<cycc:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">183118</cycc:StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">13684000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">13681000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">3000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_EquitySaleAgreementAxis_FbrSalesAgreementMember" unitRef="USD" decimals="-5">1100000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_10_Jul_2015T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember" unitRef="shares" decimals="INF">114078</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember" unitRef="shares" decimals="INF">41996</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">3154000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">8872</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_EquitySaleAgreementAxis_FbrSalesAgreementMember" unitRef="shares" decimals="INF">183118</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">782000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">782000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">266000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
<cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">200000</cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion>
<cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">200000</cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion>
<cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">201000</cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion>
<cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">201000</cycc:AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion>
<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_RetainedEarningsMember" unitRef="USD" decimals="-3">-89000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
<us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">89000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">133000</us-gaap:Depreciation>
<us-gaap:Depreciation contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">32000</us-gaap:Depreciation>
<us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">782000</us-gaap:ShareBasedCompensation>
<us-gaap:ShareBasedCompensation contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">266000</us-gaap:ShareBasedCompensation>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-439000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-1232000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
<us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">370000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
<us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-1540000</us-gaap:IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-10079000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-7480000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">3000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">13000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
<us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">12000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">9000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-13000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">6794000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember" unitRef="USD" decimals="-5">200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember" unitRef="USD" decimals="0">13700000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">14749000</us-gaap:ProceedsFromIssuanceOfCommonStock>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">200000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">201000</us-gaap:PaymentsOfDividendsPreferredStockAndPreferenceStock>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">6594000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">14748000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-444000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
<us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">135000</us-gaap:EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-3920000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">7390000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
<us-gaap:ProceedsFromInterestReceived contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">38000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:ProceedsFromInterestReceived contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">118000</us-gaap:ProceedsFromInterestReceived>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">1965000</us-gaap:IncomeTaxesPaid>
<us-gaap:IncomeTaxesPaid contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1815000</us-gaap:IncomeTaxesPaid>
<cycc:AccrualOfPreferredStockDividends contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">50000</cycc:AccrualOfPreferredStockDividends>
<cycc:AccrualOfPreferredStockDividends contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">50000</cycc:AccrualOfPreferredStockDividends>
<us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;1.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Organization of the Company and Basis of Presentation&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Cyclacel Pharmaceuticals Inc., (&amp;#8220;Cyclacel&amp;#8221; or &amp;#8220;the Company&amp;#8221;) is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel&amp;#8217;s transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and exploratory subgroups from a Phase&amp;#160;3 study of sapacitabine in elderly patients with AML. Cyclacel&amp;#8217;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December&amp;#160;31, 2017, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, drug candidates developed by the Company typically will require approvals or clearances from the FDA, EMA or other similar regulatory agencies in other countries prior to commercial sales. There can be no assurance that the Company&amp;#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was denied approval or clearance or such approval was delayed, or is unable to obtain the necessary financing to complete development and approval, there will be a material adverse impact on the Company&amp;#8217;s financial condition and results of operations. The Company has relied upon government grants to fund its earlier stage programs and does not expect to be able to continue to be successful in obtaining government grants to fund the Company&amp;#8217;s research and development expenditure.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Through December&amp;#160;31, 2017, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity securities, private placements of securities, government grants, research and development tax credits, interest on investments, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of&amp;#8201;$11.8&amp;#160;million and $7.5&amp;#160;million for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively. As of December&amp;#160;31, 2017, the Company had an accumulated deficit of&amp;#8201;$342.5&amp;#160;million. The Company expects to continue to generate operating losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidates, its preclinical programs and its administrative organization.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Going Concern&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&amp;#8217;s ability to continue as a going concern for a period of at
 least one year from the date the financial statements are issued. The Company expects that its cash of&amp;#8201;&amp;#8201;$23.9&amp;#160;million as of December&amp;#160;31, 2017 will be sufficient to fund its operating expenses and capital expenditure requirements through to the end of 2019.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued, including:&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;a.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s current financial condition, including its liquidity sources&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;b.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s conditional and unconditional obligations due or anticipated within one year&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;c.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The funds necessary to maintain the Company&amp;#8217;s operations considering its current financial condition, obligations, and other expected cash flows, and&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;d.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Other conditions and events, when considered in conjunction with the above that may adversely affect the Company&amp;#8217;s ability to meet its obligations.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The future viability of the Company beyond 2019 is dependent on its ability to raise additional capital to finance its operations. The Company will need to raise substantial additional capital to pursue the transcriptional regulation program, evaluating CYC065, a CDK inhibitor, in patients with advanced cancers or the DNA damage response program, evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers Additional funding may not be available to the Company on favorable terms, or at all. If the Company is unable to obtain additional funds, it will need to reduce operating expenses, enter into a collaboration or other similar arrangement with respect to development and/or commercialization rights to sapacitabine or its CDK inhibitors, if available, or be forced to delay or reduce the scope of its CDK inhibitors and sapacitabine development programs, including any potential regulatory filings
 related to the SEAMLESS study, and/or limit or cease its operations. The Company&amp;#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Reverse Stock Split&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On May&amp;#160;27, 2016, the Company completed a one-for-twelve reverse stock split (the &amp;#8220;Reverse Stock Split&amp;#8221;), which reduced the number of shares of the Company&amp;#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse Stock Split. The number of shares of the Company&amp;#8217;s authorized common stock was not affected by the Reverse Stock Split and the par value of Cyclacel&amp;#8217;s common stock remained unchanged at $0.001 per share. The Reverse Stock Split reduced the number of shares of the Company&amp;#8217;s common stock that were outstanding at May&amp;#160;27, 2016 from 36,075,730 to 3,006,311 after the cancellation of fractional shares. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise held fractional shares of the Company&amp;#8217;s common stock as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. All amounts related to number of shares and per share amounts have been retroactively restated in these consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Basis of Presentation&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&amp;#8220;GAAP&amp;#8221;) and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&amp;#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Certain amounts in the prior year&amp;#8217;s financial statements have been reclassified to conform to the current year&amp;#8217;s presentation.&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
<us-gaap:SignificantAccountingPoliciesTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;2.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Summary of Significant Accounting Policies&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Use of Estimates&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals, stock-based compensation expense and the recognition of revenue. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Foreign Currency and Currency Translation&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive loss.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Cash and Cash Equivalents&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three&amp;#160;months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&amp;#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&amp;#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s cash and cash equivalents balance at December&amp;#160;31, 2017 was $23.9&amp;#160;million and it maintains its cash accounts in several entities both within the United States and the United Kingdom. The total cash balances for amounts held in the United States are insured by the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) up to $250,000 per account. The Company has cash balances exceeding the balance insured by the FDIC that totaled approximately $23.0&amp;#160;million at December&amp;#160;31, 2017. The total cash balances for amounts held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme (&amp;#8220;FSCS&amp;#8221;) up to &amp;#163;75,000 per account. The Company has cash balances exceeding the balance insured by the FSCS that totaled approximately $0.5&amp;#160;million at December&amp;#160;31, 2017.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Property and Equipment&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five&amp;#160;years. Amortization of leasehold improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, currently between five and fifteen&amp;#160;years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss. Expenditures for maintenance and repairs are charged to operating expenses as incurred.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Impairment of Long-lived Assets&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Fair Value of Financial Instruments&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1&amp;#8201;&amp;#8212;&amp;#8201;Quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2&amp;#8201;&amp;#8212;&amp;#8201;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3&amp;#8201;&amp;#8212;&amp;#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Segments&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is managed and operated as one business which is focused on using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information with respect to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment with development operations in two geographic areas, namely the United States and the United Kingdom.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Revenue Recognition&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Collaboration, supply and licensing agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Consideration received is allocated to each of the separable elements in an arrangement using the relative selling price method. An element is separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. Revenue is recognized for each separate element when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Milestone payments which are non-refundable, non-creditable and contingent on achieving clinical milestones are recognized as revenues either on achievement of such milestones if the milestones are considered substantive or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. When determining if a milestone is substantive, the Company considers the following factors:&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The degree of certainty in achieving the milestone&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The frequency of milestone payments&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s efforts, which result in achievement of the milestone&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The amount of the milestone payment relative to the other deliverables and payment terms, and&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Whether the milestone payment is related to future performance or deliverables&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company records as deferred revenue any amounts received prior to satisfying the revenue recognition criteria. Deferred revenue not expected to be recognized within the next twelve&amp;#160;months is reported as non-current deferred revenue. The Company recognized $0 and $0.2&amp;#160;million deferred revenue as of December&amp;#160;31, 2016 and 2017 respectively. The deferred revenue reported as of December&amp;#160;31, 2017 relates to a prepayment received from ManRos Therapeutics SA for a development milestone that is not expected to be achieved until mid-2018 (see Note 3 for additional details).&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Royalty income is recognized when the licensee sells the underlying product.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Grant revenue&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Other Income&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Other income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part of the Company&amp;#8217;s ongoing operations and activities.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and Development Expenditures&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development expenses consist primarily of costs associated with the Company&amp;#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Clinical Trial Accounting&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Data management and monitoring of the Company&amp;#8217;s clinical trials are performed with the assistance of contract research organizations (&amp;#8220;CROs&amp;#8221;) or clinical research associates (&amp;#8220;CRAs&amp;#8221;) in accordance with the Company&amp;#8217;s standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are recognized upon execution of the clinical trial agreement and expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Patent Costs&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Patent prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Leased Assets&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The costs of operating leases are charged to operations on a straight-line basis over the lease term. Operating leases relate primarily to the Company&amp;#8217;s research and development facilities and corporate headquarters.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Stock-based Compensation&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over three or four&amp;#160;years. However, certain awards granted to members of the Company&amp;#8217;s Board of Directors vest in their entirety on the one-year anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain&amp;#160;years, the Company granted restricted stock&amp;#160;units to employees that were dependent upon the fulfillment of certain clinical and financial conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes expense in the period that the award becomes probable of vesting (See Note 11&amp;#8201;&amp;#8212;&amp;#8201;Stock-Based Compensation).&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&amp;#8217;s payroll costs are classified. The Company accounts for forfeitures as they occur.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of restricted stock and restricted stock&amp;#160;units is determined based on the number of shares granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&amp;#8217;s share price, expected term of the award, interest rates, and dividend yields.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company relies exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Income Taxes&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue &amp;amp; Customs (&amp;#8220;HMRC&amp;#8221;), the United Kingdom&amp;#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Net Loss Per Common Share&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Comprehensive Income (Loss)&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Recently Issued Accounting Pronouncements&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July&amp;#160;2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&amp;#8220;ASU 2017-11&amp;#8221;), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&amp;#160;years, and interim periods within those fiscal&amp;#160;years, beginning after December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In October&amp;#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&amp;#8220;ASU 2016-16&amp;#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&amp;#160;15, 2017, including interim periods within those fiscal&amp;#160;years. This standard will not have a material impact on the company&amp;#8217;s consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In August&amp;#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&amp;#160;15, 2017, including interim periods within those fiscal&amp;#160;years. This standard will not have a material impact on the company&amp;#8217;s consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February&amp;#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&amp;#160;years beginning after December&amp;#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May&amp;#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes existing revenue recognition guidance. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&amp;#160;identify the contract with a customer; (2)&amp;#160;identify the performance obligations in the contract; (3)&amp;#160;determine the transaction price; (4)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (5)&amp;#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal&amp;#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company intends to use the modified retrospective method upon adoption of the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption.&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
<cycc:SignificantContractsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;3.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Significant Contracts&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Distribution, Licensing and Research Agreements&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of products employing the technology or falling under claims of patent applications.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The most significant licensing agreement is with Daiichi Sankyo. Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&amp;#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee, Phase&amp;#160;3 entry milestone, and certain past reimbursements have been paid. A further $10.0&amp;#160;million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones which are primarily related to regulatory approval in various territories, and the Company&amp;#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten&amp;#160;years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal, with the right of first refusal ending sixty days after notification, to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six&amp;#160;months&amp;#8217; notice, or twelve&amp;#160;months&amp;#8217; notice, if after a launch of a sapacitabine-based product, or by either party for material default. There were no milestones earned in 2016 or 2017.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Collaboration, Supply and Licensing Agreements&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In June&amp;#160;2015, the Company entered into a collaboration, licensing and supply agreement with ManRos Therapeutics SA (&amp;#8220;ManRos&amp;#8221;), for the exclusive development and commercialization of the Company&amp;#8217;s oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (&amp;#8220;CF&amp;#8221;). Among other terms of the agreement, ManRos licensed rights to the Company&amp;#8217;s proprietary clinical data to enable clinical development of seliciclib for CF indications. The agreement provides for supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to the Company&amp;#8217;s know-how to facilitate these trials. The Company received an up-front payment in July&amp;#160;2015 and reached a development milestone in September&amp;#160;2015. The Company will receive further milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000;
 font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The upfront and milestone payments have been allocated to the separate deliverables within the arrangement and recognized over the period in which the deliverables are met. The consideration allocated to the main deliverable&amp;#8201;&amp;#8212;&amp;#8201;the transfer of the Company&amp;#8217;s know-how&amp;#8201;&amp;#8212;&amp;#8201;was determined based on its estimated standalone selling price, using a market approach that identified similar license deals for a Phase&amp;#160;1/2 asset. The Company reviewed various licensing transactions in the public domain in the CF area and similar stage of asset development. In the year ended December&amp;#160;31, 2016 and 2017, the Company recognized revenue of&amp;#8201;&amp;#8201;$0 and $0, respectively. In the fourth quarter of 2017, the Company received a $150,000 payment from ManRos in anticipation of ManRos achieving a clinical milestone in 2018. This payment has been recorded as deferred revenues on the balance sheet (part of other current liabilities) as the milestone was not achieved as of December&amp;#160;31, 2017.&lt;/div&gt;</cycc:SignificantContractsDisclosureTextBlock>
<us-gaap:CashAndCashEquivalentsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;4.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Cash and Cash Equivalents&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of cash and cash equivalents at December&amp;#160;31, 2016 and 2017 (in&amp;#160;thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 79.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cash&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;5,332&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,103&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.833pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; white-space: normal; padding-top: 2.167pt;"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt;"&gt;Investments with original maturity of less than three&amp;#160;months at the time of purchase&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt;
 white-space: nowrap; padding-top: 2.167pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Total cash and cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;16,520&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;23,910&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Investments with original maturity of less than three&amp;#160;months at time of purchase are made up of money market funds and commercial paper.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsDisclosureTextBlock>
<us-gaap:FairValueDisclosuresTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;5.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Fair Value of Financial Assets and Liabilities&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following tables present information about the Company&amp;#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22"&gt;
&lt;div style="text-align: center;"&gt;Fair Value Measurements&amp;#160;&lt;br /&gt;as of December&amp;#160;31, 2016 Using:&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;1&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;2&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;3&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;Assets:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right;
 padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 20pt;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11,188&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt;
 text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11,188&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22"&gt;
&lt;div style="text-align: center;"&gt;Fair Value Measurements&amp;#160;&lt;br /&gt;as of December&amp;#160;31, 2017 Using:&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;1&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;2&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;3&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;Assets:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 20pt;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;22,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;22,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:FairValueDisclosuresTextBlock>
<cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;6. &amp;#160;&amp;#160;&amp;#160;&amp;#160;Prepaid Expenses and Other Current Assets&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 11.5pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of prepaid expenses and other current assets at December&amp;#160;31, 2016 and 2017 (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 127.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development tax credit receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,730&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,054&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Prepayments&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;867&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;363&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Delaware tax receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;25&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;VAT receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;327&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;409&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deposits&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;132&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;132&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other current assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;41&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;81&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Prepaid expenses and other current assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;3,097&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,064&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</cycc:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
<us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;7.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Property and Equipment&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Property and equipment consisted of the following at December&amp;#160;31, 2016 and 2017 (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 113pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 9.25pt; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0pt; padding-top: 0pt;" rowspan="2"&gt;
&lt;div style="text-align: center; padding-bottom: 0pt; line-height: 9pt; white-space: nowrap;"&gt;Lives in&amp;#160;years&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 0pt; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Leasehold improvements&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: right;"&gt;5 to 15&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;792&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;835&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and laboratory equipment&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: right;"&gt;3 to 5&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,438&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,854&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Office equipment and furniture&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: right;"&gt;3 to 5&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,157&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,236&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6,387&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6,925&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(6,342&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(6,896&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.75pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;45&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;29&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="17"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Depreciation and amortization expense for property and equipment was $0.1&amp;#160;million and $32,000 for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively. During the year ended December&amp;#160;31, 2016, the Company sold fully depreciated assets for proceeds of approximately $12,000. The Company did not sell any property or equipment during the year ended December&amp;#160;31, 2017.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
<us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;8.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Accrued and Other Current Liabilities&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Accrued and other current liabilities consisted of the following at December&amp;#160;31, 2016 and 2017 (in&amp;#160;thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 82.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Accrued research and development&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,138&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,645&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Accrued legal and professional fees&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;194&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;248&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other current liabilities&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;430&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;662&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,762&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,555&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Other current liabilities in 2017 include $150,000 deferred income in respect of payment received in advance of achieving a milestone under the ManRos agreement (see Note 3&amp;#8201;&amp;#8212;&amp;#8201;Significant Contracts).&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
<us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;9.&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Commitments and Contingencies&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;General&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Please refer to&amp;#160;&lt;font style="font-style: italic;"&gt;Note 3&amp;#8201;&amp;#8212;&amp;#8201;Significant Contracts&lt;/font&gt;&amp;#160;for further discussion of certain of the Company&amp;#8217;s commitments and contingencies.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Leases&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In October&amp;#160;2000, the Company entered into a twenty-five year lease for its research and development facility in Dundee, Scotland. Rent expense, which includes lease payments related to the Company&amp;#8217;s research and development facilities and corporate headquarters and other rent related expenses was $0.5 and $0.5&amp;#160;million for each of the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a summary of the Company&amp;#8217;s future contractual obligations and commitments relating to its facilities leases as at December&amp;#160;31, 2017 (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 123pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Operating Lease&amp;#160;&lt;br /&gt;Obligation&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2018&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;348&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2019&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2020&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2021&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2022&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;343&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;thereafter&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;956&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Total future minimum lease obligations&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,679&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="8"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
<us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;10.&amp;#160;&amp;#160;&amp;#160;Stockholders&amp;#8217; Equity&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;The Company has completed the following equity issuances during the periods presented in the consolidated financial statements.&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;July&amp;#160;2017 Underwritten Public Offering&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On July&amp;#160;21, 2017, the Company issued (i)&amp;#160;3,154,000 Class&amp;#160;A Units for $2 per unit, each consisting of one share of the Company&amp;#8217;s common stock, and a warrant to purchase one share of common stock (the &amp;#8220;Class&amp;#160;A Warrants&amp;#8221;), and (ii) 8,872 Class&amp;#160;B Units, each consisting of one share of the Company&amp;#8217;s Series&amp;#160;A Convertible Preferred Stock, par value $0.001 per share (the &amp;#8220;Series&amp;#160;A Preferred Stock&amp;#8221;), convertible into 500 shares of Common Stock at the initial conversion price, and a warrant to purchase a number of shares of common stock equal to $1,000.00 divided by the conversion price (the &amp;#8220;Class&amp;#160;B Warrants&amp;#8221;) for $1,000 per unit. The net proceeds to the Company after the underwriters&amp;#8217; exercise in full of the over-allotment option were approximately $13,700,000, after deducting underwriting discounts, commissions and other estimated offering expenses. The Class&amp;#160;A Units and Class&amp;#160;B Units have no stand-alone rights and the shares of common stock, Series&amp;#160;A Preferred Stock and the Class&amp;#160;A and Class&amp;#160;B Warrants comprising those&amp;#160;units were immediately separable.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The common stock, Class&amp;#160;A Warrants and Class&amp;#160;B Warrants (together the &amp;#8220;Warrants&amp;#8221;) and Series&amp;#160;A Preferred Stock are freestanding financial instruments. The Warrants are classified within equity (as a component of additional paid-in capital) in the consolidated balance sheet and are not remeasured on a recurring basis. The Series&amp;#160;A Preferred Stock is classified within permanent equity in the consolidated balance sheet.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The proceeds from the Class&amp;#160;A Units were allocated to common stock and Class&amp;#160;A Warrants on a relative fair value basis. Similarly, the proceeds from the Class&amp;#160;B Units were allocated to the Series&amp;#160;A Preferred Stock and the Class&amp;#160;B Warrants based on their relative fair values. Following the allocation of the offering proceeds associated with the Class&amp;#160;B units, the Company determined that the Series&amp;#160;A Preferred Stock had a beneficial conversion feature with an aggregate intrinsic value of approximately $3,638,000.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As&amp;#160;the Series&amp;#160;A Preferred Stock contained no stated redemption date, and the conversion feature could be exercised at any time, the discount associated with the beneficial conversion feature was immediately charged against additional paid-in capital and treated as a deemed dividend for both financial reporting and earnings per share purposes.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;June&amp;#160;2016 At
 Market Issuance&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On June&amp;#160;23, 2016, the Company entered into an At Market Issuance Sales Agreement (the &amp;#8220;FBR Sales Agreement&amp;#8221;) with FBR Capital Markets &amp;amp; Co. (&amp;#8220;FBR&amp;#8221;), under which the Company was authorized to issue and sell shares of its common stock, from time to time, through FBR, acting as its sales agent. Under the FBR Sales Agreement, FBR was authorized to sell such shares of common stock by any method that is deemed to be an &amp;#8220;at the market offering&amp;#8221;. The Company was not obligated to make any sales of common stock under the FBR Sales Agreement, and the Company was required to pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares of common stock sold through FBR. During the year ended December&amp;#160;31, 2017, the Company sold 183,118 shares of common stock under the FBR Sales agreement for net proceeds of approximately $1.1&amp;#160;million, and the FBR Sales Agreement terminated automatically by its terms.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;July&amp;#160;2015 Controlled Equity Offering SM&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On July&amp;#160;10, 2015, the Company entered into a Controlled Equity Offering&lt;font style="position: relative; bottom: 4.25pt; font-size: 7.5pt;"&gt;SM&lt;/font&gt;&amp;#160;Sales Agreement with Cantor Fitzgerald (the &amp;#8220;Cantor Sales Agreement&amp;#8221;) under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $8.35&amp;#160;million through Cantor Fitzgerald. Under the Cantor Sales Agreement, Cantor Fitzgerald may sell shares of Cyclacel common stock by methods deemed to be an &amp;#8220;at-the-market&amp;#8221; offering as defined in Rule&amp;#160;415 promulgated under the Securities Act of 1933, as amended (the &amp;#8220;Securities Act&amp;#8221;). The Company will pay Cantor Fitzgerald a commission of up to 3.0% of the gross sales price per share sold. Cyclacel is not obligated to make any sales under the Cantor Sales Agreement. Effective as of June&amp;#160;17, 2016, and prior to entering into the FBR Sales Agreement, the Company and Cantor agreed to terminate the Cantor Sales Agreement. The Company had issued an aggregate of 114,078 shares pursuant to the Cantor Sales Agreement of which 41,996 were issued during the year ended December&amp;#160;31, 2016 for net proceeds of approximately $0.2&amp;#160;million.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The following is a description of the Company&amp;#8217;s outstanding equity instruments.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Warrants&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December&amp;#160;31, 2017, there were 7,490,500 warrants outstanding, each with an exercise price of $2.00. All such warrants were issued in connection with the July&amp;#160;2017 Underwritten Public Offering and are immediately exercisable. The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&amp;#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&amp;#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&amp;#8217;s common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing the cashless exercise provision of the warrants. On the expiration date, unexercised warrants will automatically be exercised via the
 &amp;#8220;cashless&amp;#8221; exercise provision.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Warrants exercised during the year ended December&amp;#160;31, 2016 and 2017 were 0 and 99,500 respectively. Gross proceeds during the year for such exercises amounted to $199,000 with a weighted average exercise price of&amp;#8201; $2.00 per share.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Series&amp;#160;A Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;8,872 shares of the Company&amp;#8217;s Series&amp;#160;A Preferred Stock were issued in the July&amp;#160;2017 Underwritten Public Offering. Each share of Series&amp;#160;A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing $1,000 by the initial conversion price of&amp;#8201; $2.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series&amp;#160;A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;During the year ended December&amp;#160;31, 2017, 8,608 shares of the Series&amp;#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&amp;#160;31, 2017, 264 shares of the Series&amp;#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&amp;#160;A Preferred Stock issued and outstanding at December&amp;#160;31, 2017, are convertible into 132,000 shares of common stock.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In the event of a liquidation, the holders of shares of the Series&amp;#160;A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series&amp;#160;A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company&amp;#8217;s ability to repurchase shares of Series&amp;#160;A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to the Series&amp;#160;A Preferred Stock.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Subject to certain conditions, at any time following the issuance of the Series&amp;#160;A Preferred Stock, the Company has the right to cause each holder of the Series&amp;#160;A Preferred Stock to convert all or part of such holder&amp;#8217;s Series&amp;#160;A Preferred Stock in the event that (i)&amp;#160;the volume weighted average price of our common stock for 30 consecutive trading days (the &amp;#8220;Measurement Period&amp;#8221;) exceeds 300% of the initial conversion price of the Series&amp;#160;A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of the Series&amp;#160;A Preferred Stock to convert all or part of such holder&amp;#8217;s Series&amp;#160;A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal;
 font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Series&amp;#160;A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series&amp;#160;A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;6% Convertible Exchangeable Preferred Stock&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;As of December&amp;#160;31, 2017, there were 335,273 shares of the Company&amp;#8217;s 6% Convertible Exchangeable (&amp;#8220;Preferred Stock&amp;#8221;) issued and outstanding at an issue price of&amp;#8201;$10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February&amp;#160;1, 2005. Any dividends must be declared by the Company&amp;#8217;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of&amp;#8201;$10.00 per share, plus accrued and unpaid dividends.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the Certificate of Designations governing the terms of the Company&amp;#8217;s Preferred Stock, including the requisite financial analysis and determination of a surplus. Accrued and unpaid dividends in arrears on preferred stock were $0.7&amp;#160;million, or $1.95 per share, of preferred stock, as of December&amp;#160;31, 2016 and 2017.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Preferred Stock is convertible at the option of the holder at any time into the Company&amp;#8217;s shares of common stock at a conversion rate of approximately 0.00507 shares of common stock for each share of Preferred Stock based on a price of&amp;#8201;&amp;#8201;$1,974. The Company has reserved 1,698 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at December&amp;#160;31, 2016. The shares of previously-converted Preferred Stock have been retired, cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&amp;#8217;s common stock has exceeded $2,961, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&amp;#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&amp;#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&amp;#160;24, 2011.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of&amp;#8201;$10.00 per share.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&amp;#160;1, 2005 (the &amp;#8220;Exchange Date&amp;#8221;) for the Company&amp;#8217;s 6% Convertible Subordinated Debentures (&amp;#8220;Debentures&amp;#8221;) at the rate of&amp;#8201;&amp;#8201;&amp;#8201;&amp;#8201; $10.00 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&amp;#160;years after the Exchange Date and have terms substantially similar to those of the Preferred Stock. No such exchanges have taken place as of December&amp;#160;31, 2017.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;For the year ended December&amp;#160;31, 2017, the company declared dividends of&amp;#8201;$0.15 per share quarterly on its Preferred Stock. These dividends were paid on May&amp;#160;1, August&amp;#160;1 and November&amp;#160;1, 2017, and February&amp;#160;1, 2018, respectively.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Common Stock&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Exercise of Stock Options&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;No stock options were exercised during the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
<us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;div style="text-align: left; line-height: 11pt; margin-top: 0pt; white-space: nowrap; margin-bottom: 0pt; float: left; font-weight: bold;"&gt;11.&amp;#160;&amp;#160;&amp;#160;Stock-Based Compensation&lt;/div&gt;
&lt;div style="line-height: 0pt; margin: 0pt; clear: both; font-size: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;Stock based compensation has been reported within the following expense line items on the consolidated statement of operations for the&amp;#160;years ended 2016 and 2017, as shown in the following table (in&amp;#160;thousands):&lt;/div&gt;
&lt;table style="margin-top: 8pt; width: 416pt; border-collapse: collapse; height: 72pt; margin-left: 20pt;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Year Ended&amp;#160;&lt;br /&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Year Ended&amp;#160;&lt;br /&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;305&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;72&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;General and administrative&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;477&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;194&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock-based compensation costs before income taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt;
 padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;782&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;266&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 11pt; font-style: italic; margin-top: 18.78pt; font-weight: bold;"&gt;2015 Plan&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;On May&amp;#160;22, 2015, the Company&amp;#8217;s stockholders approved the 2015 Equity Incentive Plan (the &amp;#8220;2015 Plan&amp;#8221;), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The company has reserved 458,753 shares of the Company&amp;#8217;s common stock under the 2015 Plan. The 2015 Plan replaces the 2006 Equity Incentive Plan (the &amp;#8220;2006 Plan&amp;#8221;), under which there were no remaining reserved shares to be granted. Stock option awards granted under the Company&amp;#8217;s equity incentive plans have a maximum life of 10&amp;#160;years and generally vest over a one to four-year period from the date of grant.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;During 2016, the Company granted 197,841 options to employees and directors with a grant date fair value of approximately $0.7&amp;#160;million. Of these options, 189,091 are performance based, which will vest upon the fulfilment of certain clinical conditions and will terminate if they have not vested by December&amp;#160;31, 2020. The Company determined that the satisfaction of the vesting criteria was not probable throughout 2016 and 2017 and, as a result, did not record any expense related to these awards for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;There were 170,853 options granted during the year ended December&amp;#160;31, 2017. Of these options, 158,853 are performance based, which will vest upon the fulfillment of certain clinical conditions. The Company determined that the satisfaction of one of the conditions was probable as of December&amp;#160;31, 2017, but that the other vesting criteria related to these awards were not probable as of December&amp;#160;31, 2017. As such, the Company recognized compensation cost for these grants under the expectation that 25% of these awards will vest.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;The weighted average grant-date fair values of options granted during the&amp;#160;years ended December&amp;#160;31, 2016 and 2017 were $3.66 and $1.59, respectively.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;As of December&amp;#160;31, 2017, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions amounted to approximately $0.2&amp;#160;million, which will be amortized over the weighted-average remaining requisite service period of 0.9&amp;#160;years.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;During the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, the Company did not settle any equity instruments with cash.&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;"&gt;There were no stock option exercises during the&amp;#160;years ended 2016 and 2017. No income tax benefits were recorded for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017 because the Company has accumulated net operating losses for tax purposes and is not likely to benefit from any deductions associated with exercises of granted option awards.&lt;/div&gt;
&lt;div style="line-height: 11pt; font-style: italic; margin-top: 12pt;"&gt;Outstanding Options&lt;/div&gt;
&lt;div style="line-height: 12pt; margin-top: 6pt; margin-left: 20pt;"&gt;A summary of the share option activity and related information is as follows:&lt;/div&gt;
&lt;table style="margin-top: 8pt; width: 456pt; border-collapse: collapse; height: 211.5pt;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Number of&amp;#160;&lt;br /&gt;Options&amp;#160;&lt;br /&gt;Outstanding&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Weighted&amp;#160;&lt;br /&gt;Average&amp;#160;&lt;br /&gt;Exercise Price&amp;#160;&lt;br /&gt;Per Share&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Weighted&amp;#160;&lt;br /&gt;Average&amp;#160;&lt;br /&gt;Remaining&amp;#160;&lt;br /&gt;Contractual&amp;#160;&lt;br /&gt;Term (Years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Aggregate&amp;#160;&lt;br /&gt;Intrinsic&amp;#160;&lt;br /&gt;Value
 ($000s)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;206,298&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;72.60&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.09&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;197,841&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4.68&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top:
 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cancelled/forfeited&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(14,760&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;396.83&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;389,379&lt;/td&gt;
&lt;td style="padding-bottom: 0pt;
 padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;25.80&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;5.83&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;121&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;170,853&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1.93&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt;
 padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cancelled/forfeited&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(24,615&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;179.92&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;535,617&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11.10&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt;
 padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.23&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Unvested at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;386,682&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;3.64&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.84&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Vested and exercisable at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;148,755&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;30.49&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6.65&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model using the following assumptions:&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 456pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 92.5pt; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 0pt;"&gt;
&lt;div style="text-align: center;"&gt;Year ended&amp;#160;&lt;br /&gt;December&amp;#160;31, 2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 0pt;"&gt;
&lt;div style="text-align: center;"&gt;Year ended&amp;#160;&lt;br /&gt;December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: center;"&gt;5&amp;#8201;&amp;#8211;&amp;#8201;6&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: center;"&gt;6&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Risk free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;1.370%&amp;#8201;&amp;#8211;&amp;#8201;1.500%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;1.890%&amp;#8201;&amp;#8211;&amp;#8201;2.265%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Volatility&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;98%&amp;#8201;&amp;#8211;&amp;#8201;104%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt;
 padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;108%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Expected dividend yield over expected term&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Resulting weighted average grant date fair value&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;$3.66&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;$1.59&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
<us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;12.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Employee Benefit Plans&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Pension Plan&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan totaled approximately $57,000 and $54,000 for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;401(k) Plan&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The 401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of 100% of the employee&amp;#8217;s deferral or 6% of the U.S. employee&amp;#8217;s qualifying compensation. The 401(k) Plan is intended to qualify under Section&amp;#160;401(k) of the Internal Revenue Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to the employees until withdrawn. Company matching contributions are tax deductible by the Company when made. Company employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit of&amp;#8201;&amp;#8201;$18,000 if under 50&amp;#160;years old and $24,000 if over 50&amp;#160;years old and to have those funds contributed to the 401(k) Plan. The Company made contributions of approximately $32,000 and $28,000 to the 401(k) Plan for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively.&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
<us-gaap:IncomeTaxDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;13.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Taxes&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;(Loss) income from continuing operations before taxes is comprised of the following components for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017 (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 67.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(2,011&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(127&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Foreign&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(11,763&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(8,336&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss from continuing operations before taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(13,774&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(8,463&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The benefit (provision) for income taxes from continuing operations consists of the following (in&amp;#160;thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;foreign&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,983&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;993&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deferred&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Income tax benefit&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of&amp;#8201;$2.0&amp;#160;million and $1.0&amp;#160;million for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017, respectively, represent UK research and development (&amp;#8220;R&amp;amp;D&amp;#8221;) tax credits for expenditures in the United Kingdom that are refundable.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 174.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 3.25pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss from continuing operations before taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(13,774&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(8,463&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Income tax expense computed at statutory federal tax rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(4,683&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(2,877&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Disallowed expenses and non-taxable income&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;12&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;3&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss surrendered to generate R&amp;amp;D credit&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,945&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;856&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Additional research and development tax relief&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(2,827&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(1,262&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Change in valuation allowance&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;2,029&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(4,487&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Foreign items, including change in tax rates, and other&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,238&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,901&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Change in US Tax Rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,112&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other foreign items&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;303&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;761&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(1,983&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(993&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 10.59pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On December&amp;#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (&amp;#8220;Tax Act&amp;#8221;), which made significant changes to U.S. federal income tax law. The Company expects that certain aspects of the Tax Act will positively impact the Company&amp;#8217;s future after-tax earnings in the U.S., primarily due to the lower federal statutory tax rate. Set forth below is a discussion of certain provisions of the Tax Act and our preliminary assessment of the effect of such provisions on the Company&amp;#8217;s results of operations, cash flows and consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Tax Act will affect 2018 and forward, including but not limited to a reduction in the federal corporate rate from 35.0% to 21.0%, elimination of the corporate alternative minimum tax, a new limitation on the deductibility of certain executive compensation, limitations on net operating losses generated after December&amp;#160;31, 2017 and various other items. We do not expect these changes to have a material impact on our financial statements due to the accumulated net operating losses in the U.S.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Tax Act provides for a one-time &amp;#8220;deemed repatriation&amp;#8221; of accumulated unrepatriated foreign earnings determined as of November&amp;#160;2, 2017, or December&amp;#160;31, 2017, whichever is greater. We do not expect to be subject to this provision due to the accumulated deficit in our foreign earnings for tax purposes. The Tax Act also created a new requirement that certain income earned by controlled foreign corporations must be included currently in the gross income of the U.S. shareholder under the Global Intangible Low-Taxed Income (GILTI) provision. We do not expect that any future foreign earnings will be subject to GILTI due to our US net operating losses.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In December&amp;#160;2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;), which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Act. SAB 118 provides for a measurement period that should not extend beyond one year from the Act enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&amp;#8220;ASC 740&amp;#8221;). In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&amp;#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. Based on our initial analysis of the Tax Act, the Company has made reasonable estimates of its 2017 impact. As a result of the federal corporate tax rate reduction from 35% to 21%, we re-measured certain deferred tax assets and liabilities, which resulted in a reduction in our DTA of approximately $4.1&amp;#160;million, that was offset by a decrease in our valuation allowance. As guidance and technical corrections, if any, are provided in the upcoming quarters, the Company will adjust its provisional estimates as required.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The primary difference between the income tax benefit at the statutory rate and the Company&amp;#8217;s effective income tax expense for the year ended December&amp;#160;31, 2017 was primarily attributable to the change in our valuation allowance and foreign operations.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are shown below (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 143pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net operating loss and tax credit carryforwards&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;42,851&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;38,948&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Depreciation, amortization and impairment of property and equipment&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;137&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;111&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;2,365&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development credits&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,021&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,021&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;49,374&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;44,887&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Valuation allowance for deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(49,374&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(44,887&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 10.8pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. The Company adopted a 17% tax rate as of December&amp;#160;31, 2017 in respect of the measurement of deferred taxes arising in the United Kingdom, which reflects the currently enacted tax rate and the anticipated timing of the unwinding of the deferred tax balances. In respect of the measurement of deferred taxes arising in the U.S, the Company has adopted a 21% tax rate as of December&amp;#160;31, 2017. This has reduced from 34% as of December&amp;#160;31, 2016 due to changes in U.S. tax laws enacted in December&amp;#160;2017. The effect of the change in tax rates on the consolidated statement of operations is $nil, after consideration of the change in valuation allowance.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;A valuation allowance has been established, as realization of such assets is uncertain. The Company&amp;#8217;s management evaluated the positive and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance of approximately $44.9&amp;#160;million has been established at December&amp;#160;31, 2017. The valuation allowance has decreased by approximately $4.5&amp;#160;million in 2017.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In certain circumstances, as specified in the Tax Reform Act of 1986, due to ownership changes, the Company&amp;#8217;s ability to utilize its net operating loss (&amp;#8220;NOL&amp;#8221;) carryforwards may be limited. The benefit of deductions from the exercise of stock options is included in the NOL carryforwards. As of December&amp;#160;31, 2016 and 2017, the Company had federal NOLs of&amp;#8201;$28.4&amp;#160;million and $28.4&amp;#160;million and foreign NOLs of&amp;#8201;$178.2&amp;#160;million and $186.2&amp;#160;million, respectively. The Company&amp;#8217;s federal NOLs will start to expire in 2026, and the state NOLs totaling $18.7&amp;#160;million will start expiring in 2023. The Company&amp;#8217;s foreign NOL&amp;#8217;s do not expire under UK tax law. However, for losses created after April&amp;#160;1, 2017 the use of these NOLs is restricted to an annual &amp;#163;5&amp;#160;million allowance in each standalone company or group and above this allowance, there will be a 50% restriction in the profits that can be covered by losses brought forward. The amount of profits restricted for the year ended December&amp;#160;31, 2017 is $0. As of December&amp;#160;31, 2017, the Company had a US&amp;#160;R&amp;amp;D credit carryforward of&amp;#8201;$4.0&amp;#160;million which will start expiring in 2019.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Utilization of the NOLs may be subject to a substantial annual limitation under Section&amp;#160;382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section&amp;#160;382 study as of June&amp;#160;30, 2014 noting there was no ownership change&amp;#160;from the Company&amp;#8217;s formation through that date. No update to this study has been performed through December&amp;#160;31, 2017. Management has evaluated all significant tax positions at December&amp;#160;31, 2016 and 2017 and concluded that there are no material uncertain tax positions. The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Tax year 2016 remains open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the United Kingdom and the United States, as carryforward attributes generated in&amp;#160;years past may still be adjusted upon examination by the United Kingdom&amp;#8217;s H.M. Revenue &amp;amp; Customs, the Internal Revenue Service (&amp;#8220;IRS&amp;#8221;) or state tax authorities. The Company is currently not under examination by the IRS or any other jurisdictions for any tax&amp;#160;years.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;We have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because it is our intent to permanently reinvest such earnings outside of the United States.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that intention. As a result of the repeal of the Section&amp;#160;902 foreign tax credit under the Tax Act, future distributions would not be offset by a foreign tax credit.&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
<us-gaap:EarningsPerShareTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;14.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Net Loss Per Share&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Basic and diluted net loss per share attributable to common stockholders was calculated as follows:&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 162pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Years ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Numerator:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Net loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(11,791&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right:
 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(7,470&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Dividend on convertible exchangeable preferred shares&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(200&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(201&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Beneficial conversion feature of Series&amp;#160;A convertible stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(3,638&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Conversion of Series&amp;#160;A convertible preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(3,537&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net loss attributable to common shareholders&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(11,991&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align:
 right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(14,846&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.25pt;"&gt;Denominator:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.333pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; white-space: normal; padding-top: 1.667pt;"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt;"&gt;Weighted-average number of common shares used in loss per share&amp;#160;&amp;#8211; basic and diluted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;"&gt;3,424,976&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;"&gt;7,631,152&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss per share&amp;#8201;&amp;#8211;&amp;#8201;basic and diluted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(3.50&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(1.95&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 13.49pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders
 is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 12pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 91.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;389,378&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;535,616&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Convertible preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;1,698&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;1,698&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Series&amp;#160;A preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top:
 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;132,000&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Common stock warrants&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;7,490,500&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Total shares excluded from calculation&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;391,076&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;8,159,814&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:EarningsPerShareTextBlock>
<us-gaap:SegmentReportingDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;15.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Geographic Information&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Geographic information for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017 is as follows (in thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 128pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Revenue&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;843&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt;
 padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Revenue&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;843&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;"&gt;Net loss&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(2,211&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(127&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width:
 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(9,580&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(7,343&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Net Loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(11,791&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(7,470&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 142pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Total Assets&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt;
 padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;15,197&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;23,522&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;4,465&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;2,481&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;19,662&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;26,003&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;"&gt;Long Lived Assets, net&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt;
 padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;2&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;0&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;43&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;29&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Long Lived Assets, net&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;45&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;29&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
<us-gaap:SubsequentEventsTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;16.&amp;#160;&amp;#160;&amp;#160;&amp;#160;Subsequent Events&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;On March&amp;#160;7, 2018, the Board of Directors declared a quarterly cash dividend in the amount of&amp;#8201;&amp;#8201;$0.15 per share on the Company&amp;#8217;s Preferred Stock. The cash dividend is due to be paid on May&amp;#160;1, 2018 to the holders of record of the Preferred Stock as of the close of business on April&amp;#160;11, 2018.&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
<us-gaap:UseOfEstimates contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Use of Estimates&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals, stock-based compensation expense and the recognition of revenue. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&amp;#8217;s consolidated financial statements.&lt;/div&gt;</us-gaap:UseOfEstimates>
<us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Foreign Currency and Currency Translation&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The assets and liabilities of the Company&amp;#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive loss.&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
<us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Cash and Cash Equivalents&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three&amp;#160;months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&amp;#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&amp;#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company&amp;#8217;s cash and cash equivalents balance at December&amp;#160;31, 2017 was $23.9&amp;#160;million and it maintains its cash accounts in several entities both within the United States and the United Kingdom. The total cash balances for amounts held in the United States are insured by the Federal Deposit Insurance Corporation (&amp;#8220;FDIC&amp;#8221;) up to $250,000 per account. The Company has cash balances exceeding the balance insured by the FDIC that totaled approximately $23.0&amp;#160;million at December&amp;#160;31, 2017. The total cash balances for amounts held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme (&amp;#8220;FSCS&amp;#8221;) up to &amp;#163;75,000 per account. The Company has cash balances exceeding the balance insured by the FSCS that totaled approximately $0.5&amp;#160;million at December&amp;#160;31, 2017.&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
<us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Property and Equipment&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five&amp;#160;years. Amortization of leasehold improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, currently between five and fifteen&amp;#160;years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss. Expenditures for maintenance and repairs are charged to operating expenses as incurred.&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
<us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Impairment of Long-lived Assets&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.&lt;/div&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
<us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Fair Value of Financial Instruments&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;1&amp;#8201;&amp;#8212;&amp;#8201;Quoted prices in active markets for identical assets or liabilities.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;2&amp;#8201;&amp;#8212;&amp;#8201;Observable inputs (other than Level&amp;#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Level&amp;#160;3&amp;#8201;&amp;#8212;&amp;#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.&lt;/div&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
<us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Segments&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company is managed and operated as one business which is focused on using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information with respect to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment with development operations in two geographic areas, namely the United States and the United Kingdom.&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
<us-gaap:RevenueRecognitionPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Revenue Recognition&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Collaboration, supply and licensing agreements&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Consideration received is allocated to each of the separable elements in an arrangement using the relative selling price method. An element is separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor-specific objective evidence (&amp;#8220;VSOE&amp;#8221;) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. Revenue is recognized for each separate element when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Milestone payments which are non-refundable, non-creditable and contingent on achieving clinical milestones are recognized as revenues either on achievement of such milestones if the milestones are considered substantive or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. When determining if a milestone is substantive, the Company considers the following factors:&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The degree of certainty in achieving the milestone&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The frequency of milestone payments&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The Company&amp;#8217;s efforts, which result in achievement of the milestone&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px;
 font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;The amount of the milestone payment relative to the other deliverables and payment terms, and&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&amp;#8226;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;&amp;#160;Whether the milestone payment is related to future performance or deliverables&lt;/div&gt;
&lt;div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;"&gt;&amp;#160;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company records as deferred revenue any amounts received prior to satisfying the revenue recognition criteria. Deferred revenue not expected to be recognized within the next twelve&amp;#160;months is reported as non-current deferred revenue. The Company recognized $0 and $0.2&amp;#160;million deferred revenue as of December&amp;#160;31, 2016 and 2017 respectively. The deferred revenue reported as of December&amp;#160;31, 2017 relates to a prepayment received from ManRos Therapeutics SA for a development milestone that is not expected to be achieved until mid-2018 (see Note 3 for additional details).&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Royalty income is recognized when the licensee sells the underlying product.&lt;/div&gt;
&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;&lt;font style="text-decoration: underline;"&gt;Grant revenue&lt;/font&gt;&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
<us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and Development Expenditures&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Research and development expenses consist primarily of costs associated with the Company&amp;#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
<cycc:ClinicalTrialAccountingPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Clinical Trial Accounting&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Data management and monitoring of the Company&amp;#8217;s clinical trials are performed with the assistance of contract research organizations (&amp;#8220;CROs&amp;#8221;) or clinical research associates (&amp;#8220;CRAs&amp;#8221;) in accordance with the Company&amp;#8217;s standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are recognized upon execution of the clinical trial agreement and expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial.&lt;/div&gt;</cycc:ClinicalTrialAccountingPolicyTextBlock>
<cycc:PatentCostsPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Patent Costs&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Patent prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.&lt;/div&gt;</cycc:PatentCostsPolicyTextBlock>
<us-gaap:LesseeLeasesPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Leased Assets&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The costs of operating leases are charged to operations on a straight-line basis over the lease term. Operating leases relate primarily to the Company&amp;#8217;s research and development facilities and corporate headquarters.&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
<us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Stock-based Compensation&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over three or four&amp;#160;years. However, certain awards granted to members of the Company&amp;#8217;s Board of Directors vest in their entirety on the one-year anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain&amp;#160;years, the Company granted restricted stock&amp;#160;units to employees that were dependent upon the fulfillment of certain clinical and financial conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes expense in the period that the award becomes probable of vesting (See Note 11&amp;#8201;&amp;#8212;&amp;#8201;Stock-Based Compensation).&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&amp;#8217;s payroll costs are classified. The Company accounts for forfeitures as they occur.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The fair value of restricted stock and restricted stock&amp;#160;units is determined based on the number of shares granted and the quoted price of the Company&amp;#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&amp;#8217;s share price, expected term of the award, interest rates, and dividend yields.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company relies exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
<us-gaap:IncomeTaxPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Income Taxes&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue &amp;amp; Customs (&amp;#8220;HMRC&amp;#8221;), the United Kingdom&amp;#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
<us-gaap:EarningsPerSharePolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Net Loss Per Common Share&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company calculates net loss per common share in accordance with ASC 260 &amp;#8220;Earnings Per Share&amp;#8221; (&amp;#8220;ASC 260&amp;#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
<us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Comprehensive Income (Loss)&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the&amp;#160;years ended December&amp;#160;31, 2016 and 2017.&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
<cycc:RecentlyIssuedAccountingPronouncementsPolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Recently Issued Accounting Pronouncements&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In July&amp;#160;2017, the FASB issued Accounting Standards Update (&amp;#8220;ASU&amp;#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&amp;#8220;ASU 2017-11&amp;#8221;), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&amp;#160;years, and interim periods within those fiscal&amp;#160;years, beginning after December&amp;#160;15, 2018. Early adoption is permitted, including adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In October&amp;#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&amp;#8220;ASU 2016-16&amp;#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&amp;#160;15, 2017, including interim periods within those fiscal&amp;#160;years. This standard will not have a material impact on the company&amp;#8217;s consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In August&amp;#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&amp;#8220;ASU 2016-15&amp;#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&amp;#160;15, 2017, including interim periods within those fiscal&amp;#160;years. This standard will not have a material impact on the company&amp;#8217;s consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In February&amp;#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&amp;#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&amp;#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&amp;#160;years beginning after December&amp;#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;In May&amp;#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&amp;#8220;ASU 2014-09&amp;#8221;), which supersedes existing revenue recognition guidance. The standard&amp;#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&amp;#160;identify the contract with a customer; (2)&amp;#160;identify the performance obligations in the contract; (3)&amp;#160;determine the transaction price; (4)&amp;#160;allocate the transaction price to the performance obligations in the contract; and (5)&amp;#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&amp;#160;15, 2017 and for interim periods within those fiscal&amp;#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted.&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company intends to use the modified retrospective method upon adoption of the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption.&lt;/div&gt;</cycc:RecentlyIssuedAccountingPronouncementsPolicyTextBlock>
<us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 79.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cash&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;5,332&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,103&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.833pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; white-space: normal; padding-top: 2.167pt;"&gt;
&lt;div style="text-indent: -10pt; margin-left: 10pt;"&gt;Investments with original maturity of less than three&amp;#160;months at the time of purchase&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Total cash and cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;16,520&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;23,910&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
<us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22"&gt;
&lt;div style="text-align: center;"&gt;Fair Value Measurements&amp;#160;&lt;br /&gt;as of December&amp;#160;31, 2016 Using:&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;1&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;2&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;3&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;Assets:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;11,188&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 20pt;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11,188&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11,188&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width:
 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22"&gt;
&lt;div style="text-align: center;"&gt;Fair Value Measurements&amp;#160;&lt;br /&gt;as of December&amp;#160;31, 2017 Using:&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;1&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;2&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Level&amp;#160;3&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;Assets:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Cash equivalents&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt;
 padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;22,807&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="margin-left: 20pt;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;22,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#160;&amp;#160;&amp;#160;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;22,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
<us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 127.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development tax credit receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,730&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,054&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Prepayments&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;867&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;363&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Delaware tax receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;25&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;VAT receivable&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;327&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;409&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deposits&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;132&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;132&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other current assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;41&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;81&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Prepaid expenses and other current assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt;
 text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;3,097&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,064&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock>
<us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 113pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 9.25pt; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0pt; padding-top: 0pt;" rowspan="2"&gt;
&lt;div style="text-align: center; padding-bottom: 0pt; line-height: 9pt; white-space: nowrap;"&gt;Lives in&amp;#160;years&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 0pt; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Leasehold improvements&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: right;"&gt;5 to 15&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;792&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;835&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and laboratory equipment&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: right;"&gt;3 to 5&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,438&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,854&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Office equipment and furniture&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: right;"&gt;3 to 5&amp;#160;&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,157&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,236&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6,387&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6,925&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Less: accumulated depreciation and amortization&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(6,342&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(6,896&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0.75pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;45&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;29&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="17"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
<us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 82.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Accrued research and development&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,138&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,645&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Accrued legal and professional fees&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;194&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;248&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other current liabilities&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right;
 padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;430&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;662&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,762&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,555&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 123pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Operating Lease&amp;#160;&lt;br /&gt;Obligation&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2018&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;348&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2019&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2020&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2021&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;344&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;2022&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;343&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space:
 nowrap;"&gt;thereafter&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;956&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Total future minimum lease obligations&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;2,679&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="8"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
<us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 72pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Year Ended&amp;#160;&lt;br /&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Year Ended&amp;#160;&lt;br /&gt;December&amp;#160;31,&amp;#160;&lt;br /&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;305&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;72&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;General and administrative&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;477&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;194&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock-based compensation costs before income taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;782&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom:
 #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;266&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
<us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="margin-top: 0pt; width: 456pt; border-collapse: collapse; height: 211.5pt;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Number of&amp;#160;&lt;br /&gt;Options&amp;#160;&lt;br /&gt;Outstanding&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Weighted&amp;#160;&lt;br /&gt;Average&amp;#160;&lt;br /&gt;Exercise Price&amp;#160;&lt;br /&gt;Per Share&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Weighted&amp;#160;&lt;br /&gt;Average&amp;#160;&lt;br /&gt;Remaining&amp;#160;&lt;br /&gt;Contractual&amp;#160;&lt;br /&gt;Term (Years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4"&gt;
&lt;div style="text-align: center;"&gt;Aggregate&amp;#160;&lt;br /&gt;Intrinsic&amp;#160;&lt;br /&gt;Value ($000s)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2015&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;206,298&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;72.60&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.09&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;197,841&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4.68&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cancelled/forfeited&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(14,760&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;396.83&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt;
 white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;389,379&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;25.80&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;5.83&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;121&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Granted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;170,853&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1.93&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom:
 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Exercised&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Cancelled/forfeited&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(24,615&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;179.92&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px
 solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Options outstanding at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;535,617&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;11.10&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.23&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Unvested at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;386,682&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;3.64&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;8.84&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Vested and exercisable at December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;148,755&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;30.49&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 13.5pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;6.65&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
<us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 456pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 92.5pt; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 0pt;"&gt;
&lt;div style="text-align: center;"&gt;Year ended&amp;#160;&lt;br /&gt;December&amp;#160;31, 2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 0pt;"&gt;
&lt;div style="text-align: center;"&gt;Year ended&amp;#160;&lt;br /&gt;December&amp;#160;31, 2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Expected term (years)&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: center;"&gt;5&amp;#8201;&amp;#8211;&amp;#8201;6&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="text-align: center;"&gt;6&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Risk free interest rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;1.370%&amp;#8201;&amp;#8211;&amp;#8201;1.500%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;1.890%&amp;#8201;&amp;#8211;&amp;#8201;2.265%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Volatility&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;98%&amp;#8201;&amp;#8211;&amp;#8201;104%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;108%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Expected dividend yield over expected term&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;0.00%&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Resulting weighted average grant date fair value&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;$3.66&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="text-align: center;"&gt;$1.59&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
<us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 67.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(2,011&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(127&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Foreign&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(11,763&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(8,336&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss from continuing operations before taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(13,774&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(8,463&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;The benefit (provision) for income taxes from continuing operations consists of the following (in&amp;#160;thousands):&lt;/div&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;foreign&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,983&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;993&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deferred&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Income tax benefit&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
<us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;foreign&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,983&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;993&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Current&amp;#8201;&amp;#8211;&amp;#8201;total&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt;
 padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deferred&amp;#8201;&amp;#8211;&amp;#8201;domestic&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Income tax benefit&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;1,983&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;993&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
<us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 174.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 3.25pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss from continuing operations before taxes&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(13,774&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(8,463&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Income tax expense computed at statutory federal tax rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(4,683&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(2,877&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Disallowed expenses and non-taxable income&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;12&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;3&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss surrendered to generate R&amp;amp;D credit&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,945&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;856&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Additional research and development tax relief&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(2,827&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(1,262&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Change in valuation allowance&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;2,029&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(4,487&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Foreign items, including change in tax rates, and other&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,238&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,901&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Change in US Tax Rate&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,112&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other foreign items&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;303&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;761&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(1,983&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;(993&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
<us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 143pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net operating loss and tax credit carryforwards&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;42,851&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;38,948&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Depreciation, amortization and impairment of property and equipment&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;137&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;111&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;2,365&lt;/td&gt;
&lt;td
 style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;1,807&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Research and development credits&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,021&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;4,021&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Other&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;49,374&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;44,887&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Valuation allowance for deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(49,374&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;"&gt;(44,887&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net deferred tax assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 2.5pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4pt; height: 4pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
<us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 162pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Years ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Numerator:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="margin-left: 10pt;"&gt;Net loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(11,791&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(7,470&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Dividend on convertible exchangeable preferred shares&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(200&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td
 style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(201&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Beneficial conversion feature of Series&amp;#160;A convertible stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(3,638&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Conversion of Series&amp;#160;A convertible preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(3,537&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Net loss attributable to common shareholders&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(11,991&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(14,846&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.25pt;"&gt;Denominator:&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.333pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; white-space: normal; padding-top: 1.667pt;"&gt;
&lt;div style="text-indent: -10pt; margin-left: 20pt;"&gt;Weighted-average number of common shares used in loss per share&amp;#160;&amp;#8211; basic and diluted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;"&gt;3,424,976&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;"&gt;7,631,152&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Loss per share&amp;#8201;&amp;#8211;&amp;#8201;basic and diluted&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(3.50&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(1.95&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
<us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 91.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Stock options&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;389,378&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;535,616&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Convertible preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;1,698&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;1,698&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Series&amp;#160;A preferred stock&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding:
 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;132,000&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Common stock warrants&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;7,490,500&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;Total shares excluded from calculation&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;391,076&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;8,159,814&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
<us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 128pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;Year Ended December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Revenue&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;843&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Revenue&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px
 double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;843&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;&amp;#8212;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;"&gt;Net loss&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 23.25pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(2,211&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 19.5pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(127&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(9,580&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;(7,343&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif;
 white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Net Loss&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(11,791&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;(7,470&lt;font style="position: absolute;"&gt;)&lt;/font&gt;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;
&lt;table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 142pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;
&lt;tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;December&amp;#160;31,&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2016&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4"&gt;
&lt;div style="text-align: center; white-space: nowrap;"&gt;2017&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;Total Assets&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap;
 padding-top: 3pt;"&gt;15,197&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;23,522&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;4,465&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;2,481&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Assets&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;19,662&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;26,003&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;"&gt;Long Lived Assets, net&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United States&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td
 style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;2&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;$&lt;/td&gt;
&lt;td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;0&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;"&gt;
&lt;div style="white-space: nowrap;"&gt;United Kingdom&lt;/div&gt;
&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;43&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;"&gt;29&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;"&gt;
&lt;td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;
&lt;div style="white-space: nowrap; font-weight: bold;"&gt;Total Long Lived Assets, net&lt;/div&gt;
&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;45&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 6pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;"&gt;$&lt;/td&gt;
&lt;td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;"&gt;29&lt;/td&gt;
&lt;td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;td style="width: 0pt; padding: 0pt;"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr style="line-height: 4.5pt; height: 4.5pt;"&gt;
&lt;td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14"&gt;&amp;#160;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;</us-gaap:ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock>
<us-gaap:StockholdersEquityReverseStockSplit contextRef="Context_0ME_01-May-2016T00_00_00_TO_27-May-2016T00_00_00">one-for-twelve</us-gaap:StockholdersEquityReverseStockSplit>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MaximumMember">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember_RangeAxis_MinimumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_PropertyPlantAndEquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember_RangeAxis_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
<us-gaap:NumberOfOperatingSegments contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
<us-gaap:NumberOfCountriesInWhichEntityOperates contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="Segment" decimals="INF">2</us-gaap:NumberOfCountriesInWhichEntityOperates>
<us-gaap:CashFDICInsuredAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">250000</us-gaap:CashFDICInsuredAmount>
<us-gaap:CashUninsuredAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-5">23000000</us-gaap:CashUninsuredAmount>
<cycc:CashFinancialServicesCompensationSchemeInsuredAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="EUR" decimals="0">75000</cycc:CashFinancialServicesCompensationSchemeInsuredAmount>
<cycc:CashExceedingBalanceInsuredByFinancialServicesCompensationScheme contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-5">500000</cycc:CashExceedingBalanceInsuredByFinancialServicesCompensationScheme>
<cycc:LicenseAgreementPotentialFutureMilestonePayments contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember" unitRef="USD" decimals="-5">10000000</cycc:LicenseAgreementPotentialFutureMilestonePayments>
<cycc:LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember">P10Y</cycc:LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry>
<cycc:LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember">P6M</cycc:LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason>
<cycc:LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_DaiichiSankyoCompanyLimitedMember">P12M</cycc:LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">5332000</us-gaap:Cash>
<us-gaap:Cash contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1103000</us-gaap:Cash>
<us-gaap:ShortTermInvestments contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">11188000</us-gaap:ShortTermInvestments>
<us-gaap:ShortTermInvestments contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">22807000</us-gaap:ShortTermInvestments>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">11188000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">11188000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">0</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">0</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">22807000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">22807000</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">0</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:CashEquivalentsAtCarryingValue contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">0</us-gaap:CashEquivalentsAtCarryingValue>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">11188000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">11188000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2016T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel1Member" unitRef="USD" decimals="-3">22807000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember" unitRef="USD" decimals="-3">22807000</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel3Member" unitRef="USD" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:AssetsFairValueDisclosure contextRef="Context_As_Of_31-Dec-2017T00_00_00_FairValueByMeasurementBasisAxis_EstimateOfFairValueFairValueDisclosureMember_FairValueByMeasurementFrequencyAxis_FairValueMeasurementsRecurringMember_FairValueByFairValueHierarchyLevelAxis_FairValueInputsLevel2Member" unitRef="USD" decimals="-3">0</us-gaap:AssetsFairValueDisclosure>
<us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">1730000</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
<us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1054000</us-gaap:DeferredIncomeTaxesAndOtherTaxReceivableCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">867000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:PrepaidExpenseCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">363000</us-gaap:PrepaidExpenseCurrent>
<us-gaap:ValueAddedTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">327000</us-gaap:ValueAddedTaxReceivableCurrent>
<us-gaap:ValueAddedTaxReceivableCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">409000</us-gaap:ValueAddedTaxReceivableCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">132000</us-gaap:DepositsAssetsCurrent>
<us-gaap:DepositsAssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">132000</us-gaap:DepositsAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">41000</us-gaap:OtherAssetsCurrent>
<us-gaap:OtherAssetsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">81000</us-gaap:OtherAssetsCurrent>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">6387000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="-3">792000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="USD" decimals="-3">4438000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember" unitRef="USD" decimals="-3">1157000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">6925000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_LeaseholdImprovementsMember" unitRef="USD" decimals="-3">835000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_EquipmentMember" unitRef="USD" decimals="-3">4854000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:PropertyPlantAndEquipmentGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_PropertyPlantAndEquipmentByTypeAxis_OfficeEquipmentAndFurnitureMember" unitRef="USD" decimals="-3">1236000</us-gaap:PropertyPlantAndEquipmentGross>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">6342000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">6896000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-5">100000</us-gaap:DepreciationDepletionAndAmortization>
<us-gaap:DepreciationDepletionAndAmortization contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">32000</us-gaap:DepreciationDepletionAndAmortization>
<cycc:AccruedResearchAndDevelopmentCostsCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">2138000</cycc:AccruedResearchAndDevelopmentCostsCurrent>
<cycc:AccruedResearchAndDevelopmentCostsCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1645000</cycc:AccruedResearchAndDevelopmentCostsCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">194000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:AccruedProfessionalFeesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">248000</us-gaap:AccruedProfessionalFeesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">430000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OtherAccruedLiabilitiesCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">662000</us-gaap:OtherAccruedLiabilitiesCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">348000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">344000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">344000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">344000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">343000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">956000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
<us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">2679000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
<us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract contextRef="Context_Custom_01_Oct_2000T00_00_00_TO_31_Oct_2000T00_00_00">P25Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-5">500000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:OperatingLeasesRentExpenseNet contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-5">500000</us-gaap:OperatingLeasesRentExpenseNet>
<us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">2.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
<us-gaap:PreferredStockRedemptionPricePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:PreferredStockRedemptionPricePerShare>
<us-gaap:PreferredStockDividendRatePercentage contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">0.06</us-gaap:PreferredStockDividendRatePercentage>
<us-gaap:PreferredStockLiquidationPreference contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:PreferredStockLiquidationPreference>
<cycc:ConvertiblePreferredStockConversionPricePerShare contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="0">1974</cycc:ConvertiblePreferredStockConversionPricePerShare>

<us-gaap:SharePrice contextRef="Context_As_Of_21-Jul-2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember" unitRef="USD_per_Share" decimals="0">2</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_21_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember" unitRef="USD_per_Share" decimals="0">1000</us-gaap:SharePrice>
<us-gaap:SharePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="0">2961</us-gaap:SharePrice>
<cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">1.50</cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice>
<cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P20D</cycc:PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays>
<cycc:PreferredStockConversionObligationNumberOfTradingDays contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P30D</cycc:PreferredStockConversionObligationNumberOfTradingDays>
<cycc:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P5D</cycc:PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion>
<us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="pure" decimals="2">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
<cycc:PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</cycc:PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation>
<us-gaap:DebtInstrumentTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">P25Y</us-gaap:DebtInstrumentTerm>
<us-gaap:DividendsPayableDateDeclaredDayMonthAndYear contextRef="Context_Custom_01_Mar_2018T00_00_00_TO_07_Mar_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember">2018-03-07</us-gaap:DividendsPayableDateDeclaredDayMonthAndYear>
<us-gaap:PreferredStockDividendsPerShareDeclared contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:PreferredStockDividendsPerShareDeclared>
<us-gaap:PreferredStockDividendsPerShareDeclared contextRef="Context_Custom_01_Mar_2018T00_00_00_TO_07_Mar_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember" unitRef="USD_per_Share" decimals="2">0.15</us-gaap:PreferredStockDividendsPerShareDeclared>
<us-gaap:DividendPayableDateToBePaidDayMonthAndYear contextRef="Context_Custom_01_Mar_2018T00_00_00_TO_07_Mar_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember">2018-05-01</us-gaap:DividendPayableDateToBePaidDayMonthAndYear>
<us-gaap:DividendsPayableDateOfRecordDayMonthAndYear contextRef="Context_Custom_01_Mar_2018T00_00_00_TO_07_Mar_2018T00_00_00_TitleOfIndividualAxis_BoardOfDirectorsChairmanMember_SubsequentEventTypeAxis_SubsequentEventMember">2018-04-11</us-gaap:DividendsPayableDateOfRecordDayMonthAndYear>
<cycc:PercentageOfCommissionOnGrossEquitySales contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_10_Jul_2015T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember" unitRef="pure" decimals="4">0.0300</cycc:PercentageOfCommissionOnGrossEquitySales>
<cycc:PercentageOfCommissionOnGrossEquitySales contextRef="Context_Custom_01_Jun_2016T00_00_00_TO_23_Jun_2016T00_00_00_EquitySaleAgreementAxis_FbrSalesAgreementMember" unitRef="pure" decimals="3">0.030</cycc:PercentageOfCommissionOnGrossEquitySales>
<cycc:MaximumAmountOfOfferingPriceForCommonStock contextRef="Context_Custom_01_Jul_2015T00_00_00_TO_10_Jul_2015T00_00_00_AgreementAxis_ControlledEquityOfferingSalesAgreementMember_TitleOfIndividualAxis_SalesAgentMember" unitRef="USD" decimals="-4">8350000</cycc:MaximumAmountOfOfferingPriceForCommonStock>
<us-gaap:SharesIssuedPricePerShare contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">10.00</us-gaap:SharesIssuedPricePerShare>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">782000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">305000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">477000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">266000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="-3">72000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:AllocatedShareBasedCompensationExpense contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeStatementLocationAxis_GeneralAndAdministrativeExpenseMember" unitRef="USD" decimals="-3">194000</us-gaap:AllocatedShareBasedCompensationExpense>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">389379</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">535617</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">206298</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">197841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member" unitRef="shares" decimals="INF">197841</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_PerformanceBasedOptionsMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member" unitRef="shares" decimals="INF">189091</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">170853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_PerformanceBasedOptionsMember" unitRef="shares" decimals="INF">158853</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">14760</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">24615</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">386682</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="shares" decimals="INF">148755</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">25.80</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">11.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="Context_As_Of_01_Jan_2016T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">72.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">4.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.93</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">396.83</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">179.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.64</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">30.49</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2015T00_00_00_TO_31_Dec_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P8Y10M2D</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y7M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD" decimals="-3">121000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="5">0.01370</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="5">0.01500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="5">0.01890</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="5">0.02265</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember" unitRef="pure" decimals="2">0.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember" unitRef="pure" decimals="2">1.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">1.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="4">0.0000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">3.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="USD_per_Share" decimals="2">1.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized contextRef="Context_As_Of_22_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_Plan2015Member" unitRef="shares" decimals="INF">458753</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_PlanNameAxis_Plan2015Member">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MinimumMember_PlanNameAxis_Plan2015Member">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="Context_Custom_01_May_2015T00_00_00_TO_22_May_2015T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_RangeAxis_MaximumMember_PlanNameAxis_Plan2015Member">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
<cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member" unitRef="USD" decimals="-5">700000</cycc:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member" unitRef="USD" decimals="-5">200000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
<us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember_TitleOfIndividualAxis_EmployeesAndDirectorsMember_PlanNameAxis_Plan2015Member">P10M24D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RetirementPlanTypeAxis_PensionPlanMember" unitRef="USD" decimals="0">57000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_PensionPlanMember" unitRef="USD" decimals="0">54000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
<cycc:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="pure" decimals="2">1.00</cycc:DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral>
<us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="pure" decimals="2">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
<cycc:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="USD" decimals="0">18000</cycc:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge>
<cycc:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="USD" decimals="0">24000</cycc:DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge>
<cycc:DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember">P50Y</cycc:DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="USD" decimals="0">32000</us-gaap:DefinedContributionPlanCostRecognized>
<us-gaap:DefinedContributionPlanCostRecognized contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RetirementPlanTypeAxis_Plan401KMember" unitRef="USD" decimals="0">28000</us-gaap:DefinedContributionPlanCostRecognized>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-2011000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-127000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-11763000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-8336000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:CurrentFederalTaxExpenseBenefit>
<us-gaap:CurrentFederalTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:CurrentFederalTaxExpenseBenefit>
<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-1983000</us-gaap:CurrentForeignTaxExpenseBenefit>
<us-gaap:CurrentForeignTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-993000</us-gaap:CurrentForeignTaxExpenseBenefit>
<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-1983000</us-gaap:CurrentIncomeTaxExpenseBenefit>
<us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-993000</us-gaap:CurrentIncomeTaxExpenseBenefit>
<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
<us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-4683000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-2877000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
<cycc:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">12000</cycc:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome>
<cycc:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">3000</cycc:IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">1945000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
<us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">856000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">-2827000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:IncomeTaxReconciliationOtherAdjustments contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-1262000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">2029000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">-4487000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
<us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">4112000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">303000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
<us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">761000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">42851000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">38948000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
<cycc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">137000</cycc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses>
<cycc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">111000</cycc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">2365000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1807000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
<cycc:DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">4021000</cycc:DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits>
<cycc:DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">4021000</cycc:DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits>
<us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsOther contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsOther>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">49374000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsGross contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">44887000</us-gaap:DeferredTaxAssetsGross>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">49374000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsValuationAllowance contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">44887000</us-gaap:DeferredTaxAssetsValuationAllowance>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
<us-gaap:DeferredTaxAssetsNet contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredTaxAssetsNet>
<us-gaap:TaxCreditCarryforwardAmount contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_TaxCreditCarryforwardAxis_ResearchMember_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="USD" decimals="-6">2000000</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:TaxCreditCarryforwardAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_TaxCreditCarryforwardAxis_ResearchMember_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="USD" decimals="-6">1000000</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:TaxCreditCarryforwardAmount contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="USD" decimals="-6">4000000</us-gaap:TaxCreditCarryforwardAmount>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="USD" decimals="-5">28400000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="USD" decimals="-5">178200000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_InternalRevenueServiceIRSMember" unitRef="USD" decimals="-5">28400000</us-gaap:OperatingLossCarryforwards>
<us-gaap:OperatingLossCarryforwards contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="USD" decimals="-5">186200000</us-gaap:OperatingLossCarryforwards>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="0">391076</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">389378</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">1698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CommonStockWarrantsMember" unitRef="shares" decimals="0">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="0">8159814</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_EmployeeStockOptionMember" unitRef="shares" decimals="0">535616</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="0">1698</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_CommonStockWarrantsMember" unitRef="shares" decimals="0">7490500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="0">132000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
<us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember">Black-Scholes option-pricing model</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed>

<us-gaap:CapitalUnitsAuthorized contextRef="Context_As_Of_21_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember" unitRef="shares" decimals="INF">8872</us-gaap:CapitalUnitsAuthorized>
<cycc:NumberOfSecuritiesCalledByEachUnit contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1</cycc:NumberOfSecuritiesCalledByEachUnit>
<us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="Context_As_Of_21_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">1</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_21-Jul-2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="shares" decimals="INF">500</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>

<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">132000</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<cycc:NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight contextRef="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_LegalEntityAxis_LadenburgThalmannAndCoIncMember_StatementEquityComponentsAxis_CommonStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="USD_per_Share" decimals="2">1000.00</cycc:NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight>

<cycc:AggregateIntrinsicValueOfStock contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_21_Jul_2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD" decimals="0">3638000</cycc:AggregateIntrinsicValueOfStock>
<us-gaap:WarrantsAndRightsOutstanding contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="0">7490500</us-gaap:WarrantsAndRightsOutstanding>
<cycc:ConditionRelatedToExcercisingWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or any of such holder's affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise.</cycc:ConditionRelatedToExcercisingWarrants>




<cycc:ConditionRelatedToEventsOccurenceForConversionOfPreferredStock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember">(i) the volume weighted average price of our common stock for 30 consecutive trading days (the "Measurement Period") exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company.</cycc:ConditionRelatedToEventsOccurenceForConversionOfPreferredStock>
<us-gaap:ProceedsFromWarrantExercises contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">199000</us-gaap:ProceedsFromWarrantExercises>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">4304000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_PreferredStockMember" unitRef="shares" decimals="INF">-8608</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
<us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities>
<us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">3537000</us-gaap:ConvertiblePreferredStockConvertedToOtherSecurities>
<cycc:BeneficialConversionFeatureOfConvertibleStock contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</cycc:BeneficialConversionFeatureOfConvertibleStock>
<cycc:BeneficialConversionFeatureOfConvertibleStock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">3638000</cycc:BeneficialConversionFeatureOfConvertibleStock>
<us-gaap:DeferredRevenue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:DeferredRevenue>
<us-gaap:DeferredRevenue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-5">200000</us-gaap:DeferredRevenue>
<us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">200000</us-gaap:ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">-4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="USD" decimals="-3">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
<us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">1238000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
<us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">1901000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
<us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_LegalEntityAxis_ManrosTherapeuticsSaManrosMember_TypeOfArrangementAxis_CollaborationSupplyAndLicensingAgreementsMember" unitRef="USD" decimals="0">150000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_RangeAxis_MaximumMember" unitRef="pure" decimals="2">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
<cycc:FutureFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="pure" decimals="2">0.21</cycc:FutureFederalStatutoryIncomeTaxRate>
<us-gaap:IncomeTaxesReceivable contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="USD" decimals="-3">0</us-gaap:IncomeTaxesReceivable>
<us-gaap:IncomeTaxesReceivable contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">25000</us-gaap:IncomeTaxesReceivable>
<cycc:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_IncomeTaxAuthorityAxis_ForeignCountryMember" unitRef="pure" decimals="2">0.17</cycc:PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement>
<us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-5">700000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
<us-gaap:PreferredStockAmountOfPreferredDividendsInArrears contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-5">700000</us-gaap:PreferredStockAmountOfPreferredDividendsInArrears>
<us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
<us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD_per_Share" decimals="2">1.95</us-gaap:PreferredStockPerShareAmountsOfPreferredDividendsInArrears>
<cycc:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-3">199000</cycc:StockIssuedDuringPeriodValueStockWarrantsExercised>
<cycc:StockIssuedDuringPeriodValueStockWarrantsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_AdditionalPaidInCapitalMember" unitRef="USD" decimals="-3">199000</cycc:StockIssuedDuringPeriodValueStockWarrantsExercised>
<cycc:StockIssuedDuringPeriodSharesStockWarrantsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember" unitRef="shares" decimals="INF">99500</cycc:StockIssuedDuringPeriodSharesStockWarrantsExercised>
<us-gaap:CommonStockConversionBasis contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember">0.00507</us-gaap:CommonStockConversionBasis>
<cycc:NumberOfWarrantsExercised contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="shares" decimals="INF">0</cycc:NumberOfWarrantsExercised>
<cycc:NumberOfWarrantsExercised contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="shares" decimals="INF">99500</cycc:NumberOfWarrantsExercised>
<cycc:WeightedAverageExercisePrice contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD_per_Share" decimals="2">2.00</cycc:WeightedAverageExercisePrice>
<us-gaap:OperatingLossCarryforwardsLimitationsOnUse contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div&gt;&lt;font style="font-family: times new roman,times;" size="2"&gt;use of these NOLs is restricted to an annual &amp;#163;5 million allowance in each standalone company or group and above this allowance, there will be a 50% restriction in the profits that can be covered by losses brought forward&lt;/font&gt;&lt;/div&gt;</us-gaap:OperatingLossCarryforwardsLimitationsOnUse>
<cycc:OtherIncomePolicyTextBlock contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00">&lt;div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Other Income&lt;/div&gt;
&lt;div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"&gt;Other income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part of the Company&amp;#8217;s ongoing operations and activities.&lt;/div&gt;</cycc:OtherIncomePolicyTextBlock>

<!-- Footnote Section -->
<link:footnoteLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
</link:footnoteLink>
<xbrli:context id="Context_As_Of_21-Jul-2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier>

<xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassAMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:instant>2017-07-21</xbrli:instant></xbrli:period></xbrli:context>
	<us-gaap:CapitalUnitsAuthorized contextRef="Context_As_Of_21-Jul-2017T00_00_00_TypeOfArrangementAxis_CollaborativeArrangementMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassAMember" unitRef="shares" decimals="INF">3154000</us-gaap:CapitalUnitsAuthorized>
<xbrli:context id="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_TypeOfArrangementAxis_CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-21</xbrli:endDate></xbrli:period></xbrli:context>
	<cycc:NumberOfSecuritiesCalledByEachUnit contextRef="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_TypeOfArrangementAxis_CollaborativeArrangementMember" unitRef="shares" decimals="INF">1</cycc:NumberOfSecuritiesCalledByEachUnit>
<xbrli:context id="Context_As_Of_21-Jul-2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_TypeOfArrangementAxis_CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesAPreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-07-21</xbrli:instant></xbrli:period></xbrli:context>
	<xbrli:context id="Context_As_Of_21-Jul-2017T00_00_00_StatementEquityComponentsAxis_CommonStockMember_LegalEntityAxis_LadenburgThalmannAndCoIncMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_TypeOfArrangementAxis_CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:instant>2017-07-21</xbrli:instant></xbrli:period></xbrli:context>
	<xbrli:context id="Context_0ME_01-Jul-2017T00_00_00_TO_21-Jul-2017T00_00_00_LegalEntityAxis_LadenburgThalmannAndCoIncMember_StatementEquityComponentsAxis_CommonStockMember_CapitalUnitsByClassAxis_CapitalUnitClassBMember_TypeOfArrangementAxis_CollaborativeArrangementMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001130166</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">cycc:LadenburgThalmannAndCoIncMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:CapitalUnitsByClassAxis">us-gaap:CapitalUnitClassBMember</xbrldi:explicitMember>
<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
</xbrli:segment>
</xbrli:entity><xbrli:period><xbrli:startDate>2017-07-01</xbrli:startDate><xbrli:endDate>2017-07-21</xbrli:endDate></xbrli:period></xbrli:context>
	<us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">8608</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
<us-gaap:ConversionOfStockSharesConverted1 contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">4304000</us-gaap:ConversionOfStockSharesConverted1>
<cycc:NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="0">1000</cycc:NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight>
<cycc:ConvertiblePreferredStockConversionPrice contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="USD_per_Share" decimals="2">2.00</cycc:ConvertiblePreferredStockConversionPrice>
<cycc:ConvertiblePreferredStockConversionPercentageBlockerProvision contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="4">0.0499</cycc:ConvertiblePreferredStockConversionPercentageBlockerProvision>
<cycc:ConvertiblePreferredStockConversionPercentage contextRef="Context_Custom_01_Jul_2017T00_00_00_TO_31_Jul_2017T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="pure" decimals="4">0.0999</cycc:ConvertiblePreferredStockConversionPercentage>
<us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">1698</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
<us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00_AwardTypeAxis_EmployeeStockOptionMember" unitRef="pure" decimals="2">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
<us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="Context_FYE_01_Jan_2016T00_00_00_TO_31_Dec_2016T00_00_00" unitRef="pure" decimals="2">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>

<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="shares" decimals="INF">335273</us-gaap:PreferredStockSharesOutstanding>


<us-gaap:PreferredStockSharesIssued contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesIssued>
<us-gaap:PreferredStockSharesOutstanding contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_SeriesAPreferredStockMember" unitRef="shares" decimals="INF">0</us-gaap:PreferredStockSharesOutstanding>

<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2017T00_00_00_TO_31_Dec_2017T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-3">4006512000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:PreferredStockLiquidationPreferenceValue contextRef="Context_As_Of_31_Dec_2016T00_00_00_TO_31_Dec_2016T00_00_00_StatementClassOfStockAxis_ConvertiblePreferredStockMember" unitRef="USD" decimals="-3">4006512000</us-gaap:PreferredStockLiquidationPreferenceValue>
<us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability contextRef="Context_FYE_01_Jan_2017T00_00_00_TO_31_Dec_2017T00_00_00" unitRef="USD" decimals="-5">4100000</us-gaap:IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>8
<FILENAME>cycc-20171231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<schema targetNamespace="http://www.cyclacel.com/20171231" elementFormDefault="qualified" xmlns:cycc="http://www.cyclacel.com/20171231" xmlns="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:us-gaap-att="http://fasb.org/us-gaap/attributes" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric">
<annotation><appinfo>
<link:roleType roleURI="http://www.cyclacel.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
<link:definition>001 - Document - Document and Entity Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheets" id="ConsolidatedBalanceSheets">
<link:definition>002 - Statement - CONSOLIDATED BALANCE SHEETS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheetsParentheticals" id="ConsolidatedBalanceSheetsParentheticals">
<link:definition>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss" id="ConsolidatedStatementsOfOperationsLoss">
<link:definition>005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss" id="ConsolidatedStatementsOfComprehensiveLoss">
<link:definition>006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity" id="ConsolidatedStatementsOfStockholdersEquity">
<link:definition>007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Consolidatedstatementsofcashflows" id="Consolidatedstatementsofcashflows">
<link:definition>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation" id="OrganizationOfCompanyAndBasisOfPresentation">
<link:definition>009 - Disclosure - Organization of the Company and Basis of Presentation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPolicies" id="SummaryOfSignificantAccountingPolicies">
<link:definition>010 - Disclosure - Summary of Significant Accounting Policies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/SignificantContracts" id="SignificantContracts">
<link:definition>011 - Disclosure - Significant Contracts</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/CashAndCashEquivalents" id="CashAndCashEquivalents">
<link:definition>012 - Disclosure - Cash and Cash Equivalents</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Fairvalueoffinancialassetsandliabilities" id="Fairvalueoffinancialassetsandliabilities">
<link:definition>013 - Disclosure - Fair Value of Financial Assets and Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets" id="PrepaidExpensesAndOtherCurrentAssets">
<link:definition>014 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
<link:definition>015 - Disclosure - Property and Equipment</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilities" id="AccruedAndOtherCurrentLiabilities">
<link:definition>016 - Disclosure - Accrued and Other Current Liabilities</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureCommitmentsandcontingencies" id="DisclosureCommitmentsandcontingencies">
<link:definition>017 - Disclosure - Commitments and Contingencies</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureStockholdersequity" id="DisclosureStockholdersequity">
<link:definition>018 - Disclosure - Stockholders' Equity</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Disclosurestockbasedcompensation" id="Disclosurestockbasedcompensation">
<link:definition>019 - Disclosure - Stock-Based Compensation</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureEmployeeBenefitPlans" id="DisclosureEmployeeBenefitPlans">
<link:definition>020 - Disclosure - Employee Benefit Plans</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureTaxes" id="DisclosureTaxes">
<link:definition>021 - Disclosure - Taxes</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureNetlosspershare" id="DisclosureNetlosspershare">
<link:definition>022 - Disclosure - Net Loss Per Share</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Disclosuregeographicinformation" id="Disclosuregeographicinformation">
<link:definition>023 - Disclosure - Geographic Information</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Disclosuresubsequentevents" id="Disclosuresubsequentevents">
<link:definition>024 - Disclosure - Subsequent Events</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/Disclosuresummaryofsignificantaccountingpoliciespolicies" id="Disclosuresummaryofsignificantaccountingpoliciespolicies">
<link:definition>025 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureCashAndCashEquivalentsTables" id="DisclosureCashAndCashEquivalentsTables">
<link:definition>026 - Disclosure - Cash and Cash Equivalents (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables" id="FairValueOfFinancialAssetsAndLiabilitiesTables">
<link:definition>027 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
<link:definition>028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosurePropertyAndEquipmentTables" id="DisclosurePropertyAndEquipmentTables">
<link:definition>029 - Disclosure - Property and Equipment (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="DisclosureAccruedAndOtherCurrentLiabilitiesTables">
<link:definition>030 - Disclosure - Accrued and Other Current Liabilities (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables" id="DisclosureCommitmentsAndContingenciesTables">
<link:definition>031 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
<link:definition>032 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/DisclosureTaxesTables" id="DisclosureTaxesTables">
<link:definition>033 - Disclosure - Taxes (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/NetLossPerShareTables" id="NetLossPerShareTables">
<link:definition>034 - Disclosure - Net Loss Per Share (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/GeographicInformationTables" id="GeographicInformationTables">
<link:definition>035 - Disclosure - Geographic Information (Tables)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals" id="OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals">
<link:definition>036 - Disclosure - Organization of the Company and Basis of Presentation (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals" id="SummaryOfSignificantAccountingPoliciesDetailTextuals">
<link:definition>038 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/SignificantContractsDetailTextuals" id="SignificantContractsDetailTextuals">
<link:definition>039 - Disclosure - Significant Contracts (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/CashAndCashEquivalentsDetails" id="CashAndCashEquivalentsDetails">
<link:definition>040 - Disclosure - Cash and Cash Equivalents (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails" id="FairValueOfFinancialAssetsAndLiabilitiesDetails">
<link:definition>041 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails" id="PrepaidExpensesAndOtherCurrentAssetsDetails">
<link:definition>042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails" id="PropertyPlantAndEquipmentDetails">
<link:definition>043 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetailTextuals" id="PropertyPlantAndEquipmentDetailTextuals">
<link:definition>044 - Disclosure - Property, Plant and Equipment (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails" id="AccruedAndOtherCurrentLiabilitiesDetails">
<link:definition>045 - Disclosure - Accrued and Other Current Liabilities (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals" id="AccruedAndOtherCurrentLiabilitiesDetailTextuals">
<link:definition>046 - Disclosure - Accrued and Other Current Liabilities (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails" id="CommitmentsAndContingenciesDetails">
<link:definition>047 - Disclosure - Commitments and Contingencies (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetailTextuals" id="CommitmentsAndContingenciesDetailTextuals">
<link:definition>048 - Disclosure - Commitments and Contingencies (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals" id="StockholdersEquityDetailTextuals">
<link:definition>049 - Disclosure - Stockholders' Equity (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1" id="StockholdersEquityDetailTextuals1">
<link:definition>050 - Disclosure - Stockholders' Equity (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2" id="StockholdersEquityDetailTextuals2">
<link:definition>051 - Disclosure - Stockholders' Equity (Detail Textuals 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals3" id="StockholdersEquityDetailTextuals3">
<link:definition>052 - Disclosure - Stockholders' Equity (Detail Textuals 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4" id="StockholdersEquityDetailTextuals4">
<link:definition>053 - Disclosure - Stockholders' Equity (Detail Textuals 4)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails" id="StockBasedCompensationArrangementsDetails">
<link:definition>054 - Disclosure - Stock-Based Compensation Arrangements (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1" id="StockBasedCompensationArrangementsDetails1">
<link:definition>055 - Disclosure - Stock-Based Compensation Arrangements (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2" id="StockBasedCompensationArrangementsDetails2">
<link:definition>056 - Disclosure - Stock-Based Compensation Arrangements (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1" id="StockBasedCompensationArrangementsDetailTextuals1">
<link:definition>057 - Disclosure - Stock-Based Compensation Arrangements (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals" id="EmployeeBenefitPlansDetailTextuals">
<link:definition>058 - Disclosure - Employee Benefit Plans (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/TaxesDetails" id="TaxesDetails">
<link:definition>059 - Disclosure - Taxes (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/TaxesDetails2" id="TaxesDetails2">
<link:definition>060 - Disclosure - Taxes (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/TaxesDetails3" id="TaxesDetails3">
<link:definition>061 - Disclosure - Taxes (Details 2)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/TaxesDetails4" id="TaxesDetails4">
<link:definition>062 - Disclosure - Taxes (Details 3)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/TaxesDetails5" id="TaxesDetails5">
<link:definition>063 - Disclosure - Taxes (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/NetLossPerShareDetails" id="NetLossPerShareDetails">
<link:definition>064 - Disclosure - Net Loss Per Share (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/NetLossPerShareDetail1" id="NetLossPerShareDetail1">
<link:definition>065 - Disclosure - Net Loss Per Share (Details 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/GeographicInformationDetails" id="GeographicInformationDetails">
<link:definition>066 - Disclosure - Geographic Information (Details)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/SubsequentEventsDetails" id="SubsequentEventsDetails">
<link:definition>067 - Disclosure - Subsequent Events (Detail Textuals)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:linkbaseRef xlink:type="simple" xlink:href="cycc-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cycc-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cycc-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:linkbaseRef xlink:type="simple" xlink:href="cycc-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase"/>
<link:roleType roleURI="http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1" id="OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1"><link:definition>037 - Disclosure - Organization of the Company and Basis of Presentation (Detail Textuals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
<link:roleType roleURI="http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1" id="CONSOLIDATEDBALANCESHEETSParentheticals1"><link:definition>004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals 1)</link:definition>
<link:usedOn>link:presentationLink</link:usedOn>
<link:usedOn>link:definitionLink</link:usedOn>
<link:usedOn>link:calculationLink</link:usedOn>
</link:roleType>
</appinfo></annotation>
<import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
<import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
<import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
<import namespace="http://fasb.org/us-gaap/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/currency/2017-01-31" schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/exch/2017-01-31" schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
<import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd"/>
<import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
<import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
<import namespace="http://fasb.org/us-types/2017-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd"/>
<element name="DocumentAndEntityInformationAbstract" id="cycc_DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="BeneficialConversionFeatureOfConvertibleStock" id="cycc_BeneficialConversionFeatureOfConvertibleStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" id="cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueStockWarrantsExercised" id="cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesStockWarrantsExercised" id="cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" id="cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" id="cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" id="cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" id="cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodValueSharePurchaseAgreement" id="cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="StockIssuedDuringPeriodSharesSharePurchaseAgreement" id="cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" id="cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashReceivedDuringPeriodForAbstract" id="cycc_CashReceivedDuringPeriodForAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccrualOfPreferredStockDividends" id="cycc_AccrualOfPreferredStockDividends" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SignificantContractsDisclosureAbstract" id="cycc_SignificantContractsDisclosureAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SignificantContractsDisclosureTextBlock" id="cycc_SignificantContractsDisclosureTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PrepaidExpensesAndOtherCurrentAssetsAbstract" id="cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" id="cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OtherIncomePolicyTextBlock" id="cycc_OtherIncomePolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ClinicalTrialAccountingPolicyTextBlock" id="cycc_ClinicalTrialAccountingPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PatentCostsPolicyTextBlock" id="cycc_PatentCostsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="RecentlyIssuedAccountingPronouncementsPolicyTextBlock" id="cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" type="nonnum:textBlockItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationOfCompanyAndBasisOfPresentationTable" id="cycc_OrganizationOfCompanyAndBasisOfPresentationTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="BeforeReverseStockSplitMember" id="cycc_BeforeReverseStockSplitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AfterReverseStockSplitMember" id="cycc_AfterReverseStockSplitMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OrganizationOfCompanyAndBasisOfPresentationLineItems" id="cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccountingPoliciesTable" id="cycc_AccountingPoliciesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AccountingPoliciesLineItems" id="cycc_AccountingPoliciesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashFinancialServicesCompensationSchemeInsuredAmount" id="cycc_CashFinancialServicesCompensationSchemeInsuredAmount" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" id="cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DaiichiSankyoCompanyLimitedMember" id="cycc_DaiichiSankyoCompanyLimitedMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ManrosTherapeuticsSaManrosMember" id="cycc_ManrosTherapeuticsSaManrosMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CollaborationSupplyAndLicensingAgreementsMember" id="cycc_CollaborationSupplyAndLicensingAgreementsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementPotentialFutureMilestonePayments" id="cycc_LicenseAgreementPotentialFutureMilestonePayments" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" id="cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" id="cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" id="cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CollaborationAndResearchAndDevelopmentRevenue" id="cycc_CollaborationAndResearchAndDevelopmentRevenue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="OfficeEquipmentAndFurnitureMember" id="cycc_OfficeEquipmentAndFurnitureMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedResearchAndDevelopmentCostsCurrent" id="cycc_AccruedResearchAndDevelopmentCostsCurrent" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AccruedAndOtherCurrentLiabilitiesTable" id="cycc_AccruedAndOtherCurrentLiabilitiesTable" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:hypercubeItem"/>
<element name="AccruedAndOtherCurrentLiabilitiesLineItems" id="cycc_AccruedAndOtherCurrentLiabilitiesLineItems" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MarketIssuanceSalesAgreementMember" id="cycc_MarketIssuanceSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="LadenburgThalmannAndCoIncMember" id="cycc_LadenburgThalmannAndCoIncMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSecuritiesCalledByEachUnit" id="cycc_NumberOfSecuritiesCalledByEachUnit" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" id="cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ComissionAsPercentageOfGrossProceedsOfSale" id="cycc_ComissionAsPercentageOfGrossProceedsOfSale" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AggregateIntrinsicValueOfStock" id="cycc_AggregateIntrinsicValueOfStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="credit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EquitySaleAgreementAxis" id="cycc_EquitySaleAgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="EquitySaleAgreementDomain" id="cycc_EquitySaleAgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FbrSalesAgreementMember" id="cycc_FbrSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfCommissionOnGrossEquitySales" id="cycc_PercentageOfCommissionOnGrossEquitySales" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="AgreementAxis" id="cycc_AgreementAxis" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrldt:dimensionItem"/>
<element name="AgreementDomain" id="cycc_AgreementDomain" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ControlledEquityOfferingSalesAgreementMember" id="cycc_ControlledEquityOfferingSalesAgreementMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="SalesAgentMember" id="cycc_SalesAgentMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="MaximumAmountOfOfferingPriceForCommonStock" id="cycc_MaximumAmountOfOfferingPriceForCommonStock" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConditionRelatedToExcercisingWarrants" id="cycc_ConditionRelatedToExcercisingWarrants" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="NumberOfWarrantsExercised" id="cycc_NumberOfWarrantsExercised" type="xbrli:sharesItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="WeightedAverageExercisePrice" id="cycc_WeightedAverageExercisePrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePreferredStockConversionPrice" id="cycc_ConvertiblePreferredStockConversionPrice" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePreferredStockConversionPercentageBlockerProvision" id="cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePreferredStockConversionPercentage" id="cycc_ConvertiblePreferredStockConversionPercentage" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" id="cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" type="xbrli:stringItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ConvertiblePreferredStockConversionPricePerShare" id="cycc_ConvertiblePreferredStockConversionPricePerShare" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" id="cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" id="cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockConversionObligationNumberOfTradingDays" id="cycc_PreferredStockConversionObligationNumberOfTradingDays" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" id="cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" id="cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" type="num:perShareItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" id="cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" id="cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" id="cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" type="xbrli:stringItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" id="cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PerformanceBasedOptionsMember" id="cycc_PerformanceBasedOptionsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="EmployeesAndDirectorsMember" id="cycc_EmployeesAndDirectorsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Plan2015Member" id="cycc_Plan2015Member" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" id="cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PensionPlanMember" id="cycc_PensionPlanMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="Plan401KMember" id="cycc_Plan401KMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" id="cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" id="cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" id="cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" id="cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" type="xbrli:durationItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" id="cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="duration" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" id="cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" id="cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" type="xbrli:monetaryItemType" abstract="false" xbrli:periodType="instant" xbrli:balance="debit" nillable="true" substitutionGroup="xbrli:item"/>
<element name="PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" id="cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="FutureFederalStatutoryIncomeTaxRate" id="cycc_FutureFederalStatutoryIncomeTaxRate" type="num:percentItemType" abstract="false" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
<element name="CommonStockWarrantsMember" id="cycc_CommonStockWarrantsMember" type="nonnum:domainItemType" abstract="true" xbrli:periodType="duration" nillable="true" substitutionGroup="xbrli:item"/>
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>9
<FILENAME>cycc-20171231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheets"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_AssetsCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccountsPayableCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_LiabilitiesCurrent" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_PreferredStockValue" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_CommonStockValue" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AdditionalPaidInCapital" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="40" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit" order="50" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_Liabilities" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_CommitmentsAndContingencies" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaap_StockholdersEquity" order="30" use="optional" weight="1"/></calculationLink>





<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfOperationsLoss" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_SalesRevenueNet" xlink:to="loc_us-gaap_RevenueFromGrants" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CostsAndExpenses" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_SalesRevenueNet" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="loc_us-gaap_CostsAndExpenses" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_InvestmentIncomeInterest" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="loc_us-gaap_OtherNonoperatingIncome" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_OperatingIncomeLoss" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_NonoperatingIncomeExpense" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments" order="20" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeneficialConversionFeatureOfConvertibleStock" xlink:label="loc_cycc_BeneficialConversionFeatureOfConvertibleStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_cycc_BeneficialConversionFeatureOfConvertibleStock" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" order="40" use="optional" weight="-1"/></calculationLink>






<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Consolidatedstatementsofcashflows" roleURI="http://www.cyclacel.com/role/Consolidatedstatementsofcashflows"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_NetIncomeLoss" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_Depreciation" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="30" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ShareBasedCompensation" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="50" use="optional" weight="-1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" order="60" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" order="20" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" order="30" use="optional" weight="-1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="20" use="optional" weight="1"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="30" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" order="40" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.cyclacel.com/role/CashAndCashEquivalentsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CashAndCashEquivalentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_Cash" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaap_ShortTermInvestments" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue" order="10" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_PrepaidExpenseCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_IncomeTaxesReceivable" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_DepositsAssetsCurrent" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="loc_us-gaap_OtherAssetsCurrent" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="20" use="optional" weight="-1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_cycc_AccruedResearchAndDevelopmentCostsCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_cycc_AccruedResearchAndDevelopmentCostsCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent" order="30" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="60" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails" roleURI="http://www.cyclacel.com/role/TaxesDetails"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" order="20" use="optional" weight="1"/>
</calculationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails2" roleURI="http://www.cyclacel.com/role/TaxesDetails2"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="20" use="optional" weight="1"/></calculationLink>



<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails4" roleURI="http://www.cyclacel.com/role/TaxesDetails4"/>
<calculationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" order="20" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="30" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xlink:label="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" order="40" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="loc_us-gaap_DeferredTaxAssetsOther" order="50" use="optional" weight="1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsGross" order="10" use="optional" weight="1"/><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance"/><calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance" order="20" use="optional" weight="-1"/></calculationLink>

</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>10
<FILENAME>cycc-20171231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
<arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheets"/>

<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity"/>

<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SignificantContractsDetailTextuals" roleURI="http://www.cyclacel.com/role/SignificantContractsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#AccruedAndOtherCurrentLiabilitiesDetailTextuals" roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals1" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals2" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals4" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails1" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails2" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetailTextuals1" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#EmployeeBenefitPlansDetailTextuals" roleURI="http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails5" roleURI="http://www.cyclacel.com/role/TaxesDetails5"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#NetLossPerShareDetail1" roleURI="http://www.cyclacel.com/role/NetLossPerShareDetail1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#GeographicInformationDetails" roleURI="http://www.cyclacel.com/role/GeographicInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SubsequentEventsDetails" roleURI="http://www.cyclacel.com/role/SubsequentEventsDetails"/>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_AssetsAbstract_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_AssetsCurrentAbstract_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsCurrentAbstract_7" xlink:to="loc_us-gaap_AssetsCurrent_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsAbstract_6" xlink:to="loc_us-gaap_Assets_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccountsPayableCurrent_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrent_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_18" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_Liabilities_19" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_CommitmentsAndContingencies_20" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_StockholdersEquityAbstract_21" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_PreferredStockValue_22" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_CommonStockValue_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AdditionalPaidInCapital_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StockholdersEquityAbstract_21" xlink:to="loc_us-gaap_StockholdersEquity_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_13" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_28" order="50" use="optional"/>
</definitionLink>

<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_CommonStockMember_4" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8" xlink:to="loc_us-gaap_PreferredStockMember_3" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_0" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockholdersEquity_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_SharesIssued_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_14" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_15" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised_16" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised_17" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_18" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_19" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xlink:label="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility_20" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xlink:label="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare_21" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement_22" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement_23" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_24" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xlink:label="loc_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion_25" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_26" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_27" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_NetIncomeLoss_28" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_9" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_29" order="190" use="optional"/>
</definitionLink>

<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesLineItems" xlink:label="loc_cycc_AccountingPoliciesLineItems_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesTable" xlink:label="loc_cycc_AccountingPoliciesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_cycc_AccountingPoliciesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cycc_AccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cycc_AccountingPoliciesTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_11" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashFDICInsuredAmount_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_CashUninsuredAmount_13" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="loc_cycc_CashFinancialServicesCompensationSchemeInsuredAmount_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_cycc_CashFinancialServicesCompensationSchemeInsuredAmount_14" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xlink:label="loc_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme_15" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_NumberOfOperatingSegments_16" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_17" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccountingPoliciesLineItems_0" xlink:to="loc_us-gaap_DeferredRevenue_18" order="90" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SignificantContractsDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentLineItems" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentTable" xlink:label="loc_us-gaap_SupplyCommitmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_us-gaap_SupplyCommitmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DaiichiSankyoCompanyLimitedMember" xlink:label="loc_cycc_DaiichiSankyoCompanyLimitedMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_DaiichiSankyoCompanyLimitedMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ManrosTherapeuticsSaManrosMember" xlink:label="loc_cycc_ManrosTherapeuticsSaManrosMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_ManrosTherapeuticsSaManrosMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SupplyCommitmentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:label="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPotentialFutureMilestonePayments" xlink:label="loc_cycc_LicenseAgreementPotentialFutureMilestonePayments_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_cycc_LicenseAgreementPotentialFutureMilestonePayments_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xlink:label="loc_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xlink:label="loc_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xlink:label="loc_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault_12" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationAndResearchAndDevelopmentRevenue" xlink:label="loc_cycc_CollaborationAndResearchAndDevelopmentRevenue_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_cycc_CollaborationAndResearchAndDevelopmentRevenue_13" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_0" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_14" order="60" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_0" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_13" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_15" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_EquipmentMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OfficeEquipmentAndFurnitureMember" xlink:label="loc_cycc_OfficeEquipmentAndFurnitureMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cycc_OfficeEquipmentAndFurnitureMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_14" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xlink:label="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesTable" xlink:label="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_0" xlink:to="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ManrosTherapeuticsSaManrosMember" xlink:label="loc_cycc_ManrosTherapeuticsSaManrosMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_ManrosTherapeuticsSaManrosMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:label="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_0" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_8" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MarketIssuanceSalesAgreementMember" xlink:label="loc_cycc_MarketIssuanceSalesAgreementMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_cycc_MarketIssuanceSalesAgreementMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LadenburgThalmannAndCoIncMember" xlink:label="loc_cycc_LadenburgThalmannAndCoIncMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_cycc_LadenburgThalmannAndCoIncMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_12" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_12" xlink:to="loc_us-gaap_CapitalUnitClassDomain_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_13_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_12" xlink:to="loc_us-gaap_CapitalUnitClassDomain_13_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_13" xlink:to="loc_us-gaap_CapitalUnitClassAMember_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CapitalUnitClassDomain_13" xlink:to="loc_us-gaap_CapitalUnitClassBMember_15" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16" xlink:to="loc_us-gaap_ClassOfStockDomain_17" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16" xlink:to="loc_us-gaap_ClassOfStockDomain_17_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_17" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_18" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SharePrice_23" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_24" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesCalledByEachUnit" xlink:label="loc_cycc_NumberOfSecuritiesCalledByEachUnit_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cycc_NumberOfSecuritiesCalledByEachUnit_25" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_26" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_27" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_28" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:label="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_29" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ComissionAsPercentageOfGrossProceedsOfSale" xlink:label="loc_cycc_ComissionAsPercentageOfGrossProceedsOfSale_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cycc_ComissionAsPercentageOfGrossProceedsOfSale_30" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AggregateIntrinsicValueOfStock" xlink:label="loc_cycc_AggregateIntrinsicValueOfStock_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_cycc_AggregateIntrinsicValueOfStock_31" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_32" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_33" order="110" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementAxis" xlink:label="loc_cycc_EquitySaleAgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_cycc_EquitySaleAgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementDomain" xlink:label="loc_cycc_EquitySaleAgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cycc_EquitySaleAgreementAxis_2" xlink:to="loc_cycc_EquitySaleAgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementDomain" xlink:label="loc_cycc_EquitySaleAgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cycc_EquitySaleAgreementAxis_2" xlink:to="loc_cycc_EquitySaleAgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FbrSalesAgreementMember" xlink:label="loc_cycc_FbrSalesAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_EquitySaleAgreementDomain_3" xlink:to="loc_cycc_FbrSalesAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfCommissionOnGrossEquitySales" xlink:label="loc_cycc_PercentageOfCommissionOnGrossEquitySales_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PercentageOfCommissionOnGrossEquitySales_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_7" order="30" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementAxis" xlink:label="loc_cycc_AgreementAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_cycc_AgreementAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementDomain" xlink:label="loc_cycc_AgreementDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_cycc_AgreementAxis_2" xlink:to="loc_cycc_AgreementDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementDomain" xlink:label="loc_cycc_AgreementDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_cycc_AgreementAxis_2" xlink:to="loc_cycc_AgreementDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_cycc_ControlledEquityOfferingSalesAgreementMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AgreementDomain_3" xlink:to="loc_cycc_ControlledEquityOfferingSalesAgreementMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FbrSalesAgreementMember" xlink:label="loc_cycc_FbrSalesAgreementMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_AgreementDomain_3" xlink:to="loc_cycc_FbrSalesAgreementMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SalesAgentMember" xlink:label="loc_cycc_SalesAgentMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_cycc_SalesAgentMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MaximumAmountOfOfferingPriceForCommonStock" xlink:label="loc_cycc_MaximumAmountOfOfferingPriceForCommonStock_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_MaximumAmountOfOfferingPriceForCommonStock_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfCommissionOnGrossEquitySales" xlink:label="loc_cycc_PercentageOfCommissionOnGrossEquitySales_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PercentageOfCommissionOnGrossEquitySales_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_11" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_12" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:label="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPrice" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPrice_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPrice_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentage" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPercentage_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPercentage_12" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xlink:label="loc_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock_13" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_14" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_15" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_16" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_17" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_18" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_19" order="140" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_20" order="150" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_CommonStockConversionBasis_21" order="160" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPricePerShare" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPricePerShare_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPricePerShare_22" order="170" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_SharePrice_23" order="180" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_24" order="190" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_25" order="200" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="loc_cycc_PreferredStockConversionObligationNumberOfTradingDays_26"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PreferredStockConversionObligationNumberOfTradingDays_26" order="210" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="loc_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_27"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_27" order="220" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_28"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_28" order="230" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_29"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_29" order="240" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xlink:label="loc_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation_30"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation_30" order="250" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_31"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_DebtInstrumentTerm_31" order="260" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_32"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_32" order="270" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_0" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_6" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_8" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_9" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_10" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_11" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_13" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_14" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_15" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_16" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_12" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_17" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_19" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_18" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_20" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_18" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_21" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_22" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_23" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_22" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_24" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_22" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_25" order="20" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_11" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_12" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_13" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_14" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PerformanceBasedOptionsMember" xlink:label="loc_cycc_PerformanceBasedOptionsMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_cycc_PerformanceBasedOptionsMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EmployeesAndDirectorsMember" xlink:label="loc_cycc_EmployeesAndDirectorsMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_cycc_EmployeesAndDirectorsMember_8" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_13" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_13" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_13" xlink:to="loc_us-gaap_PlanNameDomain_14_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan2015Member" xlink:label="loc_cycc_Plan2015Member_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_cycc_Plan2015Member_15" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_16" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_17" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_18" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_19" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_20" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_21" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_22"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_22" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_23" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_24"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_24" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="100" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PensionPlanMember" xlink:label="loc_cycc_PensionPlanMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3" xlink:to="loc_cycc_PensionPlanMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan401KMember" xlink:label="loc_cycc_Plan401KMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3" xlink:to="loc_cycc_Plan401KMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="loc_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_9" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_10" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xlink:label="loc_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution_11" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_0" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_12" order="70" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1" order="10" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" xlink:to="loc_us-gaap_ResearchMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_ForeignCountryMember_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_RangeAxis_10" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MaximumMember_12" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_13"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_13" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_14"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwards_14" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="loc_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_15"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_15" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_16" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FutureFederalStatutoryIncomeTaxRate" xlink:label="loc_cycc_FutureFederalStatutoryIncomeTaxRate_17"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_cycc_FutureFederalStatutoryIncomeTaxRate_17" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_18"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_18" order="70" use="optional"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_20"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_20" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" order="80" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/NetLossPerShareDetail1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CommonStockWarrantsMember" xlink:label="loc_cycc_CommonStockWarrantsMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_cycc_CommonStockWarrantsMember_7" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_8" order="10" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/GeographicInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_StatementGeographicalAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementGeographicalAxis_2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementGeographicalAxis_2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3" xlink:to="loc_country_US_4" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="loc_country_GB_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3" xlink:to="loc_country_GB_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_SalesRevenueNet_6" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_Assets_8" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_9" order="40" use="optional"/>
</definitionLink>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6_Default" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_7"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_7" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_8"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_8" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_9"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_10"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_10" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_11"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventLineItems_0" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_11" order="40" use="optional"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1" roleURI="http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1"/>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1"><loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:label="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:to="loc_us-gaap_CommonStockSharesOutstanding" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:label="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:to="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:to="loc_us-gaap_StatementScenarioAxis" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeforeReverseStockSplitMember" xlink:label="loc_cycc_BeforeReverseStockSplitMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_cycc_BeforeReverseStockSplitMember" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AfterReverseStockSplitMember" xlink:label="loc_cycc_AfterReverseStockSplitMember"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_cycc_AfterReverseStockSplitMember" order="1" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain_Default"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain_Default" order="1"/>
</definitionLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CONSOLIDATEDBALANCESHEETSParentheticals1" roleURI="http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1"/>
<definitionLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesIssued" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_StatementTable" order="10" use="optional" xbrldt:closed="true" xbrldt:contextElement="segment"/>








<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_Default"/>



<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis_1" order="2" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1"/>
<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1" order="1" use="optional"/>

<definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_1" xlink:to="loc_us-gaap_ClassOfStockDomain_Default" order="1"/>
</definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>11
<FILENAME>cycc-20171231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DocumentAndEntityInformationAbstract" xlink:label="loc_2I0HHGGF8208_cycc_DocumentAndEntityInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_DocumentAndEntityInformationAbstract" xml:lang="en-US">Document and Entity Information [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_DocumentAndEntityInformationAbstract" xlink:to="lab_4K2JJIIH0420_cycc_DocumentAndEntityInformationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityRegistrantName"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityRegistrantName" xml:lang="en-US">Entity Registrant Name</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityRegistrantName" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityRegistrantName"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_2I0HHGGF8208_dei_EntityCentralIndexKey"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityCentralIndexKey" xml:lang="en-US">Entity Central Index Key</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityCentralIndexKey" xlink:to="lab_4K2JJIIH0420_dei_EntityCentralIndexKey"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_I9G01G3G9932937HF776_dei_TradingSymbol"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_TradingSymbol" xml:lang="en-US">Trading Symbol</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_TradingSymbol" xlink:to="lab_K1I23I5I1154159JH998_dei_TradingSymbol"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_2I0HHGGF8208_dei_EntityCurrentReportingStatus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityCurrentReportingStatus" xml:lang="en-US">Entity Current Reporting Status</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityCurrentReportingStatus" xlink:to="lab_4K2JJIIH0420_dei_EntityCurrentReportingStatus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityVoluntaryFilers"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityVoluntaryFilers" xml:lang="en-US">Entity Voluntary Filers</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityVoluntaryFilers" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityVoluntaryFilers"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_2I0HHGGF8208_dei_CurrentFiscalYearEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_CurrentFiscalYearEndDate" xml:lang="en-US">Current Fiscal Year End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_CurrentFiscalYearEndDate" xlink:to="lab_4K2JJIIH0420_dei_CurrentFiscalYearEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityFilerCategory"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityFilerCategory" xml:lang="en-US">Entity Filer Category</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityFilerCategory" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityFilerCategory"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_2I0HHGGF8208_dei_EntityWellKnownSeasonedIssuer"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityWellKnownSeasonedIssuer" xml:lang="en-US">Entity Well-known Seasoned Issuer</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_4K2JJIIH0420_dei_EntityWellKnownSeasonedIssuer"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityCommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityCommonStockSharesOutstanding" xml:lang="en-US">Entity Common Stock, Shares Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityCommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_2I0HHGGF8208_dei_EntityPublicFloat"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_EntityPublicFloat" xml:lang="en-US">Entity Public Float</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_EntityPublicFloat" xlink:to="lab_4K2JJIIH0420_dei_EntityPublicFloat"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_I9G01G3G9932937HF776_dei_DocumentType"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentType" xml:lang="en-US">Document Type</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_DocumentType" xlink:to="lab_K1I23I5I1154159JH998_dei_DocumentType"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_2I0HHGGF8208_dei_DocumentPeriodEndDate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_DocumentPeriodEndDate" xml:lang="en-US">Document Period End Date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_DocumentPeriodEndDate" xlink:to="lab_4K2JJIIH0420_dei_DocumentPeriodEndDate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_I9G01G3G9932937HF776_dei_AmendmentFlag"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_AmendmentFlag" xml:lang="en-US">Amendment Flag</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_AmendmentFlag" xlink:to="lab_K1I23I5I1154159JH998_dei_AmendmentFlag"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_2I0HHGGF8208_dei_DocumentFiscalYearFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_DocumentFiscalYearFocus" xml:lang="en-US">Document Fiscal Year Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_DocumentFiscalYearFocus" xlink:to="lab_4K2JJIIH0420_dei_DocumentFiscalYearFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_I9G01G3G9932937HF776_dei_DocumentFiscalPeriodFocus"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_DocumentFiscalPeriodFocus" xml:lang="en-US">Document Fiscal Period Focus</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_DocumentFiscalPeriodFocus" xlink:to="lab_K1I23I5I1154159JH998_dei_DocumentFiscalPeriodFocus"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementOfFinancialPositionAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfFinancialPositionAbstract" xml:lang="en-US">CONSOLIDATED BALANCE SHEETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StatementTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StatementTable" xml:lang="en-US">Statement [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StatementTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StatementTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementClassOfStockAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementClassOfStockAxis" xml:lang="en-US">Class of Stock [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementClassOfStockAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementClassOfStockAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockDomain" xml:lang="en-US">Class of Stock [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_2I0HHGGF8208_us-gaap_SeriesAPreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SeriesAPreferredStockMember" xml:lang="en-US">Series A Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SeriesAPreferredStockMember" xlink:to="lab_4K2JJIIH0420_us-gaap_SeriesAPreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">Convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockMember" xml:lang="en-US">6% Convertible Exchangeable preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementLineItems" xml:lang="en-US">Statement [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementLineItems" xml:lang="en-US">Statement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementLineItems" xml:lang="en-US">Stock Purchase Agreement</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract" xml:lang="en-US">Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract" xml:lang="en-US">ASSETS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AssetsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_AssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Assets, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract" xml:lang="en-US">Current assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AssetsCurrentAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_AssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Total cash and cash equivalents</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at beginning of period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue" xml:lang="en-US">Cash and cash equivalents at end of period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid Expense and Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xml:lang="en-US">Prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsCurrent" xml:lang="en-US">Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsCurrent" xml:lang="en-US">Total current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AssetsCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property and equipment, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Long Lived Assets, net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentNet" xml:lang="en-US">Property, Plant and Equipment, Net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_Assets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_Assets" xml:lang="en-US">Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_Assets" xml:lang="en-US">Total Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_Assets" xml:lang="en-US">Total assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_Assets" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">Liabilities and Equity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Liabilities, Current [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesCurrentAbstract" xml:lang="en-US">Current liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_AccountsPayableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts Payable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountsPayableCurrent" xml:lang="en-US">Accounts payable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccountsPayableCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Accrued liabilities and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedLiabilitiesCurrent" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent" xml:lang="en-US">Total current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LiabilitiesCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OtherLiabilitiesNoncurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other Liabilities, Noncurrent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OtherLiabilitiesNoncurrent" xml:lang="en-US">Other liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OtherLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_2I0HHGGF8208_us-gaap_Liabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_Liabilities" xml:lang="en-US">Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Liabilities" xml:lang="en-US">Total liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_Liabilities" xlink:to="lab_4K2JJIIH0420_us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingencies"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and Contingencies.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies" xml:lang="en-US">Commitments and contingencies (Note 9)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingencies" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingencies"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' Equity Attributable to Parent [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquityAbstract" xml:lang="en-US">Stockholders' equity:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockholdersEquityAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, $0.001 par value; 5,000,000 shares authorized at December 31, 2011 and September 30, 2012; 1,213,142 shares issued and outstanding at December 31, 2011 and September 30, 2012. Aggregate preference in liquidation of $13,708,505 and $14,254,419 at December 31, 2011 and September 30, 2012, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockValue" xml:lang="en-US">Preferred stock, value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockValue" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockValue" xml:lang="en-US">Common Stock, Value, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2011 and September 30, 2012; 7,745,779 and 8,434,292 shares issued and outstanding at December 31, 2011 and September 30, 2012, respectively</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockValue" xml:lang="en-US">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2016 and December 31, 2017; 4,256,829 and 11,997,447 shares issued and outstanding at December 31, 2016 and December 31, 2017, respectively.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockValue" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AdditionalPaidInCapital"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional Paid in Capital</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapital" xml:lang="en-US">Additional paid-in capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AdditionalPaidInCapital" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AdditionalPaidInCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_2I0HHGGF8208_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xml:lang="en-US">Accumulated other comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_4K2JJIIH0420_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit" xml:lang="en-US">Accumulated deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RetainedEarningsAccumulatedDeficit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_2I0HHGGF8208_us-gaap_StockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Stockholders' Equity Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Total stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquity" xml:lang="en-US">Balance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockholdersEquity" xlink:to="lab_4K2JJIIH0420_us-gaap_StockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquity"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Liabilities and Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity" xml:lang="en-US">Total liabilities and stockholders' equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementScenarioAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementScenarioAxis" xml:lang="en-US">Scenario [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementScenarioAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementScenarioAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare" xml:lang="en-US">Preferred stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized" xml:lang="en-US">Preferred stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred Stock, Shares Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued" xml:lang="en-US">Preferred stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockSharesIssued" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred Stock, Shares Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesOutstanding" xml:lang="en-US">Preferred stock, shares outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred Stock, Liquidation Preference, Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreferenceValue" xml:lang="en-US">Preferred stock, liquidation preference value (in dollars)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockParOrStatedValuePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockParOrStatedValuePerShare" xml:lang="en-US">Common stock, par value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockParOrStatedValuePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common Stock, Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesAuthorized" xml:lang="en-US">Common stock, shares authorized</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockSharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common Stock, Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockSharesIssued" xml:lang="en-US">Common stock, shares issued</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockSharesIssued" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockSharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common Stock, Shares, Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesOutstanding" xml:lang="en-US">Common stock, shares outstanding (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockSharesOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeStatementAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeStatementAbstract" xml:lang="en-US">CONSOLIDATED STATEMENTS OF OPERATIONS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeStatementAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeStatementAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SalesRevenueNetAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNetAbstract" xml:lang="en-US">Revenue, Net [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNetAbstract" xml:lang="en-US">Revenues:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SalesRevenueNetAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNetAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_2I0HHGGF8208_us-gaap_RevenueFromGrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RevenueFromGrants" xml:lang="en-US">Revenue from Grants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_RevenueFromGrants" xml:lang="en-US">Grant revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RevenueFromGrants" xlink:to="lab_4K2JJIIH0420_us-gaap_RevenueFromGrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SalesRevenueNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNet" xml:lang="en-US">Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNet" xml:lang="en-US">Recognized revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNet" xml:lang="en-US">Total revenues</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SalesRevenueNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SalesRevenueNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingExpensesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating Expenses [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract" xml:lang="en-US">Operating expenses:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingExpensesAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingExpensesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and Development Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_SellingGeneralAndAdministrativeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">Selling, General and Administrative Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SellingGeneralAndAdministrativeExpense" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_SellingGeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CostsAndExpenses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CostsAndExpenses" xml:lang="en-US">Costs and Expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CostsAndExpenses" xml:lang="en-US">Total operating expenses</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CostsAndExpenses" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CostsAndExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating Income (Loss)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss" xml:lang="en-US">Operating loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingIncomeLoss" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Nonoperating Income (Expense) [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense), net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpenseAbstract" xml:lang="en-US">Other income (expense):</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpenseAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_2I0HHGGF8208_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign Currency Transaction Gain (Loss), before Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange gains (losses)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xml:lang="en-US">Foreign exchange (losses)/gains</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_InvestmentIncomeInterest"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Investment Income, Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_InvestmentIncomeInterest" xml:lang="en-US">Interest income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_InvestmentIncomeInterest" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_InvestmentIncomeInterest"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_2I0HHGGF8208_us-gaap_OtherNonoperatingIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other Nonoperating Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherNonoperatingIncome" xml:lang="en-US">Other income, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OtherNonoperatingIncome" xlink:to="lab_4K2JJIIH0420_us-gaap_OtherNonoperatingIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NonoperatingIncomeExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Nonoperating Income (Expense)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpense" xml:lang="en-US">Total other income (expense), net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss from continuing operations before taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xml:lang="en-US">Loss from continuing operations before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit, total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit, total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit, total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit" xml:lang="en-US">Income tax benefit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_2I0HHGGF8208_us-gaap_NetIncomeLoss"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net Income (Loss) Attributable to Parent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Loss for the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss" xml:lang="en-US">Net loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetIncomeLoss" xlink:to="lab_4K2JJIIH0420_us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Preferred Stock Dividends and Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsAndOtherAdjustments" xml:lang="en-US">Dividend on convertible exchangeable preferred shares</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsAndOtherAdjustments"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeneficialConversionFeatureOfConvertibleStock" xlink:label="loc_2I0HHGGF8208_cycc_BeneficialConversionFeatureOfConvertibleStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock" xml:lang="en-US">Beneficial Conversion Feature Of Convertible Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock" xml:lang="en-US">Beneficial conversion feature of Series A convertible stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock" xml:lang="en-US">Beneficial conversion feature of Series A convertible stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock" xml:lang="en-US">Value of convertible preferred stock beneficial conversion feature of Series A.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock" xml:lang="en-US">Beneficial conversion feature of Series A convertible stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_BeneficialConversionFeatureOfConvertibleStock" xlink:to="lab_4K2JJIIH0420_cycc_BeneficialConversionFeatureOfConvertibleStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xml:lang="en-US">Convertible Preferred Stock Converted to Other Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xml:lang="en-US">Conversion of Series A convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xml:lang="en-US">Conversion of Series A convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xml:lang="en-US">Conversion of Series A convertible preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_2I0HHGGF8208_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss attributable to common shareholders</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xml:lang="en-US">Net loss applicable to common shareholders</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:to="lab_4K2JJIIH0420_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Earnings Per Share [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareAbstract" xml:lang="en-US">Basic and diluted earnings per common share:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_2I0HHGGF8208_us-gaap_EarningsPerShareBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Net loss per share - basic and diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDiluted" xml:lang="en-US">Loss per share - basic and diluted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic and Diluted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted average common shares outstanding (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xml:lang="en-US">Weighted-average number of common shares used in loss per share - basic and diluted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xml:lang="en-US">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xml:lang="en-US">Translation adjustment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_2I0HHGGF8208_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xml:lang="en-US">Other Comprehensive Income Unrealized Foreign Exchange On Intercompany Loans Net Of Tax</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xml:lang="en-US">Unrealized foreign exchange on intercompany loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xml:lang="en-US">Unrealized foreign exchange gain (loss) on intercompany loans</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xml:lang="en-US">Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:to="lab_4K2JJIIH0420_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ComprehensiveIncomeNetOfTax"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomeNetOfTax" xml:lang="en-US">Comprehensive loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomeNetOfTax"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StatementOfStockholdersEquityAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StatementOfStockholdersEquityAbstract" xml:lang="en-US">CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StatementOfStockholdersEquityAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StatementEquityComponentsAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StatementEquityComponentsAxis" xml:lang="en-US">Equity Components [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StatementEquityComponentsAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockMember" xml:lang="en-US">Preferred Stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockMember" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockMember" xml:lang="en-US">Common Stock [Member]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_2I0HHGGF8208_us-gaap_AdditionalPaidInCapitalMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AdditionalPaidInCapitalMember" xml:lang="en-US">Additional Paid-in Capital</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_4K2JJIIH0420_us-gaap_AdditionalPaidInCapitalMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xml:lang="en-US">Accumulated Other Comprehensive Loss</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_2I0HHGGF8208_us-gaap_RetainedEarningsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RetainedEarningsMember" xml:lang="en-US">Retained Earnings [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_RetainedEarningsMember" xml:lang="en-US">Accumulated Deficit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RetainedEarningsMember" xlink:to="lab_4K2JJIIH0420_us-gaap_RetainedEarningsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EquityComponentDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EquityComponentDomain" xml:lang="en-US">Equity Component [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EquityComponentDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EquityComponentDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharesIssued"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharesIssued" xml:lang="en-US">Shares, Issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharesIssued" xml:lang="en-US">Balance (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharesIssued" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharesIssued"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Proceeds from further issuance of share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Sale of stock, value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Gross proceeds from issuance of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues" xml:lang="en-US">Proceed from public offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Shares sold (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common stock issued</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xml:lang="en-US">Number of common shares sold into underwriting agreement (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xml:lang="en-US">Series A Preferred stock conversions</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_4K2JJIIH0420_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Series A Preferred stock conversions (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xml:lang="en-US">Number of shares outstanding for conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xml:lang="en-US">Stock Issued During Period Value Stock Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xml:lang="en-US">Warrant exercise</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xml:lang="en-US">value of stock issued as a result of the exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:to="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Stock Issued During Period Shares Stock Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Warrant exercise (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xml:lang="en-US">Number of shares issued as a result of the exercise of warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:to="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xml:lang="en-US">Stock Issued During Period, Value, At Market Issuance Sales Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xml:lang="en-US">Issue of common stock on At Market Issuance sales agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xml:lang="en-US">Represents amount related to Issue of common stock on At Market Issuance sales agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:to="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xml:lang="en-US">Stock Issued During Period, Shares, At Market Issuance Sales Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xml:lang="en-US">Issue of common stock on At Market Issuance sales agreement (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xml:lang="en-US">Represents shares related to Issue of common stock on At Market Issuance sales agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:to="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xlink:label="loc_2I0HHGGF8208_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xml:lang="en-US">Issue Of Common Stock Upon Draw Down Committed Equity Finance Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xml:lang="en-US">Issue of common stock upon draw down of Committed Equity Finance Facility</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xml:lang="en-US">Represent amount of Issue of common stock upon draw down of Committed Equity Finance.Facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xlink:to="lab_4K2JJIIH0420_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xlink:label="loc_I9G01G3G9932937HF776_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xml:lang="en-US">Issue Of Common Stock Upon Draw Down Committed Equity Finance Facility Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xml:lang="en-US">Issue of common stock upon draw down of Committed Equity Finance Facility (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xml:lang="en-US">Represent share information regarding Issue of common stock upon draw down of Committed Equity Finance Facility.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xlink:to="lab_K1I23I5I1154159JH998_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xlink:label="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xml:lang="en-US">Stock Issued During Period, Value, Share Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xml:lang="en-US">Purchase price for shares issued under purchase agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xml:lang="en-US">Issue of common stock on share purchase agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xml:lang="en-US">Value of shares issued as consideration for cash for development stage entities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xlink:to="lab_4K2JJIIH0420_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xlink:label="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xml:lang="en-US">Stock Issued During Period, Shares, Share Purchase Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xml:lang="en-US">Number of shares issued under purchase agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xml:lang="en-US">Issue of common stock on share purchase agreement (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xml:lang="en-US">Number of shares issued as consideration for cash for development stage entities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xlink:to="lab_K1I23I5I1154159JH998_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_2I0HHGGF8208_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_4K2JJIIH0420_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xlink:label="loc_I9G01G3G9932937HF776_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xml:lang="en-US">Adjustments To Additional Paid In Capital Preferred Stock Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xml:lang="en-US">Preferred stock conversions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xml:lang="en-US">Amount of decrease (increase) in additional paid in capital (APIC) for the conversions of preferred stock.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xml:lang="en-US">Preferred stock dividends</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xlink:to="lab_K1I23I5I1154159JH998_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_2I0HHGGF8208_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xml:lang="en-US">Cumulative effect of change in Accounting Principle for ASU 2016-09</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xml:lang="en-US">Cumulative effect of change in Accounting Principle for ASU 2016-09</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xml:lang="en-US">Cumulative effect of change in Accounting Principle for ASU 2016-09</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:to="lab_4K2JJIIH0420_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StatementOfCashFlowsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StatementOfCashFlowsAbstract" xml:lang="en-US">CONSOLIDATED STATEMENTS OF CASH FLOWS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StatementOfCashFlowsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_2I0HHGGF8208_us-gaap_Depreciation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_Depreciation" xml:lang="en-US">Depreciation, Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Depreciation" xml:lang="en-US">Depreciation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Depreciation" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_Depreciation" xlink:to="lab_4K2JJIIH0420_us-gaap_Depreciation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain on disposal of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xml:lang="en-US">Gain on disposal of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Share-based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock-based compensation expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation" xml:lang="en-US">Stock based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensation" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xml:lang="en-US">Changes in operating assets and liabilities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses and other assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xml:lang="en-US">Prepaid expenses, inventory and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_4K2JJIIH0420_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Other Operating Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US">Accounts payable and other current liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xml:lang="en-US">Accounts payable, accrued liabilities and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xml:lang="en-US">Net cash used in operating activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from investing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_2I0HHGGF8208_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xml:lang="en-US">Purchases of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_4K2JJIIH0420_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xml:lang="en-US">Proceeds from sale of asset</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by (used in) investing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="lab_4K2JJIIH0420_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xml:lang="en-US">Cash flows from financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from Issuance of Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of equity securities, net of issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock, warrants and economic rights, net of issuance costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfCommonStock" xml:lang="en-US">Proceeds from issuance of common stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromIssuanceOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from Issuance of Preferred Stock, Preference Stock, and Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xml:lang="en-US">Proceeds from the exercise of stock options and warrants, net of issuance costs</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_2I0HHGGF8208_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Payments of Ordinary Dividends, Preferred Stock and Preference Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Dividend on convertible exchangeable preferred shares</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xml:lang="en-US">Payment of preferred stock dividend</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:to="lab_4K2JJIIH0420_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xml:lang="en-US">Net cash provided by financing activities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="loc_2I0HHGGF8208_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US">Effect of Exchange Rate on Cash and Cash Equivalents, Continuing Operations</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xml:lang="en-US">Effect of exchange rate changes on cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:to="lab_4K2JJIIH0420_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Cash and Cash Equivalents, Period Increase (Decrease), Total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xml:lang="en-US">Net decrease in cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_SupplementalCashFlowInformationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental cash flow information:</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SupplementalCashFlowInformationAbstract" xml:lang="en-US">Supplemental disclosure of cash flows information:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_SupplementalCashFlowInformationAbstract"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="loc_I9G01G3G9932937HF776_cycc_CashReceivedDuringPeriodForAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_CashReceivedDuringPeriodForAbstract" xml:lang="en-US">Cash Received During Period for [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_CashReceivedDuringPeriodForAbstract" xml:lang="en-US">Cash received during the period for:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_CashReceivedDuringPeriodForAbstract" xlink:to="lab_K1I23I5I1154159JH998_cycc_CashReceivedDuringPeriodForAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromInterestReceived"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromInterestReceived" xml:lang="en-US">Proceeds from Interest Received</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromInterestReceived" xml:lang="en-US">Interest</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromInterestReceived" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromInterestReceived"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesPaid"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Income Taxes Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid" xml:lang="en-US">Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesPaid" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesPaid"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xml:lang="en-US">Non cash financing activities:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccrualOfPreferredStockDividends" xlink:label="loc_I9G01G3G9932937HF776_cycc_AccrualOfPreferredStockDividends"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccrualOfPreferredStockDividends" xml:lang="en-US">Accrual Of Preferred Stock Dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccrualOfPreferredStockDividends" xml:lang="en-US">Accrual of preferred stock dividends</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccrualOfPreferredStockDividends" xml:lang="en-US">Represents amount of accrual of preferred stock dividends.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_AccrualOfPreferredStockDividends" xlink:to="lab_K1I23I5I1154159JH998_cycc_AccrualOfPreferredStockDividends"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xml:lang="en-US">Organization of the Company</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">Organization of the Company and Basis of Presentation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xml:lang="en-US">NATURE OF OPERATIONS AND BASIS OF PRESENTATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_AccountingPoliciesAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccountingPoliciesAbstract" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_AccountingPoliciesAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Significant Accounting Policies [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">Summary of Significant Accounting Policies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SignificantAccountingPoliciesTextBlock" xml:lang="en-US">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SignificantAccountingPoliciesTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SignificantContractsDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_cycc_SignificantContractsDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_SignificantContractsDisclosureAbstract" xml:lang="en-US">Significant Contracts Disclosure [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_SignificantContractsDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_cycc_SignificantContractsDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SignificantContractsDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_cycc_SignificantContractsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_SignificantContractsDisclosureTextBlock" xml:lang="en-US">Significant Contracts Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_SignificantContractsDisclosureTextBlock" xml:lang="en-US">Significant Contracts</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_SignificantContractsDisclosureTextBlock" xml:lang="en-US">The entire disclosure of significant contracts pursuant to distribution, licensing and research agreements entered by the reporting entity during the current period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_SignificantContractsDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_cycc_SignificantContractsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CashAndCashEquivalentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashAndCashEquivalentsAbstract" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashAndCashEquivalentsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CashAndCashEquivalentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueDisclosuresAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueDisclosuresAbstract" xml:lang="en-US">Fair Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueDisclosuresAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueDisclosuresTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value Disclosures [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">Fair Value of Financial Assets and Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosuresTextBlock" xml:lang="en-US">FAIR VALUE MEASUREMENTS</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosuresTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_2I0HHGGF8208_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xml:lang="en-US">Prepaid Expenses And Other Current Assets [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:to="lab_4K2JJIIH0420_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">Prepaid Expenses and Other Current Assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">PREPAID EXPENSES AND OTHER CURRENT ASSETS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xml:lang="en-US">This element represent as Prepaid Expenses and Other Current Assets.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentAbstract" xml:lang="en-US">Property, Plant and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_PayablesAndAccrualsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PayablesAndAccrualsAbstract" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_PayablesAndAccrualsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">Accrued and Other Current Liabilities</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xml:lang="en-US">ACCRUED LIABILITIES AND OTHER CURRENT LIABILITIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xml:lang="en-US">Commitments and Contingencies</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">Commitments and Contingencies</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xml:lang="en-US">COMMITMENTS AND CONTINGENCIES</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_StockholdersEquityNoteAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquityNoteAbstract" xml:lang="en-US">Stockholders' Equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_StockholdersEquityNoteAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">Stockholders' Equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xml:lang="en-US">STOCKHOLDERS' EQUITY</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xml:lang="en-US">Stock-Based Compensation Arrangements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">Stock-Based Compensation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xml:lang="en-US">STOCK BASED COMPENSATION</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CompensationAndRetirementDisclosureAbstract" xml:lang="en-US">Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_CompensationAndRetirementDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xml:lang="en-US">Employee Benefit Plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxDisclosureAbstract" xml:lang="en-US">Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Income Tax Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock" xml:lang="en-US">Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_EarningsPerShareTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Earnings Per Share [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareTextBlock" xml:lang="en-US">Net Loss Per Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_EarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Geographic Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingAbstract" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_SegmentReportingDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Geographic Information</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SegmentReportingDisclosureTextBlock" xml:lang="en-US">Geographic Information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_SegmentReportingDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventsAbstract" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events [Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventsTextBlock" xml:lang="en-US">Subsequent Events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventsTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_UseOfEstimates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_UseOfEstimates" xml:lang="en-US">Use of Estimates</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_UseOfEstimates" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_UseOfEstimates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xml:lang="en-US">Foreign Currency and Currency Translation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xml:lang="en-US">Cash and Cash Equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xml:lang="en-US">Property and Equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xml:lang="en-US">Impairment of Long-lived Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueOfFinancialInstrumentsPolicy" xml:lang="en-US">Fair Value of Financial Instruments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueOfFinancialInstrumentsPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segment Reporting, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock" xml:lang="en-US">Segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_RevenueRecognitionPolicyTextBlock" xml:lang="en-US">Revenue Recognition</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_RevenueRecognitionPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherIncomePolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_cycc_OtherIncomePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_OtherIncomePolicyTextBlock" xml:lang="en-US">Other Income [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_OtherIncomePolicyTextBlock" xml:lang="en-US">Other Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_OtherIncomePolicyTextBlock" xml:lang="en-US">Disclosure of accounting policy for other income.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_OtherIncomePolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_cycc_OtherIncomePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_2I0HHGGF8208_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy" xml:lang="en-US">Research and Development Expenditures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_4K2JJIIH0420_us-gaap_ResearchAndDevelopmentExpensePolicy"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ClinicalTrialAccountingPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_cycc_ClinicalTrialAccountingPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ClinicalTrialAccountingPolicyTextBlock" xml:lang="en-US">Clinical Trial Accounting [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ClinicalTrialAccountingPolicyTextBlock" xml:lang="en-US">Clinical Trial Accounting</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ClinicalTrialAccountingPolicyTextBlock" xml:lang="en-US">Describes the entity's accounting policy for clinical trials performed by contract research organizations or clinical research associates.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ClinicalTrialAccountingPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_cycc_ClinicalTrialAccountingPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PatentCostsPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_cycc_PatentCostsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PatentCostsPolicyTextBlock" xml:lang="en-US">Patent Costs</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PatentCostsPolicyTextBlock" xml:lang="en-US">Describes an entity's accounting policy for recognizing and recoverability of patent prosecution costs.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PatentCostsPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_cycc_PatentCostsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LesseeLeasesPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Lessee, Leases [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LesseeLeasesPolicyTextBlock" xml:lang="en-US">Leased Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LesseeLeasesPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xml:lang="en-US">Stock-based Compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxPolicyTextBlock" xml:lang="en-US">Income Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_EarningsPerSharePolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerSharePolicyTextBlock" xml:lang="en-US">Net Loss Per Common Share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_EarningsPerSharePolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xml:lang="en-US">Comprehensive Income (Loss)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_2I0HHGGF8208_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements [Policy Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xml:lang="en-US">Recently Issued Accounting Pronouncements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xml:lang="en-US">Represent recently issued accounting pronouncements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:to="lab_4K2JJIIH0420_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xml:lang="en-US">Schedule of summary of cash and cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xml:lang="en-US">Schedule of financial assets and liabilities measured on a recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xml:lang="en-US">Schedule of prepaid expenses and other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentTextBlock" xml:lang="en-US">Schedule of property and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of accrued and other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xml:lang="en-US">Schedule of the Company's contractual obligations and commitments relating to its facilities leases</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xml:lang="en-US">Schedule of stock based compensation expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xml:lang="en-US">Schedule of stock option activity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xml:lang="en-US">Schedule of fair value of the stock options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xml:lang="en-US">Schedule of components of (loss) income before taxes from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xml:lang="en-US">Schedule of benefit for income taxes from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xml:lang="en-US">Schedule of reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss before income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xml:lang="en-US">Schedule of significant components of the entity's deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xml:lang="en-US">Schedule of basic and diluted net loss per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of antidilutive shares excluded from computation of diluted net loss per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xml:lang="en-US">Schedule of company's potential anti dilutive securities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xml:lang="en-US">Schedule of Revenue from External Customers and Long-Lived Assets, by Geographical Areas [Table Text Block]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xml:lang="en-US">Schedule of geographic information</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:label="loc_I9G01G3G9932937HF776_cycc_OrganizationOfCompanyAndBasisOfPresentationTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xml:lang="en-US">Organization Of Company And Basis Of Presentation Table</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xml:lang="en-US">This table lists the organization of the company and basis of presentation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:to="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_ScenarioUnspecifiedDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScenarioUnspecifiedDomain" xml:lang="en-US">Scenario, Unspecified [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScenarioUnspecifiedDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_ScenarioUnspecifiedDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeforeReverseStockSplitMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_BeforeReverseStockSplitMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_BeforeReverseStockSplitMember" xml:lang="en-US">Before Reverse Stock Split [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_BeforeReverseStockSplitMember" xml:lang="en-US">Before Reverse Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_BeforeReverseStockSplitMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_BeforeReverseStockSplitMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AfterReverseStockSplitMember" xlink:label="loc_2I0HHGGF8208_cycc_AfterReverseStockSplitMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AfterReverseStockSplitMember" xml:lang="en-US">After Reverse Stock Split [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_AfterReverseStockSplitMember" xml:lang="en-US">After Reverse Stock Split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AfterReverseStockSplitMember" xlink:to="lab_4K2JJIIH0420_cycc_AfterReverseStockSplitMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:label="loc_I9G01G3G9932937HF776_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xml:lang="en-US">Organization Of Company And Basis Of Presentation Line Items</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xml:lang="en-US">The line items identify information about the organization of the company and basis of presentation.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:to="lab_K1I23I5I1154159JH998_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_2I0HHGGF8208_us-gaap_StockholdersEquityReverseStockSplit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' Equity, Reverse Stock Split</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StockholdersEquityReverseStockSplit" xml:lang="en-US">Stockholders' equity, reverse stock split</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StockholdersEquityReverseStockSplit" xlink:to="lab_4K2JJIIH0420_us-gaap_StockholdersEquityReverseStockSplit"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesTable" xlink:label="loc_I9G01G3G9932937HF776_cycc_AccountingPoliciesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccountingPoliciesTable" xml:lang="en-US">Accounting Policies [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccountingPoliciesTable" xml:lang="en-US">Table of accounting policies.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_AccountingPoliciesTable" xlink:to="lab_K1I23I5I1154159JH998_cycc_AccountingPoliciesTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentTypeDomain" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, Plant and Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentMember" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentMember" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LeaseholdImprovementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold Improvements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LeaseholdImprovementsMember" xml:lang="en-US">Leasehold improvements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LeaseholdImprovementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_RangeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RangeAxis" xml:lang="en-US">Range [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RangeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_RangeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RangeMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RangeMember" xml:lang="en-US">Range [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RangeMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RangeMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_2I0HHGGF8208_us-gaap_MinimumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_MinimumMember" xml:lang="en-US">Minimum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_MinimumMember" xml:lang="en-US">Minimum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_MinimumMember" xlink:to="lab_4K2JJIIH0420_us-gaap_MinimumMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_MaximumMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember" xml:lang="en-US">Maximum [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember" xml:lang="en-US">Maximum</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_MaximumMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_MaximumMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesLineItems" xlink:label="loc_2I0HHGGF8208_cycc_AccountingPoliciesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AccountingPoliciesLineItems" xml:lang="en-US">Accounting Policies [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_AccountingPoliciesLineItems" xml:lang="en-US">Property, plant and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_AccountingPoliciesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AccountingPoliciesLineItems" xlink:to="lab_4K2JJIIH0420_cycc_AccountingPoliciesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Property, Plant and Equipment, Useful Life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Estimated useful life</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentUsefulLife" xml:lang="en-US">Lives in years</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_2I0HHGGF8208_us-gaap_CashFDICInsuredAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash, FDIC Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashFDICInsuredAmount" xml:lang="en-US">Cash balances insured by FDIC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashFDICInsuredAmount" xlink:to="lab_4K2JJIIH0420_us-gaap_CashFDICInsuredAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CashUninsuredAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashUninsuredAmount" xml:lang="en-US">Cash, Uninsured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CashUninsuredAmount" xml:lang="en-US">Cash exceeding balance insured by FDIC</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CashUninsuredAmount" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CashUninsuredAmount"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="loc_2I0HHGGF8208_cycc_CashFinancialServicesCompensationSchemeInsuredAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xml:lang="en-US">Cash Financial Services Compensation Scheme Insured Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xml:lang="en-US">Cash balance insured by FSCS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xml:lang="en-US">Represents information of UK Government Financial Services Compensation Scheme.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:to="lab_4K2JJIIH0420_cycc_CashFinancialServicesCompensationSchemeInsuredAmount"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xlink:label="loc_I9G01G3G9932937HF776_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xml:lang="en-US">Cash Exceeding Balance Insured By Financial Services Compensation Scheme</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xml:lang="en-US">Cash exceeding balance insured by FSCS</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xml:lang="en-US">This element represents amount of cash balances exceeding the balance insured by the UK Government Financial Services Compensation Scheme.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xlink:to="lab_K1I23I5I1154159JH998_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_2I0HHGGF8208_us-gaap_NumberOfOperatingSegments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of Operating Segments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_NumberOfOperatingSegments" xml:lang="en-US">Number of operating segments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_NumberOfOperatingSegments" xlink:to="lab_4K2JJIIH0420_us-gaap_NumberOfOperatingSegments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_NumberOfCountriesInWhichEntityOperates"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NumberOfCountriesInWhichEntityOperates" xml:lang="en-US">Number of Countries in which Entity Operates</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_NumberOfCountriesInWhichEntityOperates" xml:lang="en-US">Number of geographic areas for development operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_NumberOfCountriesInWhichEntityOperates"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_2I0HHGGF8208_us-gaap_DeferredRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredRevenue" xml:lang="en-US">Deferred revenue</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DeferredRevenue" xlink:to="lab_4K2JJIIH0420_us-gaap_DeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SupplyCommitmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentTable" xml:lang="en-US">Supply Commitment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SupplyCommitmentTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_2I0HHGGF8208_dei_LegalEntityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_dei_LegalEntityAxis" xml:lang="en-US">Legal Entity [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_dei_LegalEntityAxis" xlink:to="lab_4K2JJIIH0420_dei_LegalEntityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_I9G01G3G9932937HF776_dei_EntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_dei_EntityDomain" xml:lang="en-US">Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_dei_EntityDomain" xlink:to="lab_K1I23I5I1154159JH998_dei_EntityDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DaiichiSankyoCompanyLimitedMember" xlink:label="loc_2I0HHGGF8208_cycc_DaiichiSankyoCompanyLimitedMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_DaiichiSankyoCompanyLimitedMember" xml:lang="en-US">Daiichi Sankyo Company Limited [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_DaiichiSankyoCompanyLimitedMember" xml:lang="en-US">Daiichi Sankyo</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_DaiichiSankyoCompanyLimitedMember" xml:lang="en-US">Represents Daiichi Sankyo Company, Limited, with whom the entity entered into a licensing agreement with regard to the entity's sapacitabine drug.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_DaiichiSankyoCompanyLimitedMember" xlink:to="lab_4K2JJIIH0420_cycc_DaiichiSankyoCompanyLimitedMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ManrosTherapeuticsSaManrosMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_ManrosTherapeuticsSaManrosMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ManrosTherapeuticsSaManrosMember" xml:lang="en-US">Manros Therapeutics Sa ("Manros") [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ManrosTherapeuticsSaManrosMember" xml:lang="en-US">ManRos Therapeutics SA ("ManRos")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ManrosTherapeuticsSaManrosMember" xml:lang="en-US">Represents Manros Therapeutics Sa ("Manros"), Limited, with whom the entity entered into a licensing agreement with regard to the entity's sapacitabine drug.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ManrosTherapeuticsSaManrosMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_ManrosTherapeuticsSaManrosMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_TypeOfArrangementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TypeOfArrangementAxis" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TypeOfArrangementAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_TypeOfArrangementAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xml:lang="en-US">Arrangements and Non-arrangement Transactions [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:label="loc_2I0HHGGF8208_cycc_CollaborationSupplyAndLicensingAgreementsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationSupplyAndLicensingAgreementsMember" xml:lang="en-US">Collaboration Supply And Licensing Agreements [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationSupplyAndLicensingAgreementsMember" xml:lang="en-US">Collaboration, Supply and Licensing Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationSupplyAndLicensingAgreementsMember" xml:lang="en-US">Represent collaboration, supply and licensing agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:to="lab_4K2JJIIH0420_cycc_CollaborationSupplyAndLicensingAgreementsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SupplyCommitmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentLineItems" xml:lang="en-US">Supply Commitment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentLineItems" xml:lang="en-US">Licensing Agreements</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentLineItems" xml:lang="en-US">Legal proceedings</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SupplyCommitmentLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SupplyCommitmentLineItems"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPotentialFutureMilestonePayments" xlink:label="loc_2I0HHGGF8208_cycc_LicenseAgreementPotentialFutureMilestonePayments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_LicenseAgreementPotentialFutureMilestonePayments" xml:lang="en-US">License agreement potential future milestone payments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_LicenseAgreementPotentialFutureMilestonePayments" xml:lang="en-US">Future milestone payments payable</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_LicenseAgreementPotentialFutureMilestonePayments" xml:lang="en-US">The potential future milestone payments required to be made under certain contractual agreements.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_LicenseAgreementPotentialFutureMilestonePayments" xlink:to="lab_4K2JJIIH0420_cycc_LicenseAgreementPotentialFutureMilestonePayments"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xlink:label="loc_I9G01G3G9932937HF776_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xml:lang="en-US">License Agreement Period for Royalties Payment After First Commercial Sale of Licensed Products in Country</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xml:lang="en-US">Period for which royalties will be paid following first commercial sale of licensed products</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xml:lang="en-US">Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xlink:to="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xlink:label="loc_2I0HHGGF8208_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xml:lang="en-US">Licensing Agreement Notice Period for Termination of Agreement Due to Technical Scientific Efficacy Safety or Commercial Reason</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xml:lang="en-US">Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xml:lang="en-US">Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xlink:to="lab_4K2JJIIH0420_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xlink:label="loc_I9G01G3G9932937HF776_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xml:lang="en-US">License Agreement Notice Period for Termination of Agreement after Launch of Sapacitabine Based Product or in Case of Material Default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xml:lang="en-US">Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xml:lang="en-US">Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xlink:to="lab_K1I23I5I1154159JH998_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationAndResearchAndDevelopmentRevenue" xlink:label="loc_2I0HHGGF8208_cycc_CollaborationAndResearchAndDevelopmentRevenue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationAndResearchAndDevelopmentRevenue" xml:lang="en-US">Collaboration And Research And Development Revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationAndResearchAndDevelopmentRevenue" xml:lang="en-US">Collaboration and research and development revenue</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_CollaborationAndResearchAndDevelopmentRevenue" xml:lang="en-US">Represent amount of collaboration and research and development revenue.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_CollaborationAndResearchAndDevelopmentRevenue" xlink:to="lab_4K2JJIIH0420_cycc_CollaborationAndResearchAndDevelopmentRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Revenue Recognition, Milestone Method, Revenue Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xml:lang="en-US">Payment received from achieving a clinical milestone</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_2I0HHGGF8208_us-gaap_Cash"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_Cash" xml:lang="en-US">Cash</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_Cash" xml:lang="en-US">Cash</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_Cash" xlink:to="lab_4K2JJIIH0420_us-gaap_Cash"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShortTermInvestments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShortTermInvestments" xml:lang="en-US">Short-term Investments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShortTermInvestments" xml:lang="en-US">Investments with original maturity of less than three months at the time of purchase</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShortTermInvestments" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShortTermInvestments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xml:lang="en-US">Fair Value Measurements, Recurring and Nonrecurring [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueByMeasurementFrequencyAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueByMeasurementFrequencyAxis" xml:lang="en-US">Measurement Frequency [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueByMeasurementFrequencyAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementFrequencyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementFrequencyDomain" xml:lang="en-US">Fair Value, Measurement Frequency [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementFrequencyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueMeasurementsRecurringMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Fair Value, Measurements, Recurring [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueMeasurementsRecurringMember" xml:lang="en-US">Recurring basis</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueMeasurementsRecurringMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueByMeasurementBasisAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueByMeasurementBasisAxis" xml:lang="en-US">Measurement Basis [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueByMeasurementBasisAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueByMeasurementBasisAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueDisclosureItemAmountsDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosureItemAmountsDomain" xml:lang="en-US">Fair Value Measurement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueDisclosureItemAmountsDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_2I0HHGGF8208_us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US">Estimate of Fair Value, Fair Value Disclosure [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xml:lang="en-US">Total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="lab_4K2JJIIH0420_us-gaap_EstimateOfFairValueFairValueDisclosureMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueByFairValueHierarchyLevelAxis" xml:lang="en-US">Fair Value, Hierarchy [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xml:lang="en-US">Fair Value, Measurements, Fair Value Hierarchy [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueInputsLevel1Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel1Member" xml:lang="en-US">Level 1</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel1Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueInputsLevel2Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueInputsLevel2Member" xml:lang="en-US">Level 2</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueInputsLevel2Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_FairValueInputsLevel3Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel3Member" xml:lang="en-US">Level 3</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_FairValueInputsLevel3Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xml:lang="en-US">Fair value measurements</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AssetsFairValueDisclosureAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets, Fair Value Disclosure [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosureAbstract" xml:lang="en-US">Assets:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AssetsFairValueDisclosureAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosureAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_2I0HHGGF8208_us-gaap_CashEquivalentsAtCarryingValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash Equivalents, at Carrying Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CashEquivalentsAtCarryingValue" xml:lang="en-US">Cash equivalents</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CashEquivalentsAtCarryingValue" xlink:to="lab_4K2JJIIH0420_us-gaap_CashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AssetsFairValueDisclosure"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Assets, Fair Value Disclosure</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosure" xml:lang="en-US">Total Assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AssetsFairValueDisclosure"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xml:lang="en-US">Prepaid Expense and Other Assets, Current [Abstract]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xml:lang="en-US">Deferred Income Taxes and Other Tax Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xml:lang="en-US">Research and development tax credit receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepaid Expense, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseCurrent" xml:lang="en-US">Prepayments</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_PrepaidExpenseCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesReceivable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Income Taxes Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesReceivable" xml:lang="en-US">Delaware tax receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxesReceivable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxesReceivable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_ValueAddedTaxReceivableCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ValueAddedTaxReceivableCurrent" xml:lang="en-US">Value Added Tax Receivable, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ValueAddedTaxReceivableCurrent" xml:lang="en-US">VAT receivable</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ValueAddedTaxReceivableCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_ValueAddedTaxReceivableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DepositsAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DepositsAssetsCurrent" xml:lang="en-US">Deposits Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DepositsAssetsCurrent" xml:lang="en-US">Deposits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DepositsAssetsCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DepositsAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_OtherAssetsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other Assets, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherAssetsCurrent" xml:lang="en-US">Other current assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OtherAssetsCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_OtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_2I0HHGGF8208_us-gaap_EquipmentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EquipmentMember" xml:lang="en-US">Equipment [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EquipmentMember" xml:lang="en-US">Research and laboratory equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EquipmentMember" xlink:to="lab_4K2JJIIH0420_us-gaap_EquipmentMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OfficeEquipmentAndFurnitureMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_OfficeEquipmentAndFurnitureMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_OfficeEquipmentAndFurnitureMember" xml:lang="en-US">Office Equipment and Furniture [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_OfficeEquipmentAndFurnitureMember" xml:lang="en-US">Office equipment and furniture</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_OfficeEquipmentAndFurnitureMember" xml:lang="en-US">Represents information pertaining to office equipment and furniture.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_OfficeEquipmentAndFurnitureMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_OfficeEquipmentAndFurnitureMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, Plant and Equipment [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentLineItems" xml:lang="en-US">Property, plant and equipment</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_PropertyPlantAndEquipmentLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, Plant and Equipment, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentGross" xml:lang="en-US">Property, plant and equipment, gross</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PropertyPlantAndEquipmentGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_2I0HHGGF8208_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xml:lang="en-US">Less: accumulated depreciation and amortization</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_4K2JJIIH0420_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DepreciationDepletionAndAmortization"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation, Depletion and Amortization</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DepreciationDepletionAndAmortization" xml:lang="en-US">Depreciation and amortization expense</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DepreciationDepletionAndAmortization" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DepreciationDepletionAndAmortization"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_2I0HHGGF8208_cycc_AccruedResearchAndDevelopmentCostsCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Accrued Research and Development Costs Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Accrued research and development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_AccruedResearchAndDevelopmentCostsCurrent" xml:lang="en-US">Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable arising from research and development transactions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AccruedResearchAndDevelopmentCostsCurrent" xlink:to="lab_4K2JJIIH0420_cycc_AccruedResearchAndDevelopmentCostsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AccruedProfessionalFeesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued Professional Fees, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrent" xml:lang="en-US">Accrued legal and professional fees</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AccruedProfessionalFeesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_OtherAccruedLiabilitiesCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other Accrued Liabilities, Current</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OtherAccruedLiabilitiesCurrent" xml:lang="en-US">Other current liabilities</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_OtherAccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesTable" xlink:label="loc_I9G01G3G9932937HF776_cycc_AccruedAndOtherCurrentLiabilitiesTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccruedAndOtherCurrentLiabilitiesTable" xml:lang="en-US">Accrued And Other Current Liabilities [Table]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_AccruedAndOtherCurrentLiabilitiesTable" xml:lang="en-US">Table of accrued and other current liabilities.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_AccruedAndOtherCurrentLiabilitiesTable" xlink:to="lab_K1I23I5I1154159JH998_cycc_AccruedAndOtherCurrentLiabilitiesTable"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xlink:label="loc_2I0HHGGF8208_cycc_AccruedAndOtherCurrentLiabilitiesLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xml:lang="en-US">Accrued And Other Current Liabilities [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xml:lang="en-US">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xlink:to="lab_4K2JJIIH0420_cycc_AccruedAndOtherCurrentLiabilitiesLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xml:lang="en-US">Operating Lease Obligation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xml:lang="en-US">2018</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xml:lang="en-US">2019</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xml:lang="en-US">2020</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xml:lang="en-US">2021</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xml:lang="en-US">2022</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xml:lang="en-US">thereafter</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xml:lang="en-US">Total future minimum lease obligations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="lab_4K2JJIIH0420_us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_LeasesOperatingAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LeasesOperatingAbstract" xml:lang="en-US">Leases, Operating [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_LeasesOperatingAbstract" xml:lang="en-US">Leases, related disclosures</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_LeasesOperatingAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_LeasesOperatingAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_2I0HHGGF8208_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Lessee Leasing Arrangements, Operating Leases, Term of Contract</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xml:lang="en-US">Lease term for research and development facility</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="lab_4K2JJIIH0420_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesRentExpenseNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Operating Leases, Rent Expense, Net</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet" xml:lang="en-US">Rent expense, net</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLeasesRentExpenseNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLeasesRentExpenseNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventTable" xml:lang="en-US">Subsequent Event [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventTable" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTypeAxis" xml:lang="en-US">Subsequent Event Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventTypeAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventTypeDomain" xml:lang="en-US">Subsequent Event Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventTypeDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventTypeDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent Event [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventMember" xml:lang="en-US">Subsequent event</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SubsequentEventMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SubsequentEventMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_2I0HHGGF8208_us-gaap_CollaborativeArrangementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CollaborativeArrangementMember" xml:lang="en-US">Collaborative Arrangement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CollaborativeArrangementMember" xml:lang="en-US">Underwritten Public Offering</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CollaborativeArrangementMember" xlink:to="lab_4K2JJIIH0420_us-gaap_CollaborativeArrangementMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MarketIssuanceSalesAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_MarketIssuanceSalesAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_MarketIssuanceSalesAgreementMember" xml:lang="en-US">Market Issuance Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_MarketIssuanceSalesAgreementMember" xml:lang="en-US">FBR Sales Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_MarketIssuanceSalesAgreementMember" xml:lang="en-US">Represents Market Issuance Sales Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_MarketIssuanceSalesAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_MarketIssuanceSalesAgreementMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LadenburgThalmannAndCoIncMember" xlink:label="loc_2I0HHGGF8208_cycc_LadenburgThalmannAndCoIncMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_LadenburgThalmannAndCoIncMember" xml:lang="en-US">Ladenburg Thalmann And Co Inc [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_LadenburgThalmannAndCoIncMember" xml:lang="en-US">Ladenburg Thalmann &amp; Co. Inc.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_LadenburgThalmannAndCoIncMember" xml:lang="en-US">Represents the underwriter entity.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_LadenburgThalmannAndCoIncMember" xlink:to="lab_4K2JJIIH0420_cycc_LadenburgThalmannAndCoIncMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CapitalUnitsByClassAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CapitalUnitsByClassAxis" xml:lang="en-US">Capital Units by Class [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CapitalUnitsByClassAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CapitalUnitsByClassAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_CapitalUnitClassDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CapitalUnitClassDomain" xml:lang="en-US">Capital Unit, Class [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CapitalUnitClassDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_CapitalUnitClassDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CapitalUnitClassAMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CapitalUnitClassAMember" xml:lang="en-US">Capital Unit, Class A [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CapitalUnitClassAMember" xml:lang="en-US">Class A Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CapitalUnitClassAMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CapitalUnitClassAMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_2I0HHGGF8208_us-gaap_CapitalUnitClassBMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CapitalUnitClassBMember" xml:lang="en-US">Capital Unit, Class B [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CapitalUnitClassBMember" xml:lang="en-US">Class B Units</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CapitalUnitClassBMember" xlink:to="lab_4K2JJIIH0420_us-gaap_CapitalUnitClassBMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_WarrantMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WarrantMember" xml:lang="en-US">Warrant [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_WarrantMember" xml:lang="en-US">Warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_WarrantMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_WarrantMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_SubsequentEventLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent Event [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SubsequentEventLineItems" xml:lang="en-US">Subsequent events</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SubsequentEventLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_SubsequentEventLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharePrice" xml:lang="en-US">Share Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharePrice" xml:lang="en-US">Minimum bid price per share (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharePrice" xml:lang="en-US">Share price per unit (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharePrice" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_2I0HHGGF8208_us-gaap_CapitalUnitsAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CapitalUnitsAuthorized" xml:lang="en-US">Capital Units, Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CapitalUnitsAuthorized" xml:lang="en-US">Number of units authorized for issuance and sale</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CapitalUnitsAuthorized" xlink:to="lab_4K2JJIIH0420_us-gaap_CapitalUnitsAuthorized"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesCalledByEachUnit" xlink:label="loc_I9G01G3G9932937HF776_cycc_NumberOfSecuritiesCalledByEachUnit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfSecuritiesCalledByEachUnit" xml:lang="en-US">Number Of Securities Called By Each Unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfSecuritiesCalledByEachUnit" xml:lang="en-US">Number of securities called by each unit</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfSecuritiesCalledByEachUnit" xml:lang="en-US">Number of securities into which each unit may be converted.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_NumberOfSecuritiesCalledByEachUnit" xlink:to="lab_K1I23I5I1154159JH998_cycc_NumberOfSecuritiesCalledByEachUnit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Number of warrants connected with Underwritten Public Offering</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xml:lang="en-US">Number of securities called by each warrant</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="lab_4K2JJIIH0420_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xml:lang="en-US">Number of shares issued upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:label="loc_2I0HHGGF8208_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xml:lang="en-US">Number Of Securities Equivalent Price Per Share Called By Each Warrant Or Right</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xml:lang="en-US">Price per share used to determine number of shares of common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xml:lang="en-US">Represents the number of securities equivalent price per share called by each warrant.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:to="lab_4K2JJIIH0420_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ComissionAsPercentageOfGrossProceedsOfSale" xlink:label="loc_I9G01G3G9932937HF776_cycc_ComissionAsPercentageOfGrossProceedsOfSale"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ComissionAsPercentageOfGrossProceedsOfSale" xml:lang="en-US">Commission As Percentage Of Gross Proceeds Of Sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ComissionAsPercentageOfGrossProceedsOfSale" xml:lang="en-US">Commission as percentage of gross proceeds of sale</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ComissionAsPercentageOfGrossProceedsOfSale" xml:lang="en-US">Represents commission as percentage of gross proceeds of sale.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ComissionAsPercentageOfGrossProceedsOfSale" xlink:to="lab_K1I23I5I1154159JH998_cycc_ComissionAsPercentageOfGrossProceedsOfSale"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AggregateIntrinsicValueOfStock" xlink:label="loc_2I0HHGGF8208_cycc_AggregateIntrinsicValueOfStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AggregateIntrinsicValueOfStock" xml:lang="en-US">Aggregate Intrinsic Value Of Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_AggregateIntrinsicValueOfStock" xml:lang="en-US">Aggregate intrinsic value of stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_AggregateIntrinsicValueOfStock" xml:lang="en-US">Represents aggregate intrinsic value of stock .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AggregateIntrinsicValueOfStock" xlink:to="lab_4K2JJIIH0420_cycc_AggregateIntrinsicValueOfStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfStockByClassTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfStockByClassTable" xml:lang="en-US">Schedule of Stock by Class [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfStockByClassTable"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementAxis" xlink:label="loc_2I0HHGGF8208_cycc_EquitySaleAgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_EquitySaleAgreementAxis" xml:lang="en-US">Equity Sale Agreement [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_EquitySaleAgreementAxis" xlink:to="lab_4K2JJIIH0420_cycc_EquitySaleAgreementAxis"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementDomain" xlink:label="loc_I9G01G3G9932937HF776_cycc_EquitySaleAgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_EquitySaleAgreementDomain" xml:lang="en-US">Equity Sale Agreement [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_EquitySaleAgreementDomain" xlink:to="lab_K1I23I5I1154159JH998_cycc_EquitySaleAgreementDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FbrSalesAgreementMember" xlink:label="loc_2I0HHGGF8208_cycc_FbrSalesAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_FbrSalesAgreementMember" xml:lang="en-US">Fbr Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_FbrSalesAgreementMember" xml:lang="en-US">FBR (the "FBR Sales Agreement")</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_FbrSalesAgreementMember" xml:lang="en-US">Represents FBR Sales Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_FbrSalesAgreementMember" xlink:to="lab_4K2JJIIH0420_cycc_FbrSalesAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Class of Stock [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Stockholders' equity</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockLineItems" xml:lang="en-US">Stockholders equity</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfStockLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfStockLineItems"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfCommissionOnGrossEquitySales" xlink:label="loc_2I0HHGGF8208_cycc_PercentageOfCommissionOnGrossEquitySales"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfCommissionOnGrossEquitySales" xml:lang="en-US">Percentage Of Commission On Gross Equity Sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfCommissionOnGrossEquitySales" xml:lang="en-US">Percentage of commission on gross equity sales</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfCommissionOnGrossEquitySales" xml:lang="en-US">Percentage of commission to be paid on gross sales of common stock under the agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PercentageOfCommissionOnGrossEquitySales" xlink:to="lab_4K2JJIIH0420_cycc_PercentageOfCommissionOnGrossEquitySales"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementAxis" xlink:label="loc_I9G01G3G9932937HF776_cycc_AgreementAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_AgreementAxis" xml:lang="en-US">Agreement [Axis]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_AgreementAxis" xml:lang="en-US">Represents the information about Represents the information about type of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_AgreementAxis" xlink:to="lab_K1I23I5I1154159JH998_cycc_AgreementAxis"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementDomain" xlink:label="loc_2I0HHGGF8208_cycc_AgreementDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_AgreementDomain" xml:lang="en-US">Agreement [Domain]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_AgreementDomain" xml:lang="en-US">Represents the information about Represents the information about type of agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_AgreementDomain" xlink:to="lab_4K2JJIIH0420_cycc_AgreementDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_ControlledEquityOfferingSalesAgreementMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ControlledEquityOfferingSalesAgreementMember" xml:lang="en-US">Controlled Equity Offering Sales Agreement [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ControlledEquityOfferingSalesAgreementMember" xml:lang="en-US">Controlled Equity Offering Sales Agreement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ControlledEquityOfferingSalesAgreementMember" xml:lang="en-US">Represents information of Controlled Equity Offering Sales Agreement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ControlledEquityOfferingSalesAgreementMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_ControlledEquityOfferingSalesAgreementMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_TitleOfIndividualAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TitleOfIndividualAxis" xml:lang="en-US">Title of Individual [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TitleOfIndividualAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_TitleOfIndividualAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xml:lang="en-US">Relationship to Entity [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SalesAgentMember" xlink:label="loc_2I0HHGGF8208_cycc_SalesAgentMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_SalesAgentMember" xml:lang="en-US">Sales Agent [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_SalesAgentMember" xml:lang="en-US">Cantor Fitzgerald &amp; Co., ("Cantor")</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_SalesAgentMember" xlink:to="lab_4K2JJIIH0420_cycc_SalesAgentMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MaximumAmountOfOfferingPriceForCommonStock" xlink:label="loc_I9G01G3G9932937HF776_cycc_MaximumAmountOfOfferingPriceForCommonStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_MaximumAmountOfOfferingPriceForCommonStock" xml:lang="en-US">Maximum Amount Of Offering Price For Common Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_MaximumAmountOfOfferingPriceForCommonStock" xml:lang="en-US">Maximum amount of offering price for common stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_MaximumAmountOfOfferingPriceForCommonStock" xml:lang="en-US">Represents maximum amount of offering price for common stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_MaximumAmountOfOfferingPriceForCommonStock" xlink:to="lab_K1I23I5I1154159JH998_cycc_MaximumAmountOfOfferingPriceForCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_2I0HHGGF8208_us-gaap_WarrantsAndRightsOutstanding"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Warrants and Rights Outstanding</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding" xml:lang="en-US">Number of warrant outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_WarrantsAndRightsOutstanding" xlink:to="lab_4K2JJIIH0420_us-gaap_WarrantsAndRightsOutstanding"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Weighted Average Exercise Price (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xml:lang="en-US">Warrant exercise price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConditionRelatedToExcercisingWarrants" xlink:label="loc_2I0HHGGF8208_cycc_ConditionRelatedToExcercisingWarrants"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToExcercisingWarrants" xml:lang="en-US">Condition Related To Exercising Warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToExcercisingWarrants" xml:lang="en-US">Condition related to exercising warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToExcercisingWarrants" xml:lang="en-US">Represents condition related to exercising warrants.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_ConditionRelatedToExcercisingWarrants" xlink:to="lab_4K2JJIIH0420_cycc_ConditionRelatedToExcercisingWarrants"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfWarrantsExercised" xlink:label="loc_I9G01G3G9932937HF776_cycc_NumberOfWarrantsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfWarrantsExercised" xml:lang="en-US">Number Of Warrants Exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfWarrantsExercised" xml:lang="en-US">Number of warrants exercised</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_NumberOfWarrantsExercised" xml:lang="en-US">Represents number of warrants exercised.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_NumberOfWarrantsExercised" xlink:to="lab_K1I23I5I1154159JH998_cycc_NumberOfWarrantsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_2I0HHGGF8208_us-gaap_ProceedsFromWarrantExercises"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from Warrant Exercises</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises" xml:lang="en-US">Proceeds from exercise of warrants</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ProceedsFromWarrantExercises" xlink:to="lab_4K2JJIIH0420_us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_WeightedAverageExercisePrice" xlink:label="loc_I9G01G3G9932937HF776_cycc_WeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_WeightedAverageExercisePrice" xml:lang="en-US">Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_WeightedAverageExercisePrice" xml:lang="en-US">Weighted average exercise price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_WeightedAverageExercisePrice" xml:lang="en-US">Represents weighted average exercise price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_WeightedAverageExercisePrice" xlink:to="lab_K1I23I5I1154159JH998_cycc_WeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_2I0HHGGF8208_us-gaap_ConversionOfStockSharesConverted1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of shares converted</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ConversionOfStockSharesConverted1" xml:lang="en-US">Number of shares converted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ConversionOfStockSharesConverted1" xlink:to="lab_4K2JJIIH0420_us-gaap_ConversionOfStockSharesConverted1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPrice" xlink:label="loc_I9G01G3G9932937HF776_cycc_ConvertiblePreferredStockConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPrice" xml:lang="en-US">Convertible Preferred Stock, Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPrice" xml:lang="en-US">Conversion price of convertible preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPrice" xml:lang="en-US">Represents the conversion price of Convertible Preferred Stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ConvertiblePreferredStockConversionPrice" xlink:to="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPrice"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xlink:label="loc_2I0HHGGF8208_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xml:lang="en-US">Convertible Preferred Stock, Conversion Percentage, Blocker Provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xml:lang="en-US">Percentage of blocker provision</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xml:lang="en-US">Represents the percentage of blocker provision.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xlink:to="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentage" xlink:label="loc_I9G01G3G9932937HF776_cycc_ConvertiblePreferredStockConversionPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPercentage" xml:lang="en-US">Convertible Preferred Stock, Conversion Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPercentage" xml:lang="en-US">Conversion percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPercentage" xml:lang="en-US">Represents the percentage of conversion price.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ConvertiblePreferredStockConversionPercentage" xlink:to="lab_K1I23I5I1154159JH998_cycc_ConvertiblePreferredStockConversionPercentage"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xlink:label="loc_2I0HHGGF8208_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xml:lang="en-US">Condition Related To Events Occurrence For Conversion Of Preferred Stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xml:lang="en-US">Condition related to events occurrence for conversion of preferred stock</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xml:lang="en-US">Represents condition related to events occurrence for conversion of preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xlink:to="lab_4K2JJIIH0420_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendRatePercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Dividend rate (as a percent)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendRatePercentage" xml:lang="en-US">Dividend rate on convertible exchangeable preferred stock (in percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendRatePercentage" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendRatePercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_2I0HHGGF8208_us-gaap_SharesIssuedPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Shares Issued, Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Share issue price per share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharesIssuedPricePerShare" xml:lang="en-US">Share price per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_4K2JJIIH0420_us-gaap_SharesIssuedPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockLiquidationPreference"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Preferred Stock, Liquidation Preference Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreference" xml:lang="en-US">Liquidation preference (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockLiquidationPreference" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockLiquidationPreference"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_2I0HHGGF8208_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xml:lang="en-US">Preferred Stock, Amount of Preferred Dividends in Arrears</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xml:lang="en-US">Accrued and unpaid dividends in arrears on preferred stock</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:to="lab_4K2JJIIH0420_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xml:lang="en-US">Preferred Stock, Per Share Amounts of Preferred Dividends in Arrears</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xml:lang="en-US">Accrued and unpaid dividends in arrears on preferred stock (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_2I0HHGGF8208_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xml:lang="en-US">Shares reserved for future issuance upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_4K2JJIIH0420_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CommonStockConversionBasis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Common Stock, Conversion Basis</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CommonStockConversionBasis" xml:lang="en-US">Number of shares to be issued for each preferred stock upon conversion</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CommonStockConversionBasis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CommonStockConversionBasis"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPricePerShare" xlink:label="loc_2I0HHGGF8208_cycc_ConvertiblePreferredStockConversionPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPricePerShare" xml:lang="en-US">Convertible Preferred Stock Conversion Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPricePerShare" xml:lang="en-US">Conversion price (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPricePerShare" xml:lang="en-US">The price per share of the conversion feature embedded in the convertible preferred stock.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_ConvertiblePreferredStockConversionPricePerShare" xlink:to="lab_4K2JJIIH0420_cycc_ConvertiblePreferredStockConversionPricePerShare"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="loc_I9G01G3G9932937HF776_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US">Preferred Stock Conversion Obligation Common Stock Closing Sales Price as Percentage of Conversion Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US">Percentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xml:lang="en-US">Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the preferred stock to be convertible.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:to="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="loc_2I0HHGGF8208_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US">Preferred Stock Conversion Obligation Common Stock Closing Sales Price Number of Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US">Number of trading days within 30 trading days in which the closing price of common stock must exceed conversion price for preferred stock to be convertible</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xml:lang="en-US">Represents the number of trading days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable price in order for the preferred stock to be convertible.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:to="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="loc_I9G01G3G9932937HF776_cycc_PreferredStockConversionObligationNumberOfTradingDays"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationNumberOfTradingDays" xml:lang="en-US">Preferred Stock Conversion Obligation Number of Trading Days</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationNumberOfTradingDays" xml:lang="en-US">Number of trading days during which closing price of common stock must exceed conversion price for at least 20 days in order for the preferred stock to be convertible</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationNumberOfTradingDays" xml:lang="en-US">Represents the number of trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the preferred stock to be convertible.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_PreferredStockConversionObligationNumberOfTradingDays" xlink:to="lab_K1I23I5I1154159JH998_cycc_PreferredStockConversionObligationNumberOfTradingDays"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="loc_2I0HHGGF8208_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xml:lang="en-US">Preferred Stock Conversion Obligation Thirty Day Trading Period Ending within Number of Trading Days Prior to Notice of Automatic Conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xml:lang="en-US">Number of trading days prior to notice of automatic conversion</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xml:lang="en-US">Represents the number of trading days within 30-day trading period required to be ended prior to notice of automatic conversion.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:to="lab_4K2JJIIH0420_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockRedemptionPricePerShare"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockRedemptionPricePerShare" xml:lang="en-US">Redemption price per share (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockRedemptionPricePerShare" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockRedemptionPricePerShare"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_2I0HHGGF8208_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentInterestRateStatedPercentage" xml:lang="en-US">Interest rate of Convertible Subordinated Debentures (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_4K2JJIIH0420_us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xlink:label="loc_I9G01G3G9932937HF776_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xml:lang="en-US">Preferred Stock Exchange Rate Principal Amount of Notes Used in Calculation</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xml:lang="en-US">Debt principal amount per share, basis for exchange (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xml:lang="en-US">Represents the unit of measurement in dollars which establishes the exchange rate of the preferred stock into debt.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xlink:to="lab_K1I23I5I1154159JH998_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_2I0HHGGF8208_us-gaap_DebtInstrumentTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt Instrument, Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DebtInstrumentTerm" xml:lang="en-US">Debt instrument, term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DebtInstrumentTerm" xlink:to="lab_4K2JJIIH0420_us-gaap_DebtInstrumentTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendsPerShareDeclared"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsPerShareDeclared" xml:lang="en-US">Preferred Stock, Dividends Per Share, Declared</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsPerShareDeclared" xml:lang="en-US">Preferred stock dividend declared, amount per share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PreferredStockDividendsPerShareDeclared" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PreferredStockDividendsPerShareDeclared"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementLocationAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementLocationAxis" xml:lang="en-US">Income Statement Location [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeStatementLocationAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeStatementLocationDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeStatementLocationDomain" xml:lang="en-US">Income Statement Location [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeStatementLocationDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and Development Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpenseMember" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ResearchAndDevelopmentExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and Administrative Expense [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember" xml:lang="en-US">General and administrative</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_4K2JJIIH0420_us-gaap_GeneralAndAdministrativeExpenseMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_2I0HHGGF8208_us-gaap_AllocatedShareBasedCompensationExpense"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Allocated Share-based Compensation Expense</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Stock-based compensation costs before income taxes</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense" xml:lang="en-US">Compensation cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_4K2JJIIH0420_us-gaap_AllocatedShareBasedCompensationExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_AwardTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AwardTypeAxis" xml:lang="en-US">Award Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AwardTypeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_AwardTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xml:lang="en-US">Award Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_2I0HHGGF8208_us-gaap_EmployeeStockOptionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Employee Stock Option [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeStockOptionMember" xml:lang="en-US">Stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EmployeeStockOptionMember" xlink:to="lab_4K2JJIIH0420_us-gaap_EmployeeStockOptionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xml:lang="en-US">Stock-based compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xml:lang="en-US">Number of Options Outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding at the beginning of the period (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xml:lang="en-US">Options outstanding at the end of the period (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xml:lang="en-US">Granted (in shares)</label>
<label xlink:type="resource" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Number of options granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Issue of common stock upon exercise of stock options (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock option exercised (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Stock-based awards exercised (in shares)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xml:lang="en-US">Exercised (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xml:lang="en-US">Cancelled / forfeited (in shares)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares, Beginning Balance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xml:lang="en-US">Unvested at December 31, 2017</label>
<label xlink:type="resource" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Unvested at December 31, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xml:lang="en-US">Vested and exercisable at December 31, 2017</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price Per Share</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xml:lang="en-US">Weighted Average Exercise Price</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options outstanding at the beginning of the period (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xml:lang="en-US">Options outstanding at the end of the period (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Granted (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xml:lang="en-US">Cancelled / forfeited (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xml:lang="en-US">Unvested at the end of the period (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xml:lang="en-US">Vested and exercisable at the end of the period (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options, Weighted Average Remaining Contractual Term [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term (Years)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xml:lang="en-US">Weighted Average Remaining Contractual Term (years)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:to="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xml:lang="en-US">Options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Unvested Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Unvested at the end of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xml:lang="en-US">Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:to="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xml:lang="en-US">Vested and exercisable at the end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options, Intrinsic Value [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xml:lang="en-US">Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xml:lang="en-US">Aggregate Intrinsic Value</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:to="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xml:lang="en-US">Options outstanding</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award, Options, Unvested Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xml:lang="en-US">Unvested at the end of the period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xml:lang="en-US">Represents the amount of difference between fair value of the underlying shares reserved for issuance and exercise price of options unvested.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:to="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xml:lang="en-US">Vested and exercisable at the end of the period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Fair value of the stock options granted calculated using Black-Scholes option-pricing model assumptions</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xml:lang="en-US">Assumptions for stock option grants to employees and directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xml:lang="en-US">Expected term</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_4K2JJIIH0420_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xml:lang="en-US">Risk free interest rate (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Volatility (as a percent)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xml:lang="en-US">Expected volatility (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xml:lang="en-US">Expected dividend yield over expected term (as a percent)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Resulting weighted average grant fair value (in dollars per share)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xml:lang="en-US">Weighted average grant-date fair value (in dollars per share)</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PerformanceBasedOptionsMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_PerformanceBasedOptionsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_PerformanceBasedOptionsMember" xml:lang="en-US">Performance Based Options [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_PerformanceBasedOptionsMember" xml:lang="en-US">Performance Based Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_PerformanceBasedOptionsMember" xml:lang="en-US">Represents performance based options .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_PerformanceBasedOptionsMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_PerformanceBasedOptionsMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EmployeesAndDirectorsMember" xlink:label="loc_2I0HHGGF8208_cycc_EmployeesAndDirectorsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_EmployeesAndDirectorsMember" xml:lang="en-US">Employees and Directors [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_EmployeesAndDirectorsMember" xml:lang="en-US">Employees and directors</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_EmployeesAndDirectorsMember" xml:lang="en-US">Represents information pertaining to employees and directors.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_EmployeesAndDirectorsMember" xlink:to="lab_4K2JJIIH0420_cycc_EmployeesAndDirectorsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_PlanNameAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_PlanNameAxis" xml:lang="en-US">Plan Name [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_PlanNameAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_PlanNameAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_PlanNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_PlanNameDomain" xml:lang="en-US">Plan Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_PlanNameDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_PlanNameDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan2015Member" xlink:label="loc_I9G01G3G9932937HF776_cycc_Plan2015Member"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan2015Member" xml:lang="en-US">Plan 2015 [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan2015Member" xml:lang="en-US">2015 Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan2015Member" xml:lang="en-US">Represents information about Plan 2015.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_Plan2015Member" xlink:to="lab_K1I23I5I1154159JH998_cycc_Plan2015Member"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xml:lang="en-US">Number of shares reserved</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xml:lang="en-US">Maximum life of stock option awards granted</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xml:lang="en-US">Vesting period</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Share Based Compensation Arrangement by Share Based Payment Award Options Grants in Period Grant Date Fair Value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Grant date fair value</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xml:lang="en-US">Represents the grant date fair value of options granted during the reporting period.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:to="lab_K1I23I5I1154159JH998_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_2I0HHGGF8208_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Stock Options</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xml:lang="en-US">Remaining unrecognized compensation cost of non-vested stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="lab_4K2JJIIH0420_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Total Compensation Cost Not yet Recognized, Period for Recognition</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xml:lang="en-US">Weighted-average remaining requisite service period of recognition of unrecognized compensation cost</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Method Used</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xml:lang="en-US">Fair value assumptions method used</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:to="lab_4K2JJIIH0420_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanTable" xml:lang="en-US">Defined Contribution Plan [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanTable" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_RetirementPlanTypeAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_RetirementPlanTypeAxis" xml:lang="en-US">Retirement Plan Type [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_RetirementPlanTypeAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_RetirementPlanTypeAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RetirementPlanTypeDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RetirementPlanTypeDomain" xml:lang="en-US">Retirement Plan Type [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RetirementPlanTypeDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RetirementPlanTypeDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PensionPlanMember" xlink:label="loc_2I0HHGGF8208_cycc_PensionPlanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PensionPlanMember" xml:lang="en-US">Pension Plan [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PensionPlanMember" xml:lang="en-US">Pension Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PensionPlanMember" xml:lang="en-US">Represents information pertaining to Pension Plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PensionPlanMember" xlink:to="lab_4K2JJIIH0420_cycc_PensionPlanMember"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan401KMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_Plan401KMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan401KMember" xml:lang="en-US">Plan 401k [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan401KMember" xml:lang="en-US">401 (k) Plan</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_Plan401KMember" xml:lang="en-US">Represents information pertaining to 401(k) Plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_Plan401KMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_Plan401KMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_DefinedContributionPlanDisclosureLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Defined Contribution Plan Disclosure [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DefinedContributionPlanDisclosureLineItems" xml:lang="en-US">Employee benefit plans</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_DefinedContributionPlanDisclosureLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xml:lang="en-US">Contribution made by the entity under the pension plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="loc_2I0HHGGF8208_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xml:lang="en-US">Defined Contribution Plan Employer Matching Contribution As Percentage of Employee Deferral</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xml:lang="en-US">Matching contribution by employer as a percentage of the employee's deferral</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xml:lang="en-US">Represents the percentage of employees' deferral for which the employer contributes a matching contribution to the defined contribution plan.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:to="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xml:lang="en-US">Matching contribution by employer as a percentage of U.S. employee's qualifying compensation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="loc_2I0HHGGF8208_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xml:lang="en-US">Defined Contribution Plan Employee Statutorily Prescribed Annual Contribution Limit before Attaining Specified Age</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xml:lang="en-US">Statutorily prescribed annual limit of contributions made by an employee before attaining age of 50 years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xml:lang="en-US">Represents the statutorily prescribed annual limit of contributions made by an employee to the defined contribution plan before attaining specified age.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:to="lab_4K2JJIIH0420_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="loc_I9G01G3G9932937HF776_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xml:lang="en-US">Defined Contribution Plan Employee Statutorily Prescribed Annual Contribution Limit after Attaining Specified Age</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xml:lang="en-US">Statutorily prescribed annual limit of contributions made by an employee after attaining age of 50 years</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xml:lang="en-US">Represents the statutorily prescribed annual limit of contributions made by an employee to the defined contribution plan after attaining specified age.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:to="lab_K1I23I5I1154159JH998_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xlink:label="loc_2I0HHGGF8208_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xml:lang="en-US">Defined Contribution Plan Specified Age Limit of Employees for Calculation of Statutorily Prescribed Annual Limit of Contribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xml:lang="en-US">Specified age limit of employees for calculation of statutorily prescribed annual limit of contribution</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xml:lang="en-US">Represents the specified age limit of employees for calculation of statutorily prescribed annual limit of contribution.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xlink:to="lab_4K2JJIIH0420_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanCostRecognized"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Defined Contribution Plan, Cost Recognized</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanCostRecognized" xml:lang="en-US">Contribution made by the entity under the 401(k) Plan</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DefinedContributionPlanCostRecognized"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Extraordinary Items, Noncontrolling Interest [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xml:lang="en-US">Loss (income) from continuing operations before taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xml:lang="en-US">Domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xml:lang="en-US">Foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xml:lang="en-US">Benefit for income taxes from continuing operations</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_2I0HHGGF8208_us-gaap_CurrentFederalTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current Federal Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current - domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentFederalTaxExpenseBenefit" xml:lang="en-US">Current - domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_4K2JJIIH0420_us-gaap_CurrentFederalTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_CurrentForeignTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current - foreign</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_CurrentForeignTaxExpenseBenefit" xml:lang="en-US">Current - foreign</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_CurrentForeignTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_2I0HHGGF8208_us-gaap_CurrentIncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current - total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current - total</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_CurrentIncomeTaxExpenseBenefit" xml:lang="en-US">Current - total</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_4K2JJIIH0420_us-gaap_CurrentIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred - domestic</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xml:lang="en-US">Deferred - domestic</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Income Tax Reconciliation [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xml:lang="en-US">Reconciliation of the (benefit) provision for income taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income Tax Reconciliation, Income Tax Expense (Benefit), at Federal Statutory Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Income tax expense computed at statutory federal tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:label="loc_2I0HHGGF8208_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xml:lang="en-US">Income Tax Reconciliation Nondeductible Expense and Tax Exempt Income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xml:lang="en-US">Disallowed expenses and non-taxable income</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xml:lang="en-US">The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to nondeductible expenses under enacted tax laws, differences in the methodologies used to determine expense amounts for financial statements prepared in accordance with generally accepted accounting principles and income that is exempt from income taxes under enacted tax laws.</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xml:lang="en-US">Disallowed expenses and non-taxable income</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:to="lab_4K2JJIIH0420_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Income Tax Reconciliation, Nondeductible Expense, Research and Development</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xml:lang="en-US">Loss surrendered to generate R&amp;D credit</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Income Tax Reconciliation, Other Adjustments</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Additional research and development tax relief</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherAdjustments" xml:lang="en-US">Other foreign items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherAdjustments"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Income Tax Reconciliation, Change in Deferred Tax Assets Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xml:lang="en-US">Change in valuation allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xml:lang="en-US">Foreign items, including change in tax rates, and other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Income Tax Reconciliation, Change in Enacted Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xml:lang="en-US">Change in US Tax Rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xml:lang="en-US">Other foreign items</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xml:lang="en-US">Net operating loss and tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ComponentsOfDeferredTaxAssetsAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xml:lang="en-US">Net operating loss and tax credit carryforwards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="loc_I9G01G3G9932937HF776_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Reserves and Accruals Depreciation Amortization and Impairment Losses</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xml:lang="en-US">Depreciation, amortization and impairment of property and equipment</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xml:lang="en-US">Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible temporary differences from depreciation, amortization and estimated impairment losses.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:to="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xml:lang="en-US">Stock options</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xlink:label="loc_I9G01G3G9932937HF776_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xml:lang="en-US">Deferred Tax Assets Tax Deferred Expense Research And Development Credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xml:lang="en-US">Research and development credits</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xml:lang="en-US">This element represents amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Research and development credits reserves not separately disclosed.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xlink:to="lab_K1I23I5I1154159JH998_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsOther"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Deferred Tax Assets, Other</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOther" xml:lang="en-US">Other</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsOther"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DeferredTaxAssetsGross"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred Tax Assets, Gross</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsGross" xml:lang="en-US">Deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsGross"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/zeroVerboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsValuationAllowance" xml:lang="en-US">Valuation allowance for deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_4K2JJIIH0420_us-gaap_DeferredTaxAssetsValuationAllowance"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DeferredTaxAssetsNet"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsNet" xml:lang="en-US">Net deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DeferredTaxAssetsNet" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DeferredTaxAssetsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardTable" xml:lang="en-US">Tax Credit Carryforward [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardTable" xlink:to="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TaxCreditCarryforwardAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TaxCreditCarryforwardAxis" xml:lang="en-US">Tax Credit Carryforward [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TaxCreditCarryforwardAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardNameDomain" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardNameDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ResearchMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchMember" xml:lang="en-US">Research Tax Credit Carryforward [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ResearchMember" xml:lang="en-US">Research and development</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ResearchMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ResearchMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_2I0HHGGF8208_us-gaap_IncomeTaxAuthorityAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_IncomeTaxAuthorityAxis" xml:lang="en-US">Income Tax Authority [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_4K2JJIIH0420_us-gaap_IncomeTaxAuthorityAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxAuthorityDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxAuthorityDomain" xml:lang="en-US">Income Tax Authority [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_IncomeTaxAuthorityDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_2I0HHGGF8208_us-gaap_InternalRevenueServiceIRSMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Internal Revenue Service (IRS) [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_InternalRevenueServiceIRSMember" xml:lang="en-US">Federal</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_InternalRevenueServiceIRSMember" xlink:to="lab_4K2JJIIH0420_us-gaap_InternalRevenueServiceIRSMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_ForeignCountryMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ForeignCountryMember" xml:lang="en-US">Foreign Tax Authority [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ForeignCountryMember" xml:lang="en-US">UK</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_ForeignCountryMember" xml:lang="en-US">United Kingdom</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_ForeignCountryMember" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_ForeignCountryMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_2I0HHGGF8208_us-gaap_StateAndLocalJurisdictionMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State and Local Jurisdiction [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_StateAndLocalJurisdictionMember" xml:lang="en-US">State</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_4K2JJIIH0420_us-gaap_StateAndLocalJurisdictionMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_TaxCreditCarryforwardLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TaxCreditCarryforwardLineItems" xml:lang="en-US">Tax Credit Carryforward [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_TaxCreditCarryforwardLineItems" xml:lang="en-US">Taxes</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_TaxCreditCarryforwardLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_TaxCreditCarryforwardLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Tax Credit Carryforward, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardAmount" xml:lang="en-US">Income tax credits</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_4K2JJIIH0420_us-gaap_TaxCreditCarryforwardAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLossCarryforwards"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">Operating Loss Carryforwards</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwards" xml:lang="en-US">NOLs carryforward</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLossCarryforwards" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwards"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="loc_2I0HHGGF8208_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xml:lang="en-US">Percentage Of Tax Rate Adopted In Respect Of Deferred Tax Assets Measurement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xml:lang="en-US">Percentage of tax rate adopted in respect of deferred tax assets measurement</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xml:lang="en-US">Represents the percentage of tax rate adopted in respect of deferred tax assets measurement.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:to="lab_4K2JJIIH0420_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xml:lang="en-US">US corporate income tax rate</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FutureFederalStatutoryIncomeTaxRate" xlink:label="loc_2I0HHGGF8208_cycc_FutureFederalStatutoryIncomeTaxRate"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_cycc_FutureFederalStatutoryIncomeTaxRate" xml:lang="en-US">Future Federal Statutory Income Tax Rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_cycc_FutureFederalStatutoryIncomeTaxRate" xml:lang="en-US">Corporate income tax rate</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_4K2JJIIH0420_cycc_FutureFederalStatutoryIncomeTaxRate" xml:lang="en-US">Represents future federal statutory income tax rate effective in 2018.</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_cycc_FutureFederalStatutoryIncomeTaxRate" xlink:to="lab_4K2JJIIH0420_cycc_FutureFederalStatutoryIncomeTaxRate"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Operating Loss Carryforwards, Limitations on Use</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xml:lang="en-US">Use of these NOLs restricted to an annual allowance</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_OperatingLossCarryforwardsLimitationsOnUse"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_2I0HHGGF8208_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xml:lang="en-US">Numerator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:to="lab_4K2JJIIH0420_us-gaap_EarningsPerShareBasicAndDilutedAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Earnings Per Share, Basic and Diluted, Other Disclosures [Abstract]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xml:lang="en-US">Denominator:</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xml:lang="en-US">Antidilutive Securities [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesNameDomain" xml:lang="en-US">Antidilutive Securities, Name [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesNameDomain"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CommonStockWarrantsMember" xlink:label="loc_I9G01G3G9932937HF776_cycc_CommonStockWarrantsMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_cycc_CommonStockWarrantsMember" xml:lang="en-US">Common Stock Warrants [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_cycc_CommonStockWarrantsMember" xml:lang="en-US">Common stock warrants</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="lab_K1I23I5I1154159JH998_cycc_CommonStockWarrantsMember" xml:lang="en-US">Represents Common stock warrants .</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_cycc_CommonStockWarrantsMember" xlink:to="lab_K1I23I5I1154159JH998_cycc_CommonStockWarrantsMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xml:lang="en-US">Net loss per common share</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_4K2JJIIH0420_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xml:lang="en-US">Total shares excluded from calculation</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_2I0HHGGF8208_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_4K2JJIIH0420_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_StatementGeographicalAxis"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_StatementGeographicalAxis" xml:lang="en-US">Geographical [Axis]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_StatementGeographicalAxis" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_StatementGeographicalAxis"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_2I0HHGGF8208_us-gaap_SegmentGeographicalDomain"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_SegmentGeographicalDomain" xml:lang="en-US">Geographical [Domain]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_SegmentGeographicalDomain" xlink:to="lab_4K2JJIIH0420_us-gaap_SegmentGeographicalDomain"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_I9G01G3G9932937HF776_country_US"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_country_US" xml:lang="en-US">UNITED STATES</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_K1I23I5I1154159JH998_country_US" xml:lang="en-US">United States</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_country_US" xlink:to="lab_K1I23I5I1154159JH998_country_US"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="loc_2I0HHGGF8208_country_GB"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_country_GB" xml:lang="en-US">UNITED KINGDOM</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_country_GB" xml:lang="en-US">United Kingdom</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_country_GB" xlink:to="lab_4K2JJIIH0420_country_GB"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_2I0HHGGF8208_us-gaap_BoardOfDirectorsChairmanMember"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors Chairman [Member]</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_BoardOfDirectorsChairmanMember" xml:lang="en-US">Board of Directors</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_BoardOfDirectorsChairmanMember" xlink:to="lab_4K2JJIIH0420_us-gaap_BoardOfDirectorsChairmanMember"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xml:lang="en-US">Dividends Payable, Date Declared</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xml:lang="en-US">Dividend declared, date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:label="loc_2I0HHGGF8208_us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_4K2JJIIH0420_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xml:lang="en-US">Dividends Payable, Date to be Paid</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="lab_4K2JJIIH0420_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xml:lang="en-US">Dividend paid, date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_2I0HHGGF8208_us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:to="lab_4K2JJIIH0420_us-gaap_DividendPayableDateToBePaidDayMonthAndYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="loc_I9G01G3G9932937HF776_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xml:lang="en-US">Dividend, record date</label>
<label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xml:lang="en-US">Dividend, record date</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_I9G01G3G9932937HF776_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:to="lab_K1I23I5I1154159JH998_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Percentage of vesting of awards</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
<label xlink:type="resource" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/label" xml:lang="en-US">Income Tax Expense (Benefit), Continuing Operations, Adjustment of Deferred Tax (Asset) Liability</label>
<label xlink:type="resource" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xml:lang="en-US">Reduction in deferred tax assets</label>
<labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
</labelLink></linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>12
<FILENAME>cycc-20171231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Modified with Ez-Editor Version 1.7.0.1 on Friday, March 30, 2018 07:46:08 PM -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DocumentAndEntityInformation" roleURI="http://www.cyclacel.com/role/DocumentAndEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedBalanceSheets" roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheets"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedBalanceSheetsParentheticals" roleURI="http://www.cyclacel.com/role/ConsolidatedBalanceSheetsParentheticals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfOperationsLoss" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfComprehensiveLoss" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#ConsolidatedStatementsOfStockholdersEquity" roleURI="http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Consolidatedstatementsofcashflows" roleURI="http://www.cyclacel.com/role/Consolidatedstatementsofcashflows"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#OrganizationOfCompanyAndBasisOfPresentation" roleURI="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SummaryOfSignificantAccountingPolicies" roleURI="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPolicies"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SignificantContracts" roleURI="http://www.cyclacel.com/role/SignificantContracts"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CashAndCashEquivalents" roleURI="http://www.cyclacel.com/role/CashAndCashEquivalents"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Fairvalueoffinancialassetsandliabilities" roleURI="http://www.cyclacel.com/role/Fairvalueoffinancialassetsandliabilities"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PrepaidExpensesAndOtherCurrentAssets" roleURI="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PropertyAndEquipment" roleURI="http://www.cyclacel.com/role/PropertyAndEquipment"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#AccruedAndOtherCurrentLiabilities" roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilities"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureCommitmentsandcontingencies" roleURI="http://www.cyclacel.com/role/DisclosureCommitmentsandcontingencies"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureStockholdersequity" roleURI="http://www.cyclacel.com/role/DisclosureStockholdersequity"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Disclosurestockbasedcompensation" roleURI="http://www.cyclacel.com/role/Disclosurestockbasedcompensation"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureEmployeeBenefitPlans" roleURI="http://www.cyclacel.com/role/DisclosureEmployeeBenefitPlans"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureTaxes" roleURI="http://www.cyclacel.com/role/DisclosureTaxes"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureNetlosspershare" roleURI="http://www.cyclacel.com/role/DisclosureNetlosspershare"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Disclosuregeographicinformation" roleURI="http://www.cyclacel.com/role/Disclosuregeographicinformation"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Disclosuresubsequentevents" roleURI="http://www.cyclacel.com/role/Disclosuresubsequentevents"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#Disclosuresummaryofsignificantaccountingpoliciespolicies" roleURI="http://www.cyclacel.com/role/Disclosuresummaryofsignificantaccountingpoliciespolicies"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureCashAndCashEquivalentsTables" roleURI="http://www.cyclacel.com/role/DisclosureCashAndCashEquivalentsTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#FairValueOfFinancialAssetsAndLiabilitiesTables" roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" roleURI="http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosurePropertyAndEquipmentTables" roleURI="http://www.cyclacel.com/role/DisclosurePropertyAndEquipmentTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureAccruedAndOtherCurrentLiabilitiesTables" roleURI="http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureCommitmentsAndContingenciesTables" roleURI="http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#DisclosureTaxesTables" roleURI="http://www.cyclacel.com/role/DisclosureTaxesTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#NetLossPerShareTables" roleURI="http://www.cyclacel.com/role/NetLossPerShareTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#GeographicInformationTables" roleURI="http://www.cyclacel.com/role/GeographicInformationTables"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals" roleURI="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SummaryOfSignificantAccountingPoliciesDetailTextuals" roleURI="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SignificantContractsDetailTextuals" roleURI="http://www.cyclacel.com/role/SignificantContractsDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CashAndCashEquivalentsDetails" roleURI="http://www.cyclacel.com/role/CashAndCashEquivalentsDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#FairValueOfFinancialAssetsAndLiabilitiesDetails" roleURI="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PrepaidExpensesAndOtherCurrentAssetsDetails" roleURI="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PropertyPlantAndEquipmentDetails" roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#PropertyPlantAndEquipmentDetailTextuals" roleURI="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#AccruedAndOtherCurrentLiabilitiesDetails" roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#AccruedAndOtherCurrentLiabilitiesDetailTextuals" roleURI="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CommitmentsAndContingenciesDetails" roleURI="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CommitmentsAndContingenciesDetailTextuals" roleURI="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals1" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals2" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals3" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals3"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockholdersEquityDetailTextuals4" roleURI="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails1" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetails2" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#StockBasedCompensationArrangementsDetailTextuals1" roleURI="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#EmployeeBenefitPlansDetailTextuals" roleURI="http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails" roleURI="http://www.cyclacel.com/role/TaxesDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails2" roleURI="http://www.cyclacel.com/role/TaxesDetails2"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails3" roleURI="http://www.cyclacel.com/role/TaxesDetails3"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails4" roleURI="http://www.cyclacel.com/role/TaxesDetails4"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#TaxesDetails5" roleURI="http://www.cyclacel.com/role/TaxesDetails5"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#NetLossPerShareDetails" roleURI="http://www.cyclacel.com/role/NetLossPerShareDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#NetLossPerShareDetail1" roleURI="http://www.cyclacel.com/role/NetLossPerShareDetail1"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#GeographicInformationDetails" roleURI="http://www.cyclacel.com/role/GeographicInformationDetails"/>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#SubsequentEventsDetails" roleURI="http://www.cyclacel.com/role/SubsequentEventsDetails"/>
<roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel"/> <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel"/>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DocumentAndEntityInformation">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DocumentAndEntityInformationAbstract" xlink:label="loc_cycc_DocumentAndEntityInformationAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityRegistrantName_1" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCentralIndexKey_2" order="10" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_TradingSymbol_3" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCurrentReportingStatus_4" order="30" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityVoluntaryFilers_5" order="40" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_CurrentFiscalYearEndDate_6" order="50" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityFilerCategory_7" order="60" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_8" order="70" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_9" order="80" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_EntityPublicFloat_10" order="90" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentType_11" order="100" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentPeriodEndDate_12" order="110" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_AmendmentFlag_13" order="120" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalYearFocus_14" order="130" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_DocumentAndEntityInformationAbstract_0" xlink:to="loc_dei_DocumentFiscalPeriodFocus_15" order="140" use="optional"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedBalanceSheets">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_AssetsAbstract_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaap_AssetsCurrentAbstract_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_AssetsCurrentAbstract_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_8" xlink:to="loc_us-gaap_AssetsCurrent_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_7" xlink:to="loc_us-gaap_Assets_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_6" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccountsPayableCurrent_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_15" xlink:to="loc_us-gaap_LiabilitiesCurrent_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_19" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_Liabilities_20" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_CommitmentsAndContingencies_21" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaap_StockholdersEquityAbstract_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_StockholdersEquityAbstract_22" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_PreferredStockValue_23" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_CommonStockValue_24" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AdditionalPaidInCapital_25" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_26" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_27" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_22" xlink:to="loc_us-gaap_StockholdersEquity_28" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_14" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedBalanceSheetsParentheticals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_0"/>






















<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesIssued_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_0" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>




</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetAbstract" xlink:label="loc_us-gaap_SalesRevenueNetAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_SalesRevenueNetAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:label="loc_us-gaap_RevenueFromGrants_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_1" xlink:to="loc_us-gaap_RevenueFromGrants_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SalesRevenueNetAbstract_1" xlink:to="loc_us-gaap_SalesRevenueNet_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaap_OperatingExpensesAbstract_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingExpensesAbstract_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_5" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CostsAndExpenses" xlink:label="loc_us-gaap_CostsAndExpenses_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_4" xlink:to="loc_us-gaap_CostsAndExpenses_7" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaap_OperatingIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_OperatingIncomeLoss_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNonoperatingIncome" xlink:label="loc_us-gaap_OtherNonoperatingIncome_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_OtherNonoperatingIncome_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NonoperatingIncomeExpenseAbstract_9" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_16" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsAndOtherAdjustments" xlink:label="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_PreferredStockDividendsAndOtherAdjustments_17" order="70" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeneficialConversionFeatureOfConvertibleStock" xlink:label="loc_cycc_BeneficialConversionFeatureOfConvertibleStock_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_cycc_BeneficialConversionFeatureOfConvertibleStock_18" order="80" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_19" order="90" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_20" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareAbstract_21" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_21" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_0" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_0" xlink:to="loc_us-gaap_StatementTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_PreferredStockMember_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_CommonStockMember_4" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_5" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_RetainedEarningsMember_7" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_2" xlink:to="loc_us-gaap_EquityComponentDomain_8" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_1" xlink:to="loc_us-gaap_StatementLineItems_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_9" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockholdersEquity_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_SharesIssued_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueStockWarrantsExercised" xlink:label="loc_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement_20" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility" xlink:label="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacility_21" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare" xlink:label="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_IssueOfCommonStockUponDrawDownCommittedEquityFinanceFacilityShare_22" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodValueSharePurchaseAgreement_23" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement" xlink:label="loc_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_StockIssuedDuringPeriodSharesSharePurchaseAgreement_24" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_25" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion" xlink:label="loc_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion_26" order="150" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax" xlink:label="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax_27" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_28" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_NetIncomeLoss_29" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_30" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_StockholdersEquity_31" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_10" xlink:to="loc_us-gaap_SharesIssued_32" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Consolidatedstatementsofcashflows">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Depreciation" xlink:label="loc_us-gaap_Depreciation_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_Depreciation_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_ShareBasedCompensation_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_3" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_7" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_11" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_16" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants_17" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_18" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_15" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_19" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_0" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashReceivedDuringPeriodForAbstract" xlink:label="loc_cycc_CashReceivedDuringPeriodForAbstract_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_24" xlink:to="loc_cycc_CashReceivedDuringPeriodForAbstract_25" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromInterestReceived" xlink:label="loc_us-gaap_ProceedsFromInterestReceived_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_CashReceivedDuringPeriodForAbstract_25" xlink:to="loc_us-gaap_ProceedsFromInterestReceived_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="loc_us-gaap_IncomeTaxesPaid_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_CashReceivedDuringPeriodForAbstract_25" xlink:to="loc_us-gaap_IncomeTaxesPaid_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_24" xlink:to="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccrualOfPreferredStockDividends" xlink:label="loc_cycc_AccrualOfPreferredStockDividends_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_28" xlink:to="loc_cycc_AccrualOfPreferredStockDividends_29" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SignificantContracts">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SignificantContractsDisclosureAbstract" xlink:label="loc_cycc_SignificantContractsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SignificantContractsDisclosureTextBlock" xlink:label="loc_cycc_SignificantContractsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_SignificantContractsDisclosureAbstract_0" xlink:to="loc_cycc_SignificantContractsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CashAndCashEquivalents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsDisclosureTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Fairvalueoffinancialassetsandliabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_0" xlink:to="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PropertyAndEquipment">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilities">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureCommitmentsandcontingencies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureStockholdersequity">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Disclosurestockbasedcompensation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureEmployeeBenefitPlans">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureTaxes">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureNetlosspershare">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Disclosuregeographicinformation">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Disclosuresubsequentevents">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaap_SubsequentEventsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/Disclosuresummaryofsignificantaccountingpoliciespolicies">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_UseOfEstimates_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_FairValueOfFinancialInstrumentsPolicy_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_SegmentReportingPolicyPolicyTextBlock_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_8" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OtherIncomePolicyTextBlock" xlink:label="loc_cycc_OtherIncomePolicyTextBlock_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cycc_OtherIncomePolicyTextBlock_9" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_10" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ClinicalTrialAccountingPolicyTextBlock" xlink:label="loc_cycc_ClinicalTrialAccountingPolicyTextBlock_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cycc_ClinicalTrialAccountingPolicyTextBlock_11" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PatentCostsPolicyTextBlock" xlink:label="loc_cycc_PatentCostsPolicyTextBlock_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cycc_PatentCostsPolicyTextBlock_12" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_13" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_14" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_15" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_16" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_17" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock" xlink:label="loc_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock_18" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureCashAndCashEquivalentsTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract" xlink:label="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract_0" xlink:to="loc_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosurePropertyAndEquipmentTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/DisclosureTaxesTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/NetLossPerShareTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/GeographicInformationTables">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0"/>












<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_NetIncomeLoss_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_9" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="loc_us-gaap_StockholdersEquityReverseStockSplit_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_StockholdersEquityReverseStockSplit_10" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_0" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesTable" xlink:label="loc_cycc_AccountingPoliciesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_0" xlink:to="loc_cycc_AccountingPoliciesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentMember" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesTable_1" xlink:to="loc_us-gaap_RangeAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_6" xlink:to="loc_us-gaap_RangeMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MinimumMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_7" xlink:to="loc_us-gaap_MaximumMember_9" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccountingPoliciesLineItems" xlink:label="loc_cycc_AccountingPoliciesLineItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesTable_1" xlink:to="loc_cycc_AccountingPoliciesLineItems_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashFDICInsuredAmount" xlink:label="loc_us-gaap_CashFDICInsuredAmount_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_CashFDICInsuredAmount_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashUninsuredAmount" xlink:label="loc_us-gaap_CashUninsuredAmount_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_CashUninsuredAmount_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashFinancialServicesCompensationSchemeInsuredAmount" xlink:label="loc_cycc_CashFinancialServicesCompensationSchemeInsuredAmount_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_cycc_CashFinancialServicesCompensationSchemeInsuredAmount_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme" xlink:label="loc_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_NumberOfOperatingSegments_17" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfCountriesInWhichEntityOperates" xlink:label="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_NumberOfCountriesInWhichEntityOperates_18" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="loc_us-gaap_DeferredRevenue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccountingPoliciesLineItems_10" xlink:to="loc_us-gaap_DeferredRevenue_19" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SignificantContractsDetailTextuals">
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SignificantContractsDisclosureAbstract" xlink:label="loc_cycc_SignificantContractsDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentTable" xlink:label="loc_us-gaap_SupplyCommitmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_SignificantContractsDisclosureAbstract_0" xlink:to="loc_us-gaap_SupplyCommitmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DaiichiSankyoCompanyLimitedMember" xlink:label="loc_cycc_DaiichiSankyoCompanyLimitedMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_DaiichiSankyoCompanyLimitedMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ManrosTherapeuticsSaManrosMember" xlink:label="loc_cycc_ManrosTherapeuticsSaManrosMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_ManrosTherapeuticsSaManrosMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_6" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:label="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_7" xlink:to="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SupplyCommitmentLineItems" xlink:label="loc_us-gaap_SupplyCommitmentLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentTable_1" xlink:to="loc_us-gaap_SupplyCommitmentLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPotentialFutureMilestonePayments" xlink:label="loc_cycc_LicenseAgreementPotentialFutureMilestonePayments_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_cycc_LicenseAgreementPotentialFutureMilestonePayments_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry" xlink:label="loc_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason" xlink:label="loc_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault" xlink:label="loc_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationAndResearchAndDevelopmentRevenue" xlink:label="loc_cycc_CollaborationAndResearchAndDevelopmentRevenue_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_cycc_CollaborationAndResearchAndDevelopmentRevenue_14" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplyCommitmentLineItems_9" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_15" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CashAndCashEquivalentsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAbstract" xlink:label="loc_us-gaap_CashAndCashEquivalentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaap_Cash_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_Cash_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_ShortTermInvestments_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CashAndCashEquivalentsAbstract_0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_0" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_2" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_3" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_5" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_6" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_8" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosureAbstract" xlink:label="loc_us-gaap_AssetsFairValueDisclosureAbstract_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_13" xlink:to="loc_us-gaap_AssetsFairValueDisclosureAbstract_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashEquivalentsAtCarryingValue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14" xlink:to="loc_us-gaap_CashEquivalentsAtCarryingValue_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsFairValueDisclosureAbstract_14" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent" xlink:label="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="loc_us-gaap_IncomeTaxesReceivable_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_IncomeTaxesReceivable_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValueAddedTaxReceivableCurrent" xlink:label="loc_us-gaap_ValueAddedTaxReceivableCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_ValueAddedTaxReceivableCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepositsAssetsCurrent" xlink:label="loc_us-gaap_DepositsAssetsCurrent_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_DepositsAssetsCurrent_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_OtherAssetsCurrent_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_7" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_2" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:label="loc_us-gaap_EquipmentMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_us-gaap_EquipmentMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OfficeEquipmentAndFurnitureMember" xlink:label="loc_cycc_OfficeEquipmentAndFurnitureMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_3" xlink:to="loc_cycc_OfficeEquipmentAndFurnitureMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_RangeAxis_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_7" xlink:to="loc_us-gaap_RangeMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MinimumMember_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_8" xlink:to="loc_us-gaap_MaximumMember_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_14" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_11" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_15" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_0" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedResearchAndDevelopmentCostsCurrent" xlink:label="loc_cycc_AccruedResearchAndDevelopmentCostsCurrent_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_cycc_AccruedResearchAndDevelopmentCostsCurrent_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_OtherAccruedLiabilitiesCurrent_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesTable" xlink:label="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0" xlink:to="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" xlink:to="loc_dei_LegalEntityAxis_2" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_2" xlink:to="loc_dei_EntityDomain_3" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ManrosTherapeuticsSaManrosMember" xlink:label="loc_cycc_ManrosTherapeuticsSaManrosMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_3" xlink:to="loc_cycc_ManrosTherapeuticsSaManrosMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CollaborationSupplyAndLicensingAgreementsMember" xlink:label="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_cycc_CollaborationSupplyAndLicensingAgreementsMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AccruedAndOtherCurrentLiabilitiesLineItems" xlink:label="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesTable_1" xlink:to="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:label="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AccruedAndOtherCurrentLiabilitiesLineItems_8" xlink:to="loc_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CommitmentsAndContingenciesDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="loc_us-gaap_LeasesOperatingAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_0" xlink:to="loc_us-gaap_LeasesOperatingAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:label="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_1" xlink:to="loc_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesOperatingAbstract_1" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TypeOfArrangementAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_5" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_us-gaap_CollaborativeArrangementMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MarketIssuanceSalesAgreementMember" xlink:label="loc_cycc_MarketIssuanceSalesAgreementMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6" xlink:to="loc_cycc_MarketIssuanceSalesAgreementMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_dei_LegalEntityAxis_9" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9" xlink:to="loc_dei_EntityDomain_10" order="0" use="optional"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_LadenburgThalmannAndCoIncMember" xlink:label="loc_cycc_LadenburgThalmannAndCoIncMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_10" xlink:to="loc_cycc_LadenburgThalmannAndCoIncMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsByClassAxis" xlink:label="loc_us-gaap_CapitalUnitsByClassAxis_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_CapitalUnitsByClassAxis_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassDomain" xlink:label="loc_us-gaap_CapitalUnitClassDomain_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitsByClassAxis_12" xlink:to="loc_us-gaap_CapitalUnitClassDomain_13" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassAMember" xlink:label="loc_us-gaap_CapitalUnitClassAMember_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_13" xlink:to="loc_us-gaap_CapitalUnitClassAMember_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitClassBMember" xlink:label="loc_us-gaap_CapitalUnitClassBMember_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CapitalUnitClassDomain_13" xlink:to="loc_us-gaap_CapitalUnitClassBMember_15" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_16" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_16" xlink:to="loc_us-gaap_ClassOfStockDomain_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_17" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_18" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_19" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_19" xlink:to="loc_us-gaap_EquityComponentDomain_20" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_CommonStockMember_21" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaap_WarrantMember_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_20" xlink:to="loc_us-gaap_WarrantMember_22" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_SharePrice_24" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalUnitsAuthorized" xlink:label="loc_us-gaap_CapitalUnitsAuthorized_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_CapitalUnitsAuthorized_25" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesCalledByEachUnit" xlink:label="loc_cycc_NumberOfSecuritiesCalledByEachUnit_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_cycc_NumberOfSecuritiesCalledByEachUnit_26" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_27" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_28" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_29" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:label="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_30" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ComissionAsPercentageOfGrossProceedsOfSale" xlink:label="loc_cycc_ComissionAsPercentageOfGrossProceedsOfSale_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_cycc_ComissionAsPercentageOfGrossProceedsOfSale_31" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AggregateIntrinsicValueOfStock" xlink:label="loc_cycc_AggregateIntrinsicValueOfStock_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_cycc_AggregateIntrinsicValueOfStock_32" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_33" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_34"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_23" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_34" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementAxis" xlink:label="loc_cycc_EquitySaleAgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_cycc_EquitySaleAgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EquitySaleAgreementDomain" xlink:label="loc_cycc_EquitySaleAgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_EquitySaleAgreementAxis_2" xlink:to="loc_cycc_EquitySaleAgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FbrSalesAgreementMember" xlink:label="loc_cycc_FbrSalesAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_EquitySaleAgreementDomain_3" xlink:to="loc_cycc_FbrSalesAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfCommissionOnGrossEquitySales" xlink:label="loc_cycc_PercentageOfCommissionOnGrossEquitySales_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_cycc_PercentageOfCommissionOnGrossEquitySales_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_7" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_5" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementAxis" xlink:label="loc_cycc_AgreementAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_cycc_AgreementAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AgreementDomain" xlink:label="loc_cycc_AgreementDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AgreementAxis_2" xlink:to="loc_cycc_AgreementDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ControlledEquityOfferingSalesAgreementMember" xlink:label="loc_cycc_ControlledEquityOfferingSalesAgreementMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AgreementDomain_3" xlink:to="loc_cycc_ControlledEquityOfferingSalesAgreementMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FbrSalesAgreementMember" xlink:label="loc_cycc_FbrSalesAgreementMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_AgreementDomain_3" xlink:to="loc_cycc_FbrSalesAgreementMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_SalesAgentMember" xlink:label="loc_cycc_SalesAgentMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_cycc_SalesAgentMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_MaximumAmountOfOfferingPriceForCommonStock" xlink:label="loc_cycc_MaximumAmountOfOfferingPriceForCommonStock_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_cycc_MaximumAmountOfOfferingPriceForCommonStock_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfCommissionOnGrossEquitySales" xlink:label="loc_cycc_PercentageOfCommissionOnGrossEquitySales_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_cycc_PercentageOfCommissionOnGrossEquitySales_11" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_12" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_9" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WarrantsAndRightsOutstanding" xlink:label="loc_us-gaap_WarrantsAndRightsOutstanding_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_WarrantsAndRightsOutstanding_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConditionRelatedToExcercisingWarrants" xlink:label="loc_cycc_ConditionRelatedToExcercisingWarrants_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cycc_ConditionRelatedToExcercisingWarrants_3" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfWarrantsExercised" xlink:label="loc_cycc_NumberOfWarrantsExercised_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cycc_NumberOfWarrantsExercised_4" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaap_ProceedsFromWarrantExercises_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ProceedsFromWarrantExercises_5" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_WeightedAverageExercisePrice" xlink:label="loc_cycc_WeightedAverageExercisePrice_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_cycc_WeightedAverageExercisePrice_6" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_0" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_StatementClassOfStockAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_2" xlink:to="loc_us-gaap_ClassOfStockDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="loc_us-gaap_ClassOfStockLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_1" xlink:to="loc_us-gaap_ClassOfStockLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConversionOfStockSharesConverted1" xlink:label="loc_us-gaap_ConversionOfStockSharesConverted1_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_ConversionOfStockSharesConverted1_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight" xlink:label="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPrice" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPrice_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPrice_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPercentage" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPercentage_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPercentage_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock" xlink:label="loc_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock_14" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_15" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_16" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_17" order="100" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreference" xlink:label="loc_us-gaap_PreferredStockLiquidationPreference_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockLiquidationPreference_18" order="110" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockAmountOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears_19" order="120" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears" xlink:label="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears_20" order="130" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_21" order="140" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockConversionBasis" xlink:label="loc_us-gaap_CommonStockConversionBasis_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_CommonStockConversionBasis_22" order="150" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ConvertiblePreferredStockConversionPricePerShare" xlink:label="loc_cycc_ConvertiblePreferredStockConversionPricePerShare_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_ConvertiblePreferredStockConversionPricePerShare_23" order="160" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_SharePrice_24" order="170" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice" xlink:label="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice_25" order="180" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays" xlink:label="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays_26" order="190" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationNumberOfTradingDays" xlink:label="loc_cycc_PreferredStockConversionObligationNumberOfTradingDays_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_PreferredStockConversionObligationNumberOfTradingDays_27" order="200" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion" xlink:label="loc_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion_28" order="210" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_29"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_29" order="220" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_30"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_30" order="230" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation" xlink:label="loc_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation_31"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation_31" order="240" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaap_DebtInstrumentTerm_32"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_DebtInstrumentTerm_32" order="250" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_33"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_6" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_33" order="260" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_3" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_6" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_16" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_17" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_18" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_19" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_14" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_20" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_21" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_22" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_21" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm_23" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract_21" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_24" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_5" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_25" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_26" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_27"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_25" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedIntrinsicValue_27" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract_25" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_28" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_5" xlink:to="loc_us-gaap_RangeMember_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MinimumMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_6" xlink:to="loc_us-gaap_MaximumMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_13" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_14" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_10" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_15" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_AwardTypeAxis_2" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PerformanceBasedOptionsMember" xlink:label="loc_cycc_PerformanceBasedOptionsMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_3" xlink:to="loc_cycc_PerformanceBasedOptionsMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_6" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_6" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_EmployeesAndDirectorsMember" xlink:label="loc_cycc_EmployeesAndDirectorsMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_7" xlink:to="loc_cycc_EmployeesAndDirectorsMember_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_RangeAxis_9" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_9" xlink:to="loc_us-gaap_RangeMember_10" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:label="loc_us-gaap_MinimumMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MinimumMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_10" xlink:to="loc_us-gaap_MaximumMember_12" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_PlanNameAxis_13" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_13" xlink:to="loc_us-gaap_PlanNameDomain_14" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan2015Member" xlink:label="loc_cycc_Plan2015Member_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_14" xlink:to="loc_cycc_Plan2015Member_15" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_17" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_18" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_19" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_20" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue" xlink:label="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue_21" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_22" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_23" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_24" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_25"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed_25" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_16" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanTable" xlink:label="loc_us-gaap_DefinedContributionPlanTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_0" xlink:to="loc_us-gaap_DefinedContributionPlanTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PensionPlanMember" xlink:label="loc_cycc_PensionPlanMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3" xlink:to="loc_cycc_PensionPlanMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_Plan401KMember" xlink:label="loc_cycc_Plan401KMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3" xlink:to="loc_cycc_Plan401KMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanTable_1" xlink:to="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral" xlink:label="loc_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge" xlink:label="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge" xlink:label="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge_11" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution" xlink:label="loc_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution_12" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedContributionPlanDisclosureLineItems_6" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_13" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails2">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails3">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome" xlink:label="loc_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherAdjustments_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_10" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_1" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_11" order="90" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails4">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses" xlink:label="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits" xlink:label="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_8" order="60" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_1" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_9" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/TaxesDetails5">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardTable" xlink:label="loc_us-gaap_TaxCreditCarryforwardTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0" xlink:to="loc_us-gaap_TaxCreditCarryforwardTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_2" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchMember" xlink:label="loc_us-gaap_ResearchMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_3" xlink:to="loc_us-gaap_ResearchMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_5" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InternalRevenueServiceIRSMember" xlink:label="loc_us-gaap_InternalRevenueServiceIRSMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_InternalRevenueServiceIRSMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="loc_us-gaap_ForeignCountryMember_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_ForeignCountryMember_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_6" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:label="loc_us-gaap_RangeAxis_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_RangeAxis_10" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:label="loc_us-gaap_RangeMember_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeAxis_10" xlink:to="loc_us-gaap_RangeMember_11" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:label="loc_us-gaap_MaximumMember_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RangeMember_11" xlink:to="loc_us-gaap_MaximumMember_12" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardLineItems" xlink:label="loc_us-gaap_TaxCreditCarryforwardLineItems_13"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardTable_1" xlink:to="loc_us-gaap_TaxCreditCarryforwardLineItems_13" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_14"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_14" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaap_OperatingLossCarryforwards_15"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_OperatingLossCarryforwards_15" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement" xlink:label="loc_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_16"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement_16" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_17"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_17" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_FutureFederalStatutoryIncomeTaxRate" xlink:label="loc_cycc_FutureFederalStatutoryIncomeTaxRate_18"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_cycc_FutureFederalStatutoryIncomeTaxRate_18" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_19" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/zeroVerboseLabel"/>


<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLossCarryforwardsLimitationsOnUse" xlink:label="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_21"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_OperatingLossCarryforwardsLimitationsOnUse_21" order="80" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardLineItems_13" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability" order="70" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/NetLossPerShareDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedAbstract_1" xlink:to="loc_us-gaap_NetIncomeLoss_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock" xlink:label="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock_3" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeneficialConversionFeatureOfConvertibleStock" xlink:label="loc_cycc_BeneficialConversionFeatureOfConvertibleStock_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_cycc_BeneficialConversionFeatureOfConvertibleStock_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities" xlink:label="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities_5" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_6" order="40" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_7" order="50" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract_7" xlink:to="loc_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_8" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaap_EarningsPerShareBasicAndDiluted_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_EarningsPerShareBasicAndDiluted_9" order="60" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/NetLossPerShareDetail1">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_0" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_EmployeeStockOptionMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_6" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_CommonStockWarrantsMember" xlink:label="loc_cycc_CommonStockWarrantsMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_3" xlink:to="loc_cycc_CommonStockWarrantsMember_7" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_1" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_8" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/GeographicInformationDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementGeographicalAxis" xlink:label="loc_us-gaap_StatementGeographicalAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_StatementGeographicalAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentGeographicalDomain" xlink:label="loc_us-gaap_SegmentGeographicalDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementGeographicalAxis_2" xlink:to="loc_us-gaap_SegmentGeographicalDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3" xlink:to="loc_country_US_4" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="loc_country_GB_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentGeographicalDomain_3" xlink:to="loc_country_GB_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNet" xlink:label="loc_us-gaap_SalesRevenueNet_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_SalesRevenueNet_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_NetIncomeLoss_8" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_Assets_9" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_10" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/SubsequentEventsDetails">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaap_SubsequentEventsAbstract_0"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="loc_us-gaap_SubsequentEventTable_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventsAbstract_0" xlink:to="loc_us-gaap_SubsequentEventTable_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_2"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_2" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_3"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_2" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_3" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_4"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_3" xlink:to="loc_us-gaap_SubsequentEventMember_4" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualAxis" xlink:label="loc_us-gaap_TitleOfIndividualAxis_5"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_TitleOfIndividualAxis_5" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualAxis_5" xlink:to="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BoardOfDirectorsChairmanMember" xlink:label="loc_us-gaap_BoardOfDirectorsChairmanMember_7"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TitleOfIndividualWithRelationshipToEntityDomain_6" xlink:to="loc_us-gaap_BoardOfDirectorsChairmanMember_7" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="loc_us-gaap_SubsequentEventLineItems_8"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTable_1" xlink:to="loc_us-gaap_SubsequentEventLineItems_8" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_PreferredStockDividendsPerShareDeclared_9"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_PreferredStockDividendsPerShareDeclared_9" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateDeclaredDayMonthAndYear" xlink:label="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_10"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear_10" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendPayableDateToBePaidDayMonthAndYear" xlink:label="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_11"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_DividendPayableDateToBePaidDayMonthAndYear_11" order="20" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DividendsPayableDateOfRecordDayMonthAndYear" xlink:label="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_12"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventLineItems_8" xlink:to="loc_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear_12" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
</presentationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1" roleURI="http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1"/>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>










<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:label="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaap_StatementScenarioAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:to="loc_us-gaap_StatementScenarioAxis" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaap_ScenarioUnspecifiedDomain"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementScenarioAxis" xlink:to="loc_us-gaap_ScenarioUnspecifiedDomain" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_BeforeReverseStockSplitMember" xlink:label="loc_cycc_BeforeReverseStockSplitMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_cycc_BeforeReverseStockSplitMember" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_AfterReverseStockSplitMember" xlink:label="loc_cycc_AfterReverseStockSplitMember"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScenarioUnspecifiedDomain" xlink:to="loc_cycc_AfterReverseStockSplitMember" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="cycc-20171231.xsd#cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:label="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationTable" xlink:to="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaap_CommonStockSharesOutstanding"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems" xlink:to="loc_us-gaap_CommonStockSharesOutstanding" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
</presentationLink>
<roleRef xlink:type="simple" xlink:href="cycc-20171231.xsd#CONSOLIDATEDBALANCESHEETSParentheticals1" roleURI="http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1"/>
<presentationLink xlink:type="extended" xlink:role="http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1"><loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="loc_us-gaap_StatementTable" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>








<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementLineItems" order="30" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>




<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesIssued" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="loc_us-gaap_PreferredStockLiquidationPreferenceValue"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="loc_us-gaap_PreferredStockLiquidationPreferenceValue" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>








<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable" xlink:to="loc_us-gaap_StatementClassOfStockAxis" order="20" use="optional"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="loc_us-gaap_ClassOfStockDomain_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConvertiblePreferredStockMember" xlink:label="loc_us-gaap_ConvertiblePreferredStockMember_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_ConvertiblePreferredStockMember_1" order="0" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SeriesAPreferredStockMember" xlink:label="loc_us-gaap_SeriesAPreferredStockMember_1"/>
<presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1" xlink:to="loc_us-gaap_SeriesAPreferredStockMember_1" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
</presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826145360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Mar. 27, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DocumentAndEntityInformationAbstract', window );"><strong>Document and Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Cyclacel Pharmaceuticals, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001130166<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">cycc<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Smaller Reporting Company<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,997,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,719,813<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826460432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,910<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,064<span></span>
</td>
<td class="nump">3,097<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">25,974<span></span>
</td>
<td class="nump">19,617<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">26,003<span></span>
</td>
<td class="nump">19,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">1,558<span></span>
</td>
<td class="nump">2,497<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued and other current liabilities</a></td>
<td class="nump">2,555<span></span>
</td>
<td class="nump">2,762<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">4,113<span></span>
</td>
<td class="nump">5,259<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="nump">124<span></span>
</td>
<td class="nump">130<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">5,389<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 9)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value; 100,000,000 shares authorized at December 31, 2016 and December 31, 2017; 4,256,829 and 11,997,447 shares issued and outstanding at December 31, 2016 and December 31, 2017, respectively.</a></td>
<td class="nump">12<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">365,057<span></span>
</td>
<td class="nump">350,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(794)<span></span>
</td>
<td class="num">(743)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(342,509)<span></span>
</td>
<td class="num">(335,039)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">21,766<span></span>
</td>
<td class="nump">14,273<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">26,003<span></span>
</td>
<td class="nump">19,662<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">6% Convertible Exchangeable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, value</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826147520">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>CONSOLIDATED BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">11,997,447<span></span>
</td>
<td class="nump">4,256,829<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">11,997,447<span></span>
</td>
<td class="nump">4,256,829<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826147712">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED BALANCE SHEETS (Parentheticals 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">6% Convertible Exchangeable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreferenceValue', window );">Preferred stock, liquidation preference value (in dollars)</a></td>
<td class="nump">$ 4,006,512<span></span>
</td>
<td class="nump">$ 4,006,512<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreferenceValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of the difference between preference in liquidation and the par or stated values of the preferred shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreferenceValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826309424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNetAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Grant revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Total revenues</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">4,237<span></span>
</td>
<td class="nump">9,477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">5,254<span></span>
</td>
<td class="nump">5,516<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpenses', window );">Total operating expenses</a></td>
<td class="nump">9,491<span></span>
</td>
<td class="nump">14,993<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(9,491)<span></span>
</td>
<td class="num">(14,150)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign exchange gains (losses)</a></td>
<td class="num">(39)<span></span>
</td>
<td class="nump">273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncome', window );">Other income, net</a></td>
<td class="nump">949<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense), net</a></td>
<td class="nump">1,028<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before taxes</a></td>
<td class="num">(8,463)<span></span>
</td>
<td class="num">(13,774)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,470)<span></span>
</td>
<td class="num">(11,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsAndOtherAdjustments', window );">Dividend on convertible exchangeable preferred shares</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_BeneficialConversionFeatureOfConvertibleStock', window );">Beneficial conversion feature of Series A convertible stock</a></td>
<td class="num">(3,638)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities', window );">Conversion of Series A convertible preferred stock</a></td>
<td class="num">(3,537)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss applicable to common shareholders</a></td>
<td class="num">$ (14,846)<span></span>
</td>
<td class="num">$ (11,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Basic and diluted earnings per common share:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share - basic and diluted</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">7,631,152<span></span>
</td>
<td class="nump">3,424,976<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_BeneficialConversionFeatureOfConvertibleStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock beneficial conversion feature of Series A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_BeneficialConversionFeatureOfConvertibleStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock that was converted to other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total costs of sales and operating expenses for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30700-110894<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=64836518&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsAndOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate value of preferred stock dividends and other adjustments necessary to derive net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsAndOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6820549552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,470)<span></span>
</td>
<td class="num">$ (11,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="num">(14,687)<span></span>
</td>
<td class="nump">27,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange gain (loss) on intercompany loans</a></td>
<td class="nump">14,636<span></span>
</td>
<td class="num">(27,351)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (7,521)<span></span>
</td>
<td class="num">$ (11,938)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827097904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">$ 342,587<span></span>
</td>
<td class="num">$ (596)<span></span>
</td>
<td class="num">$ (323,159)<span></span>
</td>
<td class="nump">$ 18,835<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2015</a></td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">2,965,208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement', window );">Issue of common stock on At Market Issuance sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">6,793<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement', window );">Issue of common stock on At Market Issuance sales agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,291,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,351)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(27,351)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11,791)<span></span>
</td>
<td class="num">(11,791)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Cumulative effect of change in Accounting Principle for ASU 2016-09 at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(89)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">350,051<span></span>
</td>
<td class="num">(743)<span></span>
</td>
<td class="num">(335,039)<span></span>
</td>
<td class="nump">14,273<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2016</a></td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">4,256,829<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">13,681<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13,684<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issue of common stock, preferred stock and associated warrants on underwritten offering, net of expenses (in shares)</a></td>
<td class="nump">8,872<span></span>
</td>
<td class="nump">3,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Series A Preferred stock conversions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Series A Preferred stock conversions (in shares)</a></td>
<td class="num">(8,608)<span></span>
</td>
<td class="nump">4,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised', window );">Warrant exercise</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised', window );">Warrant exercise (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement', window );">Issue of common stock on At Market Issuance sales agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,066<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement', window );">Issue of common stock on At Market Issuance sales agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion', window );">Preferred stock dividends</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(201)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax', window );">Unrealized foreign exchange on intercompany loans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Translation adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,687)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,687)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Loss for the period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,470)<span></span>
</td>
<td class="num">(7,470)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">$ 365,057<span></span>
</td>
<td class="num">$ (794)<span></span>
</td>
<td class="num">$ (342,509)<span></span>
</td>
<td class="nump">$ 21,766<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Balance (in shares) at Dec. 31, 2017</a></td>
<td class="nump">335,537<span></span>
</td>
<td class="nump">11,997,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease (increase) in additional paid in capital (APIC) for the conversions of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AdjustmentsToAdditionalPaidInCapitalPreferredStockConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in the balance sheet adjustment that results from the process of translating subsidiary financial statements and foreign equity investments into functional currency of the reporting entity, net of tax. If the entity's functional currency is a foreign currency, translation adjustments result from the process of translating that entity's financial statements into the reporting currency. It includes gain (loss) on foreign exchange on intercompany loans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_OtherComprehensiveIncomeUnrealizedForeignExchangeOnIntercompanyLoansNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents shares related to Issue of common stock on At Market Issuance sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_StockIssuedDuringPeriodSharesAtMarketIssuanceSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_StockIssuedDuringPeriodSharesStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount related to Issue of common stock on At Market Issuance sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_StockIssuedDuringPeriodValueAtMarketIssuanceSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_StockIssuedDuringPeriodValueStockWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>value of stock issued as a result of the exercise of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_StockIssuedDuringPeriodValueStockWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=64808268&amp;loc=d3e32211-110900<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827204144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,470)<span></span>
</td>
<td class="num">$ (11,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation expense</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">133<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on disposal of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">1,232<span></span>
</td>
<td class="nump">439<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities', window );">Accounts payable and other current liabilities</a></td>
<td class="num">(1,540)<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash used in operating activities</a></td>
<td class="num">(7,480)<span></span>
</td>
<td class="num">(10,079)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(13)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(13)<span></span>
</td>
<td class="nump">9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity securities, net of issuance costs</a></td>
<td class="nump">14,749<span></span>
</td>
<td class="nump">6,794<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants', window );">Proceeds from the exercise of stock options and warrants, net of issuance costs</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Payment of preferred stock dividend</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(200)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">14,748<span></span>
</td>
<td class="nump">6,594<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations', window );">Effect of exchange rate changes on cash and cash equivalents</a></td>
<td class="nump">135<span></span>
</td>
<td class="num">(444)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
<td class="nump">7,390<span></span>
</td>
<td class="num">(3,920)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
<td class="nump">16,520<span></span>
</td>
<td class="nump">20,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
<td class="nump">23,910<span></span>
</td>
<td class="nump">16,520<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CashReceivedDuringPeriodForAbstract', window );"><strong>Cash received during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromInterestReceived', window );">Interest</a></td>
<td class="nump">118<span></span>
</td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Taxes</a></td>
<td class="nump">1,815<span></span>
</td>
<td class="nump">1,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Non cash financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccrualOfPreferredStockDividends', window );">Accrual of preferred stock dividends</a></td>
<td class="nump">$ 50<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AccrualOfPreferredStockDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents amount of accrual of preferred stock dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AccrualOfPreferredStockDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CashReceivedDuringPeriodForAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_CashReceivedDuringPeriodForAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash balances in continuing operations held in foreign currencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashAndCashEquivalentsContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligations incurred but not paid, and operating obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromInterestReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest received on loans and other debt instruments during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromInterestReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholder, which takes precedence over common stockholders in the event of liquidation and from issuance of rights to purchase common shares at a predetermined price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockPreferenceStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817196736">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization of the Company and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization of the Company</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization of the Company and Basis of Presentation</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">1.&#160;&#160;&#160;&#160;&#160;Organization of the Company and Basis of Presentation</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cyclacel Pharmaceuticals Inc., (&#8220;Cyclacel&#8221; or &#8220;the Company&#8221;) is a clinical-stage biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. Cyclacel&#8217;s transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and exploratory subgroups from a Phase&#160;3 study of sapacitabine in elderly patients with AML. Cyclacel&#8217;s strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December&#160;31, 2017, substantially all efforts of the Company to date have been devoted to performing research and development, conducting clinical trials, developing and acquiring intellectual property, raising capital and recruiting and training personnel.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is subject to risks and uncertainties common to early-stage companies in the biopharmaceutical industry, including, but not limited to, drug candidates developed by the Company typically will require approvals or clearances from the FDA, EMA or other similar regulatory agencies in other countries prior to commercial sales. There can be no assurance that the Company&#8217;s drug candidates will receive any of the required approvals or clearances. If the Company was denied approval or clearance or such approval was delayed, or is unable to obtain the necessary financing to complete development and approval, there will be a material adverse impact on the Company&#8217;s financial condition and results of operations. The Company has relied upon government grants to fund its earlier stage programs and does not expect to be able to continue to be successful in obtaining government grants to fund the Company&#8217;s research and development expenditure.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Through December&#160;31, 2017, the Company has funded all of its operations and capital expenditures with proceeds from the issuance of public equity securities, private placements of securities, government grants, research and development tax credits, interest on investments, product revenue and licensing revenue. The Company has incurred recurring losses since its inception, including net losses of&#8201;$11.8&#160;million and $7.5&#160;million for the&#160;years ended December&#160;31, 2016 and 2017, respectively. As of December&#160;31, 2017, the Company had an accumulated deficit of&#8201;$342.5&#160;million. The Company expects to continue to generate operating losses for the foreseeable future due to, among other things, costs related to the clinical development of its drug candidates, its preclinical programs and its administrative organization.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Going Concern</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Management considers that there are no conditions or events, in the aggregate, that raise substantial doubt about the entity&#8217;s ability to continue as a going concern for a period of at
 least one year from the date the financial statements are issued. The Company expects that its cash of&#8201;&#8201;$23.9&#160;million as of December&#160;31, 2017 will be sufficient to fund its operating expenses and capital expenditure requirements through to the end of 2019.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">This evaluation is based on relevant conditions and events that are known and reasonably knowable at the date that the financial statements are issued, including:</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">a.&#160;&#160;&#160;&#160;&#160;The Company&#8217;s current financial condition, including its liquidity sources</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">b.&#160;&#160;&#160;&#160;&#160;The Company&#8217;s conditional and unconditional obligations due or anticipated within one year</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">c.&#160;&#160;&#160;&#160;&#160;The funds necessary to maintain the Company&#8217;s operations considering its current financial condition, obligations, and other expected cash flows, and</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 7.59pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">d.&#160;&#160;&#160;&#160;&#160;Other conditions and events, when considered in conjunction with the above that may adversely affect the Company&#8217;s ability to meet its obligations.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The future viability of the Company beyond 2019 is dependent on its ability to raise additional capital to finance its operations. The Company will need to raise substantial additional capital to pursue the transcriptional regulation program, evaluating CYC065, a CDK inhibitor, in patients with advanced cancers or the DNA damage response program, evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers Additional funding may not be available to the Company on favorable terms, or at all. If the Company is unable to obtain additional funds, it will need to reduce operating expenses, enter into a collaboration or other similar arrangement with respect to development and/or commercialization rights to sapacitabine or its CDK inhibitors, if available, or be forced to delay or reduce the scope of its CDK inhibitors and sapacitabine development programs, including any potential regulatory filings
 related to the SEAMLESS study, and/or limit or cease its operations. The Company&#8217;s inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Reverse Stock Split</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On May&#160;27, 2016, the Company completed a one-for-twelve reverse stock split (the &#8220;Reverse Stock Split&#8221;), which reduced the number of shares of the Company&#8217;s common stock that were issued and outstanding immediately prior to the effectiveness of the Reverse Stock Split. The number of shares of the Company&#8217;s authorized common stock was not affected by the Reverse Stock Split and the par value of Cyclacel&#8217;s common stock remained unchanged at $0.001 per share. The Reverse Stock Split reduced the number of shares of the Company&#8217;s common stock that were outstanding at May&#160;27, 2016 from 36,075,730 to 3,006,311 after the cancellation of fractional shares. No fractional shares were issued in connection with the Reverse Stock Split. Stockholders who otherwise held fractional shares of the Company&#8217;s common stock as a result of the Reverse Stock Split received a cash payment in lieu of such fractional shares. All amounts related to number of shares and per share amounts have been retroactively restated in these consolidated financial statements.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basis of Presentation</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The accompanying consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and include the financial statements of Cyclacel Pharmaceuticals, Inc. and all of the Company&#8217;s wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated. Certain amounts in the prior year&#8217;s financial statements have been reclassified to conform to the current year&#8217;s presentation.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6663710000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">2.&#160;&#160;&#160;&#160;&#160;Summary of Significant Accounting Policies</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Use of Estimates</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals, stock-based compensation expense and the recognition of revenue. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&#8217;s consolidated financial statements.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Foreign Currency and Currency Translation</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive loss.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cash and Cash Equivalents</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s cash and cash equivalents balance at December&#160;31, 2017 was $23.9&#160;million and it maintains its cash accounts in several entities both within the United States and the United Kingdom. The total cash balances for amounts held in the United States are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per account. The Company has cash balances exceeding the balance insured by the FDIC that totaled approximately $23.0&#160;million at December&#160;31, 2017. The total cash balances for amounts held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme (&#8220;FSCS&#8221;) up to &#163;75,000 per account. The Company has cash balances exceeding the balance insured by the FSCS that totaled approximately $0.5&#160;million at December&#160;31, 2017.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and Equipment</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five&#160;years. Amortization of leasehold improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, currently between five and fifteen&#160;years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss. Expenditures for maintenance and repairs are charged to operating expenses as incurred.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Impairment of Long-lived Assets</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair Value of Financial Instruments</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&#8201;&#8212;&#8201;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Segments</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is managed and operated as one business which is focused on using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information with respect to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment with development operations in two geographic areas, namely the United States and the United Kingdom.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Revenue Recognition</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Collaboration, supply and licensing agreements</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Consideration received is allocated to each of the separable elements in an arrangement using the relative selling price method. An element is separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor-specific objective evidence (&#8220;VSOE&#8221;) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. Revenue is recognized for each separate element when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Milestone payments which are non-refundable, non-creditable and contingent on achieving clinical milestones are recognized as revenues either on achievement of such milestones if the milestones are considered substantive or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. When determining if a milestone is substantive, the Company considers the following factors:</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The degree of certainty in achieving the milestone</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The frequency of milestone payments</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company&#8217;s efforts, which result in achievement of the milestone</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The amount of the milestone payment relative to the other deliverables and payment terms, and</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Whether the milestone payment is related to future performance or deliverables</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company records as deferred revenue any amounts received prior to satisfying the revenue recognition criteria. Deferred revenue not expected to be recognized within the next twelve&#160;months is reported as non-current deferred revenue. The Company recognized $0 and $0.2&#160;million deferred revenue as of December&#160;31, 2016 and 2017 respectively. The deferred revenue reported as of December&#160;31, 2017 relates to a prepayment received from ManRos Therapeutics SA for a development milestone that is not expected to be achieved until mid-2018 (see Note 3 for additional details).</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Royalty income is recognized when the licensee sells the underlying product.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Grant revenue</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other Income</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part of the Company&#8217;s ongoing operations and activities.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and Development Expenditures</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development expenses consist primarily of costs associated with the Company&#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Clinical Trial Accounting</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Data management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations (&#8220;CROs&#8221;) or clinical research associates (&#8220;CRAs&#8221;) in accordance with the Company&#8217;s standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are recognized upon execution of the clinical trial agreement and expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Patent Costs</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Patent prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Leased Assets</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The costs of operating leases are charged to operations on a straight-line basis over the lease term. Operating leases relate primarily to the Company&#8217;s research and development facilities and corporate headquarters.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Stock-based Compensation</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over three or four&#160;years. However, certain awards granted to members of the Company&#8217;s Board of Directors vest in their entirety on the one-year anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain&#160;years, the Company granted restricted stock&#160;units to employees that were dependent upon the fulfillment of certain clinical and financial conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes expense in the period that the award becomes probable of vesting (See Note 11&#8201;&#8212;&#8201;Stock-Based Compensation).</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified. The Company accounts for forfeitures as they occur.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of restricted stock and restricted stock&#160;units is determined based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected term of the award, interest rates, and dividend yields.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company relies exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Income Taxes</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue &amp; Customs (&#8220;HMRC&#8221;), the United Kingdom&#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Net Loss Per Common Share</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2016 and 2017.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Comprehensive Income (Loss)</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the&#160;years ended December&#160;31, 2016 and 2017.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Recently Issued Accounting Pronouncements</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July&#160;2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&#8220;ASU 2017-11&#8221;), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2018. Early adoption is permitted, including adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In October&#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August&#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February&#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May&#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&#160;identify the contract with a customer; (2)&#160;identify the performance obligations in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations in the contract; and (5)&#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal&#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company intends to use the modified retrospective method upon adoption of the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817125776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_SignificantContractsDisclosureAbstract', window );"><strong>Significant Contracts Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_SignificantContractsDisclosureTextBlock', window );">Significant Contracts</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">3.&#160;&#160;&#160;&#160;&#160;Significant Contracts</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Distribution, Licensing and Research Agreements</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has entered into licensing agreements with academic and research organizations. Under the terms of these agreements, the Company has received licenses to technology and patent applications. The Company is required to pay royalties on future sales of products employing the technology or falling under claims of patent applications.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The most significant licensing agreement is with Daiichi Sankyo. Pursuant to the Daiichi Sankyo license under which the Company licenses certain patent rights for sapacitabine the Company is under an obligation to use reasonable endeavors to develop a product and obtain regulatory approval to sell a product and has agreed to pay Daiichi Sankyo an up-front fee, reimbursement for Daiichi Sankyo&#8217;s enumerated expenses, milestone payments and royalties on a country-by-country basis. The up-front fee, Phase&#160;3 entry milestone, and certain past reimbursements have been paid. A further $10.0&#160;million in aggregate milestone payments could be payable subject to achievement of all the specific contractual milestones which are primarily related to regulatory approval in various territories, and the Company&#8217;s decision to continue with these projects. Royalties are payable in each country for the term of patent protection in the country or for ten&#160;years following the first commercial sale of licensed products in the country, whichever is later. Royalties are payable on net sales. Net sales are defined as the gross amount invoiced by the Company or its affiliates or licensees, less discounts, credits, taxes, shipping and bad debt losses. The agreement extends from its commencement date to the date on which no further amounts are owed under it. If the Company wishes to appoint a third party to develop or commercialize a sapacitabine-based product in Japan, within certain limitations, Daiichi Sankyo must be notified and given a right of first refusal, with the right of first refusal ending sixty days after notification, to develop and/or commercialize in Japan. In general, the license may be terminated by the Company for technical, scientific, efficacy, safety, or commercial reasons on six&#160;months&#8217; notice, or twelve&#160;months&#8217; notice, if after a launch of a sapacitabine-based product, or by either party for material default. There were no milestones earned in 2016 or 2017.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Collaboration, Supply and Licensing Agreements</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In June&#160;2015, the Company entered into a collaboration, licensing and supply agreement with ManRos Therapeutics SA (&#8220;ManRos&#8221;), for the exclusive development and commercialization of the Company&#8217;s oral seliciclib capsules by ManRos as a treatment for cystic fibrosis (&#8220;CF&#8221;). Among other terms of the agreement, ManRos licensed rights to the Company&#8217;s proprietary clinical data to enable clinical development of seliciclib for CF indications. The agreement provides for supply of seliciclib investigational product for initial and later stage clinical trials of seliciclib in CF and technical assistance related to the Company&#8217;s know-how to facilitate these trials. The Company received an up-front payment in July&#160;2015 and reached a development milestone in September&#160;2015. The Company will receive further milestone payments and tiered royalties, if seliciclib is commercialized for the treatment of CF.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000;
 font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The upfront and milestone payments have been allocated to the separate deliverables within the arrangement and recognized over the period in which the deliverables are met. The consideration allocated to the main deliverable&#8201;&#8212;&#8201;the transfer of the Company&#8217;s know-how&#8201;&#8212;&#8201;was determined based on its estimated standalone selling price, using a market approach that identified similar license deals for a Phase&#160;1/2 asset. The Company reviewed various licensing transactions in the public domain in the CF area and similar stage of asset development. In the year ended December&#160;31, 2016 and 2017, the Company recognized revenue of&#8201;&#8201;$0 and $0, respectively. In the fourth quarter of 2017, the Company received a $150,000 payment from ManRos in anticipation of ManRos achieving a clinical milestone in 2018. This payment has been recorded as deferred revenues on the balance sheet (part of other current liabilities) as the milestone was not achieved as of December&#160;31, 2017.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_SignificantContractsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_SignificantContractsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_SignificantContractsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of significant contracts pursuant to distribution, licensing and research agreements entered by the reporting entity during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_SignificantContractsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6768991376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">4.&#160;&#160;&#160;&#160;&#160;Cash and Cash Equivalents</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of cash and cash equivalents at December&#160;31, 2016 and 2017 (in&#160;thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 79.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Cash</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">5,332</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,103</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.833pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; white-space: normal; padding-top: 2.167pt;">
<div style="text-indent: -10pt; margin-left: 10pt;">Investments with original maturity of less than three&#160;months at the time of purchase</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt;
 white-space: nowrap; padding-top: 2.167pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 10pt;">Total cash and cash equivalents</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">16,520</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">23,910</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Investments with original maturity of less than three&#160;months at time of purchase are made up of money market funds and commercial paper.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for cash and cash equivalent footnotes,  which may include the types of deposits and money market instruments, applicable carrying amounts, restricted amounts and compensating balance arrangements. Cash and equivalents include: (1) currency on hand (2) demand deposits with banks or financial institutions (3) other kinds of accounts that have the general characteristics of demand deposits (4) short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Generally, only investments maturing within three months from the date of acquisition qualify.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -URI http://asc.fasb.org/topic&amp;trid=2122426<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817041952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value of Financial Assets and Liabilities</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">5.&#160;&#160;&#160;&#160;&#160;Fair Value of Financial Assets and Liabilities</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22">
<div style="text-align: center;">Fair Value Measurements&#160;<br />as of December&#160;31, 2016 Using:</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;1</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;2</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;3</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Total</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">Assets:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right;
 padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="margin-left: 10pt;">Cash equivalents</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 20pt;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11,188</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt;
 text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11,188</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22">
<div style="text-align: center;">Fair Value Measurements&#160;<br />as of December&#160;31, 2017 Using:</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;1</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;2</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;3</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Total</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">Assets:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="margin-left: 10pt;">Cash equivalents</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 20pt;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">22,807</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">22,807</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6612799328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">6. &#160;&#160;&#160;&#160;Prepaid Expenses and Other Current Assets</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 11.5pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of prepaid expenses and other current assets at December&#160;31, 2016 and 2017 (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 127.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Research and development tax credit receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,730</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,054</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Prepayments</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">867</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding:
 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">363</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Delaware tax receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">25</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">VAT receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">327</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">409</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Deposits</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">132</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">132</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other current assets</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">41</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">81</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Prepaid expenses and other current assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">3,097</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,064</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represent as Prepaid Expenses and Other Current Assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6706707088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">7.&#160;&#160;&#160;&#160;&#160;Property and Equipment</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and equipment consisted of the following at December&#160;31, 2016 and 2017 (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 113pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 9.25pt; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0pt; padding-top: 0pt;" rowspan="2">
<div style="text-align: center; padding-bottom: 0pt; line-height: 9pt; white-space: nowrap;">Lives in&#160;years</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 0pt; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Leasehold improvements</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.25pt;">
<div style="text-align: right;">5 to 15&#160;</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">792</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">835</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Research and laboratory equipment</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;">
<div style="text-align: right;">3 to 5&#160;</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,438</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,854</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Office equipment and furniture</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;">
<div style="text-align: right;">3 to 5&#160;</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,157</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,236</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6,387</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6,925</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Less: accumulated depreciation and amortization</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(6,342<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(6,896<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0.75pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">45</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">29</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="17">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Depreciation and amortization expense for property and equipment was $0.1&#160;million and $32,000 for the&#160;years ended December&#160;31, 2016 and 2017, respectively. During the year ended December&#160;31, 2016, the Company sold fully depreciated assets for proceeds of approximately $12,000. The Company did not sell any property or equipment during the year ended December&#160;31, 2017.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817193984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">8.&#160;&#160;&#160;&#160;&#160;Accrued and Other Current Liabilities</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Accrued and other current liabilities consisted of the following at December&#160;31, 2016 and 2017 (in&#160;thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 82.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Accrued research and development</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,138</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,645</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Accrued legal and professional fees</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">194</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding:
 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">248</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other current liabilities</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">430</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">662</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,762</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,555</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other current liabilities in 2017 include $150,000 deferred income in respect of payment received in advance of achieving a milestone under the ManRos agreement (see Note 3&#8201;&#8212;&#8201;Significant Contracts).</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817196048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">9.&#160;&#160;&#160;&#160;&#160;Commitments and Contingencies</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">General</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Please refer to&#160;<font style="font-style: italic;">Note 3&#8201;&#8212;&#8201;Significant Contracts</font>&#160;for further discussion of certain of the Company&#8217;s commitments and contingencies.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Leases</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In October&#160;2000, the Company entered into a twenty-five year lease for its research and development facility in Dundee, Scotland. Rent expense, which includes lease payments related to the Company&#8217;s research and development facilities and corporate headquarters and other rent related expenses was $0.5 and $0.5&#160;million for each of the&#160;years ended December&#160;31, 2016 and 2017, respectively.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a summary of the Company&#8217;s future contractual obligations and commitments relating to its facilities leases as at December&#160;31, 2017 (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 123pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Operating Lease&#160;<br />Obligation</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">2018</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">348</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2019</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2020</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2021</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2022</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">343</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">thereafter</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">956</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Total future minimum lease obligations</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,679</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="8">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6806922160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">10.&#160;&#160;&#160;Stockholders&#8217; Equity</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">The Company has completed the following equity issuances during the periods presented in the consolidated financial statements.</font></div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">July&#160;2017 Underwritten Public Offering</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On July&#160;21, 2017, the Company issued (i)&#160;3,154,000 Class&#160;A Units for $2 per unit, each consisting of one share of the Company&#8217;s common stock, and a warrant to purchase one share of common stock (the &#8220;Class&#160;A Warrants&#8221;), and (ii) 8,872 Class&#160;B Units, each consisting of one share of the Company&#8217;s Series&#160;A Convertible Preferred Stock, par value $0.001 per share (the &#8220;Series&#160;A Preferred Stock&#8221;), convertible into 500 shares of Common Stock at the initial conversion price, and a warrant to purchase a number of shares of common stock equal to $1,000.00 divided by the conversion price (the &#8220;Class&#160;B Warrants&#8221;) for $1,000 per unit. The net proceeds to the Company after the underwriters&#8217; exercise in full of the over-allotment option were approximately $13,700,000, after deducting underwriting discounts, commissions and other estimated offering expenses. The Class&#160;A Units and Class&#160;B Units have no stand-alone rights and the shares of common stock, Series&#160;A Preferred Stock and the Class&#160;A and Class&#160;B Warrants comprising those&#160;units were immediately separable.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The common stock, Class&#160;A Warrants and Class&#160;B Warrants (together the &#8220;Warrants&#8221;) and Series&#160;A Preferred Stock are freestanding financial instruments. The Warrants are classified within equity (as a component of additional paid-in capital) in the consolidated balance sheet and are not remeasured on a recurring basis. The Series&#160;A Preferred Stock is classified within permanent equity in the consolidated balance sheet.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The proceeds from the Class&#160;A Units were allocated to common stock and Class&#160;A Warrants on a relative fair value basis. Similarly, the proceeds from the Class&#160;B Units were allocated to the Series&#160;A Preferred Stock and the Class&#160;B Warrants based on their relative fair values. Following the allocation of the offering proceeds associated with the Class&#160;B units, the Company determined that the Series&#160;A Preferred Stock had a beneficial conversion feature with an aggregate intrinsic value of approximately $3,638,000.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As&#160;the Series&#160;A Preferred Stock contained no stated redemption date, and the conversion feature could be exercised at any time, the discount associated with the beneficial conversion feature was immediately charged against additional paid-in capital and treated as a deemed dividend for both financial reporting and earnings per share purposes.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">June&#160;2016 At
 Market Issuance</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On June&#160;23, 2016, the Company entered into an At Market Issuance Sales Agreement (the &#8220;FBR Sales Agreement&#8221;) with FBR Capital Markets &amp; Co. (&#8220;FBR&#8221;), under which the Company was authorized to issue and sell shares of its common stock, from time to time, through FBR, acting as its sales agent. Under the FBR Sales Agreement, FBR was authorized to sell such shares of common stock by any method that is deemed to be an &#8220;at the market offering&#8221;. The Company was not obligated to make any sales of common stock under the FBR Sales Agreement, and the Company was required to pay FBR a commission of 3.0% of the gross proceeds of the sale of any shares of common stock sold through FBR. During the year ended December&#160;31, 2017, the Company sold 183,118 shares of common stock under the FBR Sales agreement for net proceeds of approximately $1.1&#160;million, and the FBR Sales Agreement terminated automatically by its terms.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">July&#160;2015 Controlled Equity Offering SM</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On July&#160;10, 2015, the Company entered into a Controlled Equity Offering<font style="position: relative; bottom: 4.25pt; font-size: 7.5pt;">SM</font>&#160;Sales Agreement with Cantor Fitzgerald (the &#8220;Cantor Sales Agreement&#8221;) under which the Company may, from time to time, sell shares of its common stock having an aggregate offering price of up to $8.35&#160;million through Cantor Fitzgerald. Under the Cantor Sales Agreement, Cantor Fitzgerald may sell shares of Cyclacel common stock by methods deemed to be an &#8220;at-the-market&#8221; offering as defined in Rule&#160;415 promulgated under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;). The Company will pay Cantor Fitzgerald a commission of up to 3.0% of the gross sales price per share sold. Cyclacel is not obligated to make any sales under the Cantor Sales Agreement. Effective as of June&#160;17, 2016, and prior to entering into the FBR Sales Agreement, the Company and Cantor agreed to terminate the Cantor Sales Agreement. The Company had issued an aggregate of 114,078 shares pursuant to the Cantor Sales Agreement of which 41,996 were issued during the year ended December&#160;31, 2016 for net proceeds of approximately $0.2&#160;million.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The following is a description of the Company&#8217;s outstanding equity instruments.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Warrants</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December&#160;31, 2017, there were 7,490,500 warrants outstanding, each with an exercise price of $2.00. All such warrants were issued in connection with the July&#160;2017 Underwritten Public Offering and are immediately exercisable. The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder&#8217;s affiliates, and any persons acting as a group together with such holder or any of such holder&#8217;s affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The exercise price and the number of shares issuable upon exercise of the warrants is subject to appropriate adjustment in the event of recapitalization events, stock dividends, stock splits, stock combinations, reclassifications, reorganizations or similar events affecting the Company&#8217;s common stock. The warrant holders must pay the exercise price in cash upon exercise of the warrants, unless such warrant holders are utilizing the cashless exercise provision of the warrants. On the expiration date, unexercised warrants will automatically be exercised via the
 &#8220;cashless&#8221; exercise provision.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Prior to the exercise of any warrants to purchase common stock, holders of the warrants will not have any of the rights of holders of the common stock purchasable upon exercise, including the right to vote, except as set forth therein.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Warrants exercised during the year ended December&#160;31, 2016 and 2017 were 0 and 99,500 respectively. Gross proceeds during the year for such exercises amounted to $199,000 with a weighted average exercise price of&#8201; $2.00 per share.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Series&#160;A Preferred Stock</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">8,872 shares of the Company&#8217;s Series&#160;A Preferred Stock were issued in the July&#160;2017 Underwritten Public Offering. Each share of Series&#160;A Preferred Stock is convertible at any time at the option of the holder thereof, into a number of shares of common stock determined by dividing $1,000 by the initial conversion price of&#8201; $2.00 per share, subject to a 4.99% blocker provision, or, upon election by a holder prior to the issuance of shares of Series&#160;A Preferred Stock, 9.99%, and is subject to adjustment for stock splits, stock dividends, distributions, subdivisions and combinations.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">During the year ended December&#160;31, 2017, 8,608 shares of the Series&#160;A Preferred Stock were converted into 4,304,000 shares of common stock. As of December&#160;31, 2017, 264 shares of the Series&#160;A Preferred Stock remain issued and outstanding. The 264 shares of Series&#160;A Preferred Stock issued and outstanding at December&#160;31, 2017, are convertible into 132,000 shares of common stock.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In the event of a liquidation, the holders of shares of the Series&#160;A Preferred Stock may participate on an as-converted-to-common-stock basis in any distribution of assets of the Company. The Company shall not pay any dividends on shares of common stock (other than dividends in the form of common stock) unless and until such time as dividends on each share of Series&#160;A Preferred Stock are paid on an as-converted basis. There is no restriction on the Company&#8217;s ability to repurchase shares of Series&#160;A Preferred Stock while there is any arrearage in the payment of dividends on such shares, and there are no sinking fund provisions applicable to the Series&#160;A Preferred Stock.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Subject to certain conditions, at any time following the issuance of the Series&#160;A Preferred Stock, the Company has the right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock in the event that (i)&#160;the volume weighted average price of our common stock for 30 consecutive trading days (the &#8220;Measurement Period&#8221;) exceeds 300% of the initial conversion price of the Series&#160;A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company. The right to cause each holder of the Series&#160;A Preferred Stock to convert all or part of such holder&#8217;s Series&#160;A Preferred Stock shall be exercised ratably among the holders of the then outstanding preferred stock.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal;
 font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Series&#160;A Preferred Stock has no maturity date, will carry the same dividend rights as the common stock, and with certain exceptions contains no voting rights. In the event of any liquidation or dissolution of the Company, the Series&#160;A Preferred Stock ranks senior to the common stock in the distribution of assets, to the extent legally available for distribution.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">6% Convertible Exchangeable Preferred Stock</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">As of December&#160;31, 2017, there were 335,273 shares of the Company&#8217;s 6% Convertible Exchangeable (&#8220;Preferred Stock&#8221;) issued and outstanding at an issue price of&#8201;$10.00 per share. Dividends on the Preferred Stock are cumulative from the date of original issuance at the annual rate of 6% of the liquidation preference of the Preferred Stock, payable quarterly on the first day of February, May, August and November, commencing February&#160;1, 2005. Any dividends must be declared by the Company&#8217;s Board of Directors and must come from funds that are legally available for dividend payments. The Preferred Stock has a liquidation preference of&#8201;$10.00 per share, plus accrued and unpaid dividends.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s Board of Directors considers numerous factors in determining whether to declare the quarterly dividend pursuant to the Certificate of Designations governing the terms of the Company&#8217;s Preferred Stock, including the requisite financial analysis and determination of a surplus. Accrued and unpaid dividends in arrears on preferred stock were $0.7&#160;million, or $1.95 per share, of preferred stock, as of December&#160;31, 2016 and 2017.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Preferred Stock is convertible at the option of the holder at any time into the Company&#8217;s shares of common stock at a conversion rate of approximately 0.00507 shares of common stock for each share of Preferred Stock based on a price of&#8201;&#8201;$1,974. The Company has reserved 1,698 shares of common stock for issuance upon conversion of the remaining shares of Preferred Stock outstanding at December&#160;31, 2016. The shares of previously-converted Preferred Stock have been retired, cancelled and restored to the status of authorized but unissued shares of preferred stock, subject to reissuance by the Board of Directors as shares of Preferred Stock of one or more series.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company may automatically convert the Preferred Stock into common stock if the closing price of the Company&#8217;s common stock has exceeded $2,961, which is 150% of the conversion price of the Preferred Stock, for at least 20 trading days during any 30-day trading period, ending within five trading days prior to notice of automatic conversion.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Certificate of Designations governing the Preferred Stock provides that if the Company fails to pay dividends on its Preferred Stock for six quarterly periods, holders of Preferred Stock are entitled to nominate and elect two directors to the Company&#8217;s Board of Directors. This right accrued to the holders of Preferred Stock as of August&#160;2, 2010 and two directors were nominated and elected at the annual meeting held on May&#160;24, 2011.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Preferred Stock has no maturity date and no voting rights prior to conversion into common stock, except under limited circumstances.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal;
 -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company may, at its option, redeem the Preferred Stock in whole or in part, out of funds legally available at the redemption price of&#8201;$10.00 per share.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Preferred Stock is exchangeable, in whole but not in part, at the option of the Company on any dividend payment date beginning on November&#160;1, 2005 (the &#8220;Exchange Date&#8221;) for the Company&#8217;s 6% Convertible Subordinated Debentures (&#8220;Debentures&#8221;) at the rate of&#8201;&#8201;&#8201;&#8201; $10.00 principal amount of Debentures for each share of Preferred Stock. The Debentures, if issued, will mature 25&#160;years after the Exchange Date and have terms substantially similar to those of the Preferred Stock. No such exchanges have taken place as of December&#160;31, 2017.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">For the year ended December&#160;31, 2017, the company declared dividends of&#8201;$0.15 per share quarterly on its Preferred Stock. These dividends were paid on May&#160;1, August&#160;1 and November&#160;1, 2017, and February&#160;1, 2018, respectively.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Common Stock</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Exercise of Stock Options</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">No stock options were exercised during the&#160;years ended December&#160;31, 2016 and 2017.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6706713840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<div style="text-align: left; line-height: 11pt; margin-top: 0pt; white-space: nowrap; margin-bottom: 0pt; float: left; font-weight: bold;">11.&#160;&#160;&#160;Stock-Based Compensation</div>
<div style="line-height: 0pt; margin: 0pt; clear: both; font-size: 0pt; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">Stock based compensation has been reported within the following expense line items on the consolidated statement of operations for the&#160;years ended 2016 and 2017, as shown in the following table (in&#160;thousands):</div>
<table style="margin-top: 8pt; width: 416pt; border-collapse: collapse; height: 72pt; margin-left: 20pt;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Year Ended&#160;<br />December&#160;31,&#160;<br />2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Year Ended&#160;<br />December&#160;31,&#160;<br />2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Research and development</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">305</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">72</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">General and administrative</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">477</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">194</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Stock-based compensation costs before income taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt;
 padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">782</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">266</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 11pt; font-style: italic; margin-top: 18.78pt; font-weight: bold;">2015 Plan</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">On May&#160;22, 2015, the Company&#8217;s stockholders approved the 2015 Equity Incentive Plan (the &#8220;2015 Plan&#8221;), under which Cyclacel may make equity incentive grants to its officers, employees, directors and consultants. The company has reserved 458,753 shares of the Company&#8217;s common stock under the 2015 Plan. The 2015 Plan replaces the 2006 Equity Incentive Plan (the &#8220;2006 Plan&#8221;), under which there were no remaining reserved shares to be granted. Stock option awards granted under the Company&#8217;s equity incentive plans have a maximum life of 10&#160;years and generally vest over a one to four-year period from the date of grant.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">During 2016, the Company granted 197,841 options to employees and directors with a grant date fair value of approximately $0.7&#160;million. Of these options, 189,091 are performance based, which will vest upon the fulfilment of certain clinical conditions and will terminate if they have not vested by December&#160;31, 2020. The Company determined that the satisfaction of the vesting criteria was not probable throughout 2016 and 2017 and, as a result, did not record any expense related to these awards for the&#160;years ended December&#160;31, 2016 and 2017.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">There were 170,853 options granted during the year ended December&#160;31, 2017. Of these options, 158,853 are performance based, which will vest upon the fulfillment of certain clinical conditions. The Company determined that the satisfaction of one of the conditions was probable as of December&#160;31, 2017, but that the other vesting criteria related to these awards were not probable as of December&#160;31, 2017. As such, the Company recognized compensation cost for these grants under the expectation that 25% of these awards will vest.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">The weighted average grant-date fair values of options granted during the&#160;years ended December&#160;31, 2016 and 2017 were $3.66 and $1.59, respectively.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">As of December&#160;31, 2017, the total remaining unrecognized compensation cost related to the non-vested stock options with service conditions amounted to approximately $0.2&#160;million, which will be amortized over the weighted-average remaining requisite service period of 0.9&#160;years.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">During the&#160;years ended December&#160;31, 2016 and 2017, the Company did not settle any equity instruments with cash.</div>
<div style="line-height: 12pt; margin-top: 6pt; text-indent: 20pt;">There were no stock option exercises during the&#160;years ended 2016 and 2017. No income tax benefits were recorded for the&#160;years ended December&#160;31, 2016 and 2017 because the Company has accumulated net operating losses for tax purposes and is not likely to benefit from any deductions associated with exercises of granted option awards.</div>
<div style="line-height: 11pt; font-style: italic; margin-top: 12pt;">Outstanding Options</div>
<div style="line-height: 12pt; margin-top: 6pt; margin-left: 20pt;">A summary of the share option activity and related information is as follows:</div>
<table style="margin-top: 8pt; width: 456pt; border-collapse: collapse; height: 211.5pt;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Number of&#160;<br />Options&#160;<br />Outstanding</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Weighted&#160;<br />Average&#160;<br />Exercise Price&#160;<br />Per Share</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Weighted&#160;<br />Average&#160;<br />Remaining&#160;<br />Contractual&#160;<br />Term (Years)</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Aggregate&#160;<br />Intrinsic&#160;<br />Value
 ($000s)</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2015</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">206,298</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">72.60</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.09</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Granted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">197,841</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4.68</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Exercised</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top:
 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Cancelled/forfeited</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(14,760<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">396.83</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2016</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">389,379</td>
<td style="padding-bottom: 0pt;
 padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">25.80</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">5.83</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">121</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Granted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">170,853</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1.93</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Exercised</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt;
 padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Cancelled/forfeited</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(24,615<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">179.92</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2017</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">535,617</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11.10</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt;
 padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.23</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Unvested at December&#160;31, 2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">386,682</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">3.64</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.84</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Vested and exercisable at December&#160;31, 2017</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">148,755</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">30.49</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6.65</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table>
</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of the stock options granted is calculated using the Black-Scholes option-pricing model using the following assumptions:</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 456pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 92.5pt; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 0pt;">
<div style="text-align: center;">Year ended&#160;<br />December&#160;31, 2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 0pt;">
<div style="text-align: center;">Year ended&#160;<br />December&#160;31, 2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Expected term (years)</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="text-align: center;">5&#8201;&#8211;&#8201;6</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="text-align: center;">6</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Risk free interest rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">1.370%&#8201;&#8211;&#8201;1.500%</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">1.890%&#8201;&#8211;&#8201;2.265%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Volatility</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">98%&#8201;&#8211;&#8201;104%</div>
</td>
<td style="width: 6pt;
 padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">108%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Expected dividend yield over expected term</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">0.00%</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">0.00%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Resulting weighted average grant date fair value</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">$3.66</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">$1.59</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817061520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plans</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">12.&#160;&#160;&#160;&#160;Employee Benefit Plans</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Pension Plan</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company operates a defined contribution group personal pension plan for all of its UK based employees. Company contributions to the plan totaled approximately $57,000 and $54,000 for the&#160;years ended December&#160;31, 2016 and 2017, respectively.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">401(k) Plan</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The 401(k) Plan provides for matching contributions by the Company in an amount equal to the lesser of 100% of the employee&#8217;s deferral or 6% of the U.S. employee&#8217;s qualifying compensation. The 401(k) Plan is intended to qualify under Section&#160;401(k) of the Internal Revenue Code, so that contributions to the 401(k) Plan by employees or by the Company, and the investment earnings thereon, are not taxable to the employees until withdrawn. Company matching contributions are tax deductible by the Company when made. Company employees may elect to reduce their current compensation by up to the statutorily prescribed annual limit of&#8201;&#8201;$18,000 if under 50&#160;years old and $24,000 if over 50&#160;years old and to have those funds contributed to the 401(k) Plan. The Company made contributions of approximately $32,000 and $28,000 to the 401(k) Plan for the&#160;years ended December&#160;31, 2016 and 2017, respectively.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6626929888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Taxes</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">13.&#160;&#160;&#160;&#160;Taxes</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">(Loss) income from continuing operations before taxes is comprised of the following components for the&#160;years ended December&#160;31, 2016 and 2017 (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 67.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Domestic</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(2,011<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(127<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Foreign</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(11,763<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(8,336<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Loss from continuing operations before taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(13,774<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(8,463<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The benefit (provision) for income taxes from continuing operations consists of the following (in&#160;thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;foreign</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,983</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">993</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;total</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Deferred&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Income tax benefit</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has incurred a taxable loss in each of the operating periods since incorporation. The income tax credits of&#8201;$2.0&#160;million and $1.0&#160;million for the&#160;years ended December&#160;31, 2016 and 2017, respectively, represent UK research and development (&#8220;R&amp;D&#8221;) tax credits for expenditures in the United Kingdom that are refundable.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss from continuing operations before income taxes is as follows (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 174.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 3.25pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Loss from continuing operations before taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(13,774<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(8,463<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Income tax expense computed at statutory federal tax rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(4,683<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(2,877<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Disallowed expenses and non-taxable income</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">12</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">3</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Loss surrendered to generate R&amp;D credit</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,945</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">856</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Additional research and development tax relief</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(2,827<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(1,262<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Change in valuation allowance</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">2,029</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(4,487<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Foreign items, including change in tax rates, and other</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,238</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,901</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Change in US Tax Rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,112</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other foreign items</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">303</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">761</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(1,983<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(993<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 10.59pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On December&#160;22, 2017, the United States enacted the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;), which made significant changes to U.S. federal income tax law. The Company expects that certain aspects of the Tax Act will positively impact the Company&#8217;s future after-tax earnings in the U.S., primarily due to the lower federal statutory tax rate. Set forth below is a discussion of certain provisions of the Tax Act and our preliminary assessment of the effect of such provisions on the Company&#8217;s results of operations, cash flows and consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Tax Act will affect 2018 and forward, including but not limited to a reduction in the federal corporate rate from 35.0% to 21.0%, elimination of the corporate alternative minimum tax, a new limitation on the deductibility of certain executive compensation, limitations on net operating losses generated after December&#160;31, 2017 and various other items. We do not expect these changes to have a material impact on our financial statements due to the accumulated net operating losses in the U.S.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Tax Act provides for a one-time &#8220;deemed repatriation&#8221; of accumulated unrepatriated foreign earnings determined as of November&#160;2, 2017, or December&#160;31, 2017, whichever is greater. We do not expect to be subject to this provision due to the accumulated deficit in our foreign earnings for tax purposes. The Tax Act also created a new requirement that certain income earned by controlled foreign corporations must be included currently in the gross income of the U.S. shareholder under the Global Intangible Low-Taxed Income (GILTI) provision. We do not expect that any future foreign earnings will be subject to GILTI due to our US net operating losses.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In December&#160;2017, the SEC staff issued Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;), which addresses how a company recognizes provisional amounts when a company does not have the necessary information available, prepared or analyzed (including computations) in reasonable detail to complete its accounting for the effect of the changes in the Act. SAB 118 provides for a measurement period that should not extend beyond one year from the Act enactment date for companies to complete the accounting under Accounting Standards Codification Topic 740, Income Taxes (&#8220;ASC 740&#8221;). In accordance with SAB 118, a company must reflect the income tax effects of those aspects of the Act for which the accounting under ASC 740 is complete. To the extent that a company&#8217;s accounting for certain income tax effects of the Tax Act is incomplete but it is able to determine a reasonable estimate, it must record a provisional estimate to be included in the financial statements. If a company cannot determine a provisional estimate to be included in the financial statements, it should continue to apply ASC 740 on the basis of the provision of the tax laws that were in effect immediately before the enactment of the Act. Based on our initial analysis of the Tax Act, the Company has made reasonable estimates of its 2017 impact. As a result of the federal corporate tax rate reduction from 35% to 21%, we re-measured certain deferred tax assets and liabilities, which resulted in a reduction in our DTA of approximately $4.1&#160;million, that was offset by a decrease in our valuation allowance. As guidance and technical corrections, if any, are provided in the upcoming quarters, the Company will adjust its provisional estimates as required.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The primary difference between the income tax benefit at the statutory rate and the Company&#8217;s effective income tax expense for the year ended December&#160;31, 2017 was primarily attributable to the change in our valuation allowance and foreign operations.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Significant components of the Company&#8217;s deferred tax assets are shown below (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 143pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Net operating loss and tax credit carryforwards</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">42,851</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">38,948</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Depreciation, amortization and impairment of property and equipment</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">137</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">111</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Stock options</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">2,365</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,807</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Research and development credits</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,021</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,021</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Deferred tax assets</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">49,374</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">44,887</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Valuation allowance for deferred tax assets</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(49,374<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(44,887<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Net deferred tax assets</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 10.8pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Deferred income taxes reflect the net tax effect of temporary differences between the carrying amounts of assets and liabilities for financial reporting and tax purposes. The Company adopted a 17% tax rate as of December&#160;31, 2017 in respect of the measurement of deferred taxes arising in the United Kingdom, which reflects the currently enacted tax rate and the anticipated timing of the unwinding of the deferred tax balances. In respect of the measurement of deferred taxes arising in the U.S, the Company has adopted a 21% tax rate as of December&#160;31, 2017. This has reduced from 34% as of December&#160;31, 2016 due to changes in U.S. tax laws enacted in December&#160;2017. The effect of the change in tax rates on the consolidated statement of operations is $nil, after consideration of the change in valuation allowance.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">A valuation allowance has been established, as realization of such assets is uncertain. The Company&#8217;s management evaluated the positive and negative evidence bearing upon the realizability of its deferred assets, and has determined that, at present, the Company may not be able to recognize the benefits of the deferred tax assets under the more likely than not criteria. Accordingly, a valuation allowance of approximately $44.9&#160;million has been established at December&#160;31, 2017. The valuation allowance has decreased by approximately $4.5&#160;million in 2017.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In certain circumstances, as specified in the Tax Reform Act of 1986, due to ownership changes, the Company&#8217;s ability to utilize its net operating loss (&#8220;NOL&#8221;) carryforwards may be limited. The benefit of deductions from the exercise of stock options is included in the NOL carryforwards. As of December&#160;31, 2016 and 2017, the Company had federal NOLs of&#8201;$28.4&#160;million and $28.4&#160;million and foreign NOLs of&#8201;$178.2&#160;million and $186.2&#160;million, respectively. The Company&#8217;s federal NOLs will start to expire in 2026, and the state NOLs totaling $18.7&#160;million will start expiring in 2023. The Company&#8217;s foreign NOL&#8217;s do not expire under UK tax law. However, for losses created after April&#160;1, 2017 the use of these NOLs is restricted to an annual &#163;5&#160;million allowance in each standalone company or group and above this allowance, there will be a 50% restriction in the profits that can be covered by losses brought forward. The amount of profits restricted for the year ended December&#160;31, 2017 is $0. As of December&#160;31, 2017, the Company had a US&#160;R&amp;D credit carryforward of&#8201;$4.0&#160;million which will start expiring in 2019.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Utilization of the NOLs may be subject to a substantial annual limitation under Section&#160;382 of the Internal Revenue Code of 1986 due to ownership change limitations that have occurred previously or that could occur in the future. These ownership changes may limit the amount of NOL and R&amp;D credit carryforwards that can be utilized annually to offset future taxable income and tax, respectively. The Company completed a Section&#160;382 study as of June&#160;30, 2014 noting there was no ownership change&#160;from the Company&#8217;s formation through that date. No update to this study has been performed through December&#160;31, 2017. Management has evaluated all significant tax positions at December&#160;31, 2016 and 2017 and concluded that there are no material uncertain tax positions. The Company would recognize both interest and penalties related to unrecognized benefits in income tax expense. The Company has not recorded any interest and penalties on any unrecognized tax benefits since its inception.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Tax year 2016 remains open to examination by major taxing jurisdictions to which the Company is subject, which are primarily in the United Kingdom and the United States, as carryforward attributes generated in&#160;years past may still be adjusted upon examination by the United Kingdom&#8217;s H.M. Revenue &amp; Customs, the Internal Revenue Service (&#8220;IRS&#8221;) or state tax authorities. The Company is currently not under examination by the IRS or any other jurisdictions for any tax&#160;years.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">We have not provided a deferred tax liability on the cumulative amount of unremitted foreign earnings of international subsidiaries because it is our intent to permanently reinvest such earnings outside of the United States.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company has an aggregate deficit in foreign earnings and therefore has not provided any deferred tax liability on its outside book-tax basis difference in its foreign subsidiaries and because it is also our intent to permanently reinvest any earnings outside of the United States. We would recognize this deferred tax liability if we were to experience a change in circumstances producing a change in that intention. As a result of the repeal of the Section&#160;902 foreign tax credit under the Tax Act, future distributions would not be offset by a foreign tax credit.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817211456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">14.&#160;&#160;&#160;&#160;Net Loss Per Share</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Basic and diluted net loss per share attributable to common stockholders was calculated as follows:</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 162pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Years ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Numerator:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="margin-left: 10pt;">Net loss</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(11,791<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right:
 0pt; white-space: nowrap; padding-top: 3pt;">(7,470<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Dividend on convertible exchangeable preferred shares</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(200<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(201<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Beneficial conversion feature of Series&#160;A convertible stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(3,638<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Conversion of Series&#160;A convertible preferred stock</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(3,537<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Net loss attributable to common shareholders</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(11,991<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align:
 right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(14,846<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.25pt;">Denominator:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.333pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; white-space: normal; padding-top: 1.667pt;">
<div style="text-indent: -10pt; margin-left: 20pt;">Weighted-average number of common shares used in loss per share&#160;&#8211; basic and diluted</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;">3,424,976</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;">7,631,152</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Loss per share&#8201;&#8211;&#8201;basic and diluted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(3.50<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(1.95<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 13.49pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Potential dilutive securities have been excluded from the computation of diluted net loss per share as the effect would be to reduce the net loss per share. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders
 is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at each period end, from the computation of diluted net loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 12pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 91.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Stock options</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">389,378</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">535,616</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Convertible preferred stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">1,698</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">1,698</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Series&#160;A preferred stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top:
 3pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">132,000</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Common stock warrants</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">7,490,500</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Total shares excluded from calculation</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">391,076</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">8,159,814</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6661486080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Geographic Information</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">15.&#160;&#160;&#160;&#160;Geographic Information</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Geographic information for the&#160;years ended December&#160;31, 2016 and 2017 is as follows (in thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 128pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Revenue</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">843</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt;
 padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Revenue</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">843</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;">Net loss</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(2,211<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(127<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width:
 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(9,580<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(7,343<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Net Loss</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(11,791<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(7,470<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 142pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Total Assets</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt;
 padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">15,197</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">23,522</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">4,465</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">2,481</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">19,662</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">26,003</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;">Long Lived Assets, net</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt;
 padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">2</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">0</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">43</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">29</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Long Lived Assets, net</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">45</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">29</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662138480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><div style="text-align: left; line-height: 11pt; widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; float: left; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">16.&#160;&#160;&#160;&#160;Subsequent Events</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">On March&#160;7, 2018, the Board of Directors declared a quarterly cash dividend in the amount of&#8201;&#8201;$0.15 per share on the Company&#8217;s Preferred Stock. The cash dividend is due to be paid on May&#160;1, 2018 to the holders of record of the Preferred Stock as of the close of business on April&#160;11, 2018.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826300464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Use of Estimates</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities and related disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Critical estimates include inputs used to determine clinical trial accruals, stock-based compensation expense and the recognition of revenue. Cyclacel reviews its estimates on an ongoing basis. The estimates are based on historical experience and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results may differ from these estimates. Cyclacel believes the judgments and estimates required by the following accounting policies to be significant in the preparation of the Company&#8217;s consolidated financial statements.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency and Currency Translation</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Foreign Currency and Currency Translation</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Transactions that are denominated in a foreign currency are remeasured into the functional currency at the current exchange rate on the date of the transaction. Any foreign currency-denominated monetary assets and liabilities are subsequently remeasured at current exchange rates, with gains or losses recognized as foreign exchange (losses) gains in the statement of operations.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The assets and liabilities of the Company&#8217;s international subsidiary are translated from its functional currency into United States dollars at exchange rates prevailing at the balance sheet date. Average rates of exchange during the period are used to translate the statement of operations, while historical rates of exchange are used to translate any equity transactions. Translation adjustments arising on consolidation due to differences between average rates and balance sheet rates, as well as unrealized foreign exchange gains or losses arising from translation of intercompany loans that are of a long-term-investment nature, are recorded in other comprehensive loss.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Cash and Cash Equivalents</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash and cash equivalents. The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the time of initial purchase to be cash equivalents. The objectives of the Company&#8217;s cash management policy are to safeguard and preserve funds, to maintain liquidity sufficient to meet Cyclacel&#8217;s cash flow requirements and to attain a market rate of return. The Company deposits its cash in financial institutions that it believes have high credit quality and has not experienced any losses on such accounts and does not believe it is exposed to any significant credit risk on cash and cash equivalents.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company&#8217;s cash and cash equivalents balance at December&#160;31, 2017 was $23.9&#160;million and it maintains its cash accounts in several entities both within the United States and the United Kingdom. The total cash balances for amounts held in the United States are insured by the Federal Deposit Insurance Corporation (&#8220;FDIC&#8221;) up to $250,000 per account. The Company has cash balances exceeding the balance insured by the FDIC that totaled approximately $23.0&#160;million at December&#160;31, 2017. The total cash balances for amounts held in the United Kingdom are insured by the UK Government Financial Services Compensation Scheme (&#8220;FSCS&#8221;) up to &#163;75,000 per account. The Company has cash balances exceeding the balance insured by the FSCS that totaled approximately $0.5&#160;million at December&#160;31, 2017.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Property and Equipment</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The components of property and equipment are stated at cost and depreciated on a straight-line basis over the estimated useful lives of the related assets, which are generally three to five&#160;years. Amortization of leasehold improvements is performed using the straight-line method over the shorter of the remaining lease term or the estimated useful life of the related assets, currently between five and fifteen&#160;years. Upon sale or retirement of assets, the costs and related accumulated depreciation and amortization are removed from the balance sheet and the resulting gain or loss on sale is reflected as a component of operating income or loss. Expenditures for maintenance and repairs are charged to operating expenses as incurred.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Impairment of Long-lived Assets</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company reviews property and equipment for impairment whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable. The Company assesses the recoverability of the potentially affected long-lived assets by determining whether the carrying value of such assets can be recovered through undiscounted future operating cash flows.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Impairment, if any, is measured as the amount by which the carrying amount of a long-lived asset (or asset group) exceeds its fair value.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair Value of Financial Instruments</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. Assets and liabilities measured at fair value are classified and disclosed in one of the following three levels of the fair value hierarchy, of which the first two are considered observable and the last is considered unobservable:</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;1&#8201;&#8212;&#8201;Quoted prices in active markets for identical assets or liabilities.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;2&#8201;&#8212;&#8201;Observable inputs (other than Level&#160;1 quoted prices), such as quoted prices in active markets for similar assets or liabilities, quoted prices in markets that are not active for identical or similar assets or liabilities, or other inputs that are observable or can be corroborated by observable market data.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: nowrap; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Level&#160;3&#8201;&#8212;&#8201;Unobservable inputs that are supported by little or no market activity that are significant to determining the fair value of the assets or liabilities, including pricing models, discounted cash flow methodologies and similar techniques.</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The carrying values of cash and cash equivalents, other receivables, accounts payable and accrued expenses approximate their fair values due to the short-term nature of these assets and liabilities.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Segments</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company is managed and operated as one business which is focused on using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and other proliferative diseases. The entire business is managed by a single management team that reports to the Chief Executive Officer. The Company does not operate separate lines of business with respect to any of its products or product candidates and the Company does not prepare discrete financial information with respect to separate products or product candidates or by location. Accordingly, the Company views its business as one reportable operating segment with development operations in two geographic areas, namely the United States and the United Kingdom.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Revenue Recognition</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Collaboration, supply and licensing agreements</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Consideration received is allocated to each of the separable elements in an arrangement using the relative selling price method. An element is separable if it has value to the customer on a stand-alone basis. The selling price used for each separable element will be based on vendor-specific objective evidence (&#8220;VSOE&#8221;) if available, third party evidence if VSOE is not available, or estimated selling price if neither VSOE nor third party evidence is available. The best estimate of the selling price is determined after considering all reasonably available information, including market data and conditions, entity-specific factors such as the cost structure of the deliverable and internal profit and pricing objectives. Revenue is recognized for each separate element when persuasive evidence of an arrangement exists; delivery has occurred or services have been rendered; the fee is fixed or determinable; and collectability is reasonably assured.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Milestone payments which are non-refundable, non-creditable and contingent on achieving clinical milestones are recognized as revenues either on achievement of such milestones if the milestones are considered substantive or over the period the Company has continuing performance obligations, if the milestones are not considered substantive. When determining if a milestone is substantive, the Company considers the following factors:</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The degree of certainty in achieving the milestone</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The frequency of milestone payments</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company&#8217;s efforts, which result in achievement of the milestone</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px;
 font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The amount of the milestone payment relative to the other deliverables and payment terms, and</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="text-align: left; line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 8.98pt; text-indent: -20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; margin-bottom: 0pt; letter-spacing: normal; color: #000000; margin-left: 40pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">&#8226;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Whether the milestone payment is related to future performance or deliverables</div>
<div style="line-height: 0pt; widows: 2; text-transform: none; font-style: normal; text-indent: 0px; margin: 0pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; clear: both; font-size: 0pt; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial; padding: 0pt;">&#160;</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company records as deferred revenue any amounts received prior to satisfying the revenue recognition criteria. Deferred revenue not expected to be recognized within the next twelve&#160;months is reported as non-current deferred revenue. The Company recognized $0 and $0.2&#160;million deferred revenue as of December&#160;31, 2016 and 2017 respectively. The deferred revenue reported as of December&#160;31, 2017 relates to a prepayment received from ManRos Therapeutics SA for a development milestone that is not expected to be achieved until mid-2018 (see Note 3 for additional details).</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Royalty income is recognized when the licensee sells the underlying product.</div>
<div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 12pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;"><font style="text-decoration: underline;">Grant revenue</font></div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Grant revenues from government agencies and private research foundations are recognized as the related qualified research and development costs are incurred, up to the limit of the prior approval funding amounts. Grant revenues are not refundable.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OtherIncomePolicyTextBlock', window );">Other Income</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other Income</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Other income is primarily related to royalty income received under a historical Asset Purchase Agreement for activities which are not part of the Company&#8217;s ongoing operations and activities.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenditures</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and Development Expenditures</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Research and development expenses consist primarily of costs associated with the Company&#8217;s product candidates, upfront fees, milestones, compensation and other expenses for research and development personnel, supplies and development materials, costs for consultants and related contract research, facility costs and depreciation. Expenditures relating to research and development are expensed as incurred.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ClinicalTrialAccountingPolicyTextBlock', window );">Clinical Trial Accounting</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Clinical Trial Accounting</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Data management and monitoring of the Company&#8217;s clinical trials are performed with the assistance of contract research organizations (&#8220;CROs&#8221;) or clinical research associates (&#8220;CRAs&#8221;) in accordance with the Company&#8217;s standard operating procedures. Typically, CROs and CRAs bill monthly for services performed, and others bill based upon milestones achieved. For outstanding amounts, the Company accrues unbilled clinical trial expenses based on estimates of the level of services performed each period. Costs of setting up clinical trial sites for participation in the trials are recognized upon execution of the clinical trial agreement and expensed immediately as research and development expenses. Clinical trial costs related to patient enrollment are accrued as patients are entered into and progress through the trial.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PatentCostsPolicyTextBlock', window );">Patent Costs</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Patent Costs</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Patent prosecution costs are charged to general and administrative expenses as incurred as recoverability of such expenditure is uncertain.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leased Assets</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Leased Assets</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The costs of operating leases are charged to operations on a straight-line basis over the lease term. Operating leases relate primarily to the Company&#8217;s research and development facilities and corporate headquarters.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Compensation</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Stock-based Compensation</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company measures all stock options and other stock-based awards granted to employees and directors based on the fair value on the date of the grant and recognizes compensation expense of those awards, over the requisite service period, which for the Company is the period between the grant date and the date the award vests or becomes exercisable. Most of the awards granted by the Company (and still outstanding) vest ratably over three or four&#160;years. However, certain awards granted to members of the Company&#8217;s Board of Directors vest in their entirety on the one-year anniversary following the date of grant. Generally, the Company issues stock options and restricted stock awards to employees with only service-based vesting conditions and records the expense for these awards using the straight-line method. However, in certain&#160;years, the Company granted restricted stock&#160;units to employees that were dependent upon the fulfillment of certain clinical and financial conditions. In such instances where the performance condition must be met for the award to vest, the company only recognizes expense in the period that the award becomes probable of vesting (See Note 11&#8201;&#8212;&#8201;Stock-Based Compensation).</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company classifies stock-based compensation expense in its statement of operations in the same manner in which the award recipient&#8217;s payroll costs are classified. The Company accounts for forfeitures as they occur.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The fair value of restricted stock and restricted stock&#160;units is determined based on the number of shares granted and the quoted price of the Company&#8217;s common stock on the date of grant. The determination of grant-date fair value for stock option awards is estimated using the Black-Scholes model, which includes variables such as the expected volatility of the Company&#8217;s share price, expected term of the award, interest rates, and dividend yields.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company relies exclusively on its historical volatility as an input to the option pricing model as management believes that this rate will be representative of future volatility over the expected term of the options.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The expected term assumption is estimated using past history of early exercise behavior and expectations about future behaviors.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The weighted average risk-free interest rate represents interest rate for treasury constant maturities published by the Federal Reserve Board. If the term of available treasury constant maturity instruments is not equal to the expected term of an employee option, Cyclacel uses the weighted average of the two Federal Reserve securities closest to the expected term of the employee option.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The expected dividend yield is based on the fact that the Company has never paid cash dividends on common stock and does not expect to pay any cash dividends in the foreseeable future.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Income Taxes</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for income taxes using the liability method. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to affect taxable income. Valuation allowances are established when necessary to reduce deferred tax assets to the amounts expected to be realized.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company accounts for uncertainty in income taxes recognized in the financial statements by applying a two-step process to determine the amount of tax benefit to be recognized. First, the tax position must be evaluated to determine the likelihood that it will be sustained upon external examination by the taxing authorities. If the tax position is deemed more-likely-than-not to be sustained, the tax position is then assessed to determine the amount of benefit to recognize in the financial statements. The amount of the benefit that may be recognized is the largest amount that has a greater than 50% likelihood of being realized upon ultimate settlement. The provision for income taxes includes the effects of any resulting tax reserves, or unrecognized tax benefits, that are considered appropriate as well as the related net interest and penalties.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Credit is taken in the accounting period for research and development tax credits, which will be claimed from H.M. Revenue &amp; Customs (&#8220;HMRC&#8221;), the United Kingdom&#8217;s taxation and customs authority, in respect of qualifying research and development costs incurred in the same accounting period.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Net Loss Per Common Share</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company calculates net loss per common share in accordance with ASC 260 &#8220;Earnings Per Share&#8221; (&#8220;ASC 260&#8221;). Basic and diluted net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted average number of common shares outstanding during the period.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In periods in which the Company reports a net loss attributable to common stockholders, diluted net loss per share attributable to common stockholders is the same as basic net loss per share attributable to common stockholders since dilutive common shares are not assumed to have been issued if their effect is anti-dilutive. The Company reported a net loss attributable to common stockholders for the&#160;years ended December&#160;31, 2016 and 2017.</div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Comprehensive Income (Loss)</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">All components of comprehensive income (loss), including net income (loss), are reported in the financial statements in the period in which they are recognized. Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Net income (loss) and other comprehensive income (loss), including foreign currency translation adjustments, are reported, net of any related tax effect, to arrive at comprehensive income (loss). No taxes were recorded on items of other comprehensive income (loss). There were no reclassifications out of other comprehensive income (loss) during the&#160;years ended December&#160;31, 2016 and 2017.</div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><div style="line-height: 11pt; widows: 2; text-transform: none; font-style: italic; margin-top: 0pt; text-indent: 0px; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: bold; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">Recently Issued Accounting Pronouncements</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In July&#160;2017, the FASB issued Accounting Standards Update (&#8220;ASU&#8221;) No. 2017-11, Accounting for Certain Financial Instruments with Down Round Features (&#8220;ASU 2017-11&#8221;), which simplifies the accounting for certain financial instruments with down-round features. A down round feature is a provision in a financial instrument that reduces the strike price of an issued financial instrument if the issuer sells shares of its stock for an amount less than the currently stated strike price of the issued financial instrument or issues an equity-linked financial instrument with a strike price below the currently stated strike price of the issued financial instrument. ASU 2017-11 is effective for fiscal&#160;years, and interim periods within those fiscal&#160;years, beginning after December&#160;15, 2018. Early adoption is permitted, including adoption in an interim period. ASU 2017-11 should be adopted retrospectively for each prior reporting period presented or retrospectively as of the beginning of the year of adoption. The Company anticipates this standard will not have a material impact on its consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In October&#160;2016, the FASB issued ASU No. 2016-16, Income Taxes (Topic 740): Intra-Entity Transfer of Assets Other than Inventory (&#8220;ASU 2016-16&#8221;), which requires the recognition of the income tax consequences of an intra-entity transfer of an asset, other than inventory, when the transfer occurs. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In August&#160;2016, the FASB issued ASU No. 2016-15, Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments (&#8220;ASU 2016-15&#8221;), to address diversity in practice in how certain cash receipts and cash payments are presented and classified in the statement of cash flows. The standard is effective for annual periods beginning after December&#160;15, 2017, including interim periods within those fiscal&#160;years. This standard will not have a material impact on the company&#8217;s consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In February&#160;2016, the FASB issued guidance on accounting for leases in ASU No, 2016-02. The guidance requires that lessees recognize a lease liability, which is a lessee&#8217;s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee&#8217;s right to use, or control the use of, a specified asset for the lease term at the commencement date. The guidance is effective for fiscal&#160;years beginning after December&#160;15, 2018. Early application is permitted. The guidance must be adopted on a modified retrospective transition approach for leases existing, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The Company is currently evaluating the impact of the guidance on the consolidated financial statements.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">In May&#160;2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606) (&#8220;ASU 2014-09&#8221;), which supersedes existing revenue recognition guidance. The standard&#8217;s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the Company expects to be entitled in exchange for those goods or services. The standard defines a five-step process to achieve this principle; (1)&#160;identify the contract with a customer; (2)&#160;identify the performance obligations in the contract; (3)&#160;determine the transaction price; (4)&#160;allocate the transaction price to the performance obligations in the contract; and (5)&#160;recognize revenue when, or as, the Company satisfies a performance obligation. ASU 2014-09 also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts. The guidance is effective for annual periods beginning after December&#160;15, 2017 and for interim periods within those fiscal&#160;years. ASU 2014-09 was amended by multiple accounting standards updates from 2014-2016.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The Company anticipates this standard will not have a material impact on its consolidated financial statements. The Company currently believes the most significant impact relates to its accounting for revenues related to grants received from government agencies or nonprofit organizations. Under the new standard, the Company expects to report the inflows from the types of grants it typically receives in other income (or in some cases as a contra-expense). Historically, grants have been reported in revenue. As the grantor is not likely to be receiving a good or service in exchange for the payment, the grant cannot be reported in revenue under ASU 2014-09. The Company also expects to recognize revenue associated with contingent milestone-based payments at the time the contingent event is probable to be met, rather than when the milestone is achieved. However, given the limited number of potential milestones owed to Cyclacel, and the inherent risk involved in developing drugs, the timing of revenue recognition associated with contingent milestones is unlikely to be significantly impacted.</div>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 6pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">ASU 2014-09 permits two methods of adoption: retrospectively to each prior reporting period presented (full retrospective method), or retrospectively with the cumulative effect of initially applying the guidance recognized at the date of initial application (the modified retrospective method). The Company intends to use the modified retrospective method upon adoption of the new accounting standard, and does not anticipate recording a material adjustment to opening accumulated deficit as of the date of adoption.</div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ClinicalTrialAccountingPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the entity's accounting policy for clinical trials performed by contract research organizations or clinical research associates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ClinicalTrialAccountingPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_OtherIncomePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for other income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_OtherIncomePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PatentCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes an entity's accounting policy for recognizing and recoverability of patent prosecution costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PatentCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent recently issued accounting pronouncements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_RecentlyIssuedAccountingPronouncementsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13279-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=64802544&amp;loc=d3e202-110218<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817063408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of summary of cash and cash equivalents</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 79.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Cash</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">5,332</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,103</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.833pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; white-space: normal; padding-top: 2.167pt;">
<div style="text-indent: -10pt; margin-left: 10pt;">Investments with original maturity of less than three&#160;months at the time of purchase</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.167pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 1.833pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.167pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 10pt;">Total cash and cash equivalents</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">16,520</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">23,910</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817054448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of financial assets and liabilities measured on a recurring basis</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22">
<div style="text-align: center;">Fair Value Measurements&#160;<br />as of December&#160;31, 2016 Using:</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;1</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;2</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;3</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Total</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">Assets:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="margin-left: 10pt;">Cash equivalents</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td
 style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">11,188</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 20pt;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11,188</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11,188</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 76.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width:
 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="22">
<div style="text-align: center;">Fair Value Measurements&#160;<br />as of December&#160;31, 2017 Using:</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;1</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;2</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Level&#160;3</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">Total</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">Assets:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 15pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="margin-left: 10pt;">Cash equivalents</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt;
 padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 15pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">22,807</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 194pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="margin-left: 20pt;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">22,807</td>
<td style="padding-bottom: 0pt; padding-left: 4.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 15pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#160;&#160;&#160;&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 8.5pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">22,807</td>
<td style="padding-bottom: 0pt; padding-left: 7.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808427616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract', window );"><strong>Prepaid Expenses And Other Current Assets [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock', window );">Schedule of prepaid expenses and other current assets</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 127.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Research and development tax credit receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,730</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,054</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Prepayments</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">867</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">363</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Delaware tax receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top:
 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">25</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">VAT receivable</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">327</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">409</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Deposits</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">132</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">132</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other current assets</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">41</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">81</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Prepaid expenses and other current assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt;
 text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">3,097</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,064</td>
<td style="padding-bottom: 0pt; padding-left: 10.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PrepaidExpensesAndOtherCurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6612801392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of property and equipment</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 113pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 9.25pt; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0pt; padding-top: 0pt;" rowspan="2">
<div style="text-align: center; padding-bottom: 0pt; line-height: 9pt; white-space: nowrap;">Lives in&#160;years</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;" rowspan="2">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; height: 0pt; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Leasehold improvements</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.25pt;">
<div style="text-align: right;">5 to 15&#160;</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">792</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">835</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Research and laboratory equipment</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;">
<div style="text-align: right;">3 to 5&#160;</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,438</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,854</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Office equipment and furniture</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 3.5pt;">
<div style="text-align: right;">3 to 5&#160;</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,157</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,236</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6,387</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6,925</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Less: accumulated depreciation and amortization</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(6,342<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(6,896<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 251.15pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0.75pt; padding-left: 0pt; width: 44.85pt; padding-right: 0.5pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">45</td>
<td style="padding-bottom: 0pt; padding-left: 3.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">29</td>
<td style="padding-bottom: 0pt; padding-left: 6.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="17">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6805097552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of accrued and other current liabilities</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 82.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Accrued research and development</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,138</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,645</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Accrued legal and professional fees</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">194</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">248</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other current liabilities</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right;
 padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">430</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">662</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 308pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,762</td>
<td style="padding-bottom: 0pt; padding-left: 5.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,555</td>
<td style="padding-bottom: 0pt; padding-left: 8.645pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6808107728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of the Company's contractual obligations and commitments relating to its facilities leases</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 123pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Operating Lease&#160;<br />Obligation</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">2018</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">348</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2019</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2020</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2021</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">344</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">2022</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">343</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space:
 nowrap;">thereafter</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">956</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 348.75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Total future minimum lease obligations</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">2,679</td>
<td style="padding-bottom: 0pt; padding-left: 13.77pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="8">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787394608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation Arrangements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of stock based compensation expense</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 72pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Year Ended&#160;<br />December&#160;31,&#160;<br />2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Year Ended&#160;<br />December&#160;31,&#160;<br />2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Research and development</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">305</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">72</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">General and administrative</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">477</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">194</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 290pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Stock-based compensation costs before income taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">782</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom:
 #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">266</td>
<td style="padding-bottom: 0pt; padding-left: 17pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of stock option activity</a></td>
<td class="text"><table style="margin-top: 0pt; width: 456pt; border-collapse: collapse; height: 211.5pt;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Number of&#160;<br />Options&#160;<br />Outstanding</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Weighted&#160;<br />Average&#160;<br />Exercise Price&#160;<br />Per Share</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Weighted&#160;<br />Average&#160;<br />Remaining&#160;<br />Contractual&#160;<br />Term (Years)</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="4">
<div style="text-align: center;">Aggregate&#160;<br />Intrinsic&#160;<br />Value ($000s)</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2015</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">206,298</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">72.60</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.09</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Granted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">197,841</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4.68</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Exercised</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Cancelled/forfeited</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(14,760<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">396.83</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt;
 white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2016</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">389,379</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">25.80</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">5.83</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">121</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Granted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">170,853</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1.93</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom:
 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Exercised</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Cancelled/forfeited</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(24,615<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">179.92</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px
 solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Options outstanding at December&#160;31, 2017</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">535,617</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">11.10</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.23</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #cceeff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Unvested at December&#160;31, 2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">386,682</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">3.64</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 13.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">8.84</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding:
 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #ffffff 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 230.37pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Vested and exercisable at December&#160;31, 2017</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">148,755</td>
<td style="padding-bottom: 0pt; padding-left: 4.22pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">30.49</td>
<td style="padding-bottom: 0pt; padding-left: 7.505pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 13.5pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">6.65</td>
<td style="padding-bottom: 0pt; padding-left: 12.955pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 1.75pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 12.57pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="26">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of fair value of the stock options granted</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 456pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 92.5pt; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: center; text-transform: none; font: bold 8pt/9pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 0pt;">
<div style="text-align: center;">Year ended&#160;<br />December&#160;31, 2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.167pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 0pt;">
<div style="text-align: center;">Year ended&#160;<br />December&#160;31, 2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Expected term (years)</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="text-align: center;">5&#8201;&#8211;&#8201;6</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="text-align: center;">6</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Risk free interest rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">1.370%&#8201;&#8211;&#8201;1.500%</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">1.890%&#8201;&#8211;&#8201;2.265%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Volatility</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">98%&#8201;&#8211;&#8201;104%</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">108%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Expected dividend yield over expected term</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">0.00%</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">0.00%</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 276pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Resulting weighted average grant date fair value</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 75pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">$3.66</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 1.5pt; padding-left: 0pt; width: 81pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="text-align: center;">$1.59</div>
</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662387808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of components of (loss) income before taxes from continuing operations</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 67.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Domestic</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(2,011<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(127<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Foreign</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(11,763<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(8,336<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Loss from continuing operations before taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(13,774<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(8,463<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<div style="line-height: 12pt; widows: 2; text-transform: none; font-style: normal; margin-top: 12.98pt; text-indent: 20pt; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; color: #000000; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">The benefit (provision) for income taxes from continuing operations consists of the following (in&#160;thousands):</div>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 8pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;foreign</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,983</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">993</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;total</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Deferred&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Income tax benefit</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of benefit for income taxes from continuing operations</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 98pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;foreign</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,983</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">993</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Current&#8201;&#8211;&#8201;total</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt;
 padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 17.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 11.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Deferred&#8201;&#8211;&#8201;domestic</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 17.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 11.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Income tax benefit</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 17.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">1,983</td>
<td style="padding-bottom: 0pt; padding-left: 7.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 11.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">993</td>
<td style="padding-bottom: 0pt; padding-left: 14pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of reconciliation of the (benefit) provision for income taxes from continuing operations with the amount computed by applying the statutory federal tax rate to loss before income taxes</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 174.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 3.25pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Loss from continuing operations before taxes</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(13,774<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(8,463<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Income tax expense computed at statutory federal tax rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(4,683<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(2,877<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Disallowed expenses and non-taxable income</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">12</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">3</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Loss surrendered to generate R&amp;D credit</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,945</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">856</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Additional research and development tax relief</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(2,827<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(1,262<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Change in valuation allowance</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">2,029</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(4,487<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Foreign items, including change in tax rates, and other</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,238</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,901</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Change in US Tax Rate</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,112</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other foreign items</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">303</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">761</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 0.75pt; padding-left: 0pt; width: 302pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(1,983<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">(993<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 8.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of significant components of the entity's deferred tax assets</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 143pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2.5pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Net operating loss and tax credit carryforwards</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">42,851</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">38,948</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Depreciation, amortization and impairment of property and equipment</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">137</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">111</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Stock options</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">2,365</td>
<td
 style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">1,807</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Research and development credits</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,021</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">4,021</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Other</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Deferred tax assets</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">49,374</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">44,887</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2.5pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.5pt;">
<div style="white-space: nowrap;">Valuation allowance for deferred tax assets</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td
 style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(49,374<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.5pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.5pt;">(44,887<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 317.5pt; padding-right: 0pt; padding-top: 3.25pt;">
<div style="white-space: nowrap;">Net deferred tax assets</div>
</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 3.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="width: 2.5pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3.25pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3.25pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 4.73pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4pt; height: 4pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662204144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of basic and diluted net loss per share</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 162pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Years ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Numerator:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="margin-left: 10pt;">Net loss</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(11,791<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(7,470<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Dividend on convertible exchangeable preferred shares</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(200<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td
 style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(201<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Beneficial conversion feature of Series&#160;A convertible stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(3,638<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Conversion of Series&#160;A convertible preferred stock</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(3,537<font style="position: absolute;">)</font></td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Net loss attributable to common shareholders</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(11,991<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(14,846<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.25pt;">Denominator:</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td
 style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/12pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 1.333pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; white-space: normal; padding-top: 1.667pt;">
<div style="text-indent: -10pt; margin-left: 20pt;">Weighted-average number of common shares used in loss per share&#160;&#8211; basic and diluted</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;">3,424,976</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; padding-top: 1.667pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 1.333pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 1.667pt;">7,631,152</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Loss per share&#8201;&#8211;&#8201;basic and diluted</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(3.50<font style="position: absolute;">)</font></td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(1.95<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 2.795pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of company's potential anti dilutive securities</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 91.5pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Stock options</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">389,378</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">535,616</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Convertible preferred stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">1,698</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">1,698</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Series&#160;A preferred stock</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 24.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding:
 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 0pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="min-width: 30.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">132,000</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">Common stock warrants</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">7,490,500</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap;">Total shares excluded from calculation</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 24.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">391,076</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 0pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 30.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">8,159,814</td>
<td style="padding-bottom: 0pt; padding-left: 5.295pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817044304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Geographic Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock', window );">Schedule of geographic information</a></td>
<td class="text"><table style="widows: 2; text-transform: none; font-style: normal; margin-top: 0pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 128pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">Year Ended December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Revenue</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">843</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">&#8212;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Revenue</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px
 double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">843</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">&#8212;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;">Net loss</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 23.25pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(2,211<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 19.5pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(127<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(9,580<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">(7,343<font style="position: absolute;">)</font></td>
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif;
 white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Net Loss</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 23.25pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(11,791<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 4.48pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 19.5pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">(7,470<font style="position: absolute;">)</font></td>
<td style="padding-bottom: 0pt; padding-left: 9.98pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table>
<table style="widows: 2; text-transform: none; font-style: normal; margin-top: 13pt; text-indent: 0px; width: 416pt; border-collapse: collapse; font-family: 'times new roman', times, serif; white-space: normal; orphans: 2; letter-spacing: normal; height: 142pt; color: #000000; margin-left: 20pt; font-size: 13px; font-weight: 400; word-spacing: 0px; font-variant-ligatures: normal; font-variant-caps: normal; -webkit-text-stroke-width: 0px; text-decoration-style: initial; text-decoration-color: initial;">
<tr style="text-align: left; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; text-align: center; padding-bottom: 2pt; padding-left: 0pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;" colspan="10">
<div style="text-align: center; white-space: nowrap;">December&#160;31,</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: center; text-transform: none; font: bold 8pt/8pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #ffffff 1px solid; text-align: left; padding-bottom: 0.5pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2016</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #ffffff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;" colspan="4">
<div style="text-align: center; white-space: nowrap;">2017</div>
</td>
<td style="border-bottom: #ffffff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">Total Assets</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap;
 padding-top: 3pt;">15,197</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">23,522</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">4,465</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">2,481</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Assets</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">19,662</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">26,003</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: bold 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 8.25pt;">Long Lived Assets, net</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 0.5pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 1pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United States</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td
 style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">2</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="min-width: 3.75pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">$</td>
<td style="min-width: 21pt; text-align: right; padding-bottom: 1pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">0</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; background-color: #cceeff; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="border-bottom: #cceeff 1px solid; text-align: left; padding-bottom: 2pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 3pt;">
<div style="white-space: nowrap;">United Kingdom</div>
</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">43</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 6pt; padding: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 3pt;">&#160;</td>
<td style="border-bottom: #000000 1px solid; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 3pt;">29</td>
<td style="border-bottom: #cceeff 1px solid; padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #cceeff 1px solid; width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="text-align: right; text-transform: none; font: 10pt/10pt 'times new roman', times, serif; white-space: nowrap; color: #000000; vertical-align: bottom;">
<td style="text-align: left; padding-bottom: 2.75pt; padding-left: 0pt; width: 296pt; padding-right: 0pt; padding-top: 2.75pt;">
<div style="white-space: nowrap; font-weight: bold;">Total Long Lived Assets, net</div>
</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">45</td>
<td style="padding-bottom: 0pt; padding-left: 6.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="width: 6pt; padding: 0pt;">&#160;</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="border-bottom: #000000 3px double; min-width: 3.75pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; padding-top: 2.75pt;">$</td>
<td style="border-bottom: #000000 3px double; min-width: 21pt; text-align: right; padding-bottom: 2pt; padding-left: 0pt; padding-right: 0pt; white-space: nowrap; padding-top: 2.75pt;">29</td>
<td style="padding-bottom: 0pt; padding-left: 9.145pt; width: 0pt; padding-right: 0pt; padding-top: 0pt;">&#160;</td>
<td style="width: 0pt; padding: 0pt;">&#160;</td>
</tr>
<tr style="line-height: 4.5pt; height: 4.5pt;">
<td style="line-height: 0pt; font-size: 0pt; padding: 0pt;" colspan="14">&#160;</td>
</tr>
</table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information concerning material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -URI http://asc.fasb.org/extlink&amp;oid=68060357&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsByGeographicalAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6825984688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization of the Company and Basis of Presentation (Detail Textuals) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>May 27, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization of the Company</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (7,470)<span></span>
</td>
<td class="num">$ (11,791)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(342,509)<span></span>
</td>
<td class="num">(335,039)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,910<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="nump">$ 20,440<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Stockholders' equity, reverse stock split</a></td>
<td class="text">one-for-twelve<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827204256">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Organization of the Company and Basis of Presentation (Detail Textuals 1) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>May 27, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems', window );"><strong>Organization Of Company And Basis Of Presentation Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">11,997,447<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,256,829<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=cycc_BeforeReverseStockSplitMember', window );">Before Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems', window );"><strong>Organization Of Company And Basis Of Presentation Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,075,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=cycc_AfterReverseStockSplitMember', window );">After Reverse Stock Split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems', window );"><strong>Organization Of Company And Basis Of Presentation Line Items</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,006,311<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The line items identify information about the organization of the company and basis of presentation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_OrganizationOfCompanyAndBasisOfPresentationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=cycc_BeforeReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=cycc_BeforeReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=cycc_AfterReverseStockSplitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=cycc_AfterReverseStockSplitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819045536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 23,910,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,520,000<span></span>
</td>
<td class="nump">$ 20,440,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFDICInsuredAmount', window );">Cash balances insured by FDIC</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashUninsuredAmount', window );">Cash exceeding balance insured by FDIC</a></td>
<td class="nump">23,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CashFinancialServicesCompensationSchemeInsuredAmount', window );">Cash balance insured by FSCS | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme', window );">Cash exceeding balance insured by FSCS</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segment</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfCountriesInWhichEntityOperates', window );">Number of geographic areas for development operations | Segment</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember', window );">Property, plant and equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccountingPoliciesLineItems', window );"><strong>Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount of cash balances exceeding the balance insured by the UK Government Financial Services Compensation Scheme.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_CashExceedingBalanceInsuredByFinancialServicesCompensationScheme</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CashFinancialServicesCompensationSchemeInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents information of UK Government Financial Services Compensation Scheme.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_CashFinancialServicesCompensationSchemeInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFDICInsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFDICInsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashUninsuredAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash as of the balance sheet date that is not insured by the Federal Deposit Insurance Corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashUninsuredAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfCountriesInWhichEntityOperates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of countries in which the entity operates as of balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfCountriesInWhichEntityOperates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_PropertyPlantAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6814844992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Contracts (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_CollaborationAndResearchAndDevelopmentRevenue', window );">Collaboration and research and development revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cycc_DaiichiSankyoCompanyLimitedMember', window );">Daiichi Sankyo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_LicenseAgreementPotentialFutureMilestonePayments', window );">Future milestone payments payable</a></td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry', window );">Period for which royalties will be paid following first commercial sale of licensed products</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason', window );">Notice period for termination of license by the entity for technical, scientific, efficacy, safety, or commercial reasons</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault', window );">Notice period for termination of license after launch of a sapacitabine-based product by the entity, or by either party for material default</a></td>
<td class="text">12 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember', window );">ManRos Therapeutics SA ("ManRos") | Collaboration, Supply and Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplyCommitmentLineItems', window );"><strong>Supply Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Payment received from achieving a clinical milestone</a></td>
<td class="nump">$ 150,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_CollaborationAndResearchAndDevelopmentRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represent amount of collaboration and research and development revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_CollaborationAndResearchAndDevelopmentRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for the termination of license after a launch of a sapacitabine-based product, or by either party for material default.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_LicenseAgreementNoticePeriodForTerminationOfAgreementAfterLaunchOfSapacitabineBasedProductOrInCaseOfMaterialDefault</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the period for which royalties will be paid following the first commercial sale of licensed products in the country.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_LicenseAgreementPeriodForRoyaltiesPaymentAfterFirstCommercialSaleOfLicensedProductsInCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_LicenseAgreementPotentialFutureMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The potential future milestone payments required to be made under certain contractual agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_LicenseAgreementPotentialFutureMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the notice period for the termination of license by the reporting entity for technical, scientific, efficacy, safety, or commercial reasons.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_LicensingAgreementNoticePeriodForTerminationOfAgreementDueToTechnicalScientificEfficacySafetyOrCommercialReason</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplyCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplyCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cycc_DaiichiSankyoCompanyLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cycc_DaiichiSankyoCompanyLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cycc_CollaborationSupplyAndLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cycc_CollaborationSupplyAndLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6812974096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cash and Cash Equivalents (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAbstract', window );"><strong>Cash and Cash Equivalents</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 1,103<span></span>
</td>
<td class="nump">$ 5,332<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Investments with original maturity of less than three months at the time of purchase</a></td>
<td class="nump">22,807<span></span>
</td>
<td class="nump">11,188<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Total cash and cash equivalents</a></td>
<td class="nump">$ 23,910<span></span>
</td>
<td class="nump">$ 16,520<span></span>
</td>
<td class="nump">$ 20,440<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827004224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value of Financial Assets and Liabilities (Details) - Recurring basis - Total - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">$ 22,807<span></span>
</td>
<td class="nump">$ 11,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">22,807<span></span>
</td>
<td class="nump">11,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">22,807<span></span>
</td>
<td class="nump">11,188<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">22,807<span></span>
</td>
<td class="nump">11,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosureAbstract', window );"><strong>Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashEquivalentsAtCarryingValue', window );">Cash equivalents</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total Assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827200848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent', window );">Research and development tax credit receivable</a></td>
<td class="nump">$ 1,054<span></span>
</td>
<td class="nump">$ 1,730<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepayments</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">867<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Delaware tax receivable</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValueAddedTaxReceivableCurrent', window );">VAT receivable</a></td>
<td class="nump">409<span></span>
</td>
<td class="nump">327<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepositsAssetsCurrent', window );">Deposits</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">132<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">41<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">$ 2,064<span></span>
</td>
<td class="nump">$ 3,097<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and other tax receivables expected to be realized or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxesAndOtherTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepositsAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value of amounts transferred to third parties for security purposes that are expected to be returned or applied towards payment within one year or during the operating cycle, if shorter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepositsAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValueAddedTaxReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of value added taxes due either from customers arising from sales on credit terms, or as previously overpaid to tax authorities. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValueAddedTaxReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827735328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 6,925<span></span>
</td>
<td class="nump">$ 6,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(6,896)<span></span>
</td>
<td class="num">(6,342)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, Plant and Equipment, Net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 835<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Research and laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 4,854<span></span>
</td>
<td class="nump">4,438<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Research and laboratory equipment | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Research and laboratory equipment | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cycc_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property, plant and equipment, gross</a></td>
<td class="nump">$ 1,236<span></span>
</td>
<td class="nump">$ 1,157<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cycc_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cycc_OfficeEquipmentAndFurnitureMember', window );">Office equipment and furniture | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Lives in years</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=cycc_OfficeEquipmentAndFurnitureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=cycc_OfficeEquipmentAndFurnitureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6650077296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 32,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from sale of asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6765144672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Accrued and Other Current Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccruedResearchAndDevelopmentCostsCurrent', window );">Accrued research and development</a></td>
<td class="nump">$ 1,645<span></span>
</td>
<td class="nump">$ 2,138<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued legal and professional fees</a></td>
<td class="nump">248<span></span>
</td>
<td class="nump">194<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">430<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 2,555<span></span>
</td>
<td class="nump">$ 2,762<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AccruedResearchAndDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the carrying value, as of the balance sheet date, of obligations incurred through that date and payable arising from research and development transactions. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AccruedResearchAndDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6817047632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities (Detail Textuals)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember', window );">ManRos Therapeutics SA ("ManRos") | Collaboration, Supply and Licensing Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AccruedAndOtherCurrentLiabilitiesLineItems', window );"><strong>Accrued And Other Current Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Payment received from achieving a clinical milestone</a></td>
<td class="nump">$ 150,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AccruedAndOtherCurrentLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AccruedAndOtherCurrentLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cycc_ManrosTherapeuticsSaManrosMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=cycc_CollaborationSupplyAndLicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=cycc_CollaborationSupplyAndLicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662376128">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Lease Obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">344<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">343<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">thereafter</a></td>
<td class="nump">956<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease obligations</a></td>
<td class="nump">$ 2,679<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6763052560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Detail Textuals) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2000</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases, related disclosures</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Lease term for research and development facility</a></td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expense, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6828104352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Jul. 21, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,749,000<span></span>
</td>
<td class="nump">$ 6,794,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">132,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight', window );">Price per share used to determine number of shares of common stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AggregateIntrinsicValueOfStock', window );">Aggregate intrinsic value of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,638,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Class A Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per unit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Number of units authorized for issuance and sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,154,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Class A Units | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfSecuritiesCalledByEachUnit', window );">Number of securities called by each unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Number of securities called by each warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Class B Units</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price per unit (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalUnitsAuthorized', window );">Number of units authorized for issuance and sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,872<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Class B Units | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight', window );">Price per share used to determine number of shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Underwritten Public Offering | Ladenburg Thalmann &amp; Co. Inc. | Class B Units | Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfSecuritiesCalledByEachUnit', window );">Number of securities called by each unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AggregateIntrinsicValueOfStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents aggregate intrinsic value of stock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AggregateIntrinsicValueOfStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_NumberOfSecuritiesCalledByEachUnit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each unit may be converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_NumberOfSecuritiesCalledByEachUnit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of securities equivalent price per share called by each warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of authorized capital units or capital shares. This element is relevant to issuers of face-amount certificates and registered investment companies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04.16(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488278&amp;loc=d3e603758-122996<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=cycc_LadenburgThalmannAndCoIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=cycc_LadenburgThalmannAndCoIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalUnitsByClassAxis=us-gaap_CapitalUnitClassBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6810265088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail Textuals 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 23, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_EquitySaleAgreementAxis=cycc_FbrSalesAgreementMember', window );">FBR (the "FBR Sales Agreement")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PercentageOfCommissionOnGrossEquitySales', window );">Percentage of commission on gross equity sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">183,118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Sale of stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PercentageOfCommissionOnGrossEquitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission to be paid on gross sales of common stock under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PercentageOfCommissionOnGrossEquitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_EquitySaleAgreementAxis=cycc_FbrSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_EquitySaleAgreementAxis=cycc_FbrSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815670080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail Textuals 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity securities, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,749<span></span>
</td>
<td class="nump">$ 6,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_AgreementAxis=cycc_ControlledEquityOfferingSalesAgreementMember', window );">Controlled Equity Offering Sales Agreement | Cantor Fitzgerald &amp; Co., ("Cantor")</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_MaximumAmountOfOfferingPriceForCommonStock', window );">Maximum amount of offering price for common stock</a></td>
<td class="nump">$ 8,350<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PercentageOfCommissionOnGrossEquitySales', window );">Percentage of commission on gross equity sales</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock issued</a></td>
<td class="nump">114,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of equity securities, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_MaximumAmountOfOfferingPriceForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents maximum amount of offering price for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_MaximumAmountOfOfferingPriceForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PercentageOfCommissionOnGrossEquitySales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of commission to be paid on gross sales of common stock under the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PercentageOfCommissionOnGrossEquitySales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_AgreementAxis=cycc_ControlledEquityOfferingSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_AgreementAxis=cycc_ControlledEquityOfferingSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cycc_SalesAgentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cycc_SalesAgentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6799721696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail Textuals 3) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstanding', window );">Number of warrant outstanding</a></td>
<td class="nump">$ 7,490,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConditionRelatedToExcercisingWarrants', window );">Condition related to exercising warrants</a></td>
<td class="text">The Warrants expire in 2024. Subject to limited exceptions, a holder of warrants will not have the right to exercise any portion of its warrants if the holder (together with such holder's affiliates, and any persons acting as a group together with such holder or any of such holder's affiliates) would beneficially own a number of shares of common stock in excess of 4.99% (or, at the election of the purchaser, 9.99%) of the shares of our Common Stock then outstanding after giving effect to such exercise.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfWarrantsExercised', window );">Number of warrants exercised</a></td>
<td class="nump">99,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 199,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_WeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConditionRelatedToExcercisingWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents condition related to exercising warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConditionRelatedToExcercisingWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_NumberOfWarrantsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents number of warrants exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_NumberOfWarrantsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_WeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents weighted average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_WeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of outstanding derivative securities that permit the holder the right to purchase securities (usually equity) from the issuer at a specified price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827584448">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Detail Textuals 4) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">8,872<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Number of shares issued upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockSharesConverted1', window );">Number of shares converted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,304,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight', window );">Price per share used to determine number of shares of common stock</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConvertiblePreferredStockConversionPrice', window );">Conversion price of convertible preferred stock</a></td>
<td class="nump">$ 2.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision', window );">Percentage of blocker provision</a></td>
<td class="nump">4.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConvertiblePreferredStockConversionPercentage', window );">Conversion percentage</a></td>
<td class="nump">9.99%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock', window );">Condition related to events occurrence for conversion of preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">(i) the volume weighted average price of our common stock for 30 consecutive trading days (the "Measurement Period") exceeds 300% of the initial conversion price of the Series A Preferred Stock (subject to adjustment for forward and reverse stock splits, recapitalizations, stock dividends and similar transactions), (ii) the daily trading volume on each Trading Day during such Measurement Period exceeds $500,000 per trading day and (iii) the holder is not in possession of any information that constitutes or might constitute, material non-public information which was provided by the Company.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember', window );">6% Convertible Exchangeable preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
<td class="nump">335,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Dividend rate on convertible exchangeable preferred stock (in percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share issue price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockLiquidationPreference', window );">Liquidation preference (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears', window );">Accrued and unpaid dividends in arrears on preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears', window );">Accrued and unpaid dividends in arrears on preferred stock (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
<td class="nump">$ 1.95<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for future issuance upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockConversionBasis', window );">Number of shares to be issued for each preferred stock upon conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">0.00507<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ConvertiblePreferredStockConversionPricePerShare', window );">Conversion price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,974<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,961<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice', window );">Percentage of closing sales price of common stock that conversion price must exceed in order for preferred stock to be convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays', window );">Number of trading days within 30 trading days in which the closing price of common stock must exceed conversion price for preferred stock to be convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockConversionObligationNumberOfTradingDays', window );">Number of trading days during which closing price of common stock must exceed conversion price for at least 20 days in order for the preferred stock to be convertible</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion', window );">Number of trading days prior to notice of automatic conversion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Redemption price per share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate of Convertible Subordinated Debentures (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation', window );">Debt principal amount per share, basis for exchange (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Debt instrument, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">25 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred stock dividend declared, amount per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents condition related to events occurrence for conversion of preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConditionRelatedToEventsOccurenceForConversionOfPreferredStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConvertiblePreferredStockConversionPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of conversion price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConvertiblePreferredStockConversionPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of blocker provision.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConvertiblePreferredStockConversionPercentageBlockerProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConvertiblePreferredStockConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the conversion price of Convertible Preferred Stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConvertiblePreferredStockConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ConvertiblePreferredStockConversionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share of the conversion feature embedded in the convertible preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ConvertiblePreferredStockConversionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of securities equivalent price per share called by each warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_NumberOfSecuritiesEquivalentPricePerShareCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of the closing sales price of the entity's common stock for at least 20 days within 30 trading days that the closing sales price of the entity's common stock must exceed the conversion price in order for the preferred stock to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceAsPercentageOfConversionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days within a period of 30 consecutive trading days the closing price of the entity's common stock must exceed the applicable price in order for the preferred stock to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PreferredStockConversionObligationCommonStockClosingSalesPriceNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockConversionObligationNumberOfTradingDays">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days during which the closing price of the entity's common stock must exceed the applicable conversion price for at least 20 days in order for the preferred stock to be convertible.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PreferredStockConversionObligationNumberOfTradingDays</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the number of trading days within 30-day trading period required to be ended prior to notice of automatic conversion.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PreferredStockConversionObligationThirtyDayTradingPeriodEndingWithinNumberOfTradingDaysPriorToNoticeOfAutomaticConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the unit of measurement in dollars which establishes the exchange rate of the preferred stock into debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PreferredStockExchangeRatePrincipalAmountOfNotesUsedInCalculation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockConversionBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describe the conversion features of common stock if such stock is convertible. That is, shares of common stock into which another convertible security was converted, or shares of common stock into which another class of common stock was converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockConversionBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockSharesConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockSharesConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockAmountOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockAmountOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockLiquidationPreference">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The per share liquidation preference (or restrictions) of nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) that has a preference in involuntary liquidation considerably in excess of the par or stated value of the shares. The liquidation preference is the difference between the preference in liquidation and the par or stated values of the share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21484-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(d)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockLiquidationPreference</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount of cumulative preferred dividends in arrears.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockPerShareAmountsOfPreferredDividendsInArrears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21564-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21488-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769896976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Arrangements (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs before income taxes</a></td>
<td class="nump">$ 266<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs before income taxes</a></td>
<td class="nump">72<span></span>
</td>
<td class="nump">305<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation costs before income taxes</a></td>
<td class="nump">$ 194<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815660848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Arrangements (Details 1) - Stock options - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Options Outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the beginning of the period (in shares)</a></td>
<td class="nump">389,379<span></span>
</td>
<td class="nump">206,298<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">170,853<span></span>
</td>
<td class="nump">197,841<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Cancelled / forfeited (in shares)</a></td>
<td class="num">(24,615)<span></span>
</td>
<td class="num">(14,760)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at the end of the period (in shares)</a></td>
<td class="nump">535,617<span></span>
</td>
<td class="nump">389,379<span></span>
</td>
<td class="nump">206,298<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Unvested at December 31, 2017</a></td>
<td class="nump">386,682<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Vested and exercisable at December 31, 2017</a></td>
<td class="nump">148,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the beginning of the period (in dollars per share)</a></td>
<td class="nump">$ 25.80<span></span>
</td>
<td class="nump">$ 72.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">1.93<span></span>
</td>
<td class="nump">4.68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Cancelled / forfeited (in dollars per share)</a></td>
<td class="nump">179.92<span></span>
</td>
<td class="nump">396.83<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding at the end of the period (in dollars per share)</a></td>
<td class="nump">11.10<span></span>
</td>
<td class="nump">$ 25.80<span></span>
</td>
<td class="nump">$ 72.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested at the end of the period (in dollars per share)</a></td>
<td class="nump">3.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Vested and exercisable at the end of the period (in dollars per share)</a></td>
<td class="nump">$ 30.49<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract', window );"><strong>Weighted Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding</a></td>
<td class="text">8 years 2 months 23 days<span></span>
</td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm', window );">Unvested at the end of the period</a></td>
<td class="text">8 years 10 months 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable at the end of the period</a></td>
<td class="text">6 years 7 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 121<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for unvested options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price of options that were either forfeited or expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)-(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6819104480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Arrangements (Details 2) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value of the stock options granted calculated using Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="nump">108.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield over expected term (as a percent)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Resulting weighted average grant fair value (in dollars per share)</a></td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value of the stock options granted calculated using Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">1.89%<span></span>
</td>
<td class="nump">1.37%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value of the stock options granted calculated using Black-Scholes option-pricing model assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate (as a percent)</a></td>
<td class="nump">2.265%<span></span>
</td>
<td class="nump">1.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility (as a percent)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">104.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827727264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation Arrangements (Detail Textuals) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 22, 2015</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,853<span></span>
</td>
<td class="nump">197,841<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.59<span></span>
</td>
<td class="nump">$ 3.66<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed', window );">Fair value assumptions method used</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Black-Scholes option-pricing model<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Percentage of vesting of awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=cycc_PerformanceBasedOptionsMember', window );">Performance Based Options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">158,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cycc_Plan2015Member', window );">2015 Plan | Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved</a></td>
<td class="nump">458,753<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Maximum life of stock option awards granted</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cycc_Plan2015Member', window );">2015 Plan | Stock options | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cycc_Plan2015Member', window );">2015 Plan | Stock options | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cycc_Plan2015Member', window );">2015 Plan | Stock options | Employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">197,841<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue', window );">Grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Remaining unrecognized compensation cost of non-vested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average remaining requisite service period of recognition of unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=cycc_Plan2015Member', window );">2015 Plan | Performance Based Options | Employees and directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock-based compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189,091<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the grant date fair value of options granted during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested options awarded to employees as compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For each plan, identification of the award pricing model or other valuation method used in calculating the weighted average fair values disclosed. The model is also used to calculate the compensation expense that is shown within the balance sheet, income statement, and cash flow. Examples of valuation techniques are lattice models (binomial model), closed-form models (Black-Scholes-Merton formula), and a Monte Carlo simulation technique. Fair value is the amount at which an asset or liability could be bought or incurred or sold or settled in a current transaction between willing parties, that is, other than in a forced or liquidation sale. May include disclosures about the assumptions underlying application of the method selected.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsMethodUsed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=cycc_PerformanceBasedOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=cycc_PerformanceBasedOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=cycc_Plan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=cycc_Plan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=cycc_EmployeesAndDirectorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=cycc_EmployeesAndDirectorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815664768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plans (Detail Textuals) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=cycc_PensionPlanMember', window );">Pension Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Contribution made by the entity under the pension plan</a></td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 57,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=cycc_Plan401KMember', window );">401 (k) Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanDisclosureLineItems', window );"><strong>Employee benefit plans</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral', window );">Matching contribution by employer as a percentage of the employee's deferral</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Matching contribution by employer as a percentage of U.S. employee's qualifying compensation</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge', window );">Statutorily prescribed annual limit of contributions made by an employee before attaining age of 50 years</a></td>
<td class="nump">$ 18,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge', window );">Statutorily prescribed annual limit of contributions made by an employee after attaining age of 50 years</a></td>
<td class="nump">$ 24,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution', window );">Specified age limit of employees for calculation of statutorily prescribed annual limit of contribution</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Contribution made by the entity under the 401(k) Plan</a></td>
<td class="nump">$ 28,000<span></span>
</td>
<td class="nump">$ 32,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the statutorily prescribed annual limit of contributions made by an employee to the defined contribution plan after attaining specified age.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitAfterAttainingSpecifiedAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the statutorily prescribed annual limit of contributions made by an employee to the defined contribution plan before attaining specified age.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DefinedContributionPlanEmployeeStatutorilyPrescribedAnnualContributionLimitBeforeAttainingSpecifiedAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of employees' deferral for which the employer contributes a matching contribution to the defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DefinedContributionPlanEmployerMatchingContributionAsPercentageOfEmployeeDeferral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the specified age limit of employees for calculation of statutorily prescribed annual limit of contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DefinedContributionPlanSpecifiedAgeLimitOfEmployeesForCalculationOfStatutorilyPrescribedAnnualLimitOfContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=cycc_PensionPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=cycc_PensionPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=cycc_Plan401KMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=cycc_Plan401KMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6662075776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract', window );"><strong>Loss (income) from continuing operations before taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">Domestic</a></td>
<td class="num">$ (127)<span></span>
</td>
<td class="num">$ (2,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">Foreign</a></td>
<td class="num">(8,336)<span></span>
</td>
<td class="num">(11,763)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before taxes</a></td>
<td class="num">$ (8,463)<span></span>
</td>
<td class="num">$ (13,774)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6665285328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details 1) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Benefit for income taxes from continuing operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Current - domestic</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current - foreign</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Current - total</a></td>
<td class="nump">993<span></span>
</td>
<td class="nump">1,983<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Deferred - domestic</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit, total</a></td>
<td class="nump">$ 993<span></span>
</td>
<td class="nump">$ 1,983<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826388560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Details 2) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Reconciliation of the (benefit) provision for income taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Loss from continuing operations before taxes</a></td>
<td class="num">$ (8,463)<span></span>
</td>
<td class="num">$ (13,774)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax expense computed at statutory federal tax rate</a></td>
<td class="num">(2,877)<span></span>
</td>
<td class="num">(4,683)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome', window );">Disallowed expenses and non-taxable income</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment', window );">Loss surrendered to generate R&amp;D credit</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">1,945<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Additional research and development tax relief</a></td>
<td class="num">(1,262)<span></span>
</td>
<td class="num">(2,827)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(4,487)<span></span>
</td>
<td class="nump">2,029<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Foreign items, including change in tax rates, and other</a></td>
<td class="nump">1,901<span></span>
</td>
<td class="nump">1,238<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Change in US Tax Rate</a></td>
<td class="nump">4,112<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other foreign items</a></td>
<td class="nump">761<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit, total</a></td>
<td class="num">$ (993)<span></span>
</td>
<td class="num">$ (1,983)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the differences between total income tax expense or benefit as reported in the Income Statement for the period and the expected income tax expense or benefit computed by applying the domestic federal statutory income tax rates to pretax income from continuing operations attributable to nondeductible expenses under enacted tax laws, differences in the methodologies used to determine expense amounts for financial statements prepared in accordance with generally accepted accounting principles and income that is exempt from income taxes under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_IncomeTaxReconciliationNondeductibleExpenseAndTaxExemptIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax exempt income, equity in earnings (loss) of an unconsolidated subsidiary, minority noncontrolling interest income (loss), tax holiday, disposition of a business, disposition of an asset, repatriation of foreign earnings, repatriation of foreign earnings jobs creation act of 2004, increase (decrease) in enacted tax rate, prior year income taxes, increase (decrease) in deferred tax asset valuation allowance, and other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6797189248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Taxes (Details 3) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Net operating loss and tax credit carryforwards</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss and tax credit carryforwards</a></td>
<td class="nump">$ 38,948<span></span>
</td>
<td class="nump">$ 42,851<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses', window );">Depreciation, amortization and impairment of property and equipment</a></td>
<td class="nump">111<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock options</a></td>
<td class="nump">1,807<span></span>
</td>
<td class="nump">2,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits', window );">Research and development credits</a></td>
<td class="nump">4,021<span></span>
</td>
<td class="nump">4,021<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Deferred tax assets</a></td>
<td class="nump">44,887<span></span>
</td>
<td class="nump">49,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="num">(44,887)<span></span>
</td>
<td class="num">(49,374)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from Research and development credits reserves not separately disclosed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DeferredTaxAssetsTaxDeferredExpenseResearchAndDevelopmentCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount before allocation of valuation allowances of deferred tax assets attributable to deductible temporary differences from depreciation, amortization and estimated impairment losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsDepreciationAmortizationAndImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6826341872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Taxes (Detail Textuals) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US corporate income tax rate</a></td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_FutureFederalStatutoryIncomeTaxRate', window );">Corporate income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance for deferred tax assets</a></td>
<td class="nump">$ 44,887<span></span>
</td>
<td class="nump">$ 49,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability', window );">Reduction in deferred tax assets</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse', window );">Use of these NOLs restricted to an annual allowance</a></td>
<td class="text"><div><font style="font-family: times new roman,times;" size="2">use of these NOLs is restricted to an annual &#163;5 million allowance in each standalone company or group and above this allowance, there will be a 50% restriction in the profits that can be covered by losses brought forward</font></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">US corporate income tax rate</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember', window );">Federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOLs carryforward</a></td>
<td class="nump">$ 28,400<span></span>
</td>
<td class="nump">28,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Income tax credits</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">NOLs carryforward</a></td>
<td class="nump">$ 186,200<span></span>
</td>
<td class="nump">178,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement', window );">Percentage of tax rate adopted in respect of deferred tax assets measurement</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and development | United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardLineItems', window );"><strong>Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Income tax credits</a></td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="nump">$ 2,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_FutureFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents future federal statutory income tax rate effective in 2018.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_FutureFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the percentage of tax rate adopted in respect of deferred tax assets measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_PercentageOfTaxRateAdoptedInRespectOfDeferredTaxAssetsMeasurement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from continuing operations attributable to an adjustment of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsLimitationsOnUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A description of the limitations on the use of all operating loss carryforwards available to reduce future taxable income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsLimitationsOnUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_InternalRevenueServiceIRSMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6801268496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract', window );"><strong>Numerator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (7,470)<span></span>
</td>
<td class="num">$ (11,791)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock', window );">Dividend on convertible exchangeable preferred shares</a></td>
<td class="nump">201<span></span>
</td>
<td class="nump">200<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_cycc_BeneficialConversionFeatureOfConvertibleStock', window );">Beneficial conversion feature of Series A convertible stock</a></td>
<td class="nump">3,638<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities', window );">Conversion of Series A convertible preferred stock</a></td>
<td class="nump">3,537<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net loss attributable to common shareholders</a></td>
<td class="num">$ (14,846)<span></span>
</td>
<td class="num">$ (11,991)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Denominator:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average common shares outstanding (in shares)</a></td>
<td class="nump">7,631,152<span></span>
</td>
<td class="nump">3,424,976<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Loss per share - basic and diluted (in dollars per share)</a></td>
<td class="num">$ (1.95)<span></span>
</td>
<td class="num">$ (3.50)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cycc_BeneficialConversionFeatureOfConvertibleStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock beneficial conversion feature of Series A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cycc_BeneficialConversionFeatureOfConvertibleStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cycc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of convertible preferred stock that was converted to other securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21475-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockConvertedToOtherSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1505-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow in the form of ordinary dividends to preferred shareholders of the parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDividendsPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6827200848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Details 1) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">8,159,814<span></span>
</td>
<td class="nump">391,076<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">535,616<span></span>
</td>
<td class="nump">389,378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember', window );">Convertible preferred stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">1,698<span></span>
</td>
<td class="nump">1,698<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember', window );">Series A Preferred Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">132,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cycc_CommonStockWarrantsMember', window );">Common stock warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Total shares excluded from calculation</a></td>
<td class="nump">7,490,500<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_SeriesAPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cycc_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=cycc_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6815934240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Geographic Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,470)<span></span>
</td>
<td class="num">(11,791)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">26,003<span></span>
</td>
<td class="nump">19,662<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_GB', window );">United Kingdom</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SalesRevenueNet', window );">Revenue</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">843<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(7,343)<span></span>
</td>
<td class="num">(9,580)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="nump">4,465<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementGeographicalAxis=country_US', window );">United States</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(127)<span></span>
</td>
<td class="num">(2,211)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Assets</a></td>
<td class="nump">23,522<span></span>
</td>
<td class="nump">15,197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Long Lived Assets, net</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SalesRevenueNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SalesRevenueNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6612800048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events (Detail Textuals) - Subsequent event - Board of Directors<br></strong></div></th>
<th class="th">
<div>Mar. 07, 2018 </div>
<div>$ / shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsPerShareDeclared', window );">Preferred stock dividend declared, amount per share</a></td>
<td class="nump">$ 0.15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear', window );">Dividend declared, date</a></td>
<td class="text">Mar.  07,  2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear', window );">Dividend paid, date</a></td>
<td class="text">May  01,  2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear', window );">Dividend, record date</a></td>
<td class="text">Apr. 11,  2018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendPayableDateToBePaidDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the declared dividend will be paid, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendPayableDateToBePaidDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateDeclaredDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the dividend to be paid was declared, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateDeclaredDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableDateOfRecordDayMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the holder must own the stock to be entitled to the dividend, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableDateOfRecordDayMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of preferred stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TitleOfIndividualAxis=us-gaap_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>80
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( !:$?DP?(\\#P    !,"   +    7W)E;',O+G)E;'.MDD^+
MPD ,Q;]*F?L:5\'#8CUYZ6U9_ )Q)OU#.Y,A$[%^>X>];+=44/ 87O+>CT?V
M/S2@=AQ2V\54C'X(J32M:OP"2+8ECVG%D4)6:A:/FD=I(*+ML2'8K-<[D*F'
M.>RGGD7E2B.5^S3%":4A+<TXP)6E/S/WJVR;A5ND9T*YKCM+1[873T$7LF<;
M!I99-G\LCNVW<+ZT+/0:S>,*P).B0\5?UX^8 TBTH_0(:+L A#&^NQT:E8(C
M-R."?S]PN -02P,$%     @ %H1^3&;S"V""    L0   !    !D;V-0<F]P
M<R]A<' N>&UL38Y-"\(P$$3_2NG=;BGB06) L$?!D_>0;FP@R8;-"OGYIH(?
MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W$?:]=3OWCXW/@KJ!7W>AOP!02P,$%     @ %H1^3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M4C<3U>;=N=EU)&OZ*P$-]U+^%U!+ P04    "  6A'Y,T7![&@("   ]!@
M&    'AL+W=O<FMS:&5E=',O<VAE970T+GAM;(V5VVZ<,!"&7P7Q #%GT J0
MFHVB5FJE5:JVUUX8%A2#J>U=TK>O;0AEP2JYP:?_'W]CPY .E+WR&D!8;RWI
M>&;70O0'A'A10XOY ^VADRL592T6<L@NB/<,<*E-+4&>XT2HQ4UGYZF>.[$\
MI5=!F@Y.S.+7ML7LSR,0.F2V:[]/O#276J@)E*<]OL!W$#_Z$Y,C-$<IFQ8Z
MWM#.8E!E]B?W<$R47@M^-C#P1=]2F9PI?56#+V5F.PH("!1"1<"RN<$1"%&!
M),;O*:8];ZF,R_Y[]&>=N\SEC#D<*?G5E*+.[,2V2JCPE8@7.GR&*9_0MJ;D
MO\(-B)0K$KE'00G73ZNX<D';*8I$:?';V#:=;H=Q)?8FF]G@309O-KC!?PW^
M9/!7!C22Z52?L,!YRNA@L?&R>JS>"??@R\,LU*0^.[TFL^5R]I9'88IN*LXD
M>1PEWD+BW2N.6X7_3X+D_C.$9X3PM#]8^,/([/>-?G_CCZ)5$J,DU))N1/1#
M+_97F>S*[F@"(TVPI8E7-,'':'9E=S2AD2;<TB0KFE$2+;8)9!4(W?4U[^ON
M>"(C3[2]Z]#LCXW^>/^NX\VQ>5&PRF6K<<P4B9$BV;_CY ,46\V: BT^9%58
MOV%V:3ING:F0-4%_N16E F0TYT$&JF4MGP<$*J&ZL>RSL:*- T'[J5BC^8^1
M_P502P,$%     @ %H1^3)[$Y31] P  [PX  !@   !X;"]W;W)K<VAE971S
M+W-H965T-2YX;6R-E]N.VC 0AE\EROV2C)V#O0*DA:IJI59:M6I[G04#T28Q
M3<RR??LZAV7!,ZYZ XGYQ_-/F'S)S,^Z?>X.2IG@M:Z:;A$>C#G>1U&W.:BZ
MZ&;ZJ!K[RTZW=6'L:;N/NF.KBNT05%<1B^,LJHNR"9?S8>VQ7<[UR51EHQ[;
MH#O5=='^6:E*GQ<AA&\+W\K]P?0+T7)^+/;JNS(_CH^M/8LNNVS+6C5=J9N@
M5;M%^ #W:Y;V 8/B9ZG.W=5QT)?RI/5S?_)YNPCCWI&JU,;T6Q3VZT6M557U
M.UD?OZ=-PTO./O#Z^&WWCT/QMIBGHE-K7?TJM^:P"$48;-6N.%7FFSY_4E-!
M:1A,U7]1+ZJR\MZ)S;'153=\!IM39W0][6*MU,7K^%TVP_=Y_"5_"Z,#V!3
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M7@!WG/#L0.+C 1@N"1&*8:]<N@5A$?-U/]"@ 8Z\B-CUPO'_",+U@D7<T_Y
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M[QM&R2IZ'P+-FNVDH:7FKHA,]'L*0BFVY$RGQP0[5\$)9^"P"#[.YP]%I#B
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MRFTKM",7X_%E8_\;8SR@E.0&1ZC##[88$AH?CN_P;*<QFPQO^OD'L>4;EW\
M4$L#!!0    ( !:$?DQ0.(N7LP$  -(#   9    >&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;'U3VV[<(!#]%<0'A#6[W48KVU(V591(K;1*U>:9M<<7!1@'
M\#K]^P)V'+=U\P+,,.?,F6%(!S3/M@%PY%5);3/:.-<=&+-% TK8*^Q ^YL*
MC1+.FZ9FMC,@R@A2DO'-9L^4:#7-T^@[F3S%WLE6P\D0VRLES*\C2!PRFM W
MQV-;-RXX6)YVHH;OX'YT)^,M-K.4K0)M6]3$0)71F^1PW(7X&/"SA<$NSB14
M<D9\#L9#F=%-$ 02"A<8A-\N< M2!B(OXV7BI'/* %R>W]CO8NV^EK.P<(OR
MJ2U=D]%K2DJH1"_=(P[W,-7SB9*I^*]P >G#@Q*?HT!IXTJ*WCI4$XN7HL3K
MN+<Z[L-XP_<3;!W )P"? =<Q#QL31>5?A!-Y:G @9NQ])\(3)P?N>U,$9VQ%
MO//BK?=>\F2?I.P2B*:8XQC#ES%S!//L<PJ^EN+(_X'S=?AV5>$VPK?_4?@'
MP6Z58!<)=A^6N!;SMTJVZ*D"4\=ILJ3 7L=)7GCG@;WA\4W>P\=I_R9,W6I+
MSNC\R\;^5X@.O)3-E1^AQG^PV9!0N7#\[,]F'+/1<-A-/XC-WSC_#5!+ P04
M    "  6A'Y,XUU%UK0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q]4]N.W" ,_17$!RPS3/:B41)I9ZNJE5IIM%7;9R9Q$K1<4B"3[=_7
MD&R:ME%? !N?XV-C\M&Z%]\!!/*JE?$%[4+HCXSYJ@,M_(WMP>!-8YT6 4W7
M,M\[$'4":<7X;G?'M)"&EGGRG5V9VR$H:>#LB!^T%N[G"90="[JG;XYGV78A
M.EB9]Z*%+Q"^]F>'%EM8:JG!>&D-<= 4]'%_/&4Q/@5\DS#ZU9G$2B[6OD3C
M8UW0710$"JH0&01N5W@"I2(1RO@Q<](E902NSV_L[U/M6,M%>'BRZKNL0U?0
M!TIJ:,2@PK,=/\!<SRTE<_&?X H*PZ,2S%%9Y=-*JL$'JV<6E*+%Z[1+D_9Q
MNLGN9]@V@,\ O@ >4AXV)4K*WXD@RMS9D;BI][V(3[P_<NQ-%9VI%>D.Q7OT
M7LO]W2%GUT@TQYRF&+Z.62(8LB\I^%:*$_\'SK?AATV%AP0__*$PVR;(-@FR
M1)#]M\2MF-N_DK!53S6X-DV3)Y4=3)KDE7<9V$>>WN1W^#3MGX5KI?'D8@.^
M;.I_8VT E+*[P1'J\(,MAH(FQ.,]GMTT9I,1;#__(+9\X_(74$L#!!0    (
M !:$?DPT3+ UM $  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM
M;'U386_;(!#]*X@?4!*2IE%D6VHZ39NT25&G;9^)?;91@?, Q]V_'V#7\S9K
M7X [[KU[=QS9@/;%M0">O&IE7$Y;[[L38ZYL00MWAQV8<%.CU<('TS;,=19$
ME4!:,;[9')@6TM B2[Z++3+LO9(&+I:X7FMA?YY!X9#3+7US/,NF]='!BJP3
M#7P!_[6[V&"QF:62&HR3:(B%.J>/V]-Y'^-3P#<)@UN<2:SDBO@2C8]53C=1
M$"@H?6008;O!$R@5B8*,'Q,GG5-&X/+\QOX^U1YJN0H'3ZB^R\JW.3U24D$M
M>N6?<?@ 4SWWE$S%?X(;J! >E80<)2J75E+VSJ.>6((4+5['79JT#^/-_6Z"
MK0/X!. SX)CRL#%14OY.>%%D%@=BQ]YW(C[Q]L1#;\KH3*U(=T&\"]Y;L3T<
M,G:+1%/,>8SARY@Y@@7V.05?2W'F_\#Y.GRWJG"7X+L_%#ZL$^Q7"?:)8/_?
M$M=BCG\E88N>:K!-FB9'2NQ-FN2%=Q[81Y[>Y'?X..V?A6VD<>2*/KQLZG^-
MZ"%(V=R%$6K#!YL-!;6/QX=PMN.8C8;';OI!;/[&Q2]02P,$%     @ %H1^
M3 ZE=""T 0  T@,  !D   !X;"]W;W)K<VAE971S+W-H965T,34N>&UL?5/;
M;IPP$/T5RQ\0L^PVFZX *9NJ:J5&6J5J\NR% :SX0FVS)'_?L6$):E%?;,_X
MG#,7C[/!V%?7 GCRIJ1V.6V][PZ,N;(%Q=V-Z4#C36VLXAY-VS#76>!5)"G)
MTB2Y98H+38LL^DZVR$SOI=!PLL3U2G'[?@1IAIQNZ-7Q))K6!P<KLHXW\!/\
MK^YDT6*S2B44:">,)A;JG-YO#L==P$? LX#!+<XD5'(VYC48WZN<)B$AD%#Z
MH,!QN\ #2!F$,(W?DR:=0P;B\GQ5_QIKQUK.W,&#D2^B\FU.[RBIH.:]]$]F
M^ 93/9\HF8K_ 1>0" ^98(S22!=74O;.&S6I8"J*OXV[T'$?QIOME;9.2"="
M.A/N(H&-@6+F7[CG16;-0.S8^XZ')]X<4NQ-&9RQ%?$.DW?HO12;V\\9NP2A
M"7,<,>D2,R,8JL\ATK40Q_0?>KI.WZYFN(WT[3+Z/ED7V*T*[*+ [K\EKF#V
M?Q?)%CU58)LX38Z4IM=QDA?>>6#OT_@F'_!QVA^Y;81VY&P\OFSL?VV,!TPE
MN<$1:O&#S8:$VH?C'L]V'+/1\*:;?A";OW'Q!U!+ P04    "  6A'Y,=SR$
M+[0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q]4]MNVS ,
M_15!'U E<M8&@6V@Z5!TP 8$';8^*S9]075Q)3GN_GZ4[+K>YO5%$BF>PT.*
M2@=CGUT#X,FKDMIEM/&^.S#FB@:4<%>F XTWE;%*>#1MS5QG0901I"3CF\TU
M4Z+5-$^C[V3SU/1>MAI.EKA>*6%_'4&:(:-;^N9X;.O&!P?+TT[4\!W\C^YD
MT6(S2]DJT*XUFEBH,GJ[/1QW(3X&_&QA<(LS"96<C7D.QI<RHYL@""04/C (
MW"YP!U(&(I3Q,G'2.64 +L]O[/>Q=JSE+!S<&?G4EK[)Z)Z2$BK12_]HA@>8
MZOE$R53\5[B Q/"@!',41KJXDJ)WWJB)!:4H\3KNK8[[,-XD^PFV#N 3@,^
M?<S#QD11^6?A19Y:,Q []KX3X8FW!XZ]*8(SMB+>H7B'WDN^O>$INP2B*>8X
MQO!ES!S!D'U.P==2'/D_<+X.3U85)A&>_$?A'P2[58)=)-A]6.):3/)7$K;H
MJ0);QVERI#"]CI.\\,X#>\OCF[R'C]/^3=BZU8Z<C<>7C?VOC/& 4C97.$(-
M?K#9D%#Y<+S!LQW';#2\Z:8?Q.9OG/\&4$L#!!0    ( !:$?DQU0/0ULP$
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M[<+QQI_-.&:CX;";?A";OW'Q#E!+ P04    "  6A'Y,GO(/P+0!  #2 P
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M9S..V6@X[*8?Q.9OG+\!4$L#!!0    ( !:$?DQ@NBF&M0$  -(#   9
M>&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;'U386_<( S]*X@?4'*YVYJ=DDB]
M3M,F;=*IT[K/7.(DJ( S()?NWP](FF5KU"^ C=_SLS'YB.;)=@"./"NI;4$[
MY_HC8[;J0'%[@SUH?].@4=QYT[3,]@9X'4%*LC1)WC/%A:9E'GUG4^8X."DT
MG VQ@U+<_#Z!Q+&@._KB>!!MYX*#E7G/6_@.[D=_-MYB"TLM%&@K4!,#34'O
M=L?3(<3'@$<!HUV=2:CD@O@4C"]U09,@""14+C!POUWA'J0,1%[&KYF3+BD#
M<'U^8?\4:_>U7+B%>Y0_1>VZ@F:4U-#P0;H''#_#7,\[2N;BO\(5I \/2GR.
M"J6-*ZD&ZU#-+%Z*XL_3+G3<Q^EFG\VP;4 Z ](%D,4\;$H4E7_DCI>YP9&8
MJ?<]#T^\.Z:^-U5PQE;$.R_>>N^UW-UF.;L&HCGF-,6DZY@E@GGV)46ZE>*4
MOH*GV_#]IL)]A.__4?AAF^"P27"(!(<W2]R(R9+_DK!53Q68-DZ3)14..D[R
MRKL,[%T:W^1O^#3MW[AIA;;D@LZ_;.Q_@^C 2TEN_ AU_H,MAH3&A>.M/YMI
MS";#83__(+9\X_(/4$L#!!0    ( !:$?DRX<P2_L@$  -(#   9    >&PO
M=V]R:W-H965T<R]S:&5E=#(P+GAM;'U3VX[3,!#]%<L?L&[< E651-HN0B"!
M5"T"GMUDDECK2["=9OE[QDXV! B\V)[QG#-GQN-\M.[)=P"!/&ME?$&[$/H3
M8[[J0 M_9WLP>--8IT5 T[7,]PY$G4!:,;[;O69:2$/+//DNKLSM$)0T<''$
M#UH+]^,,RHX%S>B+XU&V78@.5N:]:.$SA"_]Q:'%%I9::C!>6D,<- 6]ST[G
M0XQ/ 5\EC'YU)K&2J[5/T?A0%W07!8&"*D0&@=L-'D"I2(0ROL^<=$D9@>OS
M"_N[5#O6<A4>'JSZ)NO0%?1(20V-&%1XM.-[F.MY1<E<_$>X@<+PJ 1S5%;Y
MM))J\,'JF06E:/$\[=*D?9QN^'Z&;0/X#. +X)CRL"E14OY6!%'FSH[$3;WO
M17SB[,2Q-U5TIE:D.Q3OT7LKLV.6LULDFF/.4PQ?QRP1#-F7%'PKQ9G_!>?;
M\/VFPGV"[_^A\#>"PR;!(1$<_EOB5LR?*MFJIQI<FZ;)D\H.)DWRRKL,[#U/
M;_(K?)KV3\*UTGARM0%?-O6_L38 2MG=X0AU^,$60T$3XO$-GMTT9I,1;#__
M(+9\X_(G4$L#!!0    ( !:$?DR@3AQZM $  -$#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#(Q+GAM;'U386_;(!#]*X@?4!PG[:+(MM2TFC9IE:)6VSX3
M^VRC N<!CMM_7\"NYVU>OP!WO'OW[CBR <VS;0$<>5%2VYRVSG4'QFS9@N+V
M"CO0_J9&H[CSIFF8[0SP*@8IR=(DN6&*"TV++/I.ILBP=U)H.!EB>Z6X>3V"
MQ"&G&_KN>!1-ZX*#%5G'&W@"][T[&6^QF:42"K05J(F!.J>WF\-Q%_ 1\$/
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M?7C9U/\:T4.0LKD)(]2&#S8;"FH?C[?A;,<Q&PV/W?2#V/R-B]]02P,$%
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MTL!U+:'($HBDC@C I$LLLH(B*T"P<D00)L4B*11)/0)3K1P1A FXFTQP!DT
MA>LO" H8C 0RE0 *UV(0%/ 8@>FZ)110+%P=! HX@."\)E- X7H @@(F(#C]
MB9_;E+@V@*"0#W %('YZ4^+Y (%"/L!%@/@93HGG P0*^0#7 >(G.26>#Q H
MY -<"HB?YY1X/D"@D ]P-2 @U:GG P0*_=OA>D!!JE/7!Q 4\ '%]8""5*>N
M#R#(]4'RT"S47%YLFZ2BH[@VMD=[6!U;L2VUS<8_>-_'?6?R4C8J.@AM6A;;
M6)R%T-SL9?)DO%^8UG&<5/RLN^'2C&7?/_43+=JA-TS&!C7_"U!+ P04
M"  6A'Y,[ N1X+@!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970R-BYX
M;6QU4V%OVR 0_2N('U 2XJ999%MJ.DV;M$E1IW6?B7VV4<%X@./NW^_ KN=U
M[A?@CGOOW1U'.AC[[!H 3UZT:EU&&^^[(V.N:$ +=V,Z:/&F,E8+CZ:MF>LL
MB#*"M&)\L]DS+61+\S3ZSC9/3>^5;.%LB>NU%O;W"909,KJEKXY'63<^.%B>
M=J*&[^!_=&>+%IM92JFA==*TQ$*5T?OM\92$^!CP)&%PBS,)E5R,>0[&ES*C
MFY 0*"A\8!"X7>$!E I$F,:OB9/.D@&X/+^R?XJU8RT7X>#!J)^R]$U&#Y24
M4(E>^4<S?(:IGEM*IN*_PA44AH=,4*,PRL65%+WS1D\LF(H6+^,NV[@/XTWR
M88*M _@$X#/@$'78*!0S_RB\R%-K!F+'WG<B//'VR+$W17#&5L0[3-ZA]YIS
MOD_9-1!-,:<QAB]BMG,$0_99@J])G/A_<+X.WZUFN(OPW5)]_XY^LDJ01(+D
MGQ+OWI2X%G-X(\(6/=5@ZSA-CA2F;^,D+[SSP-[S^"9_P\=I_R9L+5M'+L;C
MR\;^5\9XP%0V-SA"#7ZPV5!0^7"\P[,=QVPTO.FF'\3F;YS_ 5!+ P04
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M_VMC/& JNRL<H18_V&(HJ'TXWN+93F,V&=[T\P]BRS<NW@%02P,$%     @
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M4]MNW" 0_17$!P0OZS3;E6TIFZA*I59:I6KRS-IC&X6+ WB=_GT!>QTW=5Z
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M/0E&2_%?X ;<PETF5J.47/LO*D=MI%A8;"J"O<UKU_MUFD\2NH2% ^@20->
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M:&5E=#,T+GAM;'54T8Z<(!3]%<('+,J,NY.)FNQLT[1)FTRV:?O,Z%7)@EC
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MRZ2ZJN9"58Q)4)K>@Y*KU4R> PJ5U-M$[?DXF<9 LGX:NFB>_,4_4$L#!!0
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M7X2J9K+.YHMY;@@Z+F\.6!^^^B]02P,$%     @ %H1^3'27Y[LC P  *@X
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M,-PJ9':#6MPL)+VBV7O0N-NC-)Y\&]8]ZL+Y$75U*VX]@GG/D0)PST!X?5$
M]PR0*UH  4'F^% !;BS C.5H>, ] S<LAX![!K %T5)K@YSV!MQ8@'@F<G@&
M<,] <H-:W#. K2_3AN]!XX8G,*W)&D.1V%44W'^ ^"]R*<(] ]GU1:&X9ZB]
MSM@M@("<#4]Q8U'$6*Y-"L4]0^$&M8X=I+W.(&JQQ6CZ;H/1SKODS=X<4J2W
M$<?*G)!&H\-!Z ',SOT#WIVB?K!FGU?2>Q%*[__-+GTGA.*:2WBGG7/0![?A
MH> [U=[.]'W3G5ZZ!R7J_F06#,?#Y3]02P,$%     @ %H1^3.;0 N#N 0
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M0VO]]IW;ZWA9HV'5N,PA67\&U1]02P,$%     @ %H1^3,G>%DSZ 0  O@4
M !D   !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL=93=CILP$(5?!?$ :S _
M@0B0FJU6K=1*T59MKQT8 EJ#6=L)V[>O;5B4@',3>^PSYYMQL+.1\3?1 $CG
MHZ.]R-U&RF&/D"@;Z(AX8@/T:J=FO"-2A?R,Q,"!5":IHPA[7HPZTO9ND9FU
M(R\R=I&T[>'('7'I.L+_'8"R,7=]]W/AM3TW4B^@(AO(&7Z!_#T<N8K0XE*U
M'?2B9;W#H<[=+_[^D&J]$?QI810W<T=W<F+L30??J]SU=$% H93:@:CA"L]
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MVK!@<-)VNC)SZ9^U7VC1]AV+#&TS_PM02P,$%     @ %H1^3!$N\^NA P
M'!$  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULE9CK;ILP%,=?!?$
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M<]7=U[L7P8_JMPBG_T%D]1]02P,$%     @ %H1^3#$G9KP8 @   @8  !D
M  !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULC53;CILP$/T5Q >LN00"$4':
MI*I:J96BK;I]=L@DH+4QM4W8_GU]85D2W&I?L&=\YIR9,9YB8/Q%U #2>Z6D
M%5N_EK+;("2J&B@6#ZR#5IV<&:=8*I-?D.@XX),)H@1%09 BBIO6+POC._"R
M8+TD30L'[HF>4LS_[("P8>N'_IOCJ;G44CM0673X C] _NP.7%EH8CDU%%K1
ML-;C<-[ZC^%FGVN\ 3PW,(C9WM.5'!E[T<;7T]8/=$) H)*: :OE"GL@1!.I
M-'Z/G/XDJ0/G^S?VSZ9V5<L1"]@S\JLYR7KK9[YW@C/NB7QBPQ<8ZTE\;RS^
M&UR!*+C.1&E4C CS]:I>2$9'%I4*Q:]V;5JS#O8D3<<P=T T!D13@-+^7T \
M!L3O 48!V<Q,J9^PQ&7!V>!Q>UD=UO]$N(E5,ROM-+TS9ZI:H;S7,LY6!;IJ
MHA&SLYAHAHG2_!:S7V+""8%4!E,:D2N-7;0(C[/D3F*)B=P2L;/2V(3'-Q*I
MFV#E)%@9@M4-P?HN1XM)#::U;8C364-O9!*G3.*0R=P$J9,@_7BA:R?!VI'!
MW7WO')@\<(MD3I%L2;#XJ2PFF7<SB\/P']W(G3KY!VXM7]Y:&-Q7@V9/B@*_
MF.DCO(KUK9E\,^\TX!XC\R3?X78Z?L?\TK3".S*I'K9Y?F?&)*A<@@=5;JT&
M\F00.$N]7:L]MV/)&I)UX\1%T]@O_P)02P,$%     @ %H1^3+ES Y(: @
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M*A : 3P1\+$W*Z/'Q ;3#)@$9[-2EJ@XR;#="[9ZP0LOX5L"D54@>G\W8JM
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M_7-P@[4-$8!;:G/K08A,2QFDMAA ,!IPQQ9"L%8B0"R9+98#Z)90G :I_7F
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MW?7.E HB?;17,C&Y'(2&34G.0BU#N6;=--!M!&WZ2<<:QJWD+U!+ P04
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M 3MZDN"()$F.!&O:N"Q\[$&5A;P8WK3PH")]$8*I/SO@LM_&.'X-/#;GVK@
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M9^4?_TE* ]9E<F>[5=MQ.!TXG(S;KNQ>#4-A.!C9C?,.34.W_ M02P,$%
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M/=".G"NF*>,G7:VSON.,DYH=E1GF>BSZ@[Z?*-X-EYAHO$DM_P%02P,$%
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M/JH70,WB/(&3R<%D<J":>)1,[LM@--%7"JI00"49J4"8%!:9@2(SCR#)*4R
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MV4YM[4*+IIM(HWXL7OT#4$L#!!0    ( !:$?DQ9S+O >0(  /$'   9
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M)A2HVX6BT[CS6'3<DAKS,0:F<PP7*,PG#P0?R,1\]D"X)I-0\QKYB1OHH>C
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MFC4PY/_X$XB\)J\?\S_].>GP%+SK#]5R#ISNW^@<-KO.!@(A+')8Z#QIF#4
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MUJCQW/6,J2.(G@@*GOE-!0S\7B0!WE8D+:"\6;%F#WB!U]43UHR_@<?7&+T
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M-7D[FX"<^>5&W:(HDRG 1:%X]E$VZ)( #EL72])9>G/(0L>>CU^@]OA0W#_
MZ^PNMO$RT831PU/<%WA)5K@WSBE9YSFR%X2WP -!*U<N 7!]]J^@Q,2XB^1.
M"F./SZZB7(/B<8_U@^\9Q8CDA=QN]!4M\OMM5K.)K@70ZNNR#FCC&0]B#N25
M[=K!ZD(.XPND&52P8M:#870J-*B%4X/)LZU;@;-Y3M[!QD=,X,U%0"/%9FN$
M3;'QTI549CPK)8._@[@N)(WT(?,A:%8:Y@E3/0<?2PGL6RW?Q:WE$_@U#(L0
M,?+:8 0KA"W][4MU[ DS].8=W@5YX^WP$"RM%4BBR) [3K.=;GV86(ZF,.I1
M&$%#H7$'-UC#%5V3314]^>U?@*G,JQ6O9,.%__@%F2K'-)VABS9\?%3T%Y0L
M347S>9O/:5ZOF1C DM.,D)NJ7JM35<W&MZ_?W3BS<;O&4WDU/N.*>K2X9<7=
MF'4X6^"?>3Y74:/[W9X9?$M425RPIHG\3BH<< @\A:$_A<AA_>'MDNV.[=?7
MOR0_^D0 SU%OX787./2-U=MO$08H]]MW>W/;VKY__9?1^>3[B[/_/5L(W]N[
MA4,3ZH_O8("2\4;3PVER*'Q G1/;*9Y'S@H=^U=0?ZN:C21+2(6!)L6ATQ;]
M[*>4&7?'[I5'L0U4<9^CUH#)*DO+E]5D5).27:WX8>\@8?% D:9'R68 16B%
MQIQ/A<6@--5OHA^ZAJ^+A=QHPAQ-0/<\G/$JWSQ@=%NGW#R@=5G[.:XDM88^
M0B$3C1-%5K?(^Q8G&O!RYS2:!2=BH76QV. O9'5?,8V(L_PQW+ 146&-;U+T
M*:W!FMYA)H:I!"$[W^Z9V!75HVJQ79736ZQHR%%N$16.L,J4Z!0+5-<72_85
MDR?149?1+RG!D*J1Y?U!\L9F .&U)CZ<<SB15[7.BIIY'TC]^IZ%22R.[U-K
M!LF[%;ZF&_8>5;,EN2VOV0:PMU.-[9XK@+,J_' 8!4%AH"%\#++X"A<7Q0CL
M84Q/!*%GH_>SK*[)Q\A\3.E%3!03PP.*(CMJAK2)1G?(6O %DLKJ5Z"G@F"O
M50Z=0W_IMT2^>;=S/@Z<%ZQ3\F?,9)U_GQ4 ?E'R$>7CY);G9 D,2#;$#I'
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MH*[>BHZG#?#A&%@SS69NS[1K]. Q EWA\G/\EQ>%:9A1%Q9GE5H7VDLQ#I5
MS VET^!R2K6X*Q8E QB6"#(GTSBWGC+*<TQQ=I],47"R"N1C,C;^T@IVL.#A
MTO;>:>-YRP+G88#C1O6>+Y2$:')*7Z-6:VQL\IU6)1:D"))/-!LBQ(B@+_NP
MF:]4:_# M1Z[LPE!S6OC<64^?VR<"4(@ ?(QOW E%_O2M7\IDN8:6P496YBT
MX<U=JBB?;RD#_8MB.J0)3HG3;. SR1W:5R3 ECOV-JI>[/; % 3*\VR,4;F_
M5=F$>U-B8%A>P#PGU,+8,X5I2C@F$E:87>K(VYE^)A^4CY+<T%SNWIXT6Q N
MV97HDA[<T-X SVQ]KBDV<I6<SY]K6DO)%G3$81@X;4'.OAJ?2ME.DW6<S63G
MSH."E^PY+ (&Z0G'[=1U2QD=&'(UZ+3N&JD+,&M\H1U=+RKOEZQ*%ET53+4Q
M-;^Z\$'R*<-0FFRD_ .>;W3I7C"96.5]+^AU-'C)V] .Y)%]8LN3J2A/E/%!
M\CXG\C#1S9D>MBF@)U]=3RB5LL*>#>7[\#?(Q?; ? A&&H15A\\#3@@'5>8\
MDQ06K&O)YJ 78$B^D0(8R;,.\C6L.BGA'LY*Z^+"29&A&2E[RE#7)G (\2BM
MULMJEZNH*.!4R!7@KF+;9=Y-KZ71%"^'[TL3SPVG%S!QC^>1^CVG1#&\F'K!
MY4*K5:01/N-J-H:HAO+\;.:<K3GWDR7.CI]-,%V/78\YJBZ-HNNQ)O0!_1X:
M& BWJX6><TP^_@VR2<,"3VA\S&HCYX"LD S+&C7$6I,??JJ>,,:>JK49.9P5
M:>J]V7T_5"0&0*=WQ_;(D.WB[V=G]6:GIX;5@E1SGI4EP481 (V)^/F#I5F
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MK;-DFDXGE_#?2Z *QDRWS9PP96);EP3&H6\ NSF[@/^.)^='Y^GD\B(Y3Z^
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M1GE[WX3HMXJ93U>9W>7A- 0AQ86R=;;YO*4@K?*<M.H';*U9"1KTE,8=]:L
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MR]&\V>Y N/[!F1P0X<V=''VJZ,+" =%3R/X1=9=%E@$<@Y-G_<JICR8P3EZ
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MX_" _2LV%[4*1$:+AD.1UMX1'R /D%RY ;T*#6]ZLWI7+:M[#8>X7C>.56C
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MH*!3ZL.[86\^HR>3+$L-#+\"[:OW#;>*FC3"1J&,,= P@_:BE.$:G.FV1LO
M.@PSM^]OR4?Q1>A!^"0"PQ'J\+P<77%B6F;S3\AAEGS2*/^U:LA,#.Q#P/VW
M<I6=@GVA?LW$,[8"F^$Z5D3C-T?RVAR)C5#\H9>27G0CYPV(9V,P+;0:-\56
MV[7*D&J C'$+J66FE[QIF/_H+68WF07%FWJFS%U3RGPIUHU>BX 72%TP?:L1
M]YEITQE$JP@=% %@]9,IRFG6N'QLR\:Q6D$CEG,H#JK^:5._<U[@?&^@Z$:U
MKB^40>I3B0]^$/LL9]9Y0+[C"F1351LLHDYZ0Y"ZVMB6A/;HT4_,82%-W@TV
M#X3N?59*?,]#D-Q\_NC;5^-AZ,?\ABF9V9>N_4N19.;8*AI!L;18_W4UR^=X
M5""J=FO\+'H&<$J<]02?2>ZHAS7*V>6.O:VJOKL],(CC\CS;C%22;#5+$3+<
M:3JH\&'6&"J+[)G#)#(<$PDRS"%VU\)9J $H(;%E\I^BJMV9M"TIPJ8LTFH"
M&]HQD%#[<]A3CR^,BWE8= U#'$;.2%4V.:$,X%(K&=IQ59.#/0_0':5A[EY>
M!:L(Q^5+:A@_SIC>*!'UUUT_=8$BY!X_P>O(J21?<EY9PE;W"%F;>+0$67@W
MNR&CXE[:UWU_2^0?,'2CN^1%K0DKW_=W9([%F7G'VE%3:8WN>%2(2-6>YWN&
M/(H'HH,_2M9&$V"A:TI"7X1<<+Z?R=#P60V#Y&-[8#Y;(YS4^=D%:H_3CC!T
ME14>G/,AS^8*.=G3N/SNP,;EW>?"5D <?..4Q1 XR8M 6R70ZJ&\I^^P8PSM
M $8W%9N[I+'X<_#+T7J$RH'OTCQ2?U1]K3?5E-1XJ_'H&^O=P@F:GFWJ%IUK
M\C!]ECJNLH<W1R6NL?W\!LD'=!9IF";<KE9CJF.*N!":A&'()]Q5%RB!/"JR
M0K+&:VHAK:DP#C/)M5/H',Z*S)O>U,](615]F]EJ44M,P*,V(#X\87MD98DF
M+"%=V_AKIY7UCYJLE+:VOT'QTB4Y@VW$?Y1%!91&@K8J87?DL(4Z75??L)VT
MFM6<!Q  H?I>NOM3H,QN%QY>C0XBWJ&[LXYM66Q:R_"PPJ#(H1>N?$$S9<Z-
MTI"%;:W\3O)2,?.5,V6>")]&Z-UY(MP[#FM^91,3B-1AOKBIFE0EL%CE,D!*
MUSW5! B#&^Y'TKOB^BC#HO2\CF_5TAW% ^;,S'[H,+.35@JV)@PTSY<V"7!&
M+W:CE%5D*PIYE63967!O6A1JWVL4VM[HR'8HWZT<=5D,K20CC8@2*"EW+V5>
M3)2Z8[\MOQ,&@+MW)'9QF.!"5WK E'TYNU08*^TJV[/!^_YZ(U/*W.+MP@+8
M$Z/MW$45B[:F9AW7]B>6RUDT03ZAWM2PARF%NI7?2U%<0V5C[&FS'GWG@GET
M#4+[5LC5H;0):=@%-.#R:1)T+Q6G8=A)M&E[P,A0I,+NAEO=".Z+\0*8"3+T
M#*4;./<E;U/8MS4+ZB=-@1I=2'01X;9KC,DU]V*%#NLVV6MIM\;EK,;6+_Q;
MPLC!$[Y,+W:&!*G$:Z7M!W9*A1L"YGB7/V2/Y,X1U7RF$&W9'0A,G:<^UO1T
M0<?,^M-N?UF_\*;U!V*!-:E&[#9'^US+-/#$UEN%\VREGW^6\@@2K 1U3UJZ
M[)6/4_6.'O;P5G^A;3K:.0',0M-6L'P2J:].W&H68V=7M SNJ>K,WB!R4,)5
ML^G]./TR_'J+#%J]=(N.9J@]1=H1%$X(I0R\H-RZX;HIPW:"N@O?$ 98<<(]
M!H*W%:ROPL-G:!D![NODNYK6$OO^UL_6 YQKS[=\KI]J%U^E+I7R,_%7Z2$X
M^U)&&6?O/?CRD9I010>D]_?!9_,*VIC3C>F*$.!1!@+3%K6IW\G!=$KM=H!9
M:#,7'>"FO&L =<G'[=NN>)27V/YI"R")HW1B'EPOMT=..X.5XV$M''/G>MC3
MGR+H*ICA_3MM-OF:'4)-$U9N^\G293,] =I1FD'R%K,865&S>(-.N3.8SNU/
M$ IR\5"IUE9L3!>?!I?KW2D2XXX@QPF*7X!!IQS03HA4$NHKA1#,IPS!?(H9
MB:?4&;@*OAM9$=MNI:9I1Q;D]\SLEP<HV]N?I!M%=&/@W@A4J3ULYK!+]#%@
MMB^_*RBBF/0O;:L22KI$@%BSWS1%W#97K$G[C%4%*TZ*POQ!G)IVC^AM<>E4
M'F+*OA\,JQI:J,"-$8G1<PIE+[RC=-]HQ<$IM+*F/E^VVM1&=! 7) XIB?@%
M5.V&>Y;]ECL/GBV#9_-AK[_=M!1-+>[L':G;Q4H#=?U(B\Z?^].'SZX6+&B?
MV$9M1.[D@@,S&46)?9>V8/]-(^]GPEK.:V9-CLY^[,>2$T"A**1<[X.AZ:1X
M54T(WV11HV+N;FRH,SX?:L.X+GZ=]HNSK9G@!=^:Z1FXNF "3R%>/%97H%S'
M;7(O(7,%S7D/T)3PJS^$[]4I-2=[VT-613!+-3DR,W-\'@XK_4?AM Q2&%Y0
M1B#[@V,QT*L#U@JWQV5QHZZ?^_[DE%TD#=LXU04]2M(]J0FQNMJ&D8;I7[1E
M+\2CZD:Y@JIT[8E'O<A?\&AR3>:_K2(,R]V%:1..PXE-4V.^&?R10QJR&_NT
MBM#W8NEPUXJ+#)*;_NE$*F<\Y*: ',@5R!RG=J !"O%APJ>/KJP[+-ZBES!9
MA "CDZ;:UH3#\G-[#\Q@!VYC!T9D$\=A"'>7X:R<N)2XC6M%0[7N65U36>)F
MWU0(O)HE,OGV'/I!I5U]T=/TW(($C9"'*$EY$3_23,,7V\U!(UF6]0<OQN=\
MQM69[_@V6RBINBHKU(JCR?0'OXA,]#^W\*!'I'][??N#LH]H1\"O#!#N!<M7
M%Y?%+I XTBF"9%V'S?-NQ),:+R(CH?8:NTM]Q@P6L(TS]LJ9S^C0[::230&6
M,+L?6SJ-;=JWB,)7<#XW?/>TIN\*:"G63=&OD^#7W(G8ZX(,GQ,9.)'T?+2(
M&O5N@_;IG7J9X]'1]R5'D1ZI)7U(Q>)"/*AH@VOE'"N_2PY49HKUK-6]4C/=
MGH/[0L\D4-/E@$&F7 B=\[_U/<\0&^%GN%G8/V,Z<"2>!LBMY3JN<7^I!OUV
M$AMPB<'%RFD)+J$.(UGAXW?Y?5%29F>KQ_#H3-#>DC?D)*-.2F(,(80SH69;
M+N@?*-EK:.<0+D&Z)1*B.?=GJO--7?EL.I^<S.E5;5@R R;*5=G!RQ[-SJ].
M?D%N B3"N?4=.<O;];!J$ND!('D4I.R[QJO1MLD$7_%\]VO@.Q]GFTK:0)U'
M6 ]LE+"3\U-\(&PXZCJ1GGR'N.UU=OJ&$LH9_&?!ZJ0$JCE!C*[%NQ(%([H]
M6WP%O]'F*PX5CXVL (J-:-5C_N.*.?U6'#ET\C K3G/WA:R2.XX3TWHMFEBA
M$TM]]J!_"2,26M"@9]&Y -*L0ZG].9*^L%1[\%61WF OH0@3PGH!7!I2R/7V
M'ITHAQ (K.G6AI0(O>@M@68G-X$$I[^*3*"G4%@6:]&6Z#>?-&>Z2R1GQF:M
MM)TQ6D,(5\W.J37F0!6,$8]=CET($8>N[<?H-RY!F\,=>J'I[[X0-P8W9HO.
M_V\CC;?Y7;U%QV.<.%P+TJILZP.21@)+8 IB)>QT..9-=&^:VY^Q9,VMLQ%+
MTBE-Q3F54U^&F,GS/@/4U1\X7$U^VYR^@0*3L5-?I4U),Z:8E#)FN# D2VH*
MFU>+TZW68=JY:%V]5@QJ\(6<9^$T:2#J<])P'9)T2Z=GN<@<F[+Y9F8\LMI_
M!HU$D2' 6LQ%V92Z^&"3]TKQ%TAE]CUT!'/K:^J257%+F[JB!M=MX<O,E]D]
MN=XR2681\J&*'Y@95VL%26,XU30N=S'05J!WCHA>4KDZLOQ9-VFTNXCXF=7D
MT$LFJ3[F/O"Y''+)$$L7.P[M9;[3T^%5ZIQ]1+XWD@@JZO6-%.HYL7T^/#]I
M\U8<IJ/8;S'!-Y^;_8Z66.CJ0C9H.$KMX"$8'29L]\V<RM]L_00)8O0_BQRF
M)(I5@9[O^PI9H<T,1=>(6Z<401J/=-A'-*BTC#;<X1")8I*2%K%DTG"(&GSK
MD MW9M.2!^Q9:,A6><P[<0_)465=S^W3]\GQZ$1P 18[G3<G^(JBKPN&1\>M
M1WN*KY2V=21X<W+2"B)8Y VR#>"AZ8DK0HT_HR&F@[^+G//X[*3GV.E:9ZT<
M(R[VH?A?SW><?H_4S%U?G!BQ920.]%@BZI06HLB-1#6I=H_%>=KHEX<!]BH$
MZ0"A!''%L;KBYCG.^U(=@3.AJOHE"H+='?0I9ROVB6!'*HR3X/4TXKIQ/@=N
M2B;N*QH!A?;_>;,E<-T;\"R#14S0,P&(,'_$E#CAQUI:B:N,,:G+]]R?(*R!
MBE4"$<I%*>6O0<Z]CW!C$=F3VY*TC]FPB2GF#=.5P^+:[-9LW<C$D#5J"KW.
MLO%@H^H-(Q))&OQYEDG*<B9T>2II82>#Y">7>X-)B_()6R[KO;&NKNV:MYP>
M)F<%G;(VE]50+<R+':?W%/ES;#+"39U"EOJ!L9!%\*LBDY *(D/9+:I$)A!L
M<)O?M&MJ3 FN*R20C#JO+1IH4N5K\@ZY?KD.2C+^>"-6J!6"R'$FI[,S@SI6
M7[#@,B_OX5RUGHUZPYJ(C>]S8HH>X$4B8$V'\6U/BQ*]JZ7 ;H+16RT?>3LE
M0$>QGGI[+ZS7M]".R?U#=DXZ, <T86XG]JZC^YG/0_;$.F1#B3J<&M)8C\EW
M'7>+0B,\ZZHY1A2TEK;)7SA)8WX<5]YB>K?YAMF"2KLTV0V!PF<+ $/H?,6S
MM<KS,7.PJ$8L<VRIH B/QWG"6T']W?LZA]F=DTS44V1-$;Z?ABE&GL&+<Y]O
MM>/F/L8@%0>E(+T; $)N&N==8[H9SA-V.![R\1?*;^S$J!"U<[Y="K2<ZPG1
MB]O3?K^G;PE]_U5REDXFV#1DE(Z&DZ-W;8#C*+JQ=0L;G.,6OK'#-1[!V)>7
MR7B<7@ZU7TH_WBU,Y3P]&P^Y:<K5:'@HAIP!)GMODIT.V58OG'LRID*[N<;$
MNMKU0M@SP0\>QJTY$IPN^?^Q_/^$=^2(I_\=GTMK0W@#;4LR_Q/_L=,^YH!7
M_NGSY!/N^6AP_&Z>![S2!7W-*9OPC2M9@L-BG^R-5*S+\(<<_5I&R^UH$HR3
MT;)H\5)O<Z-G<UT2CZA%%^]B,J3_'YY-CSZY6O4FN3R_2";GDZ/7H,(]9=P,
MV+ZK&S4^._KE^HO]RV1\D4R'5T>O%5-[!'<<_G?T,;*P9#I*+D='GP[=")CK
M)!UR5Z-T>-[I4M4#RGO88<101CME8ZH7DA70UY?I?10O]^@,>?D(>QU=7"'?
MNYR<A6<F$$?HTW<S.)K@6V?8KVER"?^]A)-B,"P+)HSVR[8N*?U?W\"^>Q?P
MW_'D_.@\G5Q>).?I%1S8>V"AW[T S/887IZ.L6G5>7IYA6T$>SLV76LI8N=:
MO)0M9F:DD!(,;SSP7NBL>K.HD)I&DTNZ">?3,_?",K^7,ADT2&#;V.;%RN]D
M=#5-QM/+%EE;QCV%NW5^/C["T2^XGU9Z=G86R0,![<QCU]^HYC<[=*^,_?-O
MC;.2T0*V;@,N$/3?LN7=C+;J:@G9,=A!*G#EBT3?1X0P 1<2-@%;L\,/4_@!
MI*?\,-(?QO##Y CW*6<#_.KL7)BQY-\3 NAV)5Y7.VO<M/.+;FNPGFJ>PS09
M"C?W%_:TW_5MY4R'N7YN"ULRI$L^/OJQO^IU>G&!-'1TVU=EQ*E]=]SX-\C2
MA*$ON3W;^?/+U"H8 8SLI/:I^>/:@?H?KK5#\=''M4L8^7_:N[;=-HXD^AQ^
MQ4 K;RA@Q,SP.I-@ TB6$CBP8T&R'2R"?1A3M,.-1&I)T8X7_OCMNO1EIJN;
M,Y+]MB^"(/7TO:NKJJO.<6D=F_$?$_5CF@[+ D<_F&9),5#VAV7.^YG3@_)R
MEA9*]BM!,I@6O7-.U[@V!9^"P@]9X]]Q6A,8&_E8G2,B QV5TT$Q:MNO*?,Q
M0E>&DT&1)>H',/KEP]SV:98IX8I_'92CMGT:CM.I&C?T*9^5@W+8MD\SYH:<
MH5(TR&&NAB[+X&O4A\G6\3\>%=-TBKM@-)B.U;?%V/GV#7^)22\FL52N*1\7
MZ6PRP6T[&)?)=#"=V*JBJJN'*5I/QN1DL$85R5^W-]]OE9VZ^,>!)@,Y^-$2
M;#I<F[WS6K)('R_=H]Y$9(]5EUSO$DQQ/T^GEP]&L^R)^%D^F&39$U6B* ,E
MAH/A=/*D]\;D,O7*(E!7-E8U9<43V_%&[@IF0=528'K9 -JGGY<FQMJ++'5R
MBNV\]P[5ZD][AVH09=)<*AU>L%\@UD,-=1@?B1P60"1YR!]K<<ELMF-89H:H
M.,\@EU-9P<2;F=5Y,S4Q&+)A3D>@?!3*6@3E P.1PQVI=Q@J'*6SV9@J+]+Q
M%%DWG9#\OHF!.O(#XB/M,+2,18DV.<S=:4E92Q(WU;6=)\]0B7ZH@QCSM%3"
MKE0R+5::R$%L68WP%>^3[I'NSS,;1Z+G]Y K/81J8[M0?]!A$;KONO_/])JH
M0U>@[=5X /M<SU$L0R1R("R4#CT6SI':F9Y$:@X]>(78H97SCM,&=1X8Z*(8
MJBVH/=W7^DM("F>:==JW&5=U'QM*7VD&!4JN85K,9LA1O\4LM$7#TH48YGKB
MFE),DA'U?XL[B1)G#(Z*JOX2<U'.M%VO5E[99(52K$_LXUPT^053A]]A[T#D
MJN&G0V6E'/6>FFCM#W[V'-C=PQ(&-RY<08UAR6ZLC8WY-DE^#M 0FJ5 >EUF
MN=/@ZRL(BDLN88!ZPX_3/-?>@W=N:TI?&26S:=Z#I<.-CRNG]GX25_]=YJS:
MS8=Q#1CE]NU62O[KO@4A%MW!D\$L!,Z4Y(5#6'0U+LI25PJQ6H\):,:C0BUI
M 7X48YNG#9:9U;7+@!)T8B3Y2*EY>=[@*!^FHREX"< U%C1F.$5*K0(8=/B3
MUZ(ID,Z$9,DQ:-WC9#Q.BV+6$Y(Q4<!(:99]_E3M2_I:[3683*FL(*ZC&4R4
MNM1&,7H;3RS:2LE2_PP$R+N[8G>[0#_/]X9+/,C\K?5'8GHT)/+ZL:]J,,I3
M7#6H5!E92NH7567O%&6[!OK $#\0[PN#?&^8Y]U62)]WY[<_2J?JX!XQH_V6
M[P_QZR:'?:.>R4@O:C0[!T:DLW-HDDH]2<H@+,93Y$=GGE684FV_'N]+RMHQ
M$4@CFXDO8&'Q1^E8V7OE;)K,U"R ?VU(0MI\+-[A?D4P?F5W\"@&Y20NL>;&
MN6/?*.$%R:93V7Q[449%=V-=*I"E7+!U.N5UEA<T3Z=E03][9@<T"^DUST=#
MH';K/77S[C\B]#1#^D(IM>_++%4F&3N(>*D0X.):!P[H3$/8?*,R3S.U(H5:
MC3(M<L\G_+/%L'_FH/*W.?X._+T#"][]%N"(LEZ#5.\P*<:NQ4\CUN%GS?_J
M@]*KX^ZC]32L6T^-=OIE.BE@LRFI,AJC_8,M&:$8DCWR:-QG%*\S^23-R3^O
M#OAPV.R*4AO4G3-4RD/N/1N5Z92\I%.U3T#[ 4^C0PZ&Z55>@_!%YC4S2H8E
M-R#7DP1]V"^=H).&=Q7/\"D!O+U++@SF"6RG,\3335XM_@+/J[*?CY4V<Y;T
M#V%*O]/[&'2<%:8<'\+OK[25V.Q$GKR@ATW<5\W_8C#CC%Q;@@]\8/QQHMN4
MA>FWG :38CS"9JNE_?;N9NF]>T#<ACH QP3<_'6F+,EATFBB(B/V'N5JK;]\
M9UH^,2V_;+3\'.+SGH$.*3GCM7!*I>1=L.WISY[D."5SXI)GD\3JE32;)^@%
M;U'PRKZY7SE:JYL#IQG?O0T8VQ@SWIK,5!,M>O[Z$@-<1]/Q#VT^F'+=T8T9
M*",-['>[6O\2(QH,$ZC#^0F4J6)ARQ8J,(4&OY+* J/HYX0GY@%MJ>^#SGB?
MK66KV@I,OOVJ2=?"VK7(\!*LK@GM'GIC39.[&PVZ:$V-S\D+>LMI?G8ND7DV
M"XWH7;5SDT UYS<YD6N37V?#/0^7EYO- ^VZ)]B&E4<N#E\:(.N-?3",GPV7
M,D?CN\E&7F"ESZKE<O[',KFJ5G]^6GNA)OKISJ-G8'XN;Q4M*@<GI2&0.>*/
M,_(&1@$XO!+(JH>)%QN*7ZU(,6,P^FM#H>2M02:OP:_K>POL28&2=5 YKED#
M/'#.&Q4$/C.E>JI[ 9G)82U3"%]3?YRKO0D\Y[!'UQNWR\1LXG5DRI%+#^X@
MO:3>5+L5<1A5JOV[:@[\)TL;9,GXY;71I,PLQ<0FQ+9##+$<?::,[&IWXTF&
M?!CH=(#,H'] _S@X4H>EP>!T91F<GAL&)X-/+V .2R0*EDND$EA=.H2_G3$9
M0DUIB^EG4(6/Y_7E ]B\-YUX!-MCX]6<>;BL!YJIOU#;;6>(8[7DBS'<8]<H
M>$3T5><%;=3M5*V-!MW$[R=OMRB[/8G;+?Y*[,$G<?<'HK":Q>J16'XE%) E
M$U#$ \[L!7QA+F GO.H!LQVYT#L5AO!Z9<+Z=W:G&*=.XTW!<&ZG),3#QZ+[
M1XH%Z_Q!6*EI]:FLW\2CS[J5#G=P_W=R[UIMU3;:UEDT*"X0*G0!J6C 7XWW
MDU97\% ],%:N\]G:%^T6*A\)=HN+C$A 7J<Q=C-=0TV=1)N**\S10#RS$/'I
M;T3))2]-,%NSI V(DR_!?;%Q#^I_P$&E1O2"6+/\ 0&M$TU^Y@7$XQBWJ4GU
MLNF LME%@3Q18#Y-4M/\?A@PJRX7ED0#77MQI]<Y(5!U$ 2_[&[L[A/_.0S\
M\VKWEJ T[I/S#_OLM;KH@.1D2T9CG5)AXU][&"FK&7-3[$M/^+,:#"Y][ U#
MN_8OC&O_2NK+Q89-%WY(V7G FAY>^)[18<;?QPTDP*^2"X!,G@,3,%%X?DZ>
M5]>+U=O=YKTZCM4-8*QKA,8U)'W/O0R8Q]:'7I-VDV&")Q$]9;F")R 3*_=5
M!@M&%J!LJ+ZAC]E;1HM"CHL$Z.[HS[P&TVSCO&)Y1\!N%X*$9\Q*33IJ-BNR
M452^[OFEAX;V),%0[CD4#@YUA2Q$8/A";AL,Y"'?\8O55QOAJ;QX7[K^/3/X
M%9IK>W!:B6MZ*VBG$/VR6PW@.4I\+I%>1+PRE1-0G=(I]BSMTTO*.#R W^"+
MK75G''@'ZF*Q 5@[1E''L/PMO:6OR*#12(EPFKP1C2!8]&'S-NPR;^IJRS/Y
M)8E6%]XE\.*(ZU4(O *'B'ME=E)CGF#74/KS3\O[_[Z'>*IKN['2I'] __;G
MDXT!!W5YK=L@@?=NO8G>-.UF;Q11$ZSP8!'AOALU"__&10Q1 ?92F#FF5W%2
MZ?D3#!+FUW-/?U3[\#?]LJY4HR4![PZSX7B0**7DWPQOKW.@X:'BCAF%JX1F
MP1G(MH$Z@!AB&E['C ">W#!1F/R4<.C-]PP!R#7W[]?OB0 7W61(JD'_^G8+
M0.X8F*C#Q;!:Y$;<8A(#./L($7N-_)V!FA#T8F59PX3ZCY*/#%JG0V. />,C
M9%GNTU,XW7Y!1V \*,LG  Z0:C?> @!2G,=0[<Y3)4HH?&0"YDWUP,KD2F3"
M)Z\E$:#']STA '#6-/#V$BD:K8*/\=S<E89JRM?SZAJH65CG6V\;-Z/4X_NY
MW2$;MWL[#]DKGD;,(4G^>)T0)@/<&(E?BLOPMS>J"+C3=>QLLSCNDE@73'7-
M0F7@2T$V$%8NT[6OC-QS0[7VC*J_/,*=^6%]L[L5$*[-3,&&K9T):&J4$7[@
M?*>1IPCRNOJTY>O12?=-Z$7HX(A?2B&B,WMB(0DIIW\NK!+\/Z1/)/VME7!.
M'CUS)"'I$KV&>5$/:,C.J[OE/0#I:XYU*F#9/U#)59)3Z<PUS.(C=4$M>?:N
M*Z3SX^'S7(+;"%3(5_SGL\H@(>,A]J?&3,SA),L@>@IU=&=6"?MGJ9MEV<?@
M(0#@MT:" UYZ0CFP,5 (YX3\,<O[W3VAK]RB8+=_3.VS$,0IWY$NZ-;"X/G5
MEO8^@^ X,2">4#)!C1C)W#*RD=9V:0Z*=P%/1:V(4.?!KG5,'S%P\_GR/X T
MP4!,"\U\TLY"<CU=NQ4^)=3X8I0 Q;A04W?P #Z\II9=O2*QR*E79,&QK\D8
M<JW=!RQC"8Q$(]Y:J-=Z__;4ZLGC#N-)+J0+IZ%FWZQ1;4*=VA7YCA#31Z+>
M$43;H[.(H$";:PI&]T9(\^!L9S\X().VJ9W0FLAD_"DE56M_KG$$Z%')XW%[
M[@WK02,89MB)EB-@^4;=?617$;NR0A15,P]V*5#/ZCJ84:?!$!Z.JG1%K_0@
M4G?W:Y"#\\B^GHAM7"ZN%[>6>\UUG+7;]\]JC&, !>M(4:7E(ZH,:@9G"Z7C
M,@9YQ9!OH@A5!>\U;!X\!I U9;J0\ELP'G"--M6NLUBS!<!.T1$L/('6EL\D
M3UX#=/T&J:H;71)53"DQ_ 0TV/<<N]/]5:5[FO;C>D8.CGIH]J,B2NV6U@G*
M+\/F:2"'600"Y5"52&"DSK".%+'9UI%")@%;C=Y)P0Y_$!D&IE2T'4 T%=M[
MA6^?>QTTITY8V=;30K>;35[Y0NNU_]BZ2[>_='B!]G_;>:WV5^DNVV/J":_H
M8VKU%OMR<5LM<:6>.A >KS#S'9.*VLQ9LTC!^,,Z="L9CL3;B!_7DM*4*\5R
MNKZ<RJEZI5)[9SY8;6;:%RONN!2>B<#-S$PK8[$9^WCSS#S>O)'<OAV%^E 2
MZE:8>T[E=@ +EGE+LZ+666VI^'&3X573JGK-UE 7 E/H+8QE>HVK&'E62 IP
M>\"$/?6+ZO5>7 4'RJ+=Z0V%U<@ %/OF9%#X#A[ K/#^6(J3%PB%(> *O]Z)
M7T.>C8-O"FVW=\?<EY#_#E,]AI'\%;W]PQI.'(#$]UK*3-+M-H)S1ITC92 B
M!3?K_L,9-V,UY3E8'Y@U[*W[1%K+"P?FF5;TI3R/".0#P5/P:-=NPK=UET+H
M=09"_GUD(LI\#JQ5L#/AR+$W/#_R%9"C_.K4C'RZQK(@C-5TSC3'6TX&W2BI
MMO:K^%F">O%%FM86:NR;GFT"\PV..[Z0M[$%]3)G-Z81Q/[>+I%.E!"'6=EA
M. F'3R;>'U_R[+F+W0D-[N'VDZN+):>,F@%5=TK#N(!H=34:^#!8N\;D@)!5
M(5)K1;G.4,UM==U,-]@9H.L[;NM.:&N<Y4G_SR.Q'R^J^_D?",/@-@4Q#-3!
M3>)>2 Z9MV;B-@ (E2>-\DR\8Q_4Y.O!U<!MT^$\=7>.?P\0[ 8XV0%#:J[:
M0[40<=_Q69,?<TQ/MF:B7;9SMMNK^WO>Y]RO22!_Y(LU3(]Y[=NU-"7O%[:=
MA=GS^,[CI$6CE.W<5\\J"'2G_096FS2T1QF?JK,K!E.6^^1J.6J+[^+YHQA7
MQ[O."6$DWM<NT2>GCT<UTH&LQ\EUH->VQ#NY_[8 H@_YWCGVNX6;\/&&4KFN
MQE1U"#BY?# L4:2SW5![_)>JMI ]XBYM!][C69^=$'R\I8[!]P2V>U?XGG";
M#H*/YZWP(7SV[)U1^[W3$6C'/P"/1MD1;,XHI(XX/<&#&08AZH"J(TU:BV*U
M50D'D ?71NV)^7ISM]Y0-*PYFM*!&XEVZ-.VGP]SV?R'+,@E,5FV&/#KK=:'
MU"^_OGR.EHVZ\.8<9@&$2'2+!@_6SJMB&:[E[W_+IZ,?)I"Z>%-?R"6'#!"-
MP VDV6JF)[7$% .%45)OUYKUR'R,M!/ _\O)M972+IZ8/O!LT*L9L*TPE=1<
M=0O?S#XL.%/]!F,(DK>J,0@-X"/D+9QH=/Y$\M7;># A[H'T'8@NGD=$O <.
M4]UB-IALFBT-.4^0S@'^+6%*W=I8#$__G05<3/)Q_YS$!R-!4XDZT4.>?!AF
M2FJS+>B2+Y(LUI)XZ=EWS&,!0ZEEP'EX4F(P(2=*FS*82%<VAON\!A_T%%4!
MHV2<5QM0P=VV8N&L[7")!(VY;5R9")#D^0@"J$:=M>E+S=:$(SC_2YDEH'A8
MHCM,$EZOWA^[&#K1&;J4X03DI%X9GB<@#PCUQS..&FDV\EWEE")>H>/D= W!
M8&H+G(6\!2^JS2#)"'BF"#OJS_R'ZFOA=L+:9FGOFV^@NF E$/,3JN!3DN_[
M/F5*&;&&DSO5A5RHX[OM]O['_P%02P,$%     @ %H1^3&+9Y4Z( @  9 X
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MT\/5AOQA@DRDBD"580*\-HV&#&(K1]'9W#ZU3#SKU%IR,X@HF4E!<@WK'<7
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M;]OANR0/SFW>Y[/IGWE7_P%02P$"% ,4    "  6A'Y,'R// \     3 @
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M2P$"% ,4    "  6A'Y,%/ROF1P"  "C!@  &               @ &"#P
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ %H1^3-%P>QH"
M @  /08  !@              ( !U!$  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( !:$?DR>Q.4T?0,  .\.   8              "
M 0P4  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    "  6A'Y,
MT$.*WBP"   +!@  &               @ &_%P  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ %H1^3+<4@6EI!   3A4  !@
M     ( !(1H  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M !:$?DPS-/] M@,  )40   8              "  < >  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    "  6A'Y,6&D\?;0!  #2 P  &
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M970Q,RYX;6Q02P$"% ,4    "  6A'Y,-$RP-;0!  #2 P  &0
M    @ %#+   >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M !:$?DP.I70@M $  -(#   9              "  2XN  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ %H1^3'<\A"^T 0  T@,  !D
M             ( !&3   'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    "  6A'Y,=4#T-;,!  #2 P  &0              @ $$,@  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( !:$?DR>\@_ M $
M -(#   9              "  >XS  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ %H1^3&"Z*8:U 0  T@,  !D              ( !
MV34  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    "  6A'Y,
MN',$O[(!  #2 P  &0              @ '%-P  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( !:$?DR@3AQZM $  -$#   9
M      "  :XY  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ %H1^3#@X/URT 0  T@,  !D              ( !F3L  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    "  6A'Y,T1V;>K,!  #2 P
M&0              @ &$/0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( !:$?DS$9"R)M $  -(#   9              "  6X_  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ %H1^3*0YKER<
M @  K H  !D              ( !64$  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    "  6A'Y,[ N1X+@!  #2 P  &0
M@ $L1   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( !:$
M?DQ/(7C4MP$  -(#   9              "  1M&  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ %H1^3+?<4&NW 0  T@,  !D
M         ( !"4@  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    "  6A'Y,E,:(?;<!  #2 P  &0              @ 'W20  >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( !:$?DR*3<[UMP$  -(#
M   9              "  >5+  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ %H1^3!@LA[ZR 0  T@,  !D              ( !TTT
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    "  6A'Y,S>Y]
M6]0!  "<!   &0              @ &\3P  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( !:$?DS F))RVP$   $%   9
M  "  <=1  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M%H1^3-GB63;% 0  -P0  !D              ( !V5,  'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    "  6A'Y,M%Z8H;8!  #2 P  &0
M            @ '550  >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( !:$?DS:FW-I90(  &<'   9              "  <)7  !X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ %H1^3'?U7=@( @
M!08  !D              ( !7EH  'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    "  6A'Y,+Q7>N.4"  #]"P  &0              @ &=
M7   >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( !:$?DQ/
M?I4/2 (  &X'   9              "  ;E?  !X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ %H1^3/Y?*('\ 0  9P4  !D
M     ( !.&(  'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !:$?DR*6XV<^ $  &\%   9              "
M =YN  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ %H1^
M3'8$\$C& 0  & 0  !D              ( !#7$  'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    "  6A'Y,R=X63/H!  "^!0  &0
M        @ $*<P  >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( !:$?DP7P=0:  (  $(%   9              "  3MU  !X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ %H1^3!$N\^NA P  '!$
M !D              ( !<G<  'AL+W=O<FMS:&5E=',O<VAE970T.2YX;6Q0
M2P$"% ,4    "  6A'Y,,2=FO!@"   "!@  &0              @ %*>P
M>&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4 Q0    ( !:$?DRY<P.2
M&@(  &@&   9              "  9E]  !X;"]W;W)K<VAE971S+W-H965T
M-3$N>&UL4$L! A0#%     @ %H1^3(O^PT(N @  7@8  !D
M ( !ZG\  'AL+W=O<FMS:&5E=',O<VAE970U,BYX;6Q02P$"% ,4    "  6
MA'Y,FU[(3\\#  #E$0  &0              @ %/@@  >&PO=V]R:W-H965T
M<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( !:$?DSNFTC%*P(  'H&   9
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M970U."YX;6Q02P$"% ,4    "  6A'Y,U4A$4!0"  " !0  &0
M    @ $'E0  >&PO=V]R:W-H965T<R]S:&5E=#4Y+GAM;%!+ 0(4 Q0    (
M !:$?DQ\?[ES*P(  ($&   9              "  5*7  !X;"]W;W)K<VAE
M971S+W-H965T-C N>&UL4$L! A0#%     @ %H1^3$<+Q *M @  50D  !D
M             ( !M)D  'AL+W=O<FMS:&5E=',O<VAE970V,2YX;6Q02P$"
M% ,4    "  6A'Y,5N=H;$L"  ">!P  &0              @ &8G   >&PO
M=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0    ( !:$?DSTS4JYT (
M "(+   9              "  1J?  !X;"]W;W)K<VAE971S+W-H965T-C,N
M>&UL4$L! A0#%     @ %H1^3%G,N\!Y @  \0<  !D              ( !
M(:(  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q02P$"% ,4    "  6A'Y,
M+37QEGD"  "U"   &0              @ '1I   >&PO=V]R:W-H965T<R]S
M:&5E=#8U+GAM;%!+ 0(4 Q0    ( !:$?DP 9-!MTP(  .@*   9
M      "  8&G  !X;"]W;W)K<VAE971S+W-H965T-C8N>&UL4$L! A0#%
M  @ %H1^3#99)/W* 0  B@0  !D              ( !BZH  'AL+W=O<FMS
M:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    "  6A'Y,N=)Q+]6'  !S_P$
M%               @ &,K   >&PO<VAA<F5D4W1R:6YG<RYX;6Q02P$"% ,4
M    "  6A'Y,8MGE3H@"  !D#@  #0              @ &3- $ >&PO<W1Y
M;&5S+GAM;%!+ 0(4 Q0    ( !:$?DQE*EY9S00  +0K   /
M  "  48W 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  6A'Y,%ZTLNCD"
M  !>*   &@              @ % / $ >&PO7W)E;',O=V]R:V)O;VLN>&UL
M+G)E;'-02P$"% ,4    "  6A'Y,<"V0'/P!  "A)P  $P
M@ &Q/@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     3 !, ,84  #>0 $
"   !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>135</ContextCount>
  <ElementCount>290</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>49</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>002 - Statement - CONSOLIDATED BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>003 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/ConsolidatedBalanceSheetsParentheticals</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>004 - Statement - CONSOLIDATED BALANCE SHEETS (Parentheticals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/CONSOLIDATEDBALANCESHEETSParentheticals1</Role>
      <ShortName>CONSOLIDATED BALANCE SHEETS (Parentheticals 1)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>005 - Statement - CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/ConsolidatedStatementsOfOperationsLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF OPERATIONS (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>006 - Statement - CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/ConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>007 - Statement - CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/ConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>008 - Statement - CONSOLIDATED STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Consolidatedstatementsofcashflows</Role>
      <ShortName>CONSOLIDATED STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>009 - Disclosure - Organization of the Company and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation</Role>
      <ShortName>Organization of the Company and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>010 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/SummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>011 - Disclosure - Significant Contracts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/SignificantContracts</Role>
      <ShortName>Significant Contracts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>012 - Disclosure - Cash and Cash Equivalents</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/CashAndCashEquivalents</Role>
      <ShortName>Cash and Cash Equivalents</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>013 - Disclosure - Fair Value of Financial Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Fairvalueoffinancialassetsandliabilities</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>014 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>015 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>016 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>017 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureCommitmentsandcontingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>018 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureStockholdersequity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>019 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Disclosurestockbasedcompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>020 - Disclosure - Employee Benefit Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureEmployeeBenefitPlans</Role>
      <ShortName>Employee Benefit Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>021 - Disclosure - Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureTaxes</Role>
      <ShortName>Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>022 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureNetlosspershare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>023 - Disclosure - Geographic Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Disclosuregeographicinformation</Role>
      <ShortName>Geographic Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>024 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Disclosuresubsequentevents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>025 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/Disclosuresummaryofsignificantaccountingpoliciespolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/SummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>026 - Disclosure - Cash and Cash Equivalents (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureCashAndCashEquivalentsTables</Role>
      <ShortName>Cash and Cash Equivalents (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/CashAndCashEquivalents</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>027 - Disclosure - Fair Value of Financial Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/Fairvalueoffinancialassetsandliabilities</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>028 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>029 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/PropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>030 - Disclosure - Accrued and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>031 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureCommitmentsandcontingencies</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>032 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/Disclosurestockbasedcompensation</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>033 - Disclosure - Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/DisclosureTaxesTables</Role>
      <ShortName>Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxes</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>034 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureNetlosspershare</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>035 - Disclosure - Geographic Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/GeographicInformationTables</Role>
      <ShortName>Geographic Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/Disclosuregeographicinformation</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>036 - Disclosure - Organization of the Company and Basis of Presentation (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentationDetailsTextuals</Role>
      <ShortName>Organization of the Company and Basis of Presentation (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>037 - Disclosure - Organization of the Company and Basis of Presentation (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/OrganizationOfTheCompanyAndBasisOfPresentationDetailsTextuals1</Role>
      <ShortName>Organization of the Company and Basis of Presentation (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/OrganizationOfCompanyAndBasisOfPresentation</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>038 - Disclosure - Summary of Significant Accounting Policies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/SummaryOfSignificantAccountingPoliciesDetailTextuals</Role>
      <ShortName>Summary of Significant Accounting Policies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/Disclosuresummaryofsignificantaccountingpoliciespolicies</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>039 - Disclosure - Significant Contracts (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/SignificantContractsDetailTextuals</Role>
      <ShortName>Significant Contracts (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/SignificantContracts</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>040 - Disclosure - Cash and Cash Equivalents (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/CashAndCashEquivalentsDetails</Role>
      <ShortName>Cash and Cash Equivalents (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureCashAndCashEquivalentsTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>041 - Disclosure - Fair Value of Financial Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesDetails</Role>
      <ShortName>Fair Value of Financial Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/FairValueOfFinancialAssetsAndLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>042 - Disclosure - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/PrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>043 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>044 - Disclosure - Property, Plant and Equipment (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/PropertyPlantAndEquipmentDetailTextuals</Role>
      <ShortName>Property, Plant and Equipment (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>045 - Disclosure - Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>046 - Disclosure - Accrued and Other Current Liabilities (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/AccruedAndOtherCurrentLiabilitiesDetailTextuals</Role>
      <ShortName>Accrued and Other Current Liabilities (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureAccruedAndOtherCurrentLiabilitiesTables</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>047 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/CommitmentsAndContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>048 - Disclosure - Commitments and Contingencies (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/CommitmentsAndContingenciesDetailTextuals</Role>
      <ShortName>Commitments and Contingencies (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureCommitmentsAndContingenciesTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>049 - Disclosure - Stockholders' Equity (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockholdersEquityDetailTextuals</Role>
      <ShortName>Stockholders' Equity (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureStockholdersequity</ParentRole>
      <Position>49</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>050 - Disclosure - Stockholders' Equity (Detail Textuals 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockholdersEquityDetailTextuals1</Role>
      <ShortName>Stockholders' Equity (Detail Textuals 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureStockholdersequity</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>051 - Disclosure - Stockholders' Equity (Detail Textuals 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockholdersEquityDetailTextuals2</Role>
      <ShortName>Stockholders' Equity (Detail Textuals 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureStockholdersequity</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>052 - Disclosure - Stockholders' Equity (Detail Textuals 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockholdersEquityDetailTextuals3</Role>
      <ShortName>Stockholders' Equity (Detail Textuals 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureStockholdersequity</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>053 - Disclosure - Stockholders' Equity (Detail Textuals 4)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockholdersEquityDetailTextuals4</Role>
      <ShortName>Stockholders' Equity (Detail Textuals 4)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureStockholdersequity</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>054 - Disclosure - Stock-Based Compensation Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails</Role>
      <ShortName>Stock-Based Compensation Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>055 - Disclosure - Stock-Based Compensation Arrangements (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails1</Role>
      <ShortName>Stock-Based Compensation Arrangements (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>056 - Disclosure - Stock-Based Compensation Arrangements (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetails2</Role>
      <ShortName>Stock-Based Compensation Arrangements (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>057 - Disclosure - Stock-Based Compensation Arrangements (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/StockBasedCompensationArrangementsDetailTextuals1</Role>
      <ShortName>Stock-Based Compensation Arrangements (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>058 - Disclosure - Employee Benefit Plans (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/EmployeeBenefitPlansDetailTextuals</Role>
      <ShortName>Employee Benefit Plans (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureEmployeeBenefitPlans</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>059 - Disclosure - Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/TaxesDetails</Role>
      <ShortName>Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxesTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>060 - Disclosure - Taxes (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/TaxesDetails2</Role>
      <ShortName>Taxes (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxesTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>061 - Disclosure - Taxes (Details 2)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/TaxesDetails3</Role>
      <ShortName>Taxes (Details 2)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>062 - Disclosure - Taxes (Details 3)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/TaxesDetails4</Role>
      <ShortName>Taxes (Details 3)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>063 - Disclosure - Taxes (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/TaxesDetails5</Role>
      <ShortName>Taxes (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/DisclosureTaxesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>064 - Disclosure - Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/NetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/NetLossPerShareTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>065 - Disclosure - Net Loss Per Share (Details 1)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/NetLossPerShareDetail1</Role>
      <ShortName>Net Loss Per Share (Details 1)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/NetLossPerShareTables</ParentRole>
      <Position>65</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>066 - Disclosure - Geographic Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/GeographicInformationDetails</Role>
      <ShortName>Geographic Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/GeographicInformationTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="cycc-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>067 - Disclosure - Subsequent Events (Detail Textuals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.cyclacel.com/role/SubsequentEventsDetails</Role>
      <ShortName>Subsequent Events (Detail Textuals)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.cyclacel.com/role/Disclosuresubsequentevents</ParentRole>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>cycc-20171231.xml</File>
    <File>cycc-20171231.xsd</File>
    <File>cycc-20171231_cal.xml</File>
    <File>cycc-20171231_def.xml</File>
    <File>cycc-20171231_lab.xml</File>
    <File>cycc-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>86
<FILENAME>0001571049-18-000206-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001571049-18-000206-xbrl.zip
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MHNG=KE#401H'GB9=[9Y)I)3[UEFV:=\$06ZL!^6ND*/5;9\@X5K==L?9A3+
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MBJ/-DY.SY:&-4NY]$*PK?&IQN]7M[90YYS1PU@?SZCKTR<GR,#_2!I^ QE\
M=B-0KKJEQ\UF>PDHZ<IGO/)[&+C;O.&UBT:"Z>"L$>B564/K^ % &R]L!UW;
M9U/1=16X5D;05KNS"%QHJQ?)D(Q$@8?0B*#/ W=S^_<]%J\"X?_R+ $>].SE
M.H%9?M-F %,,RMBDM?51@%BAS^#B-Y\)X!]];;/J-3WRNG8">S?:H'+G-_AQ
M$<?PFV[/N5,4LF405@9O=2U@8?BF!,]NQWL!"O9)Z09;#<ZZ(%YU8]NG)XV3
MSM(0SP]<_Q#&\>\\N>[=LN];V?NC3LE&O220FU[?JB=UU#D_7M?ZRIDHQE!O
M>0_#3+=S9&T@F'91<9X/V@86LO+9M(];)XU5%D*\#!OZ\"B64<+;N1(>MSI%
MJID$9 U@KFRZ:'9.3S<%YOK\\,VSL_;)+H#YL"R[.2C>:C=+-IFMKF[5ZE-+
M<Z+=/+O%<^1F+_CD_!$):@-U@I;3#7;T;&?FMLW6XT  G77VX4176..D=KV;
MYSB9ES8GYFGWCVW))1UO?DF;RC5?6M';S=6MC7.>[\-9KL)5)F_ N[G&)4FP
M9#*9O2;#+7 1>(]U&9F(1YD'UMJ7L/Y@BV664#0,?F+1=40HX9&1ZQ./*(]B
M(V=A)"8:2T*[9;W1:$ZS74X#\5=5>7]M"VLUC_Z>^D=3R&49*^U7Q1HP:35^
M,Z9/)7GES^GA&_5^N<O'!^;QH)M&_=L!\X<L",A'!1Q5O8_9'->]BRAB09^@
M4\3K^ZP;1BP!]FO\6$7):S^+32#8LI2R3023Z4:JC_9?W%L_Q4Q)@\++?SGJ
M>P9<&UC%4L>RUE4LL!9*7YNS#B#SRG5,/E_523-E]6=GG=;LI<ME_+J6Y6[7
MWS9ER>WV2:O37G#1.['DE4ZX=7J\\ $OB-F+Y5SNTWF7DC5W9O&;/?GBJB>.
MWE#!=U([6P"^*:[<G=0%'KZ<1], FHU&67K. &N=T*]#\J\1^B4DP3KV_;AU
M<GK6.I\!]Z0 6P7FM>QVEC2_"M#+<M_M[/84\;%*L8+QY+Y7/L]DQXW+ Q:)
M4#9HX[TPXI\Y2,Y8MNZY&?EB\OXU362>-CHGG?8LPMBY)5_T$AX]?,6-QFF[
M6<V--['@K=/6%/!QPX*47T7A\#>LE[-(UO^JEJ^SDGMJ @8$D(HE&7:$$"T/
MGWG,L4\K_/D6^["&E%.FOM\"Y #T\G!M;#6KFN\>O)K,RLI\'JOGTS(0-XLZ
M)0@V#=P*R5X;A7P-F/!(<*VPHXL!78W,JC#!%C#V_+C3*7&[&0"M$_*U9U,L
M#/D-]WV0,[_Q@$=PF(%WX0U%0!79T""\O<T_.6F6XCX6@FPC:UGU.$Y:)\<K
MKN4RC"G)1/VT#5G?/#X_;Y>N6$4@5@1PU6T]/SYO+@S?]0A+3<*FYP&G6]C#
MH^9Q\Z24S#8)R.IPKAP7.K&7<\"\@CN*Z <R=] =WX+R%S.J)_D;$P&^+>\Q
MTX*.U[O-Y=C0):#;W*)6C]4]7\>BW@=W/*8D-7F2[P%6N%1L0^4K":%ID*P)
MVI53-YIG2X-+$2N_AT%8I)8M[&TIS'@*(.N!=0V,>EE@)W_=GNK1[A3W=BHL
MZP)X9<QMM,Z6ASAG['A]1\A$D,('BO.'@>(G\CW@*CS^*((P$LE8DP+(VN(H
M,E3D(T\&H9?3SW8D;;M3JKRUQ07N[KZN+(7.CD_;N[.M,)Q"Y3>@//>FI,VL
M&[7.SZJV8 *6]8"[NBYWOC2T<//>LE[<[)04S@((FX5M$_&V.[*@I4TQ1^=4
MT6;GX)Y7UNBHU6IN:+]73X \[FQH2Q\GEGPWUK,\:G?:)<OM;L ]%[6;K<YB
M8!<C0]Y2BXO B[.BK=Z_T^UI8*V9P7BS@-O8DE8OCMM<PY(*QW=QQX2/I<)N
M0\/1IR*MWPH_3:8X]M<N@,]GR:M%P-ST&E?FP\UC4%[7MT;-,W5(SQL6"Q<M
MZAL[M>KXHQ;:ANHGQK+F0+;>1:PGB H7T:R?GSQH$?_DHC^ 9Q=W<.7H\]]3
M%&+7/?K,\)9O^( F/?H-RF\\/N^<YLMZ&*Q;6>V*\0NPV@Y&7IRTUKG:624B
MIIM 82SZER\]X1DCGEGY8MU&Z%;C>-+.M?:E[,EF;2?M[TEM^AH$XFDI]_I)
M[]:6,E.WN>L4%31M^"]!Q)F/$;%JDG??W0$F>%T'9)ES98.I#R%,LD7&>=3J
MM%6Z_-K!W]T]V1+R'>#>KNPN.3YMGSZU+=D.NFUX:XT0V?*0V^17<'=N%QUN
M,P!:']RKVR5/6N6 F87 7C#I8$N%2::E3)UCVZ\S(\AJ2F+"VE:SEIHDBR8N
M;'PU"Y_->E+Y=N=T=FP]&RV_L7 2PNXLY\''<]*>L1[9T!E'E,_>II$(^K*U
M(>7M720?6?2-)_@S"UQ.<<H7_8C+YLE;"/#1!6U6!'575KNYPCBP4^TGM%.S
MZ+LR.&AOMF;U.*C3TT-:[>9(!G;JY GMU"Z2C$I2WFEV,DU=:)TW3UO-V5NT
MR/JVM$>/HE*=M9O-L_5L4:;$S$#&W_D]_;(-MWBS?7I62FA9!++'6<H&F2AL
M0T65S[W<AB4Y9$4ET!U=MEPMTE1&4K3@JVY4)+2YRS[!>U(IQF5=*Y><8/;2
M+],X"8>T>EEBZJ2P^F:CXGEQS3A2%/H^]^2N7/?@9@4P5&W$UUN1^/RZ]S[P
M,,PE5;%+ZM6J_9IZMSQN=,[F;EEI!]:T9TO+RAW8L&.XC)_NQ'X]AMQL-\NY
MDGN\_G44=MOM]3^<O<[1FQZ^?",*[S:<(M[I\RZ+N8<GQH.87*J?.:PF%@F_
MX=&=<+F<ZC-WPWY HTSO([1>VT_GK-2T<\-+VKOMVYQ2]\2W?O6ZPJ=V^Q[G
M.O(86T^WVT4F*DK"2RH,&<-K6XQ+7QG6W5GP!I%HWS9K72'^![3@36+'&C<K
M"T*0@2=8]P2N5VYRW0.U3O551WT/E#Y7C'S^/I!\Z+IWX86C9-IN[4:;IE*7
MY8>O<9]V:@7,VLA^O>6C"&9A4W=@S05SVD6SF#G]"F"MRN':K86@TD5$K@.\
MN%WW/D580B 9?_*9/.[1EAS?I7X@B\$U$:/PIJS4/,*UK1J0M8"Z;CU]/JCO
M S?B\ ),1/\+I!?Q$=#Y6\7B579YE@P7QWP[E1^.2X5R'@;I5M:Z>@1_JT3.
MFUBL8K3Q)S;&]#C]:582RF@5LZTJ0C-7O 2\VUSXZH=-IM!-+/UWGERR> "\
M%%-8O3?C+T#Y[X/LLPL79"]]A4LKU_?82HQMH]$IDO5J,&]U]6NH(#!9E&%-
MBP=,T3J["](SX@6!BM7SMBCKBPK3XJ!M;$&KN\;7L:(H=#GWJ#).A=*SY3,J
MZ6-+ +< S<EB/[O <19B-@N"N]6%KRYF)HIDK&GI)JKHZ);KGN$4W&88[<)
M;7\%6_4Z5X0U3%;NV/@6-3[B%E7TRL/. 97/']"M;MF6>--WJ8&<O;/];5IW
MXENG5(EQN24H87;=RRJ?%.U[L)OR <<PMBT1^ 3R+@_EYA>Y]D(TJRUR"HN_
M$@$@P"X(X].3$M=>#>*MKGT=5'JVH<5K:ZK.M_S,$GX=X.#(">%_4.+<@?
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M*Z>!H]"G(H"-2O#)=_59CPV%/W[E_,]$#'GL!/S> 2[ @O]9<^A)S8F!"?<
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M9=0J*,BD@LR(!HLV7 ]#C2)2.XOXC4H!1OTHKR'51&,^*=?Q (-DD1Z!^.X
M6[-O8 '9*(:ZJ8H (*A:B\Q GD4 Y*0&[<K0WR;GJ1Z5R@/(VCZF;;=NBBN'
MY4W,81A95% VX,VMIJJ4B]+:.%5BZ_+D'JVXK+!X/,WB%BE&P=#_Z5.X4!J
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M$)C= 3I7?OG&%D9"A>.J6M54:\5']:RGVD!H^V*>%UYWM#P4A;(_):Q(#*3
M/D&@;<4IBPLGCQ&1153GWT6<Q*\U:#+5+W1EY@(YHW22H5E3.J#@EM?2ALH)
ML)[X+C_0YX"K?*TVS\=DC"R$*2X<14P1/C:8]Q 9]$?A ]TB@U/M+&(CQ0J.
MZ2CB6*1 ,@_\M\RQSPC$J&*)+-.%6]L=W55U0<BAGB#.:LWD1;&RZI2*[V1#
M9+E+1++&&$+2:6E4(YPK:YMW1ZZ'+%5+%1XRKTV4,TOPIZK^)7$:(D.S\7'U
MG,A8J^>M._]$\C9=&<BS\P%(%.7OEYO]Z&H8Q>@XQ<0..D3-QG7LA%/PEB0A
MJNED)I?=#E1H:T;A!9*PGC+K*;-\R/*A]?.A7D2U.%TRU@XGM!7+>"SCL8S'
M,I[U,YZJ4E*\UT,?5=XQDWH&BHE;B]6-+(NR+,JRJ VSJ&*)@0GE*+>-*^NV
M=. ;-D[5<52]KEK=PR/+LBS+LBS+LJSULJQ_&I5')IF5*+1&5E5%"C;9(NNR
M/,KR*.N!VNO#KJC8A!%N%+WF\1XG#Z?R$5&\7MY#7042R):[5& [$7%OG$<%
MR(_,KF)N!,< JZP[;\MCZ]+4KN(^W8*CRJC4&\""G.2>^W>3M<:)@>D.;+%T
MEJE^,>7%%*,8C:E^:I!&]E.CWIHLNSJY)13A.+44ZRF-136,5?0A]8V7DT\,
M9L(^:]2.8M,4J<ED#*16-W4=#BP.^)$%G\,8YXK8B/HWQ\[-!?G$62'J,!<%
MLJ9X7'4<ZH*-Y1H2@5Y%#Q2#YIGS/.;<^3U,N-.60WLR"H#YZ']CPH]?[(+C
M^C$#TPKZ2NMP]97/X9CYY*6BFI'%4 P*N* *(!2'QF5XBO2QRABVL8Q5H2A<
M&[5ZB BR;##C;Q$CKD;\T<8J'CIZ%(X[ED*LGU=U9WT>N#I9%/2..XSGPD8>
M6),(8,<H&1D[/QGG8M;XI;885!4I^U@63<XEHBK22W7F99Q7316$EQQL*#*C
MCU2 *.OL#F0>QNKD]?7BNE-:E Y<R:-Z+*L[R #]:[IIOR=1:+G5 7*K:U5@
M1.LZ>>,EPXH2%56B3$&7/8J9V4V/ZKLYGW1#I L=I"^U:IFVC]S/C Z4->QF
M=472C9F-S"*9-JO'L^SG(-G/9U.TO35$FUG W?*E ^1+GZ<I-5F*?'6K.*GR
MQ'&H&D=0<N(TMC*9+(D*$FALR*\X_BL/UJT5^\[GB:P90#WJF# %; S2#X.
M^RJ;26N !0L&(\.23W/%J@ 5+C/U$Q:4^BU@Q'$$##";LH:AO3+P/N_.8'9B
M*+4]D%X]-'2%T\%&!JT6Z-E6!P?/;R]UN/TMXB%E"J<4F&]Y[ 'RV+>8]&0D
MT5,AWQ#>""F5:E:72HTG"?$K8A-YVYN,YV+A7MGB0/+F$L>"D^BS0+6%B0O9
M:I>?K^-"MAIR0CUISJTTGR]_?%'\F"*KT"5 H,P4"92KAPTV\SQWD!(N]_#D
MZL[M>(0@8.8\@BA[WL)T3A?3\\B"[U/O^#R=*MN76BXTU/LRER_%ECMF5HBR
M4=>=*\P\21."R;B.%Q,]9.T8; 2-8Z)D*!Q.+I^RS$&=89=51Z9:R90F,P&T
M3#R362]UF#.6G9Q R:>]24?EZ6*1*%F8%:8F@:D\'P;"&+8-V@(NBS3(]DJ4
M6U<<.4OXE0TXM%020ZPT(?O,42[0',4!5E$<5TI+X[J#$-,7013Z?B8'=9$>
M%NLWY#HX)O=1/6HJ!X%6G1! C>.LT46V<"LV#U)L?F+80452AY64!R@IU0$#
M8<>:1^7&5:,_F&HF)XT3'B;MQ8FJ<%/5,$SRJW)/'LI5Y+FJCF:9-%#I4Y:#
M'"0'^<!).-N.8@?+0FZSKHF%SH34X7%:GT'4BN=WOLR;1-:=Z_+ 4JTQC"2Z
M+E:%[CM5=5*&!6VS<%5;9^X,.//^3!DVK[0FV,/D3#=)Z'X[DG<'L_VT95('
MRJ3TO5*UY*$2.W"N@ 7 EG+?BS1^Q@9VL'N&07=]=!6K>CS#D1^.N39U"M!U
MJ(!*=A,MEV:63SRC^@N-I@R?ZKH8%RVQ2K&2'X18]Y3@J.4,$E,_!=Y+]?U6
MW6=U_I7NPF246#1*/>AV2SDT!)^N4^>I$JUR6N>.Q[(07Y>CKPS[I_/(%;$L
M<O,1J\7H M3%[5*=U#4,SZF6=()6 L,"\(+&=^ $J:2*6B$EV$<8.V"$V:E^
MOG\+[[$;94VGWU><TI "].)9]IXW(9E$>L[;[ P)$'FIA_.3%1M1?Y4;!11]
MA!# -@48:AVS",TB>8NF_)0)DKKSF^[#7"N=18S&C4G\ \R$*S6%]LD?U<(*
M:$>FGC" K5(GKU 5@:?R(EFUGPS%:(Q!IJ]KY,CP:DY39V/'87/4II=.I;A"
M?1+E!>4?I8%(2@N3G<LX%HWD>%&@8E8C35&IWQ/*<)$77LC-*;+_LRXQF>]!
MW7D?R-N'"'1GTOL!3J+((8NAS[Z1?<*ZM/J,CB0E +RXS;I?M%PLG85!R7J7
M==<T75U%=4&5(VE2@NM75]:@[&4G^/Q&!VXVY[= DK+LS80LVXG83BO--BG-
MLBYR<4%F54H20$8D.&I)KXFH5-,4J9\-J01M0/$31B,YB;3H=ANAD;#H<61C
MM"F:UH.LO5VI<:^N$]XCUA[UN/+;R3BPL:S=91'W4!&WV+%B4MI5B,"RQ"C6
MRBLH74&*,I^L37#KY+D^H-4:L['13$]0.!S"F$H^!U627:8)J%IQVKY/OQW1
MF\9*R7%BB'HM<V$E>;G!7 "_\1E0\HT["#$'E1IU:)U.5OCC6)<13I%R5,VR
M?5E:P%V(7G"S'7:E5VA 'B[<C)J14H!5]TUMKB8+_2D5C<LD6-![J2J?YXP%
M]SW;S?I@239/Q*'P#OX=4#"F7!FD#*1((U#.0#R&VJ=L@I.E6$OT+_2@P?<,
M;VT79[G3NF RP$0%)"==*#3"T(\8WI3V9\!3E0QIHKR^(E7BM%*W+<(>*L(6
M3QT+= XEWE7PVQ&VO)7X2ZP2+C* U^IVB_5"!^R.8LB5;]9-=*!F%RZP&O?T
M:Q:I#A:IY!)0E4"W%G:.$/&WHQX:*0K2,6=0<>D'ND=&9'Z2=2PQ^@VCX])(
M&J%':=<7\2"WFEQQC_QN&#48 ;,C>P5<9R4?TSPM+P8\=?0Q77U5?_@LAQ!S
M+31GGN"4V/];W<L5QZPYEV-0ZUU@V6G,I<(QL2N*QV)WA#+TZ&-4*Z56UW$R
M=7)Z6)S=4M:A4E9V^D6-$M&T9%'%!B':AF*6J0W0,B7[V5.S*CT0N9D*JCPI
MKKI!B9Q8AL:,*8.Z]+6Z$@/2  IS(C')\*U3Z""=0C(AR+EEWVWX_<&RFTI+
ME$H!2O#DC9NX;C WSLS@7R@WB*XE\E$MKQ4 7T_I3D<FL6E&"T_T8 "J;V\Z
M97)3=FZQ(S,&S-(E)SA*Z>KIY IXP*14A2_HXHX,C<-D;F[4)F]&P<Z7@Q-G
M<?*ZU "3'\. JOD [EK=^8/YJ<H?0%<(R[^-T:,C=1K*,0\X_$1>$PK/]U*7
M5^Z?4@QT18N)ZA/ (/^R1?>?&)%FT6*RV':!9HVH6S&5?F+JLX9-=RCL&+54
M@)"/9"QT')LM=KF!@*22(MGQ@&.?BW(-E+IS)2+M$\(71V%<]"/Q.R(1B<'%
M*7SQC?MB$&H'D<B;HL3P-2.&H2*)5;L-_IUE1D=U58!9:4TI\"2I9.?W!!,@
M,IYRC( >@E9S1)./C[#!_!&J1')EV;P5*Y)>Y( (-8ZK%I3OF;%?V6;-.AYI
M5"W6[<O&P+T9@IY6K#ZCG-H^QAC!5JMOZ674#)G3!V:1$,N&&\U)XS_-_280
M<=LT0Y'[G/JJ50N&@\N6)!(R3",7,>["A,S(#+-T=2$V*1DT&<XPU8ED"G)B
M>1V*J=M,&AAK,5",G*FJ![311H$RV4>1($]]#+<OWR\GT <\R>^=%+8-8L!?
M-IG4<LM]X9:7U'&$Z(!]XUE" LMRG+3W>68>'Z*>[%V2E>_53 BN_&*HRQ;]
MK?XQ;^=#O@3\CW-)C:&*Z2I_^_CYTDQ7J57T/RQX(U"KR)(0736B9FAC"CS0
M;2*!L&2AB+&DWIF5(K*P9-/#.;$_]DIWD%>ZWX$=?@A!M'\"&7 I30$WZ/:R
MS/  F6$A-(+Y;BI+L:%,]!$)1M163=J#!K*"S$0*W<7-I=,Z;3@&*WO'(NQ3
M))%(8D_.V I,3WUL\KVZ\X;%V"&6?*9^JH5T-4#WK.C='DMS%/*I["/48(4K
M+;YAP;XU "JE-+QQM74V]X^;D\:%;#POC?3U=WG.:$EE7TCE?:".-RY>_W-O
MKVPXS0R\2Y)(=--D!N;5JE%<XO8"WVM]7LIH,@ #Z3QPK%@@41- Z"HNHKRN
MT4+N07F-R3L$4GBFIUJ;81RHM'M@:T?0&8[TD.5"E;I$Y%);IDTQI6A*!\,?
MO47*5UK-Y2 U%T2KB ^P+3"@I3)-/T==YH5ER ?(D"\H?G(X@@,)I.W +6"
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M%XOAR)?Y%"4K*A4M4_/GHE24YP<$#HXBFK^GYJ\[%_38*3RFRX3A44!+1.7
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MY.<HD6&!LM:ZS.-#E<Q:W>_2-!&@^56K4>A<S$8KV@L&S+!*R,FE82/A[B
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M@3<$TJ5 J:WPL<UL/=BK\27( -95;]2<FQ3MY43>^379WHP/6MNG]-; X$=
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M-ED,A]P3<HMC#I2$I@2;\WN((NV6F(2)>E.Y_1S,>IZ$?4ZD5&(QE1P%QUH
MR0$9>Q'G1$&(L[GR+0+8D51JWT2?.9B8C8Q@BIZ D>Y%,@#^HA3_YYA=3%0
M*!A0&3J\6B:R*]*("0^0S8%S0#W[1>4%H,M\*E$7#SAP/V+@$=(Y)N@/.4-S
M&#"1 *:).%;+0[B[#,2=A'/^JD5< 3_P7<!N*D^@KC#S0+,$>Z@$FTG<'NQ@
MM13XDG-S%*2NKE11T!\J"-H@=X7"F*X/<JS'A%:H%#+?"#A0%OECJ?W.!>K-
M5*"2A<ABBL0S6!  )DD/7A-1%>P ]E5F"\#!%!RJ]A I'UK\9PN"Z4)7$+!(
MC-5 I%*[-14@CP.:#H'.$&ZE"<Y?YH"A1MCE >\)MZ0T]CAAHP2#P?GT^Q'O
M8]T04$0!Z!ANH/*,D*\55:5V[;1]1FKB#O %:YY8,UNX,'!J,3Q#1PTCY)0J
M:D(-?3T^E-HV"I1:1G,5. CJM \2AV=:O(>W'<1[/#=)"5KKKB2A.2@.@MK4
M0^%2%/5QCCY#T3]#:DN@(TZSD;CWL$"LI^Y&\"->9]!.;J@3$1^%$=T4\&O.
MH@#^CHU+(]S+1F%LRXL=)OG\/0V,JQ!5/KI(?OS!^<BB;Z#DO5?FXAW@G%:C
MVHA5KW#\;5G\:E;]L0#PHXP=S@WSX1PN\H+4I9O0U9O/Y7<*ER)BC?C2I>)D
M<H)8CH'_ 6CJSO/BD$7KE*R/+2N7F> C/V4IW/DC.#[2NLA,2>PNYKYOF")$
M4K8B2I4.<(JT-<7>HS#M$[@@)J3%!5DV?!O3$ED?EE>71G*"I&+U-7HX"9H$
M*(4E3+%\=<<D:89PX0R5=@6W)L7G88 N+LS<>J5^#>6):1W/V#IEY#%V"V]T
M*@Q+#CIDWSA-*Q=8ABF=O=),?36FB/ N%\G11VQ,'S+#0(5SM.N-_]2Z:3\*
MXSA73-53!(<4/@2M>K]BK&MD'%G=>9O[O:A\WIQ*<"43-XW7/&O7FLVS:7-6
M[4=>K!UE<,%Z.*FQ-NO-B8)V^3Y6;+(C]6TI^-,$>"'%"\)8@"^(F?B[E> '
MR<4G_',GL@8MW/8 &V1P2.:=<VX^6E%^@$@PX:!K-HA[G<PL)3H=3\I1"' #
M$#+\0-L67CLZD.M8Q6$:&]O)P]$5PDT60BZS,-(!+F'[@#]>B>2O/I;E]B;]
M-O*-6=K$-$U@R,:5$GV.%H#N#'D_,LP.AK%$R*X=Z8@<4F?U=D4U4BV!)M9G
MZ@G52ZM5; JLI SUY=CU@3;\"75!J@IS=(0CF/](Z@C&5N:K9/A]CR[-<-_\
MG/J&UG@,' ?$US#UI<*0B[\;- /+$I<7LO-)\[P-.B:J/4,I=R==DN8GYK&6
M]!386-(<)C>GK$?(@YG4)J0R(\\OO^ZB@*_GNRGFJT/IG .L.^]@&ZF +*X<
M8"AJW:AB2*T;)3S $V*Q<DFKN/=$K%.UJX+C$<V:$@;2-Z2-4:L&,T$LAA%Y
MVI5?PGG0"XYKC4ZF^8S2"&\ 2>8!K1P=/Y34>-RLG9^?*E^;G,%;3AT[741_
M:M1;$R3XU(U_3Z4,:D4M7X_';B1&IJV[*LXB3)/,W9:YFG)?F\6?)X$_R\9?
M9D[>!P9"6AU[7S#C@D3-'$,!&O#QOSJUX_-&#0.D[C.W8LY?5#"8]F9EX4"9
M,OE3J]YHU)T+;0W*!C%%)UK^PR! U0*CA+1[8<F S<R1;SH=%$04_E(,,N#?
M1R+BLO-=Z[CNW*3=?V-;.]  ?#$4LDR_RXG; F8Q1V8LD Z0+0*5-U2K*% (
M8:;H(-)Z]%:@(D*>"<FTR7^JOQ>2B:N1\_@+V@+:+_E3@;VS7D_XN+Q8!9_A
M!#R**1HJ,^,Q5 Y)8YPRIH/*54"%X>?/] +07#J+M,<']C:\#Q:)<</0#=C(
MF'XYKI^?_Z?S/(QJ.K*.^^K<E433X7/PQCF^_"(SDF7#AVE4#-*#GX."V).1
M9'U!]QU.6BM9)7&A^F1V01!:YK8)M:G$AK2]<0)3*8< @T#346@P+X5O.97"
M%2MG#J2BP\!XD6#>O]-8ACBJ8!Y^I^X)$5?.3/&7#$Z@7_ 4"6.U)S-[$(]\
MD?\,!-3%NX[D/3"6BB9R\T=AU&>!&CQ&8HYE-(>:"(F72VZP2)RQ9(XZBE4E
M9SE#6!U=3I/)725W;3R8O7?HS?"1]$WFGPV/S#I-@,7\I<'$$>E]8[+P3L0&
M?]!#UYUKM>7(R)GA\H9+:>;0+K+JDDG9]'S?"8:C_?B#>8G7X)BFA$G(+",Y
M1$;R2=LO"KBOG#096IGQWD6/FT;R,C<IZ@Q* F>J [U?^K0@3=5LDVRKIMH<
M:5+*-)&[$(E"ZC*H&<2<?#=2R8JXL/A[D/AK*+J:QRUMHM*]HZ2VWJ!_GY_3
M;:#03,KYK>C6+$^$IJZ"[H5V4PPKDI:]GYHP**8FR'N$(W<>K79W/&+]"=$3
M]C1#;@!#IBM&;OC<!6RV]HW=LV_,SQ&RAH\#9XDRK2V_1RZ>J%8.O2Q9+QY@
MK:@[[YB.CD%8%DLJ,!+7C%!-?94."Z9A=<TG(1_V:MI7.O>^;@0]=\?RHH+,
M7&6/J;2T:?EPLWESK7"14L: +E8=@3<R?;KFH'E *C?:.(#A0GI%(U,STWG@
MQ07-W4UE7) 6E-(%+[_4D=RJN)X9MS=/ +**;JKN93 ._ICGIIDWN5T039:K
MK)NK+!^'=58[;9R5^-""/$=Q !WZ<%QK-V12<C4QUYWYQM[6Z?'2L$1\B!V>
M,^>J9UK?I"VA..PB[*UJK-F-)&LR5:R<SMMLMV;MB:7" Z3"]R7[&W-\\6>*
M674D47*!&!<EQ6+XCG$J(X;%"\6((@@"BBB(CS)ZA),^DEAVI")6,,<*E0-*
M)#*D!$$7QSPIZR#%X 4 41D*T  G!U%2!Z>?(KR?ARJ!$\#+WU<J"N)L^8L7
MVD*'A <W,J$<-5*OB(N3\B55%DJ[8,*KV"\CH9)4*<QA@07!+BEO0#!5/6-=
MV?\YP2\RZ\LRO 9(R>?*RX6>=0PY@9\973;59JDNT3A@<>/SH.8LE!73X2*9
M*2Z";Y3FFE((3)BI B-0(%RRVBR:+F?YU"'R*</-Z (A,.G[E)E0<:V@U?<*
M>8ZFHKL0_A1#JK"D4L$LZ+(4J(8H.O=L+L8-*0N5Z!BS+]'W@+QQEB=Q ?%O
M\F]*!RA47\'?[D(_'?))ZU#F;$:_8($;HO[>;E"&-7=3"EP#HB"]PF/C>")H
M[Z-,_B:Z_T2UI KQF&A#1?-6NY&'X,VX""VXF\^GWSW@/_<LDDI1Q'%\7KJ/
ME-U,DU<4F1^B?$/$$AAQV/A%319[H30_!K2=[8W::,WP;]7CMR"'E&6/SGER
MM[(=^NE$UO2@JY^QY;K$C)I6(9Z*3<0<^1 $8Q;P2*5X N1@TKU#:(&'F8@D
M33AYO?Y_]MZU26TC>QQ^[RI_!U7^V2J[BL$(&"Y)-E6^[L^[2>S',\[6OG)I
M1#-H+22BR]CLIW_..=TMM4!<Q""01&\E&P:DOI[[=4[PG'[9,C!X+L K :)W
MM>!:MSH*C^##Y VBSTJME0P?KBJB<+D@X[L"<@.<98DV54$L5CP(:_[Q13*H
M%HE+8S5/GYR;V>Q7K6)&J5*(-QBQO!1>5/)3V2 6+46*TIRE^;>R"$ZXYJ#B
M,A$9\B5_2\-H9,HRS??@DW>:#]4VU@1X0'Y%A$?D 2DZ!-*4$__8VE=OM;RO
MZ 'S% O2:K"*2'O.D==;J3LPPE6Z[)X<R=8#D$^2[:9\E<F[54 L[8RHGC-B
M\+=,[;.WWT&'\>Z9E5,(3;LEFJX2%(K'[/6N6]UA;P\OQC884Q.0MY3*VV*4
MLX3U+\_L_Z/9R;IDC3>J!HT+SK,4V/$\EO5>9 6:B<C7\(%-.%@J(E&#A,_#
M\CPLH1>(YP:)8*[R#B[N,$5[RJDVN*23^2L&"0U0=2E7.G6","+9%5Y]Q^X"
M> #XS>^8@_4ROL<(*3R>/_P'NCY>G0Y+LL,YR<>5'!F\TLYUVWB9,>A0H!7(
M=!.,] K6)-+,O;[R425 B'% ^H_\@(OX- 3,+0X/#1 AEYCQ;#>Q*L'/A;%#
M%+C*$Q"LS0>ZY>;A7-T8PU+M0,)1[)%%*-E[%5BDIFEE2)Y[ B]5$B5MQ0.M
M,_ !7J86_PFD,>F-1'3Z-A/EZ7R)*(0D*<JF\+R:SX54D,(G&:>UH7,OG'+&
M/1:K]*29A1+,MY'5-<JQ$G:%&3<A@(92FL8"PK4,'8ZG<D-)R2H+E,$ T02(
MPA8\(5,R&2F)B*YH<)PY_-AI#W,2[JGV9WM\K>(E3+PR1$LD]>T1#Z1QMJDX
MNSOH8&.@@6JZ3%(]\S!H@^L"WU?-:)*E9W,BD;]<=X:;!D&NEO52K.XH*3%G
MY8DN&5[6&@_[JQFE6/(#H.D!QC!;@_'&VAFXD$16H5@&96LRXI.\J&1/2P99
M7>Z^OM !7V@Z$&#W@P/$U%TJ3I=USOZ 9;P8G#:+L(X)B"^X8DJEYU9'V$Z0
M%OG#,F,Q3U5-Z[V KHO5\[BLF%E!EKXHALZ )8<C1)T\L2;<=C"\ZC2: 'U,
M=R;=7Q.FIA(FI?;!2AB_M+#FJ15$A[(&'A%3[?IAINK!/DD2A/[<Q TS_-AM
MC0> ?-R>#(32O$[= IO< 6O2 ]()*Z*><1& 3M8_(:SMN.]>YPIU$/DS[W31
MPF 3DHQXB=GIFH<CB97R_$@L(SD]99$:;QJ+-WM+OJNX([PC0HET,BB"!5G=
M4!:]ROC',<%Q=2B*HW.^*Y*ZZ-2229/(LPD 9#B1R_F/YXOZ#U3@T25.\@U4
M@81?;)$YUKD+\DM 6N[FD0JJ&&';HNA;KO@KX9[$@WF ?'9-))?+E4_2I?-B
MFXH%8\X8V<-GS"7QY'=+#2?MTP2FQM.FXND^3AF"GE7/24KB%9ZSQO>2!"!>
MY$5F.-M.8,=S%#!M+3R='+B>/CF'^$1!)DBEN1;7HIK!;+Y!?H+3]5T2L]$]
M#^2[A2H)TD!N85PW+ JRIE0BWL=$K&'O0@B;0R)TXHIHI3"&:J2, R% R[4V
M2$CVO4Q09!*O1X3RCL$]DV0#CTG3_)H5?BW^1_I(C#<P2,81@A+,GHZ6FQC[
M_PI^_X;=P:+P4C(^E_3KS"P2=;BPEF^6R/]H2(0"A0%C5%V18,=EOF0-.\TC
MW(J0OM%"P8]K]B(D8,ZK>W>5XG!+,DJFW8(RQTA,B]?'(--J&-\AOXEX#8DD
M, D%+S_<I">UX1)E!B$?6S3GB:RO#, %:YSM,E]JJV4C:<P[@9D%:N#:27L'
MX6U3%)@,D^JT3<5HGO4-YN@YA#PA4X8CZ5]&0&<D>K.UID28&4?B"K6B9 ?X
M>8-+T1RULBFYND3N-EBO:V]EM>J-ON$&4K.W2J$)+B]]X*%S%>!=.I"L_/M'
M,8>[-T3$)'&0O!(.J^+7WL4<,JSAEQ=Q>'5O68N?U*[LO(CR'W[$WC@AFLKA
MC&YA]:\P5??7IT]^D2^E/W^8HFC,O)#V]@F+*[/):S^,PAODG:_0Z_911)DD
M0U$\*/SQB4W__L-K_OG+N_^\_=(QO_S3\K[@<F\[G2_\G]L/7WKF%]AA]OL?
M?EW!AD>#?J=2H-](.%\C8?02\)Q[[R<#L1S.9YV%K5W2RB%_"ZQ%\I0LZ\V)
MA>M;D1QY712@-:%Y-4&;O$^$(E<$RH8*[?O3YDZZ"_&'[0+V_D3-C#)733\N
ML$<2OU)1A5Q95D&&L(=>PA.4%"^YK6R2+)+"58SU#-/&AE&F4JWHN4K7!V($
MFR<Q?YE&ATGK=7+D@HPM?!)"T<ZG;ADZUN+^8:Q"N+:(B$<Y.IZ:0>3'(;P;
M/O]I_>CX\^+PU),:"5Z*P-\WZ=Q0NP>\!:AV 6W@JN2GGPUYXD/UQ!6>I8!^
M%.1!ODW%LK?1+0ZPN*X7XT54F QQ#%DE,62[L"U7+H.C3F:Y$[E<L7V)7?]O
M2O\SS,5W@VY7+#Z#R@*.4Y2DLOK)U_R$.LI1=\<J_%\%"O;([Q(BD(<7T>2P
MI8OI!WLA7X4FX1>I3K)ZY-VV.1AN./3]CAFA!N#(^_L/_=TD7  R/?@?U,S?
M(@)G]W87&"^H@$*>S)+_*!* =>RMTDWHZS[N=0^/?]W[L59UDA=1L(MRTV%N
M(MQWEOT5R_%Z$RD,_3_;9FPZE33=A%6\P/\[ T'?3:[-8Y'K'N^PD@]/>1NC
M)S^Q$$#*GHGPV0?F^@OJE;(O9!P! X\PQ!H37#]3LZ\<:AD<< [RB!B^UQY>
M)V)@%HCWO_]"-_[C?@L#,;Q;SLIR46?C<GN=ZXK?9GW@>JCANC)P/>Q6_#+/
MQJ;/SXN/H5QUC\>M#V#6_V >=J_BG0DFF+@31@$E]6FY/6>2*K"1W=K%8>1U
M,R 6 ;WC;Z$((2ZVAWT(<;*Q_G#8.-"Y=%0MFS5J5#T+JIKC?N- 1YM'CF4>
MZ0H\.Y=]A+NE<CPV-KI?C3LV]:G1%14'B*SO+">8H/8:YIF$I!Z@S\2/[UQV
M,.E=X&2E*J'%UEZ(YI:GI8X>JZ9JZ\N9I9+CX(;&C)7]= >#BL/#L06)3#0#
MH;7Z1R[77H^ZV!Y;D7J[S'ZA5;Z@T(%<AIT3P+(SQ'+4'HZ2!]=#5+H=\]KX
MZ%H%0DZ*17]\6$T\Y)F-UZW-U1R4N#%>JP%K(^#3M%@>2F:\]]!%B.G)N/JU
MQ(MT7THZ1$LDJ_$$ZZ23.6: 4^?RI+>Q'/H^Z<E%Z4W3J6/#HEH&FR]<?\D8
MM6M0:R9A1$KL1E92^<C.J_/0OQZUAM?[E-S*)(NG[=23W8G*^/)/C*3!/87B
MJ<Y@[^."1[<?EU(RC"IKRTH3R:[$;N"P[L3)L4E;UE;@&3<6%I\-Y8]J?_B<
MO:_=!FS-$UD:%ES8=V<>SPW7F?+^ZYVU]!&XCWMN/'27(*&'D8'IR? NEGF
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M4&WJHA @972QDGGN5>047.^WQVL5UW.O#'>YG<:QC=<O:[53MYNUDN_7ZPL
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M$E.^/2JE/BPU#),&#<G&5]AZ 3Z=L/6/%G:9H(O0K%RS\LUM[0A..,9J[MU
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MC@,MNG<7:.S->K:M)=J&58M+TJMNI7&P+/H])=(>3)GP#_-PI"4O(J4!MZF
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M<^\9O.:QO>1K<X42/_DOJ/!T9MG3;='Q)Z8Q40O#^BYX6HO\#$& ,UO1MJ7
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M3XVR9XE/'PRVU5BN+?3H./,CQYF7XSNNC69X1J&E,M&BQUIY5?IF#K>2OHH
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M2TAJGN>^",4M3T<=/59)U;:7\S"6IT\T;I0<U3+8%D-8!8BH=4#+4>N5'3D
M)3_*)7]4D@H^+"A8[Z4=.0].M#Q-;;.UR!09AW*]*PY%7EC7-%=M3SI>8JN
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MN=8BA)'D)S'^U)H[[O*GPLH\7XX?+&:P:MJ$RZ((9L(G"$KD,Q*FQL) M&H
M4,#,[.$&Z(MO$E[QD6^PB73@3O+0@Q4X%OP7J(P5Q0$+TUDSO]NPX?0G&/ON
MJP,'CD<71H'_E:7BPW=QI!-F^P$!AKP"QW,B!]]?_5UL2/[^0QY"JM30AKMB
MP?:0DSO?G1BC1?1B7-NHD]W5(H>#$DAI10S5)4RR'K*P;OTR!\/MAY[EN+O/
M?,WNE0/)].!_F!48# C1)+NYN\!X@;\?H36=OMJM5SLRJW:U)41TE6(1WTZ1
M:VX2-X]%AP\SA[_]OF V&L3AA.?&LR7 4OB\YO;NG4>Z)Y7=>J*;L/%::C8=
M,U5RTH_P;=V;?>X\WCTIW4''6_CPSD"1+HSL'$!U/CGA5V,:, 9B.1PD"R,#
MI'76=,38F^X4QPNSW1MV_K:3]L 2._!8P\]Y;P)TR#F/QGN<<[?='5P7/F<M
M/=6+C/WINU;DN$ZT;#I&E4BYQJ,]R%:GKXG6(XA69U0'6J0)SM[:&CSL3$#G
M-Y8.<R>&#YLTF*K*-1U;2B1(G;86D4Y^?EKTJ1<E^L3"V(U@#(.[@C"D$O9G
MW3/C'KOO&A/0YXRIY03&@^7&6K4[')]^[+4'VF;TB/.#R<<GID?[>M$/]WOG
M>]3?>[8_9Z\8T#G&/]]:W]_ ?T*@/"^]R3OX'@ZH&2YTLV(N],$PWX4NML2!
MOKL:O'$97G7.P_;RJ8\JZE,O[$'O=;I[$;4:>$#/Y&;-$^;67:\[KJ% 1%@:
M-65V]F8RN;"8>F;?HF<V/[ED;Z949?]K3;#W"!$Q&I^/'S;QZ.#7%&7[1\!8
M'?!2XYNK2SQ+DS,\=RIZ^Q+1P\)9I*I3<W4Y)\Z]VQZ/#A-J]E[%H1D,)\U#
MZQ5)8"@O?^%9M]4Q35SF47N'50,0:H,4HW9?(P7,-BZ0ME8B3IC=X3DPX@10
M<#9QX/P\_R0E+O>7"@X0"H314\OUAY5<.0'#*53^\>1]$4NH8%E BBFS ZII
MMH:#WM%I=EW![L(1_01\]-(0O8!D5B:>CUJ]WJ"::'X&H-/6GM/5\RK7W/.;
M'X;&%(Z#7-B.%\-XAK]@W$D9&G?D"#<BZSL+M4FH]")>10AVV>IQP?)=102R
M$A7H7FLX[&NK4N.M2I>"5T7DG_+0:M3JEZ#E5 .2_O_VOK6Y4219]/.=B/D/
MW#YG=WLB9+=XZ-6]VQ%^SO59=]MANW=B/G5@*%F<0:#A8;?FU]^L B200 )1
M0($JSIX)-R#(=V9E96:U>C:-J!Q85;<5(B1@$*/YA>7*S\3(*"9*T&(%7-67
MEAW%-):G&8)(S4)3PQ/>+QS[U7#AT5\ + <>Q$6,002W*]*#JZ[A>JY@3P4/
MWC>U3=-^PP^]-ZRU?'DSVW=52W=_^;@=#](M7MR6'*:+%P-)YZ6+O'21ESKQ
MTD5>NLB0]O+210;TF6K&F9<N<L[QTD7&DMG4C.AAN>P+WW% 4O;.0M [6^(X
M.A45-H?M9XL&M;Q:/&DVRI^,+@990S.:ZV!L:Z1<5+B(%YI#W@H1KYRKO *Q
MQ16(>7W[E%<JEJDEJ<//'%T%4X%@I,(2)K$W&<M=E)\C5]G*_>;1Z6NC9X*N
M$)M,*M?6VD6'IUJ.+-7BV9YJ\CQ+ZQ:A12%D)>&R+\AAA+>M$?1NIUH*2SDC
M.9?=H0$+;.6YEA;G6B[1%(%[U^EOI#"RJF)EZ<:S+9W-MN1+B[=6BHY<<7G.
MI9LYEQJUEN=>6IM[:;IG\V95T1\5_?,,"V\AV]%"5B0DXJF9EFA(4S%(]]2C
M2.S!<SK4PH5V]$FFG3YPT!D!Z<<-7-CS!<1$EN=&KX57X4.*+!<^0)P[/VJ
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MXTPN"IRD--7L&X=:'N,3(\?LL[4U,CXXE>KL8V=:QIMK:(]#/9 'O:&XJ\*
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M?'S49DCW370W#4^4=:\A7KGZX2''4LT+WP4&(<<]LW3LI(F/#EST^?)79+^
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M;GF.JJ7[BF!P$H[&[S3O.W9:F_AM77_W^5Z*#S$X#)H=_'F 'X=;6U]1GL[
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M#3F&O;%V?K0R1/+JAS;#WIR$YXYA:<9"-8/):7=3H"URO[FXDOA"-36\[\J
M:!4*Q>F@G"U).(W2-$$V,D#; "; #]=C> 88+IJ]A*\","904 >U^@+@X_U
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M,=%<<D<YG4S^)KRW'8#8(X@B$R@<$@+_>^$[V@S65?#$!#_\2W1C_7K;=X3
M4 J!=8#;\/N8:*MXA)?P8KSB?Z#I-&0B02_BPFFH3;FDC5BJX/\R9?056_$[
M#:PALC2$QV"MW-;=-*GR=-:^A]F9S^^-7PA!7VW3GR/A+1QU+ZC!K'MA08Y
M#^F<8.44)$7N8^!=,/K86 J>HQ**Z^K2!6F%U[[[@E37#^9+"<$(TW>_$!%
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MPBJ9-5]]?9U6.%==HW';@ ^5ZP_ZHWCJ/ O6K>*N0SA9LL^8<&:SQ"E;&LM
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M,NM1R4X6PRZS0IAO&C2THZO!O_S];_\%4$L#!!0    ( !:$?DRYK@U;8@P
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M"@@U";Q <'55I[E5TW!J] PQ.$%"#]+=$+Y&7E?-J/ "<<U2C=Z9L69A%/.
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M\=" J>3O[P0FDI<"_ZCBB_ 4D9TW6Y7V4<BD.VC>!L/%9HZI@#M\8&Y-X.J
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MI(2R.WH:C:(%$S*[#3(VGXDIBD;]0</+.^)HRAB>:.;584\BL2ZP(ER!I=D
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M,C8I9L1QW1ANC98H8$8?"WW/#KJGHSMJKGA.I4AKFN*L$RW*&K48:WA-#">
M1F[=*-1I/6>WQI\;1G)&+#>R19<LF(^>]"KX5&KV@6;%]O@&(YZASLDGL+@
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M?4.CF/I/H;CSZ.X?8B=,X$7L*(1[%OR? 7>-$\%"Q@:S^P1HK6U[D*32LE+
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MK1=A=@+'/I@G"4T3>,]:9+'!^X5H8B!?R&1&2YTA,Z(9Z#<!&(*X_" 8/A/
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M?J1*#[\+UZ9N-];>3(?0"7D&L!YUI(X];0NTS"R+"D7!Y![MUYH?@$X>9-6
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M%[K'E6\O*@J>H!? :CM.35/0N$'4BMR-7QUDJ^2!RGJT^R'H%2OD(6>M6J?
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MI!(5\N5ZYV6AOYFOGKR=Y^/4>R$4+[+)%TMU'I.U2OX]7WWV2'-"BBNT\K*
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M#T" FM!=>.A51GX39;$U":H' X[''UZ FLA=*!Z@#AR_VMN!ZL& ;9H \M-
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M 9FRT;2])IY1O%7>&6ACZ,K7G7: "D#-2!CC:)].-DEUQ%TA/R#_40^UXHX
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M<)$M#E*43F0X.MH@5=X(>%V@W?.Z:-=W#*>YR1J0F@[&A^P]=72H'Y#_B"*
M%4< -B&*.,BS&JGB<D![.\#S]G0I7'EIC?#*VW^.PG0S"Y?_0)YHJ]<8!=K*
MJ"\/FN!<>!VH(#<0/T<7Z,'#!D(A'P2Z )&Y3*AA&Y-WA]VM@KZD^P1=MZV"
M,PITQ2,[6X4 G+7WAX8*P7QXH(T>T:I%N 1O=P=+-R^\9QZOO1#_43IM/V\0
M=>+VPCU!03-D)//50^-[Y0/$,WI+B4J=$,FG7_[R>"MYR.CXE1,AL?&XTG%.
M_SYHKO'&7"_)_24*\+)8+7GZQ7J6\]4-#KV0)O&KW0E5GFOLC%]E83_^7Z?0
MLS:;A#SB/>V8C0.Y,UGE=RN239^<56JM2=Z":JH\^2CT8ARINH:WVD.(0B?A
MYWJ M\DP:;M5!>5+2 L7X14FVKKT 8G;9Q2>WRPA/8WWX,(&8B<WW^XJBA%U
M^B#7G/RJ_;0+,/]%2*$3K&^I1-R.DND*P<.:##D,FZW(C5237\(^TV&7&'IU
MX1]1,FN-@T%DRS4?:[)'8@?R69(#F..RD<(@-W,FC=27@A-3V&T*0G B_J<)
M6$2$Z6VGMGR/OYS?/\WO;J]FS]=7%[.[V?WE]=-_7E\_/SWDU-R@E$;%J-_8
ME<?KY6ZN_/5!;^&UGM:X=CU$"<XE7\$G4J4[V 5)ZA?9;C@*?5F!#]R;4/MV
M:T]G-C-^6&:FTOOM:>-1,%7M(GMZ+%LTLD+PKOTJ69Q$MTF2:3S1MCJ-@I?2
MPU>$NGI4F>XS&PN=FMHEZSE=[K*TJT^NL/@._S,K+;4/=54D6@Q5=+(J#S%%
MIHLH4A7[L,O]41S EX&7D(M(42)+T>1\TF<4_%8[CD_Q<I_$![_X-J8F-1"?
M-H:._9%)U,EUEH5@VI;^_I+&PO*6S2J>E4*&Q T_5.MY8J?#8C&*OJS03#O4
M1SK!%R]!Y!__'U!+ 0(4 Q0    ( !:$?DR+Y_$YAA,! )M9$  1
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M &-Y8V,M,C Q-S$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( !:$?DSH6R;L+$H
M &5)!0 5              "  >7B 0!C>6-C+3(P,3<Q,C,Q7W!R92YX;6Q0
52P4&      8 !@"* 0  1"T"

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
